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Why and when bariatric surgery? 
 
Bariatric surgery is performed to cope with the sequelae of a rapidly 
growing worldwide epidemic: obesity. Estimates of the number of obese patients 
range from more than 1/3 of the U.S. to more than 1/10 in the Netherlands [1-5]. 
Despite individual differences between western countries, the overall percentage of 
obese patients (BMI > 30kg/m2) has doubled in the past two decades. Due to this 
enormous growth, this epidemic has major health care and economic consequences 
[6]. In this light obesity has been acknowledged by the World Health Organization 
as a chronic disease [7]. 
 
In many cases it is not the obesity as such but its associated diseases that 
induce severe morbidity, like type 2 diabetes mellitus (T2DM), hypertension, 
hyperlipidaemia, obstructive sleep apnoea syndrome (OSAS), cardiovascular 
diseases, osteoarthritis and even certain types of cancer [8-15]. It is mainly this 
comorbidity that reduces life expectancy and quality of life [13,14]. Young patients 
with morbid obesity have their life expectancy reduced by as much as 20 years, 
depending on the extent of their overweight [16-18]. In addition, patients with 
obesity have an increased prevalence of psychiatric disorders compared to the 
general population. Lifetime prevalence rates range from approximately 40 to 70% 
[19,20]. 
 
Many conservative treatments like diets often fail in the long term after 
good initial results. Another, far more drastic but also more effective treatment is 
bariatric surgery [12,13,21,22]. To indicate which patients are eligible for bariatric 
surgery the National Institutes of Health prepared a number of criteria that can be 
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used as a guideline [23]. An important criterion is that all other, mostly 
conservative, methods must have failed to induce a significant decrease in obesity 
in the long term [24-26]. 
  Another main criterion is the degree of obesity. The degree of 
obesity is expressed as an excess in the Body Mass Index (BMI) 
 
          Weight (kg) 
BMI (kg/m2) =  ------------------------------------------ 
   Length (meters) x Length (meters) 
 
 
  This formula defines normal weight as 20 to 24.9 kg/m2, overweight 
between 25 and 29.9 kg/m2, obesity in the range between 30 and 40 kg/m2 and 
morbid obesity in cases with a BMI above 40 kg/m2 [15]. 
The latter group represents the standard indication for bariatric surgery. In 
cases of obesity-related comorbidity, surgery is performed with a BMI of 35 kg/m2 
or more. 
 
History of bariatric surgery 
 
It is hard to define when bariatric or metabolic surgery was practiced for 
the first time. In one sense it has long been practiced, ever since subtotal 
gastrectomy, vagotomy with or without antrectomy, or pylorotomy have been 
performed to surgically treat peptic ulcer disease. These types of treatment were 
not designed to induce weight loss but were inadvertently associated with weight 
loss and co-morbidity reduction [27]. 
Introduction and outline
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indicate the true historical start of bariatric surgery. Dr. R.L. Varco, a surgeon at 
the University of Minnesota performed an end-to-end jejunoileostomy with a 
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separate ileocecostomy for drainage of the bypassed segment in 1953. This was the 
first malabsorptive procedure [28, 29].  
From then on, slowly but steadily, a number of different types of 
procedures developed that can be categorized into three groups, restrictive, 
malabsorptive and combined malabsorptive-restrictive procedures. 
 
All restrictive procedures tend to reduce intake by mechanically 
obstructing the passage of food into or through the stomach. With this type of 
technique the malabsorptive complications seen in the other two groups will, in 
theory, not appear. These procedures have the advantage of inducing weight loss 
without altering the normal passage of foods through the small intestine. Mason 
and Printen were the first to publish a technique called the horizonta l gastroplasty 
in 1971 (Figure 1 and 2). This technique divided the stomach into a small upper 
pouch and a lower larger pouch connected by a narrow passage along the greater 
curvature of the stomach. The amount of weight loss, however, was unsatisfactory, 
even with modifications, probably due to dilatation of the passage [28, 30]. 
Eventually Long et al introduced the oblique gastroplasty using the thicker wall of 
the lesser curvature  (Figure 3) [28,31]. Mason described the vertical banded 
gastroplasty, known as VBG or Mason procedure. In this procedure a pouch is 
created with the lesser curvature in which the narrow passage is reinforced with a 
prosthetic (Marlex, Dacron) band (Figure 4) [28,32]. This procedure was 
performed in the Netherlands for over 20 years but lost favour due to disappointing 
long term excess weight loss results and a large number of staple line disruptions 
and strictures which needed surgical intervention [28,33,34].  
 
The principle behind the gastric band is relatively simple. Create a stricture 
in or around the distal oesophagus or proximal stomach to reduce its diameter. 
Tretbar used a fundoplication technique in 1976 and sewed the fundus around the 
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stomach to reduce its size [28,35]. The introduction of a Marlex mesh and Dacron 
graft by Wilkinson and Molina in 1980 cleared the way for the use of gastric bands 
(Figure 5) [28,36].  
Kuzmak used the first adjustable gastric band (AGB) using an inflatable 
silastic band connected to a subcutaneous port that can be used to increase or 
decrease the diameter of the band in 1986 (Figure 6) [28,38]. After the 
introduction of the laparoscopically placed AGB by Cantona in 1993, gastric bands 
have increasingly been utilised for the treatment of morbid obesity, up to a total 
number of over 125,000 yearly procedures in 2008 just in the U.S [39]. Nowadays 
the number of patients who receive a Gastric Band  in the Netherlands is rapidly 
decreasing [40].  
 
One more important and now increasingly used procedure is the Gastric 
Sleeve, in which the majority of the stomach is resected. It was first described by 
Marceau et al in 1993 (Figure 7), forming the restrictive part of a biliopancreatic 
diversion with a duodenal switch (BPD-DS) [28,41]. Nowadays it is more often 
used as a first treatment and a standalone procedure, after which a BPD-DS or 
Roux-and-Y gastric bypass can be performed in a second stage when EWL is 
insufficient [28,42].  
 
The malabsorptive procedure first performed by Varco (jejuno-ileal 
bypass) was developed further by Payne, Sherman, Scott and Buchwald (Figure 8). 
This procedure and all its variations resulted in significant weight loss; however, it 
also led to an unacceptable percentage of malabsorptive complications [17,28]. 
New life was breathed into the idea of malabsorption by Scopinaro, who 
developed a different procedure with the same name in 1979, also known as the 
biliopancreatic diversion [28,43]. The idea was not to exclude a portion of the gut 
from the intestinal flow. A partial gastrectomy is performed in which the duodenal 
 
12 
 
stump is closed. Then the jejunum is divided in two, 250 cm from the ileocecal 
valve. The distal part (Roux-limb) is anastomosed to the stomach and the proximal 
portion is connected to the ileum, 50 cm proximal to the ileocecal valve (Figure 
9)[28]. This procedure results in a mean excess weight loss of 75% in the long 
term, but also produces many complications such as diarrhoea, metabolic disorders 
and dumping syndrome, severely reducing quality of life [28,44]. An adapted 
version of the BPD procedure is still used worldwide, but only in cases of extreme 
morbid obesity or when the cardia area of the stomach is inaccessible as a result of 
earlier operations. In the Netherlands it is performed on only a small group of 
selected patients per year. 
 
Combined restrictive and malabsorptive techniques try to combine the best 
of the two principles. They decrease stomach size to reduce intake and also shorten 
the common channel to reduce nutrient uptake. The Gastric Bypass is the best-
known procedure; an early variation was first performed in 1966 by Mason and Ito. 
They divided the stomach horizontally to create a pouch on which a loop of the 
jejunum was placed [28,45]. An important alteration was made by Griffin et al in 
1977, who described the Roux-en Y configuration instead of the jejunum loop. It 
reduced many of the complications like bile reflux and added the true 
malabsorptive component to the procedure (Figure 10) [28,46]. Since the 
introduction of the laparoscopically performed Roux-en-Y Gastric Bypass (RYGB) 
in 1993 by Wittgrove and Clarke, the essential approach has not undergone any 
further significant changes. It is performed in approximately the same number of 
patients in the U.S.as the AGB [39] and accounts for over half the procedures 
performed in the Netherlands. 
 
Another procedure already mentioned earlier is the BPD-DS. It basically 
consists of a sleeve gastrectomy combined with a BPD-like distal bypass procedure 
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of the small intestine. In 1986 Hess revised this procedure into its final form by 
preserving the pyloric sphincter, thus reducing stomal ulcers and dumping 
syndrome (Figure 11) [28,47]. This procedure is performed only in cases of severe 
overweight but may be performed more often in the future with the increasing 
number of standalone Gastric Sleeves performed. 
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Figure 2. Mason 1971 
 
  
 
16 
 
Figure 3. Long 1979 
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Figure 4. Mason 1980 
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Figure 5. Non-adjustable Gastric Band 1980 
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Figure 5. Non-adjustable Gastric Band 1980 
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Figure 6. Adjustable Gastric Band 1993 
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Figure 7. Gastric Sleeve 
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Figure 6. Adjustable Gastric Band 1993 
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Figure 8. Jejuno-Ileal bypass (Varco) 
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Figure 9. Scopinaro 
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Figure 10. Roux-en-Y Gastric Bypass 
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Figure 11. BDP-DS (Duodenal Switch) 
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Outcomes of bariatric surgery 
 
In the literature, weight is usually used as the primary outcome, because it 
is the easiest to measure and long term results can be properly tracked [48,49].  
Most authors present their results in terms of Excess Weight Loss (% EWL) 
 
   Weight Loss (kg) 
EWL (%)    = ----------------------------------------------  x 100 
  Initial weight-ideal weight (BMI=25) 
 
  The amount of EWL that can be expected depends on the bariatric 
technique used. In published meta-analyses, results in terms of EWL for the LAGB 
range roughly from 40 to 50%, 50 to 60% for the RYGB, and 70 to 80% after 
BPD-DS [50-54].  
A harder to measure outcome is the reduction in comorbidities. Patients 
often concentrate on the amount of weight loss or cosmetic results after surgery, 
but from the doctor’s perspective a reduction in comorbidities is often far more 
important. In the short term, weight reduction results in a decline in insulin 
resistance, lower blood pressure and lower lipid levels [26, 55-57]. The reduction 
in T2DM is possibly the most important parameter [58,59]. Reduced intake and the 
altered route and speed of food and digestive juices in the GI tract following 
malabsorptive procedures provide an altered release of gut hormones and incretins 
[60-65]. T2DM can be recovered in over 70% of all patients undergoing bariatric 
surgery, varying between 60 and over 90% between different types of surgery [14, 
66-68]. All other co-morbidities also seem to regress after bariatric surgery and 
mortality is lowered [12,13].  
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Less well described in the literature but, besides weight loss, most 
important for the patient, are the results for quality of life. There are, however, a 
number of publications that have looked at different types of bariatric surgery and 
showed improved social and economic opportunities, and on average, improved 
quality of life after successful bariatric surgery [69-71]. These outcomes are vital in 
reviewing the results of bariatric surgery. 
 
A number of retrospective studies have reported on reductions in mortality 
after bariatric surgery. All the studies reported reductions in mortality in all 
patients. However, especially in patients who experienced T2DM, the reduction is 
even greater compared to non-diabetics. [14,17,72,73] The only long term study to 
date also showed a significant decrease in mortality [73,74].  
 
Most randomized controlled trails have a limited follow up of only a few 
years. Whether these results are preserved in the future is not completely known. 
We know, however, that a number of treatments and patients seem to fail in the 
long run and either regain weight or experience complications [26, 40,75-77].  
A number of complications that occur in the long term have already been 
discussed in the historical part of this introduction. In particular, the LAGB is 
currently under discussion due to its high degree of complications in the long term. 
Band migration and erosion, pouch dilatation and slippage, dislocation and 
infection of the port are frequent complications after LAGB placement [78-82]. 
These complications, together with the patient’s lifestyle, will in many cases result 
in the most common problem with the LAGB: weight regain [78-80]. As a result, a 
large number of re-operations are required. After ten years, up to half the patients 
have undergone a reoperation and up to 2/3 of LAGB’s can be classified as failures 
[40].  
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 A leak from the gastro-jejunal anastomosis is the most feared complication 
immediately postoperatively after a RYGB, but for all patients undergoing bariatric 
surgery lung embolisms seem to be the leading cause of mortality [70,74,83,84].  
Dumping syndrome is seen in almost half the patients, but in most cases this is 
easily treated by avoiding certain food products [50]. The long-term complications 
of RYGB are stenosis of the gastro-jejunum anastomosis, marginal ulcers and 
internal herniation [15]. The number of re-operations required after RYGB is not 
exactly known, but relatively small [85]. Perhaps most important is the 30 days 
mortality, which varies between 0.1% in larger and 4.6% in smaller series [86]. 
 Perhaps the complication affecting the most of patients is micronutrient 
deficiencies. In this thesis a number of articles are presented describing the extent 
of deficiencies and possible solutions to this stubborn problem [87-90]. The 
literature suggests that bariatric surgery patients are at risk for deficiencies in the 
following nutrients after surgery: vitamins B12, B1, C, folate, A, D, and K, along 
with the trace minerals iron, selenium, zinc, and copper. But it is not known what 
the long term results are on vitamin deficiencies. These deficiencies might lead to 
anaemia, hair loss, genetic deformities in children of patients, and many more 
problems [87-96]. In general, it can be assumed that the more extensive the 
operation the greater the number of deficiencies. Adequate supplementation and 
screening for deficiencies is highly recommended [87-90]. 
 
The benefits of bariatric surgery appear to be evident, and many patients 
profit from them. However, it is possible that in the long term new complications 
will be diagnosed. Overall, bariatric surgery remains a radical and final treatment 
for morbid obesity and the pros and cons should be properly weighed for each 
patient.  
 
 
28 
 
This thesis addresses several questions pertinent to the topic of surgical 
treatment of morbid obesity. Several centres in The Netherlands have collected 
large surgical series; the Rijnstate Ziekenhuis in Arnhem is one of these centres. 
This thesis describes its short and long term experience and also shows data 
collected together with other centres in The Netherlands, a testament to the firm 
trend in the direction of centralizing this huge healthcare problem.  
  
The studies focus on: 
- Complications of surgical treatment;  
- The effect of surgery on body weight in the long and short term 
in order to identify ways to further improve surgical treatment. 
These first two parts include surgeries that have been conducted 
throughout the past decades in their accounts; 
- The effect of surgery on vitamin and mineral levels  in order to 
gain more insight into the secondary comorbidity caused by 
surgical treatment as such. These studies have been conducted 
to further improve treatment and to guide patients through their 
long periods of follow-up after bariatric surgery. 
 
For the sake of clarity of presentation of the data collected, the thesis has 
been subdivided into three parts described in Chapters 2 (effects of Surgery), 3 
(vitamins & minerals) and 4 (comorbidity as a result of morbid obesity and 
surgery). 
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Outline  
 
Bariatric surgery has acquired a permanent place in the treatment of 
morbid obesity in recent years. Thanks to good results in the short term, not only 
surgeons but also patients became increasingly enthusiastic about bariatric surgery. 
Unfortunately, in the beginning little research on the outcome and consequences 
was performed. When the first long-term results of some bariatric surgeries were 
published, they were not favourable. The explosive growth in the number of 
operations in recent years has fortunately attracted the interest of many researchers. 
Thanks to structural research at both the national and international level, a huge 
catch-up in knowledge regarding bariatric surgery is being made. 
 
  With this thesis we describe the results obtained in a dedicated centre and 
have tried to give more insight into the medium and long term results of bariatric 
surgery. We have focussed not only on the results in terms of weight loss, but also 
on different techniques, reoperations, mineral deficiencies, and co-morbidities. 
 
Chapter 2 describes the results of two studies performed to gain more 
insight into the long term outcomes of the gastric band (2.1) and the short term 
outcomes of one of the latest generation of gastric bands (2.2). Not only are the 
primary results are presented but also the consequences and outcomes of gastric 
band removal (2.4/2.5) or replacement by a Gastric Bypass (2.3) after failed gastric 
banding. Chapter 2.6 describes a port-fixation method that resulted in a significant 
reduction in port-related complications. 
 
 Chapter 3 further elaborates on one of the most common complications 
after bariatric surgery, vitamin and mineral deficiencies. Not only was pre-and 
postoperative anaemia researched (3.1), but also deficiencies after gastric sleeve 
 
38 
 
(3.2/3.3), vitamin D (3.4) and calcium deficiencies (3.5). Finally, an optimized 
multivitamin supplement was developed based on these data and researched in a 
double blind randomized controlled trial (3.6).  
 
 Chapter 4 provides more insights into the effects of bariatric surgery on 
co-morbidities. The results for hypogonadal hypogonadism after bariatric surgery 
are described (4.1). Chapter 4.2 shows why the determination of C-peptide prior to 
bariatric surgery in type 2 diabetes may be important. In the last chapter (4.3), the 
pre-and postoperative outcomes after surgery for hepatic steatosis are presented. 
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Abstract          
 
Background 
For over a decade, the Laparoscopic Adjustable Gastric Band (LA GB) was one of the most 
performed bariatric procedures in Europe. Th is study is a retrospective analysis with 
prospectively collected data of the experience in one specialized Dutch centre with the 
Adjustable Gastric Band over 14 years.  
 
Setting  
General Hospital specialized in Bariatric Surgery, The Netherlands Europe.  
 
Patients and methods  
Between 1995 and 2003, 201 patients underwent a LAGB for morbid obesity in our 
hospital. Data on preoperative clinical characteristic, postoperative outcome and weight -
loss patterns and co-morb idities for up to 18 years are presented and evaluated using the 
Bariatric Analysis and Reporting Outcome System (BA ROS).  
 
Results 
Average follow-up was 13.6 (±2.0) years (163 months) and 99% of patients with complete 
follow-up. Two-thirds of patients reached an Excess Weight Loss (EWL) >50% at some 
point after LA GB p lacement. However, due to insufficient weight loss or complicat ions in 
53% of patients, the LAGB had to be removed or converted to a Roux-en-Y Gastric 
Bypass. Additionally, half the remaining patients had disappointing results  according to the 
BAROS score. In total, less than one quarter (22%) of patients had a functioning band with 
a good result after the follow-up period. Although initially the number of patients 
experiencing co-morbid ities was reduced, most of them returned and a large number of 
patients developed new co-morbidit ies. Complications, other than weight regain, were 
numerous as 47% of patients experienced at least one. In total 204 re-operations were 
performed in 137 (68%) patients. Furthermore, patients who were lost to follow-up did 
almost twice as bad in terms of EW L compared to patients who had regular follow-up.   
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Conclusion 
Morbid obesity is a chronic disease that can be resolved with bariatric surgery. One of the 
treatment options is the LA GB, which in the short term shows good results in terms of 
EW L and co-morb idity reduction. In the long term, however, EWL and co -morbidity 
reduction are disappointing and the LA GB does not seem to live up to expectations. 
Besides the decrease in EW L over time, the number of reoperations required is alarming. In 
total, less than a quarter of patients still had a functioning band after a mean 14 years of 
follow-up. 
           
 
Introduction 
 
Morbid obesity presents a challenging and important health problem 
worldwide, because it is associated with an increase in co-morbidities and 
diminished life expectancy [1,2]. Conservative treatment is the obvious first 
treatment for obesity, but often proves to have little or no long-term effect. To date, 
surgical intervention, although rather radical, offers the best chance to reach 
considerable weight loss without an immediate rebound effect [3,4]. Besides the 
social advantages of weight loss, there is the prospect of resolution of co-
morbidities and an increased life expectancy. For the latter, sustained weight loss is 
indispensable [1-4].  
It is still unclear which bariatric procedure has to the best outcomes in 
terms of weight loss and resolution of comorbidities in the long term [1,5,6]. The 
Laparoscopic Adjustable Gastric Band (LAGB) is a less radical procedure 
compared to the Roux-Y gastric Bypass or Duodenal Switch and was especially in 
the past chosen for the treatment of less extreme morbid obesity (BMI 35-50) [2-4]. 
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Abstract 
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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Following the introduction of the adjustable gastric band in 1985, it soon 
acquired popularity among patients and surgeons, which led, together with the 
rising prevalence of morbid obesity, to a yearly increase in the number of band 
implantations [7,8]. The LAGB can be implanted with low morbidity and mortality. 
On average, good Excess Weight Loss (EWL) is achieved as well as a decrease in 
co-morbidities in the short term [1,5].  
There is relatively long-term experience in Europe with the LAGB. 
Nevertheless, long-term follow-up studies (3-10 years) are scarce and often only 
BMI, EWL, complications and re-operations are reported. Many study outcomes 
are in favour of the LAGB [9-14], but a large number of studies have found an 
increasing number of complications and weight regain as time since LAGB implant 
progresses [15-23]. A problem in bariatric surgery in general is the number of 
patients lost to follow-up. In most studies, a large number of patients are not 
retrieved and reported data is thus incomplete [9, 20,21,24,25]. Studies that do 
report sufficient follow-up are small [26]. Patients lost to follow-up might be of 
special importance, since a number of studies report these patients to have the 
worst results [13,27].  
There is little doubt about the effectiveness of the LAGB in the short term, 
but evidence of long-term efficacy is scarce [19,28-30]. Most reports come from a 
small number of centres [14]. With still a large number of LAGBs placed in the 
United States yearly, a long-term study seems long overdue [8,19]. This study 
describes the long-term results of the LAGB, with a mean follow-up of 14 years 
and a near-complete data set of patients. 
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Patients and Methods  
 
All consecutive LAGB procedures between 1995 and 2003 were studied. 
Patients with a Body Mass Index (BMI) of >40kg/m2, or >35kg/m2 with a co-
morbidity related to the morbid obesity, were offered a gastric band. All patients 
were screened preoperatively by a multidisciplinary team, consisting of a surgeon, 
physician/endocrinologist, psychiatrist and a clinical nutritionist. All patients met 
the criteria stated by the NIH Consensus Development Conference Panel for 
bariatric surgery [31]. The ethical board of The Rijnstate Hospital gave their 
consent for conducting this study. 
All procedures were performed by one dedicated bariatric surgeon, who 
had already performed 25 perigastrically placed LAGB procedures. From 1995 to 
1998, patients received a Swedish Adjustable Gastric Band using the perigastric 
technique [32]. From 1998 to 2003 the Lapband ® (Inamed) was placed using the 
pars-flaccid technique [33]. Weight, operative data, number and date of follow-up 
visits, complications, co-morbidities and medication use were recorded. All 
patients were followed up six times during the first 2 years and once each year after 
that. Bands were adjusted when weight loss or lack of food restriction called for it. 
Most patients were well motivated to come in for their follow-up visits during the 
initial years after surgery and follow-up was nearly complete for the first 5 years. 
As the years after surgery passed, it was harder for patients to motivate themselves 
to come in for the required control visits. A lot of effort was put into motivating 
these patients. They were instructed to come in when they regained weight or when 
they had abdominal complaints. Patients were reminded of their appointments with 
letters and telephone calls to strive for the lowest drop-out rate. When this 
approach appeared insufficient, the patient’s general practitioner was asked to visit 
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the patient for referral to the hospital for follow-up. Despite all these efforts, a 
distinct number of patients were lost to follow-up. 
For the purpose of this long-term effect study, patients were traced through 
various ways after a mean of 10 years. With the help of the patients' general 
practitioners, governmental databases and the internet, all patients were vigorously 
sought. All contacted patients agreed to come in for an extra control visit. For 
some, it had been years since they last visited our clinic. After these study visits, all 
patients were again followed in time by the regular follow-up team and again seen 
for study purposes after a mean 14 years. The number of bariatric clinics in the 
Netherlands is limited, so all but two re-operations for complications or insufficient 
weight loss were also performed in our clinic. Re-operation was considered when 
patients suffered from severe complications or in many instances had regained at 
least 25% of EWL and (again) met the criteria stated by the NIH [31]. Also, in case 
of weight regain, patients underwent additional follow up for at least a year by our 
specialized bariatric team in order to get them back on track. Patients who were 
eventually re-operated or received additional surgery for the treatment of morbid 
obesity were again followed in time. For the next 5 years, patients were motivated 
to come in every year for a control visit .  
All patients were evaluated at the extra control visits using the Bariatric 
Analysis and Reporting Outcome Scale (BAROS) on two occasions, after a mean 
10 and 14 years [34]. The frequently used BAROS score has the advantage over 
other Quality of Life (QOL) questionnaires in that it also takes into account weight 
loss, complications and re-operations. It also takes into account important issues 
for this patient group including mental state, physical activity, social contact, work, 
sexual functioning and approach to food. In total, a patient can score negative to a 
maximum of 9 points, leading to an outcome in one of the five groups; ‘failure’, 
‘fair’, ‘good’, very good’ or ‘excellent’. In this study, success was defined 
relatively low with an EWL>25% or a BAROS score of ‘fair’ or higher. 
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Statistics 
Data was analysed using SPSS20® for Windows and graphs were designed 
using GraphPad Prism®. All data are reported as mean ± 1 standard deviation 
unless otherwise specified. P<0.05 was considered significant.  
 
Results 
 
From 1995 till 2003, 201 LAGB procedures were performed for the 
treatment of morbid obesity in the Department of Bariatric Surgery of the Rijnstate 
Hospital, the Netherlands. Forty-seven (23%) males and 154 (77%) females were 
operated with a mean age of 37 (21-58) years and a mean BMI of 45.6 (±6.2). 
Demographic results are shown in Table 1. 
 
Table 1. Baseline demographics  
 
Parameter Value   (±SD)          (Range) 
Male/Female 47/154 (23%/77%) 
Age 37                           (21-58) 
Mean weight 135.4    (±23.8)      (94-230) 
Mean BMI 45.6      (±6.2)        (36.0-77.1) 
Mean % Excess weight 82.6      (±29.0)      (44.0-208.5) 
 
SD: Standard Deviation 
BMI: Body Mass Index 
 
 The first 41 patients received a Swedish Adjustable Gastric Band using the 
perigastric technique. The remaining 160 patients received a Lapband ® (Inamed) 
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using the pars flaccid technique. Outcomes for EWL, BAROS scores and number 
of re-operations and complications were almost identical in both groups and no 
significant differences were found during follow-up.  
Mean Follow-Up (FU) was 164 months (120-216). Only 2 patients (1%) 
were lost to follow-up, both after 18 months. In the follow-up period, there was no 
mortality related to the LAGB procedure. Six patients died during follow-up. Two 
patients died as a consequence of breast cancer after 15 and 54 months 
respectively. One patient died from small-cell lung carcinoma after 22 months. One 
patient committed suicide after 80 months and 1 patient died in her sleep after 92 
months possibly as a result of severe obstructive sleep apnea syndrome. The last 
patient died after a long ICU admission of sepsis of unknown origin after 155 
months. These patients were excluded from the analysis from the point they passed 
away. 
 
Excess Weight loss and BMI 
Mean EWL in patients with the band still in place was 49% after 5 years, 
41% after 10 years and 21% after 15 years. Mean EWL was over 50% after the 
second year, but then slowly dropped to 40% and 38% after 10 and 14 years 
(Figure 1). Patients converted to a Roux-en-Y Gastric Bypass (RYGB) seem to do 
a bit better with 47% EWL after 14 years. These results are somewhat flattered 
because many patients only recently got their RYGB and did not have the chance 
to achieve maximum weight loss. In total, 134 patients (67%) reached an EWL 
>50% at some point during follow-up, but only a few managed to maintain their 
early success. EWL >50% was almost 50% after 2 years, but had dropped to 48% 
and 28%  (p<0.001) after 5 and 10 years of follow-up respectively. Mean BMI was 
never below 35 kg/m2. Simultaneously, the percentage of patients with failing 
bands, insufficient weight loss and removed bands gradually rose.  
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Figure 1. %EWL in patients with LAGB in situ or converted to RYGB 
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leakage (17%), and band migration (6%) were among the most frequently 
diagnosed complications. All complications are shown in Table 2. 
 
Table 2. Complications in fourteen years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N: Number of patients 
PAC: Port a Cath 
 
Two hundred and four re-operations were performed in 133 patients (67%). 
The most performed re-operations were conversions to other bariatric procedures 
(29%) mainly because of weight (re)gain. Other frequent reoperations were: 
correction of the port or a leaking tube (18%) and band removal (12%) or 
 N (% patients) 
Technical complications  
    Leakage PAC 18 (9%) 
    Leakage tube 15 (8%) 
    Leakage band 9   (5%) 
    Lose PAC 5   (3%) 
Patient related  
    Pouch 27 (14%) 
    Slippage 16 (8%) 
    Severe reflux 10 (5%) 
    Severe esophageal dilatation 7   (4%) 
    Band migration 12 (6%) 
    Infection band 6   (3%) 
    Infected PAC 1   (1%) 
Total 126 in 94 patients (47%) 
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repositioning (10%) for pouch dilatation or slippage. Results on re-operations and 
band removal are shown in Table 3 and Figure 2.  
 
Table 3. Minor and major reoperations  
 N (%patients) 
Port/tube change 37 (18%) 
Band change 13 (6%) 
Repositioning band 20 (10%) 
Conversion to RYGB 90 (44%) 
Conversion to Gastric Sleeve 4   (2%) 
Conversion to Scopinaro 4   (2%) 
Band removal alone 25 (12%) 
Port removal 1   (0.5%) 
Total N of reoperations 204 
N of patients with reoperation(s) 133 (67%) 
N: number 
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Complications, other than weight regain, were numerous as 50% of 
patients experienced at least one. Pouch dilatation or slippage (22%), port or tube 
leakage (17%), and band migration (6%) were among the most frequently 
diagnosed co plications. All co plications are shown in Table 2. 
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 N ( patients) 
Por /tube change 37 (18%) 
Band change 13 (6%) 
Repositioning band 20 (10%) 
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Figure 2. % Of reoperations and band removals  
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removed (15) or converted to a different bariatric procedure (90). Of the 88 patients 
(46%) who still had their band in place, 45 (51%) had a low BAROS score (fail) 
and can as such be considered failures. In other words, only 43 patients (23%) still 
had a functional band and 150 patients (73%) had failing bands 14 years after band 
placement. BAROS scores are shown in Table 4.
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Figure 2. % Of reoperations and band removals 
 
 
 
Of the 193 patients evaluable after 14 years, 105 (54%) had their band 
removed (15) or converted to a different bariatric procedure (90). Of the 88 patients 
(46%) who still had their band in place, 45 (51%) had a low BAROS score (fail) 
and can as such be considered failures. In other words, only 43 patients (23%) still 
had a functional band and 150 patients (73%) had failing bands 14 years after band 
placement. BAROS scores are shown in Table 4. 
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Also investigated was whether regular follow-up influenced the outcome in 
patients with their band in place (N=121 after 10 and 88 after 14 years). An 
arbitrary line was chosen at more or less than 2 years since the last follow-up visit, 
so the two groups were divided almost equally (62/59 and 43/45 respectively). 
According to the BAROS score, there was band failure in 15 patients (35%) that 
had their last follow-up less than 2 years ago compared to 30 patients (67%) with 
their last follow-up over 2 years ago (p<0.01) after 14 years.  
 
Co-morbidities 
Before LAGB placement, 21 patients suffered from type 2 diabetes 
mellitus (T2DM). After 2 years, of these only 7 patients used the same amount or 
more of their T2DM medication, growing to 8 and 17 patients after 5 and 10 years 
respectively. In these same time intervals, 8, 7 and 6 patients were able to stop all 
their diabetes medication. From these last 6 patients, five had in the meantime 
underwent a RYGB. Unfortunately, after 10 years, 12 new patients developed 
T2DM. Between 10 and 14 years, an additional 5 patients underwent a RYGB, 
leading to more resolved and improved T2DM. An additional 12 T2DM patients 
underwent a RYGB in the last 4 years, leading to a decrease in T2DM. Results are 
shown in Figure 3a. 
Another important co-morbidity, hypertension (HT), showed a similar 
outcome. Starting with 45 patients requiring daily intake of HT medication, 20, 14 
and 10 patients could discontinue their medication after 2, 5 and 10 years 
respectively. However, 16 patients developed new HT during follow-up. Results 
are shown in Figure 3b. 
Medication used over the years was also recorded. In particular, the use of 
PPI for GastroEsophageal Reflux Disease (GERD) increased dramatically. Of the 
12 patients requiring PPIs on a daily basis, only 4 (33%) patients used them after 
 
55 
 
10 years. This is in contrast to the 55 (45%) new patients with their gastric band in 
situ using PPIs on a daily basis because of reflux disease after 10 years and 49 
(56%) patients after 14 years. Results are shown in Figure 3c. 
 
Figure 3a. Co-morbidities: T2DM 
 
 
 
T2DM: Type 2 Diabetes Mellitus 
N: Number 
 
  
0 
5 
10 
15 
20 
25 
0 2 5 10 14 
Same/Worse 
Improved T2DM 
Resolved T2DM 
New T2DM 
Years after LAGB placement 
N 
of 
pat
ien
ts 
7 
8
 
 7 
3 
 
16 
22 
7 
 
8
 
 7 7
 
 7 
7 
 5 
 
6 
12 12 
8 
14 
2 
61
Results of bariatric surgery
 
54 
 
 
Also investigated was whether regular follow-up influenced the outcome in 
patients with their band in place (N=121 after 10 and 88 after 14 years). An 
arbitrary line was chosen at more or less than 2 years since the last follow-up visit, 
so the two groups were divided almost equally (62/59 and 43/45 respectively). 
According to the BAROS score, there was band failure in 15 patients (35%) that 
had their last follow-up less than 2 years ago compared to 30 patients (67%) with 
their last follow-up over 2 years ago (p<0.01) after 14 years.  
 
Co-morbidities 
Before LAGB placement, 21 patients suffered from type 2 diabetes 
mellitus (T2DM). After 2 years, of these only 7 patients used the same amount or 
more of their T2DM medication, growing to 8 and 17 patients after 5 and 10 years 
respectively. In these same time intervals, 8, 7 and 6 patients were able to stop all 
their diabetes medication. From these last 6 patients, five had in the meantime 
underwent a RYGB. Unfortunately, after 10 years, 12 new patients developed 
T2DM. Between 10 and 14 years, an additional 5 patients underwent a RYGB, 
leading to more resolved and improved T2DM. An additional 12 T2DM patients 
underwent a RYGB in the last 4 years, leading to a decrease in T2DM. Results are 
shown in Figure 3a. 
Another important co-morbidity, hypertension (HT), showed a similar 
outcome. Starting with 45 patients requiring daily intake of HT medication, 20, 14 
and 10 patients could discontinue their medication after 2, 5 and 10 years 
respectively. However, 16 patients developed new HT during follow-up. Results 
are shown in Figure 3b. 
Medication used over the years was also recorded. In particular, the use of 
PPI for GastroEsophageal Reflux Disease (GERD) increased dramatically. Of the 
12 patients requiring PPIs on a daily basis, only 4 (33%) patients used them after 
 
55 
 
10 years. This is in contrast to the 55 (45%) new patients with their gastric band in 
situ using PPIs on a daily basis because of reflux disease after 10 years and 49 
(56%) patients after 14 years. Results are shown in Figure 3c. 
 
Figure 3a. Co-morbidities: T2DM 
 
 
 
T2DM: Type 2 Diabetes Mellitus 
N: Number 
 
  
0 
5 
10 
15 
20 
25 
0 2 5 10 14 
Same/Worse 
Improved T2DM 
Resolved T2DM 
New T2DM 
Years after LAGB placement 
N 
of 
pat
ien
ts 
7 
8
 
 7 
3 
 
16 
22 
7 
 
8
 
 7 7
 
 7 
7 
 5 
 
6 
12 12 
8 
14 
2 
N
 o
f p
at
ie
nt
s
Years after LAGB placement
	  
57	  
	  
10 years. This is in contrast o the 5  (45%) new patients with their gastric band in 
situ using P Is on a daily basis because of reflux disease after 10 years and 49 
(56%) patients after 14 years. Results are shown in Figure 3c. 
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Figure 3b. Co-morbidities: GERD 
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Figure 3b. Co-morbidities: Hypertension 
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Figure 3b. Co-morbidities: Hypert nsion 
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Figure 3b. Co-morbidities: Hypertension 
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Discussion 
 
Bariatric surgery is nowadays a widely accepted treatment for morbid 
obesity and, with the growing understanding of its working mechanisms, it even 
holds a promise for metabolic disorders in patient groups with lower rates of excess 
weight. Obesity is considered a chronic disease that often has its onset during 
childhood or adolescence. Precisely for that reason the ideal (surgical) treatment 
should be both easily administered and safe and provide a cure lasting a lifetime. 
The introduction of the laparoscopic adjustable gastric band in 1993 met the 
requirements of easy implantation and low risk but, strangely enough, only a little 
research has been performed so far into long-term effects [8, 14].  
After the initial enthusiasm, for some years now there has been a decline in 
the number of LAGB procedures in both Europe and, later, in the United States. 
There is scepticism among some bariatric surgeons about the long-term effects, 
morbidity rates and patient satisfaction. After almost 20 years of LAGB 
experience, one would expect extensive data on its long-term sequelae. However, 
long-term clinical results for laparoscopic gastric banding are still scarce. Most 
papers claiming to present long-term follow-up usually present limited data of a 
small number of patients and mean follow-up seldom exceeds 10 years [9-18, 26]. 
In order to fully understand the long-term outcome of the laparoscopic gastric 
band, it is necessary to have a sufficient follow-up time on all operated patients 
[19]. To our knowledge, this is the first study where almost all the patients were 
retrieved and with a considerable follow-up of 14 years including data on 
comorbidities.  
It is very hard to define success in bariatric surgery. Of course %EWL is an 
often-used outcome measure and a cut-off point of 25% EWL is widely accepted in 
the literature. In daily practice, however, 25% excess weight-loss is often 
synonymous with large disappointment both with patients and surgeons. In our 
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series, 36% of patients did not even meet this lowest of success criteria. When a 
threshold of 50% EWL is chosen, only 28% of patients can be named a success 
after 10 years declining to 22% after 14 years. Mean EWL in this study was also 
disappointing at 48%, 39% and 37% after 5, 10 and 14 years respectively. Taking 
into account only the patients with the band in place, this meant that 45 of the 88 
(49%) patients with the band still in place should be considered successful. 
It is often suggested that the retrogastric or pars flaccid technique would 
have better results in terms of less slippage than the perigastric technique. In the 
short term, this was also the case in this series, especially for the number of re-
operations due to slippage. The mean follow-up of the bands placed using the pars 
flaccid technique was 13 years and resulted in 108 patients (67%) requiring a re-
operation. In the group in which the perigastric technique was used, 25 patients 
(61%) were re-operated after a mean 9 years and this percentage remained the 
same after a mean of 16 years. Also, no significant difference in minor or major re-
operations and complications were found after a mean 14 years of follow-up. 
BAROS and EWL scores were also compared and were almost identical. In 
conclusion, no statistically significant differences or trends were found between the 
two operative techniques in the long term. 
 As bariatric surgery probably has more to do with improving QOL than 
with weight loss as a single parameter, a QOL score could provide a better insight 
into the long-term success than %EWL. At the onset of bariatric surgery, patients 
as well as doctors aim for excellent results even in the long term. Confronted with 
failure or even fair outcome on a quality of life scale, it is in most cases not what 
they have bargained for. In that respect, the finding that after 10 and 14 years, only 
30% of patients with the band in situ qualifies their life as ‘good’ is staggering.  
Reduction of co-morbidities is even more relevant for these patients as it 
influences quality of life and life expectancy [1,2]. In this study, the number of 
patients suffering from T2DM decreased significantly during the first years, but 
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after 14 years only 8 (38%) patients were without T2DM medication and had 
HbA1c levels under 6.5%. After 10 and 14 years, the total number of patients with 
T2DM was higher than at the start, mostly due to newly developed disease in other 
patients. Additionally, of the 8 patients with resolved T2DM, seven had undergone 
a RYGB in the meantime. This of course has grave consequences for patients, but 
also has health economic implications. Many health insurances have embarked on 
bariatric surgery hoping to save money in the long run through resolution of 
comorbidities. It is questionable if this promise holds for the LAGB. The results for 
HT showed a similar outcome. Of the 45 patients with HT, only nine were able to 
discontinue all, and 16 to reduce HT medication. However, many patients 
developed HT de novo, adding up to a total of 60 (30%) patients with HT after 10 
years. GERD is a common finding especially after a number of years following 
LAGB placement. The 53% of patients suffering from GERD in this study is 
relatively high. This can probably be explained by the long follow-up. Although all 
these results are unsatisfying, what should be kept in mind is that it is unknown 
what would have happened if the bariatric surgery had not been performed. 
The number of re-operations needed was very high with 204 procedures in 
133 patients. Most re-operations were performed for reasons of weight regain 
despite intensive follow-up by the bariatrics team and efforts and ‘back on track 
‘programs. These patients were most often converted to a different bariatric 
procedure or to band removal alone. Disconnection of the tubing from the port was 
frequently seen, but also leakage of the tubing at its passing through the 
musculofascial plane, probably due to shear and tear, was often observed. Also, the 
port often turned, probably because of insufficient suturing leading to 
inaccessibility. Although material fatigue and band system failure can be attributed 
to the earlier models of gastric band, our own recent evaluation of the latest 
generation of gastric band suggests that port and tubing failure has not improved 
much. The incidence of 6% band migrations was within the range of earlier 
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reported data [3,9,11,28]. The first three cases appeared between 2 and 3 years 
after placement, six cases between 6 and 10 years, and the remaining three after 10 
years. We expect this number to rise gradually in time. 
The complication rate increased in a linear line over the years. The overall 
complications, excluding weight regain, occurring in 47% of patients is much 
higher than described in the literature [3,17]. This is probably explained by the fact 
that follow-up was longer and over half the complications occurred in the last 5 
years. Furthermore, especially the patients that dropped out of their regular follow-
up scheme appear to perform worse in terms of complications and band failure 
compared to patients that have had regular follow-up. Even with the follow-up 
described earlier and over 87% of visits completed in the first 5 years, patients do 
seem to fail in sustaining their achieved weight loss. In the second 5 years, this 
follow-up rate dropped to 59%. After 10 years, all patients were seen again for this 
study and, including the last visits, again the percentage of yearly follow-up visits 
climbed to over 74%. Although most patients were retrieved in the end, almost half 
the patients were lost to follow-up for more than 2 years at some point. The 
outcomes of the BAROS score revealed that the group of patients who were lost to 
follow-up for >2 years had significantly worse outcomes with almost a doubled 
percentage of failed bands and a lowered EWL of 14%. This outcome is consistent 
with earlier reports [27]. To decrease the number of failures and to intervene in an 
earlier stage, structural follow-up is necessary [35-37]. Patients that failed to show 
up for control visits offered two excuses for their absence: embarrassment for their 
weight regain and secondly the fear of a revisional surgery. With these findings, 
one may fear the worst for countries where a large distance to the hospital may add 
to the large number of patients lost to follow-up. 
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Conclusion 
 
Morbid obesity is a chronic disease that can be resolved with bariatric 
surgery. One of the treatment options is the LAGB, which, in the short term, shows 
good results in terms of EWL and co-morbidity reduction. In the long term, 
however, EWL and co-morbidity reduction are disappointing and the LAGB seems 
not to live up to expectations. Beside the decrease in EWL over time, the number 
of reoperations is alarming. In total, less than a quarter of patients still had a 
satisfactory functioning band after a mean of 14 years' follow-up. 
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Abstract          
  
Background 
Bariatric surgery is currently the most effect ive treatment for morbid obesity. The main 
advantage of Laparoscopic Adjustable Gastric Banding (LA GB) compared to other 
bariatric procedures is the significant short-term weight loss with low morbid ity and 
mortality. LA GB p lacement started in our facility in 1995, and over 2500 bands have been 
placed to date. Since 2007 the latest generation of bands, the SAGB VC™ is used for this 
procedure. The aim of this study was to evaluate the results and efficiency of the SAGB 
VC™. The courses of weight loss, medication use, re-do surgery, co-morbid ities, pre- and 
postoperative complicat ions, and co-morbid ities will be presented. 
 
Methods 
Between August 2007 and January 2009, 622 patients (82% women and 18% men) 
received a SA GB-VC™ for the treatment of morb id obesity in our hospital. These patients 
were fo llowed up for at least eighteen months. All data (demographic, morphologic, and 
operative follow-up) were prospectively collected in a computerized data base. Every 
patient was enrolled in a post-operative life-style training program that included dietary 
advice, physiotherapy, and behavioural train ing. 
 
Results 
Complete fo llow-up data were available fo r 601 (97%) patients; 21 (3%) patients were lost 
to follow-up. Min imum follow-up was 18 months, mean follow-up 23 months. Mean 
Excess Weight Loss (EWL) was 35% after twelve months, 40% after 24 months, and 41 % 
after 36 months. Initial mean BMI was 44.0 kg/m²;  after twelve months 37.8 kg/m²; after 
24 months 36.0 kg/m²;  and after 36 months 36.5 kg/m². A total of 366 complications 
occurred, of which 57 (16%) needed surgical intervention. Most common complications 
were vomiting 126 (34%), access port pain 46 (13%), and reflux 41 (11%). No mortality 
occurred within the first year postoperative.     
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Conclusion 
The SA GB VC™ band results in an acceptable mean EW L of 41.3%, significant 
improvement in co-morb idit ies, and a low number of technical failures after two years.  
Although 60% of patients reported being satisfied with the procedure, only 30% achieved a 
“Good to Excellent” BAROS Score at their most recent follow-up visit. Perhaps most 
striking is the 10% of patients that underwent a surgical re-intervention, which its rather 
high in the short term. 
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The number of patients with obesity is rapidly increasing in United States 
and Europe, and is associated with an elevated risk for obesity-related co-
morbidities: diabetes, hypertension, hypercholesterolemia, heart disease, 
osteoarthritis, obstructive sleep apnoea, and many more [1-3]. Dietary treatment 
often produces an initial weight reduction of less than 15% and weight reduction 
generally decays to zero within 5 years [4]. 
Bariatric surgery has proven its effectiveness in achieving and maintaining 
weight loss and improving obesity-related co-morbidities, quality of life, and 
survival [5,6]. Short term results of the earlier Adjustable Gastric Band (AGB) 
versions have been well documented. Results most often favour AGB, although 
some studies find long-term complications and weight regain after a few years 
[7,8]. Since the introduction of the AGB in 1985 different types of the gastric band 
have been designed, but there is still room for innovation. The ultimate gastric 
band will guarantee an acceptable excess weight loss while causing fewer 
complications and providing high patient satisfaction.  A combination of ingenious 
design, durable materials, high-volume and low-pressure balloons will ensure long 
term tolerance and functionality. Ethicon Endo-Surgery has designed the new 
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Abstract          
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
stu y the utcomes of one stage AGB conversions to a Roux-en-Y Gastric B pass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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generation gastric band called SAGB-VCTM which they claim meets all criteria 
mentioned above.  In this study we describe our experiences with the SAGB-VCTM.  
 
Patients and Methods  
 
From August 2007 to January 2009, 622 LAGBs were placed at the 
Department of Bariatric Surgery of the Rijnstate Hospital. 511 (82.2%) women and 
111 (17.8%) men were operated. Mean age was 40 years and mean Body Mass 
Index (BMI) was 44 kg/m2 (Table 1). All patients received the SAGB VC™ 
(Ethicon Endo-Surgery/ a Johnson & Johnson company, New Brunswick, United 
States). All bands were placed by two experienced surgeons (> 1000 bariatric 
procedures each) using the pars flaccida technique. All data were prospectively 
entered into a computerized database. During follow-up the following data were 
analyzed: course of weight loss, postoperative complications, course of co-
morbidities (Type 2 diabetes mellitus, hypertension, sleep apnea syndrome, 
osteoarthritis, and dyslipidaemia), course of medication, and postoperative BAROS 
score. 
 
Table 1. Preoperative demographic data 
Parameter  Values  (±SD)       (Range) 
Female/male  511/111 (82.2%/17.8%) 
Age (years) 40         (± 9.6)       (18-64)  
Weight (Kg) 127.7    (±17.8)      (83.2-208.0) 
BMI  (Kg/m²) 43.9      (±4.8)        (32-60) 
Excess weight  55         (±14.3)      (26.4-112.0) 
Values are Mean (± Standard Deviation) (Range).  
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Patient’s selection and follow-up 
 
All patients were evaluated preoperatively by a multidisciplinary team 
consisting of a surgeon, a psychiatrist, and a nutritionist. The criteria for the 
bariatric surgery were: age ≥18 years, BMI ≥40 or ≥35 with significant co-
morbidities and no acute psychiatric illness or eating disorder. Patients were 
informed extensively during multiple information sessions about the life style 
changes needed and the expected post-operative outcomes in terms of weight loss. 
Patients were informed that when they followed all advised changes to expect a 
mean 40% Excess Weight Loss (EWL), which was calculated and showed to each 
individual patient. Preoperative demographic data are shown in Table 1. Post-
operative all patients followed a life-style training program that included dietary 
advice, physiotherapy, and behavioural training every three weeks during the first 
year, every six weeks during second year and every three months during the third  
year . Then patients came in for at least one visit per six months. Patients were 
repeatedly informed to stick to the suggested lifestyle program and motivated to 
make lifestyle changes.  
When a patient was unable to lose the expected amount of weight, showed 
weight regain or had other complaints or complications patients were offered a 
‘back on track program’. In this program the care for the patient is intensified with 
the help from the specialist(s) most suited for the problem.  
 
Band Adjustments 
During surgery no filling of the band was performed. All patients were 
instructed to consume  liquids only during the first 4 weeks after surgery.  The first 
adjustment was performed 8 weeks after surgery with 2cc liquid of NaCl. Only in 
patients with hunger sensations or insufficient weight loss the injected volume was 
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increased by a standard schedule of 2cc the first two adjustments and the with 
0.5cc and a maximum total of 11cc. Barium swallow tests and simultaneous band 
adjustments were performed when this standard schedule did not result in a 
satisfactory situation after 3 adjustments.  
 
BAROS Score 
Change in excess weight, obesity-related co-morbidities and Quality of 
Life (QoL) were also assessed by the Bariatric Analysis and Reporting Outcome 
System (BAROS) [9]. To quantify changes in QoL after surgery, the BAROS 
questionnaire evaluates five variables: self-esteem, physical condition, social life, 
working ability, and sexual activity. The system defines five outcome possibilities: 
failure, fair, good, very good, and excellent. All patients filled out a BAROS 
questionnaire during their last control visit at the hospital.  
 
Operative Technique   
Patients were placed in reverse Trendelenburg position in stirrups. 
Antibiotic prophylaxis (Cefazoline 2 grams) was administered during induction. 
Pneumoperitoneum was established with a Veress-type needle introduced at the left 
subcostal margin and was maintained at 14–18 mmHg. A five-trocar technique was 
used. When a patient was diagnosed prior or during surgery with a hiatal hernia 
between 2 and 3 cm, it was corrected by over sewing the hernia prior to the Gastric 
Band placement. The pars flaccida technique was utilized in all cases [10]. 
Following opening of the left phrenoesophageal and gastrohepatic ligaments, blunt 
dissection was performed to create a passage between the diaphragmatic pillars and 
the posterior aspect of the gastro-esophageal junction. The band was examined for 
leakage. The empty band was then inserted through a 15-mm trocar and pulled 
gently through the retrogastric tunnel. In all cases five gastrogastric sutures were 
used to secure the device. The catheter was then exteriorized through the 15-mm 
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trocar opening and connected to the fluid reservoir, which was implanted on the 
left pectoralis major fascia, just above the inframammillary line [11]. Patients were 
permitted to start a semi-liquid diet immediately and were discharged on the first 
postoperative day. 
 
Statistical Analysis  
Data were analysed using SPSS 16.0. All data are expressed as mean ± 1 
standard deviation. P<0.05 was considered significant.  All statistical analyses were 
performed using Intention to treat analyses, unless otherwise specified. The 
graphics have been drawn using Graphpad Prism 5.02 (Graphpad Software, Inc.) 
 
Results 
 
Preoperatively, patients (n= 622) had a mean age 40 ± 9.5 (18-64) years 
with a mean weight of 127.7 ± 17.8 kg and a mean BMI of   43.9 ±4.8 kg/m². Mean 
operating time was 38.4 minutes and mean hospitalization time was 26.3 hours. 
Peroperative a hiatal hernia was corrected in 5 patients. Complete follow-up data 
were available for 601 patients (96.6%). Twenty-one patients (3.4%) were lost to 
follow-up. The follow-up rates at each postoperative time points are 100% (6 
months), 100% (12 months), 100% (18 months), 84.5% (24 months) and 45.6% 
(36months). Three years after surgery, 7.7% of the patients experienced an 
EWL>75%; 2.3% had EWL 50-75%; 42% had EWL 25-50%; and 23, 3% an EWL 
of0-25%.  3.3% of patients experienced weight gain (Figure 1). 
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Figure 1. Distribution of Excess Weight Loss after mean 23 months  
 
 
The  mean EWL at  6, 12, 18, 24 and 36 months after SAGB-VC was  
21.0±13.4, 34.4 ±17.7, 39,4±19.8, 39,5±20.7, 41.3±22.6 % respectively (Figure 2). 
Excluding patients who underwent a RYGB resulted in a lower EWL at 24 and 36 
months by only 0.1%. In these same time intervals the initial BMI of 44±4.8 kg/m² 
dropped to 40.1±4.8, 37.6±4.9, 36.6±5, 36.7±5.1 and 36.6±5.6 kg/m² (Figure 3). 
Mean weight loss was 127.7±17.8, 116.3±17.2, 109, 1±17.3, 106.5±17, 106.7±17.7 
and 105.5±18.1 (Figure 4). Out of the 601 patients 31% had a EWL between 50-
75. However, 26% failed to reach 25% EWL.  
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Figure 2. Mean EWL at different time intervals  
 
 
 
Figure 3. Mean BMI at different time intervals  
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Figure 4.  Mean weight at different time intervals  
 
 
 
 
Table 3. Follow-up 
Time (months) EWL (%) BMI (kg/m2) Weight (kg) 
6 21.0 ±13% 40.1 ± 5 127.7 ± 17 
12 34.4 ± 18% 37.6 ± 5 116.3 ± 17 
18 39.4 ± 20% 36.6 ± 5 109.1 ± 17 
24 39.5 ± 21% 36.7 ± 5 106.5 ± 18 
36 41.3 ± 22% 36.6 ± 6 105.5 ± 18 
Values are mean ± Standard Deviation. N=601, mean 23 months 
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Outcome of Co-morbidities 
 
Table 4 shows the outcome of co-morbidities in patients. Almost 50% of 
co-morbidities related to morbid obesity significantly improved or went into 
remission. 
 
Table 4. Outcome of co-morbidities 
Values are mean ± Standard Deviation. N=601, mean 23 months 
 
Complications  
 
During follow-up a total of 366 complications occurred of which 57 
needed surgical interventions. The most common complications were vomiting 
(34%), access port pain (13%) and reflux (heartburn) (11%). Major complications 
such as band migration, slippage, and pouch dilatation occurred in 5(1.4%), 2 
(0.6%), and 16 (5%) patients respectively. Due to the large amount of weight loss 
six patients developed gallstones with clinical symptoms requiring 
cholecystectomy. 
  
Co-morbidities  
DM2 
(n = 97) 
Hypertension 
 (n = 149) 
Osteoarthritis   
(n =  203) 
Remission 25 (26%) 20 (13%) 41 (20%) 
Improved 31 (32%) 41 (27%) 62 (30%) 
Unchanged 38 (39%) 80 (54%) 72 (35%) 
Worsened 3 (3%) 8 (5%) 28 (14%) 
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Table 5. Complications  
Complication  N (%) 
Band related  
Vomiting 126 (34) 
Slippage/Pouch 18 (5) 
Migration 5 (1.4) 
Aerophagy 7 (2) 
Acute obstruction 2 (0.6) 
Leakage band 1 (0.3) 
Esophageal dilatation 1 (0.3) 
Port related  
Access port pain 46 (13) 
Port infection  10 (3) 
Other   
Heartburn  41 (11) 
Weight regain 34 (9) 
Cholelytiasis 10 (3) 
Intertrigo 8 (2) 
Re-interventions 57       (16) 
Total 366     (100) 
 N=601, mean 23 months 
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Table 5. Re-interventions 
Operation N (%) 
Conversion to RYGBP 38 (67) 
Port Replacement  6           (10.4) 
Band removal 4 (7) 
Band reposition 3 (5) 
Tube reposition 2 (3.5) 
Tube Reconnection  1 (1.8) 
Band replacement 1 (1.8) 
Repositions acessport  2 (3.5) 
Total 57      (100) 
N=601, mean 23 months 
 
Evaluation  BAROS and QoL  
 
All patients filled out a BAROS questionnaire during the control visit at 
the hospital. The outcomes are shown in tables 6 and 7. 
 
Table 6. BAROS score                            
 Score N (%) 
Failure 216 (35.9) 
Fair 202 (33.6) 
Good 124 (20.6 ) 
Very good 45        (7.5) 
Excellent 15 (2.5) 
N=601, mean 23 months 
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Table 7. Satisfaction rate 
 
 
 
     
 
 
 
 
N=601, mean 23 months 
 
Figure 5. BAROS score             
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Figure 6. Satisfaction rate 
 
 
 
Food intolerance 
 
As restriction is the basis of the weight loss after LAGB, it does not come 
as a surprise that many patients have intolerance to certain food products. Table 8 
demonstrates the percentage of patients who have difficulties with different food 
products. It is evident that carbohydrates are among the worse tolerated dietary 
choices. However, in practice crackers, chips, and cookies pass relatively easy and 
are often used as alternatives to bread and rice. Approximately 2/3 of patients 
experience difficulty eating certain food types 
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Table 8. Eating difficulties  
Food N (%) 
Bread  256 (42.6%) 
Pasta 69   (11.5%) 
Rice 127 (21.1%) 
Red meat 214 (35.6%) 
Fruit/vegetable  94   (15.6%) 
Total  387 (64.4%) 
N=601, mean 23 months 
 
Discussion  
 
Although bariatric surgery dates back to the fifties, the real health benefit 
and metabolic advantages have been fully recognized only in the last two decades 
[12-15]. For years bariatric surgery has held the promise of offering persistent 
weightloss, but often with a considerable risk of morbidity and mortality [16-18]. 
For many patients and doctors the adjustable gastric band offers a reasonable 
alternative to more invasive procedures such as the gastric bypass, because it 
combines significant weightloss in the short and medium term, without the risk of 
health-threatening complications [17,19,20]. However the need for a lifelong 
restrictive diet, recurrent dysphagia, occasional vomiting, and insufficient 
weightloss resulting in a high percentage of band failure and revisional surgery in 
the long term has diminished the initial enthusiasm with the public and many 
surgeons [21-27]. At the same time some authors report consistent favourable 
results with AGB even in the long run [17,28-32]. Although the success of LAGB 
has been well demonstrated with the follow-up program that is offered to the 
patient, there have also been suggestions of differences in surgical technique and 
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choice of band [31]. From a manufacturing perspective the latest generation of 
bands holds the best chances of success. The introduction of the SAGB-VC™ 
offered the opportunity to test the validity of LAGB in the modern bariatric era. As 
no exact dataset is present to define success in bariatric surgery, we tried to 
evaluate a large number of aspects associated with gastric banding, ranging from 
relatively ‘hard’ criteria such as weightloss to more subjective criteria such as food 
intolerance.  In literature EWL is often considered significant when it exceeds 25% 
[33,34]. In the present study 89% of patients had significant weightloss according 
to this definition at some point after placement, whereas mean EWL was 41.3% for 
the whole group. A relatively large group (31%) managed to lose more than 50% 
of their excess weight (50-75% EWL), but in 26% of patients the LAGB failed all 
together. These percentages are in concordance with published 
literature[5,21,22,35,38]. Recent meta-analysis by Garb et al [38] reported a mean 
EWL of 49% after 34 months. Other meta-analyses found EWL percentages 
ranging from 47 to 58%, however many patients were lost to follow-up. It seems 
that the patients who follow the follow-up program on regular base do better than 
patients who don’t [38,39]. 
Many patients embark on bariatric surgery for divergent reasons: medical, 
social as well as cosmetic. It is hard to weigh the importance of these factors, but 
from a medical point of view remission of comorbidities and health improvement 
are important issues. One should take into account that resolution of comorbidities 
is, in most cases, highest at the point of maximum weightloss. Many patients reach 
this point within the first or second postoperative year. Thereafter the degree of 
EWL often decreases and so does the beneficial influence of weightloss on 
underlying diseases. In this study comorbidities improved somewhat in 40 - 60% 
depending on the disease. However in 35-50% LAGB failed to improve co-
morbidities. Also in this study 60% of the patients were satisfied with the results 
and many would choose the gastric band again for the treatment of their morbid 
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obesity if they had to make the decision once more. In contrast, 40% of the patients 
were disappointed with the accomplished result or even regret having the gastric 
band placed. As described in the literature the expected weight loss of patients is 
often greater than achievable weight loss [40]. It stands to reason that the failure 
rate gets higher with longer follow-up. Well known complications associated with 
LAGB, such as band migration, slippage and pouch dilatation were relatively rare 
in this series compared to published studies [7,16,21,22,32,35]. Pouch 
dilatation/slippage, band migration, esophageal dilatation and leakage respectively 
has been   found  in 5%, 1.4%, 0.3% and 0.3%. With only half the patients having 
completed three years of follow up we expect these percentages to further rise in 
time and they might even double. In literature percentages of pouch dilatation 
ranges from 3.2 to 21%, band migration 4%-21%, esophageal dilatation 3,2%- 14% 
and band or port leakage of 7,6%-12 % are described [7,21,22,35]. On the other 
hand,  re-interventions within three years, major or minor was necessary in 57 
(16%) of patients. Although this number is considerable, it is much lower than 
generally reported in the literature with 12-48% [21,22,32,35,36]. Other 
complications, among which vomiting and chronic pain are often accepted 
inconveniences that seldom lead to surgery, may still have a heavy impact on the 
quality of life and acceptance of the band in the long run. These “complaints” are 
very common after LAGB. They are hard to quantify and difficult to compare.  
Patients report vomiting on a regular basis explained this very uncomfortable 
complaint to consuming certain food products, not chewing well and drinking 
during eating.  
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Conclusion 
 
This study shows that good results in terms of EWL are achieved with the 
latest generation of gastric bands, the SAGB-VC TM. One of the key factors for the 
success of the gastric band is adequate patient selection and providing a strict 
follow-up program by a specialized team of health care professionals. In this series 
the percentage of complications and resulting re-interventions seem lower 
compared to reports on earlier versions of the LAGB. Downsides of the gastric 
band, even in the short term, are still the relative high failure rates and complaints 
related to patient dissatisfaction. Although only a small part of these band-related 
discomforts and complaints need surgical intervention, from a patient’s point of 
view these result in lowered quality of life. When asked, many patients are 
disappointed with the eventual result and would not again choose the gastric band 
again if they had the choice.  
From our standpoint we still think the gastric band has an important place 
in the treatment of morbid obesity, however for only a limited group of patients. 
Furthermore, in these times in which more efficiency of health care is required 
using the LAGB as a step up approach should not be advocated. For the future it 
remains important to find better selection criteria for patients wanting a gastric 
band. 
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in this series compared to published studies [7,16,21,22,32,35]. Pouch 
dilatation/slippage, band migration, esophageal dilatation and leakage respectively 
has been   found  in 5%, 1.4%, 0.3% and 0.3%. With only half the patients having 
completed three years of follow up we expect these percentages to further rise in 
time and they might even double. In literature percentages of pouch dilatation 
ranges from 3.2 to 21%, band migration 4%-21%, esophageal dilatation 3,2%- 14% 
and band or port leakage of 7,6%-12 % are described [7,21,22,35]. On the other 
hand,  re-interventions within three years, major or minor was necessary in 57 
(16%) of patients. Although this number is considerable, it is much lower than 
generally reported in the literature with 12-48% [21,22,32,35,36]. Other 
complications, among which vomiting and chronic pain are often accepted 
inconveniences that seldom lead to surgery, may still have a heavy impact on the 
quality of life and acceptance of the band in the long run. These “complaints” are 
very common after LAGB. They are hard to quantify and difficult to compare.  
Patients report vomiting on a regular basis explained this very uncomfortable 
complaint to consuming certain food products, not chewing well and drinking 
during eating.  
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Conclusion 
 
This study shows that good results in terms of EWL are achieved with the 
latest generation of gastric bands, the SAGB-VC TM. One of the key factors for the 
success of the gastric band is adequate patient selection and providing a strict 
follow-up program by a specialized team of health care professionals. In this series 
the percentage of complications and resulting re-interventions seem lower 
compared to reports on earlier versions of the LAGB. Downsides of the gastric 
band, even in the short term, are still the relative high failure rates and complaints 
related to patient dissatisfaction. Although only a small part of these band-related 
discomforts and complaints need surgical intervention, from a patient’s point of 
view these result in lowered quality of life. When asked, many patients are 
disappointed with the eventual result and would not again choose the gastric band 
again if they had the choice.  
From our standpoint we still think the gastric band has an important place 
in the treatment of morbid obesity, however for only a limited group of patients. 
Furthermore, in these times in which more efficiency of health care is required 
using the LAGB as a step up approach should not be advocated. For the future it 
remains important to find better selection criteria for patients wanting a gastric 
band. 
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Abstract          
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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Introduction 
 
In the past, many forms of bariatric surgery were performed for the 
treatment of morbid obesity, one of which is the laparoscopic adjustable gastric 
Band (LAGB) [1]. In most cases short terms results in terms of weight loss are 
favourable because many patients reach an excess weight loss (EWL) of 
approximately 50% [2]. LAGB has the advantage of lower perioperative morbidity 
and mortality, compared with technically more challenging procedures like the 
Roux-en-Y gastric bypass (RYGB). For this reason, LAGB surgery has been a 
popular procedure among both patients and surgeons for several years [3,4]. 
Recent literature on mid- and long-term results of LAGB reports 
conflicting results and conclusions. Some studies claim good results even in the 
long term. However, many publications demonstrate frequent band failure, weight 
regain, or inadequate weight loss. Other often reported band related complications 
are: pouch formation or slippage, heartburn, and band migration [3-9]. 
When an increasing number of patients  receiving a LAGB, this inevitably 
leads to an increase in patients with complications [10,11]. The preferred treatment 
for a large number of complications is revisional surgery, like replacing the gastric  
band or replacing it by a different bariatric procedure [3, 4, 10, 12,13]. Although 
there are numerous reports on conversions of a gastric band to a gastric sleeve or 
replacing the gastric band, most failed bands seem to be converted to a RYGB 
[4,10,12,14,15]. There is evidence  in the literature that revisional bariatric surgery 
can be hazardous compared with primary gastric bypass surgery, with often a two-
fold mortality and morbidity rate [16-18]. For that reason, many surgeons advocate 
a two-step procedure for converting a failed gastric band to a gastric bypass 
procedure, taking the band out during the first procedure and performing a gastric 
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bypass some time later.  Unfortunately, most articles only report results of small 
numbers of patients and comparative studies are almost absent [10,15,18,19].  
   In this report, our experience with revisional surgery after primary 
adjustable gastric band (AGB) placement is presented. The technical feasibility, 
safety as a one-step procedure, and medium-term effectiveness of the RYGB as a 
one-step revisional procedure after failed AGB procedures were assessed in a 
series of 195 patients.  
 
Materials and Methods 
 
Revisional bariatric surgery, replacing an AGB to a RYGB, was first 
performed in our institution in 2000. Since then, all bariatric procedures including 
revisions were recorded in a prospective database (Microsoft Access 2000) . Before 
surgery and during every control visit, information including weight loss, prior 
bariatric surgery, medication use and co-morbidities was updated. All patients 
receiving revisional bariatric surgery from January 2000 to December 2010 were 
reviewed. Table 1 shows the patient demographics and preoperative data.  
During the yearly control visits, patients with an AGB were encouraged to 
adhere to the advised daily routines and dietary intake. When patients were unable 
to achieve sufficient EWL or regained weight, they were referred to a specialized 
dietician and psychologist. Optimal restriction of the AGB was confirmed with a 
gastrografin swallow test. 
 AGB failure was defined as insufficient weight loss or weight regain 
resulting in an EWL<25%. Other complications, such as daily vomiting, severe 
heartburn, and band migration and  slippage were other reasons to replace the AGB 
for a RYGB. 
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bypass some time later.  Unfortunately, most articles only report results of small 
numbers of patients and comparative studies are almost absent [10,15,18,19].  
   In this report, our experience with revisional surgery after primary 
adjustable gastric band (AGB) placement is presented. The technical feasibility, 
safety as a one-step procedure, and medium-term effectiveness of the RYGB as a 
one-step revisional procedure after failed AGB procedures were assessed in a 
series of 195 patients.  
 
Materials and Methods 
 
Revisional bariatric surgery, replacing an AGB to a RYGB, was first 
performed in our institution in 2000. Since then, all bariatric procedures including 
revisions were recorded in a prospective database (Microsoft Access 2000) . Before 
surgery and during every control visit, information including weight loss, prior 
bariatric surgery, medication use and co-morbidities was updated. All patients 
receiving revisional bariatric surgery from January 2000 to December 2010 were 
reviewed. Table 1 shows the patient demographics and preoperative data.  
During the yearly control visits, patients with an AGB were encouraged to 
adhere to the advised daily routines and dietary intake. When patients were unable 
to achieve sufficient EWL or regained weight, they were referred to a specialized 
dietician and psychologist. Optimal restriction of the AGB was confirmed with a 
gastrografin swallow test. 
 AGB failure was defined as insufficient weight loss or weight regain 
resulting in an EWL<25%. Other complications, such as daily vomiting, severe 
heartburn, and band migration and  slippage were other reasons to replace the AGB 
for a RYGB. 
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Patient selection 
Patients who were selected for this study had been treated for their morbid 
obesity with either an open or a laparoscopically placed gastric band. They had to 
not have received secondary bariatric surgery prior to the RYGB had to have been 
performed (band replacement/repositioning/gastric sleeve). The AGB had to have 
been in place for at least one year and converted to a RYGB for AGB failure in a 
one-step procedure. The minimum postoperative follow-up was 12 months.  
 
Surgical procedure 
Patients were asked not to gain weight prior to the operation, but no diet 
was prescribed. All bariatric procedures were performed by two bariatric surgeons 
who had performed over 1500 bariatric procedures each. In our facility, all patients 
are operated on by a dedicated operating team consisting of one bariatric surgeon, 
an anesthesiologist, an anesthesiologist-assistant, and a minimum of three 
operating nurses. A prophylactic dose of 2 g IV cefazoline is given 30 min before 
the start of surgery. 
 The RYGB was performed laparoscopically using five trocars. The band is 
first released and removed. A gastric pouch (30-50ml) was created using the 
Echelon 60 (Ethicon Endosurgery, Cincinnati, OH, USA) using gold or green 
cartridges  just below the scar of the AGB on the stomach wall. Nu buttress 
material was used during the procedure. 
A biliopancreatic limb of 50cm was measured, which was stapled side to 
end to the gastric pouch using a 35 mm linear stapler. The anterior aspect was 
closed with a running suture of Vicryl 2.0 using the Endostich device (Covidien, 
Mansfield, MA, USA). An alimentary limb was created and a side-to-side entero-
anastomosis was then constructed in the same matter as the gastrojejunostomy, 
except that a Echelon 60 with a white cartridge was used. Till 2007, patients 
received a 100 cm alimentary limb, but since then an alimentary limb of 150 cm 
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was standardized in converted patients. Finally, a leak test was performed to look 
for leaks of the gastrojejunostomy. In all patients a drain was left near the gastric 
anastomosis, which was removed when blood loss was <50ml over 24 hours. 
Finally, the access port was removed. 
 
Follow-up 
Patients were followed up by a multidisciplinary team consisting of a 
surgeon, an endocrinologist, a dietician, a psychologist, and a specialized nurse. 
Control visits were scheduled at 1, 3, 6 and 12 months postoperatively and at 
yearly intervals thereafter. When data were missing patients were invited for an 
additional follow up visit. The local board approved this study to be conducted. 
 
Statistics 
Data were prospectively collected using a computerized database and 
analysed using SPSS 16.0 for Windows. The percentage of EWL was calculated 
using the initial weight before the placement of the AGB. The ideal BMI was set at 
25kg/m2. Unpaired t-tests were performed to assess weight loss before conversion 
and at length of follow-up. All data are reported as mean ± standard deviation of 
the mean unless otherwise specified. P<0.05 was considered significant.  
 
Results 
 
From January 2000 to December 2010, a total of 198 patients matching our 
inclusion criteria underwent an AGB conversion to a RYGB . Three patients were 
lost to follow up. In total 195 patients, 35 males (18%) and 160 females (82%), 
were included in this study. Mean BMI prior to LAGB placement was 48 (± 8) 
kg/m2 and 41 (± 7)  kg/m2 before conversion (Table 1). In total, nine (5%) patients 
had received an open AGB placement and 186 (95%) patients had received a 
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LAGB at a mean age of 38 (±9) years. Eighteen (9%) patients had their AGB 
placed perigastrically; the other 177 (91%) had their bands placed using the pars-
flaccid technique. Fifty-seven (29%) patients were referred from other hospitals 
and 138 (71%) received their AGB at our institution.  
 
Table 1. Pre-operative demographics 
 Mean (±SD/Range) 
Male/Female 35/160 (17.9/82.1%) 
Prior to LAGB  
 Weight (kg) 139.3 (±25.4/83-230) 
 BMI (kg/m2) 48.0 (±7.5/34.5-77.1) 
 Age 38 (±8.5/19-61) 
Prior to RYGB   
 Weight (kg) 121.5 (±22.9/53-203) 
 BMI (kg/m2) 41.8 (±7.1/22.4-69.8) 
 Age 43 (±8.9/21-67) 
SD: Standard deviation 
BMI: Body Mass Index 
LAGB: Laparoscopic Adjustable Gastric Band 
RYGB: Roux-en-Y Gastric Bypass 
 
The reason for converting the AGB to a RYGB was as in other studies 
[3,10,20]; in most cases it was either insufficient weight loss (EWL<25%) or 
weight regain when patients  initially reached an acceptable EWL but eventually 
dropped to an EWL of <25%. These two combined were the reason for conversion 
in 125 (64%) patients. Continued vomiting in 21 (11%), pouch formation in 20 (10 
%),  band migration in 8 (4%), severe reflux in 6 (3%), and slippage that required 
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immediate operative management (acute slippage) in 2 (1%) patients were other 
complaints and complications that led to conversion. Table 2 shows the main 
reasons for converting an AGB to a RYGB. 
 
Table 2. Reasons for AGB conversion 
 N (%) 
Weight gain 87 (44.5%) 
EWL<25% 38  (19.5%) 
Vomiting 21 (10.7%) 
Pouch/Slippage 20 (10.2%) 
Migration 8 (4.1%) 
Severe reflux 6 (3.0%) 
Stomach pain 5 (2.5%) 
Increase T2DM 4 (2.0%) 
Leak band 3 (1.5%) 
Acute slippage 2 (1.0%) 
Fistula 1 (0.5%) 
AGB: Adjustable Gastric Band 
EWL: Excess Weight Loss 
T2DM: Type 2 Diabetes Mellitus 
 
Conversion was performed after a mean of 5 (±3) years at a mean age of 43 
(±9) years. The mean operative time was 112 (±37) min. In total, 175 (90%) 
patients were operated without any complications. There were three conversions to 
open surgery because of bleeding from the short gastric artery and the spleen (two 
of the patients who underwent LAGB) and firm adhesions after open band 
implantation in the past in the third patient. Perioperative blood loss was usually 
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negligible, except in the converted cases where they ranged from 200-1800 ml. The 
other 192 operations were performed laparoscopically.  
Eight other patients were re-operated within 30 days after the initial 
RYGB: two for postoperative hemorrhage; two for leakage of the gastro-
enterostomy and two for herniation through Petterson’s space. One patient was re-
operated twice for peritonitis and abscess formation, and one was reoperated for an 
unexplained temperature of 40°C without finding an abdominal cause. Two 
additional patients developed an abscess at the location where the access port of the 
AGB was located. Gastrointestinal swallow tests were only performed when 
liquids did not pass after 24 hours. Two patients had a stenosis of the gastro-
enterostomy directly after the operation. Both were gastroscopiccally dilated and 
did not need any additional re-interventions.. Four patients underwent a 
laparoscopic cholecystectomy for cholecystolithiasis in the first postoperative year. 
Table 3 shows the perioperative outcomes. 
Approximately 6 hours after surgery, patients were offered a liquid diet and 
the day after surgery, patients were offered a pureed meal. After 3 days, patients 
were allowed to eat everything, but in small portions. Patients were discharged 
from the hospital after a mean of 4.5 (±5) days. In total 4 of the patients were re-
admitted, as mentioned earlier. The mean follow-up was 40 months (±24) after the 
RYGB. Patients available at -5, -4, -3, -2, -1, 0, 1, 2, 3, 4 and 5 years pre-and post-
conversion to a RYGB were, respectively, 102, 125, 155, 185, 195, 195, 195, 123, 
84, 54 and 31.  
The mean weight prior to the RYGB was 122 (±23) kg, which meant an 
EWL of 25% (±26%) compared with the weight prior to AGB placement. Weight 
reduced to 100 (±20), 99 (±22), 101 (±23), 106 (±24) and 113 (±24) kg in the 
following 5 years, which is shown in Figure 1. At these same time intervals, EWL 
increased to 60% (±21), 65% (±24), 63% (±24), 60% (±24) and53% (±29). No 
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significant differences in weight or EWL were found between patients with an 
alimentary limb of 100 cm compared with patients with a 150 cm limb.  
 
Table 3. Peri-operative outcome  
 Mean (±SD/Range) 
Operative time (min) 111.5 (37.3/50-243) 
Blood loss (ml) 47 (209/0-1800) 
Hospital stay (days) 4.5 (5.1/2-62) 
No complications 175 (89.7%) 
Complications 20 (10.3%) 
 Conversion to open procedure 3 (1.5%) 
 Stenosis 2 (1%) 
 Cholecystolitiasis <1 year 4 (2%) 
 Wound abscess 2 (1%) 
 Abdominal hematoma 1 (0.5%) 
 Re-operation <30 days 8 (4.1%) 
 Active bleeding spleen 1 (0.5%) 
Active bleeding gastric vessel 1 (0.5%) 
Leakage gastro-enterostomie 2 (1%) 
Herniation through Petterson 2 (1%) 
Peritonitis/abscess 1 (0.5%) 
No abdominal abnormalities 1 (0.5%) 
SD: Standard Deviation 
Min: Minutes 
Ml: Millilitres 
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Figure 1. Pre- and postoperative weight (kg) 
 
Figure 2. Pre- and postoperative EWL in all patients (EWL total), patients who 
lost <50% and >50% EWL with the AGB. 
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Discussion 
 
Unfortunately, no single bariatric procedure has proven itself yet as the 
optimal treatment for morbid obesity when outcomes like EWL, morbidity, and 
mortality are combined. Even with the best efforts, proper selection of the 
procedure to fit each individual morbidly obese patient best remains challenging 
[11,21]. In every series that has been published there are at least a number of 
patients who seem not to thrive with the AGB [2-6]. Many patients are and were 
treated for their morbid obesity with an AGB. With the progression of time many 
patients experience complications of the AGB that lead inevitably to revisional 
bariatric surgery [3,4,8]. In this series, insufficient weight loss or weight regain 
accounted for almost two-thirds of the patients requiring revisional surgery, which 
raises questions about the effectiveness of band surgery in the long run. It must be 
emphasized, however, that a number of patients show good EWL and are very 
satisfied with the AGB.  
Revisional bariatric surgery can be technically demanding and holds a 
higher risk for perioperative complications than primary bariatric surgery [4, 16-
18]. However, revisional surgery is, in most cases, the best solution for patients 
who have experienced severe weight regain or complications after an AGB 
[3,4,10,11]. This is while many patients seem to regain weight when only the AGB 
is removed and might again develop obesity-related co-morbidities [7,22]. The aim 
of a revisional procedure should be to treat complications and achieve further 
weight loss in patients with insufficient EWL [4]. It should, however, not be seen 
as an easy way out for and by the patient when not enough we ight loss is achieved. 
Both the surgeon (as part of a multidisciplinary team) and the patient should 
commit to striving for an optimal result with the AGB and only when all 
possibilities have failed or complications occur should a RYGB be considered. 
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The results of this study in terms of EWL are excellent, with 150 patients 
(76%) achieving an EWL>50% and mean EWL of 60% after a mean 40 months of 
follow up. Unlike earlier reports, there were no significant differences in EWL 
between patients receiving a 100 cm and a150 cm alimentary limb at any point of 
follow-up [23,24]. Only eight patients (4%) were unable to achieve an EWL of 
>25%. However, these results seem to fade somewhat in time; while the EWL after 
2 years was  65% and lowered to 53% after 5 years. This raises the question 
whether this might be due to negative patient selection, as a failing AGB is, in 
many cases, at least partially due to patient habits. With bariatric surgery and 
especially the AGB, we only offer the patient a restriction in food intake and earlier 
satiety, not a restriction in how to deal with the causes of obesity. In this study, we 
did not perform quality of life tests or tests to gain better insight in eating 
behaviour. However, dividing patients into two groups based on their maximum 
EWL with the AGB showed a remarkable result (Figure 2). Almost all patients 
benefited by the same amount with no difference in total EWL after a RYGB. 
However, patients who achieved an EWL of >50% at some point with the AGB 
started out with a much higher EWL after the AGB and were able to reach a mean 
EWL after RYGB of 73%, compared with 59% (p<0.01) in the patients who 
achieved a maximum EWL of <50% with the AGB. This latter group thus achieved 
a lower mean EWL than has been described in the literature for primary RYGB, 
but is in accordance with earlier reports on revisional RYGB [2-4,7,22]. What is 
more important is that almost all weight regain after 4 and 5 years postoperative is 
due to the patients who lost <50% EWL with the AGB. Perhaps this is when the 
effect of the RYGB fades out in patients who do not adhere as well to the life 
changes suggested by our multidisciplinary team. These appear to be the same 
patients in this series who were not able to maintain their weight loss with the AGB 
and did not lose the ABG due to severe complications. 
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Discussion 
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 AGB revision to RYGB is relatively safe, with 90% of patients undergoing 
this procedure without complications or mortality within the first postoperative 
year and only eight patients (4%) requiring re-operations within 30 days. 
Converting this procedure was only necessary in three patients (1.5%) although the 
preoperative higher risks in these patients who have been operated before. 
Operative time was acceptable at 112 min which is approximately 25 min more 
compared with our primary performed RYGB in the researched period. Also the 
amount of blood loss was rather little with almost 50ml, and was, in large part, the 
result of the three conversions to open procedures. Post-operative only two patients 
(1%) appeared to have anastomotic strictures, which are described and in line of 
expectations with the literature after conversion [19].  
 Performing the conversion as a one-step procedure has many advantages 
when complications, morbidity, and mortality are comparable to the two-step 
variant. It is less demanding for the patient, as only one hospital stay is required. 
Patients have no interval in which they have no restriction or malabsorption, and 
are thus unable to gain weight by overeating. Adhesions that are often present only 
have to be released once. In these times cost efficiency becomes more and more 
important [25] and the costs of converting a patient in one step are, in theory, much 
lower. 
 
Conclusion 
 
 Converting an AGB to a RYGB as a one-step procedure is a relatively safe 
and feasible procedure with acceptable complication rates when performed in a 
specialized institution. The RYGB conversion results in a good EWL of 65% after 
2 years. However proper patient selection is of the utmost importance. 
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Abstract          
 
Introduction 
The Laparoscopic Adjustable Gastric Band (LA GB) is widely used for the treatment of 
morb id obesity. Many patients benefit from this procedure init ially, but experience 
complications after a few years. The treatment for many complicat ions is revisional 
bariatric surgery. A number of patients however request only band removal without 
secondary bariatric surgery. 
 
Patients and methods 
Patients were retrospectively selected using a prospectively collected database. The LA GB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. 
 
Results 
38 Patients who got their LA GB laparoscopically removed between 2000 and 2010 were 
included. Mean follow up after LA GB removal was 3.7 (±2.1/1.4-8.9) years. Only two 
complications (5%) and no mortality occurred perioperative. Excess Weight Loss (EWL) 
decreased from 48%(±39/-10-120) at band removal to 27%(±31/-20-90), 16%(±33/ -30-90 
and 19% (±30/-10-60) after one, two and five years respectively. %Weight Loss (%WL) 
was 19.9% (±16.4/ -60-10), 11.7% (±14.2/-50-10), 7.0% (±15.5/-40-10) and 9.4% (±14.9/ -
30-10) after these same time intervals. 
After a mean 2.3 (±2.6/0.5-9.9) years 17 patients underwent either a Roux-en-Y Gastric 
bypass (14 patients) or a Scopinaro (3 patients) all because of weight regain. Current EW L 
in these patients is 72% (±4.75) (%W L 21% ± 19.7))compared to 2.5% (±28.5) (%W L 
0.7%±10.2) in patients without a secondary bariatric procedure (p<0.001). 
 
Conclusion 
Patients who get their LA GB removed are guaranteed to suffer from weight regain. It is 
inadvisable to only remove the gastric band without performing an additional bariatric 
 
107 
 
procedure. In this study not a single patient was able to main tain the weight loss achieved 
with the LA GB. 
           
 
Introduction 
 
Bariatric surgery has proven to be an effective treatment for morbid obesity 
and has shown to resolve or improve associated co-morbidities [1]. For many 
years, the Laparoscopic Adjustable Gastric Band (LAGB) has been the most 
frequently performed bariatric procedure in Europe [2-5]. 
Unfortunately, there are a mounting number of reports on LAGB failure 
and disappointing Excess Weight Loss (EWL)  in the long-term. Some studies 
estimate band failure to be as high as 66% after 10 years [2-4]. Common reasons 
for LAGB failure include insufficient weight-loss or weight regain, due to an 
maladaptive eating pattern and pouch dilatation [6,7]. When an LAGB fails, 
revisional bariatric surgery is frequently offered; however, a number of patients 
refuse a second bariatric operation [8-11]. These patients are often lost to follow-up 
for example because of disappointment after LAGB removal. 
A number of patients that have been very successful with a gastric band but 
lose the band for technical reasons remain convinced that they can maintain their 
weight loss afterwards. Although they are often met with skepticism, it is unknown 
how their weight develops in the years thereafter. The little literature that is 
available shows a modest weight regain after band removal [3,12]. This 
retrospective study with prospectively collected data was performed to evaluate the 
outcome of patients that initially refuse secondary bariatric surgery after a failed 
LAGB.
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Abstract          
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass fro  our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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Methods  
 
In 1995, LAGB was introduced in our clinic to treat morbid obesity. From 
the year 2000, all patient data were prospectively entered into a computerized 
database (Microsoft Access 2000). Information about the course of weight loss, 
prior bariatric surgery, medication use and co-morbidities were entered into this 
database after each post-operative visit. All patients who had their band removed 
without secondary bariatric surgery from January 2000 to December 2010 were 
reviewed. Table 1 shows patient demographics and preoperative data.  
  
Patient selection 
Patients that were selected for this study had been treated for their morbid 
obesity with a LAGB placed using the pars-flaccid technique.  The LAGB had to 
have been in place for at least one year and the minimum postoperative follow up 
had to be 12 months for inclusion in this study. The local board gave their approval 
for conducting this study.  
 
Follow-up 
Patients were offered follow-up by a multidisciplinary team consisting of a 
surgeon, endocrinologist, dietician, psychologist and a specialized nurse. Patients 
visited our institution at one, three, six and twelve months postoperative and then 
on a yearly basis. When data were missing patients were invited for an additional 
follow-up visit. 
 
Statistics 
Data were analyzed using the Statistical Package for the Social Sciences 
(SPSS) 16.0 for Windows. The percentage of EWL and Weight Loss (WL) was 
calculated using the initial weight before the placement of the adjustable gastric 
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band. Ideal BMI was set at 25 kg/m2. Unpaired t-tests were performed to assess 
weight loss before removal and at length of follow up. All data, including all tables 
and figures, are reported as median (range)unless otherwise specified. P<0.05 was 
considered significant. 
 
Results 
 
 In total, 38 (6 male (16%)) patients that underwent LAGB removal without 
secondary bariatric surgery between 2000 and 2010 were included in the analysis. 
Median age at LAGB placement was 40 (30-59) years and 44 (31-63) at band 
removal. Median weight and BMI were 129 (98-180) kg and 44.3 (37-57) kg/m2 
prior to LAGB placement respectively and significantly dropped just before LAGB 
removal to 104 (62-167) kg and 35.5 (23-57.6) kg/m2(p<0.01). Two additional 
patients were not included because their LAGB was removed after 1 and 4 weeks 
postoperatively due to mechanical obstruction. In 16 of the 38 patients, the LAGB 
was placed in a different hospital and patients were referred for band removal to 
our facility, especially when band migration had occurred (9 of 16). Due to these 
referrals, the types of bands placed varied from the Realize Band C used in most 
instances in our institution, to the Heliogast, Obtech and Lap-Band. Many patients 
did not come in for regular post-operative visits after the first year, in most cases 
due to disappointment regarding the outcome after LAGB removal or fear of 
another bariatric procedure. Eight patients were convinced that they could maintain 
the achieved weight loss without the help of secondary bariatric surgery. All of 
these patients were traced with the help of their general practitioner and invited for 
an additional post-operative visit.  
 Prior to the LAGB removal all patients were informed of the procedure and 
advised by the surgeon to undergo secondary bariatric surgery because of 
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theoretical weight regain as a possible consequence; eventually, the patient wishes 
were respected when they refused secondary surgery. Removal of the LAGB was 
performed for a number of reasons. The most frequently observed cause for band 
removal (40%) was gastric band migration; persistent vomiting was the  second 
most common, with 29%.Together with inadequate weight loss (13%), these causes 
account for over 80% of the causes of LAGB removal. Table 1 shows all of the 
reasons for removal. Fear of the complications that occurred with the LAGB (53%) 
and the fear of changing the gut permanently (42%) were the main reasons for 
patients not choosing to have a second bariatric procedure. The remaining two 
patients could not give a viable explanation in retrospect.  
 
Table 1. Reasons for LAGB removal 
 N (%) 
Intragastric migration 15 (39.5%) 
Vomiting 11 (28.9%) 
Little weight loss 5 (13.2%) 
Acute slippage  2 (5.3%) 
Severe reflux 2 (5.3%) 
Fear for complications 1 (2.6%) 
Fistula 1 (2.6%) 
Band leak 1 (2.6%) 
 
 Operating time for band removal was 43 (13 to79) minutes. Blood loss was 
reported as 5 (0 to 100) mL, which is an underestimation while in all procedures 
there is at least some blood loss in all procedures. Median Hospital stay was 1.9 (1 
to 16) days. One patient developed perigastric abscesses and required radiological 
drainage. Another patient had bled from one of the trocar openings requiring an 
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extra suture under local anesthesia. Almost 95% of patients had their LAGB 
removed without any complications and 92% of patients were discharged the day 
of or the day after surgery. Table 2 shows the perioperative outcomes. 
 
Table 2. Peri-operative outcome (band removal)  
 Mean (±SD/Range) 
Operative time (min) 43:48 (±15.0/13-79) 
Blood loss (ml) 4.0 (±18/0-100) 
Hospital stay (days) 2.6 (±2.7/1-16) 
No complications 36 (94.7%) 
Complications 2 (5.3%) 
 
Abscesses perigastric 1 (2.6%) 
Bleeding trocar opening 1 (2.6%) 
 
The median time between LAGB placement and LAGB removal was 3.7 
(1.4 to 11.7) years and follow-up after LAGB removal was 3.0 (1.4 to 8.9) years. 
Results in terms of EWL with the LAGB were good with a maximal median 
%EWL and %WL of 56% (0 to 120) and 31% (0 to 60)). The median %EWL and 
%WL prior to LAGB removal was 47%(-10 to 120) and 19% (-60 to 10)) 
respectively. After removal, %EWL decreased dramatically, dropping to 23%(-19 
to 91), 7%(-26 to -95) and 32% (-10 to 60) after one, two and five years 
respectively. Simultaneously %WL also dropped to 9% (-47 to 9), -3% (-42 to 11) 
and 14% (-29 to 5) in these same time intervals. These outcomes, however, include 
patients who eventually chose to have a second bariatric procedure performed. This 
explains the increase in %EWL after 5 years. Figures 1a and 1b show weight loss 
and Body Mass Index (BMI), respectively. 
	  
6	  
	  
 t r  ss e c s e  t , t e e t s e  
 f t   
  r f r  s   
 ( rat ; st t t   
t , t  . t t  t t s    
  f t  .  
.  t   t   
 t   t e t er a t  (4   r  
ts t s    c r r i  t  
ts  t i  le ti   r t
l
  ( ) 
Intragastric igration 15 (39.5 ) 
o iting 11 (28.9 ) 
ittle eight loss 5 (13.2 ) 
cute slippage  2 (5.3 ) 
Severe reflux 2 (5.3 ) 
Fear for co plications 1 (2.6 ) 
istula 1 (2.6 ) 
and leak 1 (2.6 ) 
 t       
 ) ,  s  ti  ile in all r c r  
 e   ss  a  r  ita  sta  .  (  
 ) .  r  c  
a .  t    e f   s iri   
117
2
Results of bariatric surgery
 
110 
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were respected when they refused secondary surgery. Removal of the LAGB was 
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and the fear of changing the gut permanently (42%) were the main reasons for 
patients not choosing to have a second bariatric procedure. The remaining two 
patients could not give a viable explanation in retrospect.  
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there is at least some blood loss in all procedures. Median Hospital stay was 1.9 (1 
to 16) days. One patient developed perigastric abscesses and required radiological 
drainage. Another patient had bled from one of the trocar openings requiring an 
 
111 
 
extra suture under local anesthesia. Almost 95% of patients had their LAGB 
removed without any complications and 92% of patients were discharged the day 
of or the day after surgery. Table 2 shows the perioperative outcomes. 
 
Table 2. Peri-operative outcome (band removal)  
 Mean (±SD/Range) 
Operative time (min) 43:48 (±15.0/13-79) 
Blood loss (ml) 4.0 (±18/0-100) 
Hospital stay (days) 2.6 (±2.7/1-16) 
No complications 36 (94.7%) 
Complications 2 (5.3%) 
 
Abscesses perigastric 1 (2.6%) 
Bleeding trocar opening 1 (2.6%) 
 
The median time between LAGB placement and LAGB removal was 3.7 
(1.4 to 11.7) years and follow-up after LAGB removal was 3.0 (1.4 to 8.9) years. 
Results in terms of EWL with the LAGB were good with a maximal median 
%EWL and %WL of 56% (0 to 120) and 31% (0 to 60)). The median %EWL and 
%WL prior to LAGB removal was 47%(-10 to 120) and 19% (-60 to 10)) 
respectively. After removal, %EWL decreased dramatically, dropping to 23%(-19 
to 91), 7%(-26 to -95) and 32% (-10 to 60) after one, two and five years 
respectively. Simultaneously %WL also dropped to 9% (-47 to 9), -3% (-42 to 11) 
and 14% (-29 to 5) in these same time intervals. These outcomes, however, include 
patients who eventually chose to have a second bariatric procedure performed. This 
explains the increase in %EWL after 5 years. Figures 1a and 1b show weight loss 
and Body Mass Index (BMI), respectively. 
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Figure 1a.  Pre-and postoperative weight (kg) 
 
 
 
Figure 1b.  Pre-and postoperative BMI (kg/m2) 
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38 Patients initially refused additional bariatric surgery after LAGB removal, but 
17 changed their mind and underwent either a Roux-en-Y Gastric Bypass (RYGB) 
(14 patients) or a BilioPancreatic Diversion with Duodenal Switch (BPD-DS or 
Scopinaro-procedure) (3 patients) after a median of  2.1 (0.5 to 9.9) years. In all 
patients the reason for secondary surgery was weight regain. The preferred 
secondary procedure in our facility is the RYGB as it minimizes operating on the 
same area as the original band was positioned. However, when severe adhesions 
were present which could not be released without secondary damage, in light of 
minimizing complications, a BPD-DS was performed in three patients. Median 
operating time was 90 (51 to 148) minutes, median (underestimated) blood loss 5 
(0 to 300) mL and hospital stay was 3.0 (2 to 5) days. One complication occurred 
when one patient required a reoperation due to a bleeding gastric vessel in the 
staple line. No mortality occurred. Postponing the second bariatric procedure might 
explain this low percentage of morbidity in this group of patients with a high 
prevalence of band migration.  
 Figure 2 shows differences in %EWL between patients with and without a 
second procedure. The line of the patients who got a second procedure is even 
somewhat flattered while it reports the median levels of all 17 patients and patients 
did not all get their second procedure at the same moment. To make a good 
comparison, the results at the time of the last visit is the most important. At this 
visit, %EWL and %WL in patients who underwent additional bariatric surgery was 
67% (24 to 113) and 30% (12 to 53) compared to -11% (-33 to 57) and -4% (-14 to 
34) in patients without an additional bariatric procedure (p<0.001).  
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38 Patients initially refused additional bariatric surgery after LAGB removal, but 
17 changed their mind and underwent either a Roux-en-Y Gastric Bypass (RYGB) 
(14 patients) or a BilioPancreatic Diversion with Duodenal Switch (BPD-DS or 
Scopinaro-procedure) (3 patients) after a median of  2.1 (0.5 to 9.9) years. In all 
patients the reason for secondary surgery was weight regain. The preferred 
secondary procedure in our facility is the RYGB as it minimizes operating on the 
same area as the original band was positioned. However, when severe adhesions 
were present which could not be released without secondary damage, in light of 
minimizing complications, a BPD-DS was performed in three patients. Median 
operating time was 90 (51 to 148) minutes, median (underestimated) blood loss 5 
(0 to 300) mL and hospital stay was 3.0 (2 to 5) days. One complication occurred 
when one patient required a reoperation due to a bleeding gastric vessel in the 
staple line. No mortality occurred. Postponing the second bariatric procedure might 
explain this low percentage of morbidity in this group of patients with a high 
prevalence of band migration.  
 Figure 2 shows differences in %EWL between patients with and without a 
second procedure. The line of the patients who got a second procedure is even 
somewhat flattered while it reports the median levels of all 17 patients and patients 
did not all get their second procedure at the same moment. To make a good 
comparison, the results at the time of the last visit is the most important. At this 
visit, %EWL and %WL in patients who underwent additional bariatric surgery was 
67% (24 to 113) and 30% (12 to 53) compared to -11% (-33 to 57) and -4% (-14 to 
34) in patients without an additional bariatric procedure (p<0.001).  
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Figure 2.  EWL% Pre-and post LAGB removal 
 
 
 
Discussion 
 
Although the percentage of patients refusing additional bariatric surgery 
seems small, it accounts for 16% (38 of 237) of patients in our clinic who had their 
band removed in the study period. Therefore, there appears to be an important 
group of patients who deserve additional surgery to maintain the induced weight 
loss. In all cases, patients were offered additional bariatric surgery, but a number of 
patients only wanted their band removed. In this group of patients, the number of 
grave complications like band migration was high, which could explain the fear for 
undergoing a second operation. In total, over half of the patients feared 
complications of a RYGB or Scopinaro procedure. 
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During the yearly post-operative visits, patients were encouraged to adhere 
to the advised daily routines and dietary intake. When patients were unable to 
achieve or sustain an acceptable %EWL they were referred to a specialized 
dietician. Even with all of these efforts made, no patient was able to maintain the 
same weight.  Although patients were invited for their post-operative visits on a 
yearly basis, only 53% of patients attended on a regular basis. Among these were 
all of the patients that eventually underwent a second procedure. This alone proves 
the importance of regular post-operative visits. More importantly, physicians 
should actively counsel their patients on expected weight gain after LAGB 
removal. The mechanisms that led to morbid obesity did not disappear after band 
removal, even when the LAGB was highly successful. Some patients hope for a 
resetting of weight influencing factors after successful weight loss. However, in the 
context of an adjustable band this does not seem to be the case.  
Van Nieuwenhove et al. [3] showed in a series of LAGBs that removal in 
54 patients lead to weight regain, but EWL was only 11% less than patients who 
still had their band in place. Also, Lanthaler et al. [12]  reported on 41 patients who 
either had their band removed or deflated and also showed a decrease in EWL over 
time; 5 Patients (4 band desuflations) were able to maintain their weight. These 
results are different to those found in our series as a number of patients seem to be 
able to maintain or hold their EWL at an acceptable level. 
Although the number of patients in this study is limited, the results are 
uniform. In particular, the difference in %EWL between patients that eventually 
underwent secondary surgery compared to patients that only had their band 
removed is highly significant, with 67 vs. -11% (P<0.001), respectively, at the time 
of their last post-operative visit. Even with regain of weight after LAGB removal, 
these patients seem to do well after a second bariatric procedure. 
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During the yearly post-operative visits, patients were encouraged to adhere 
to the advised daily routines and dietary intake. When patients were unable to 
achieve or sustain an acceptable %EWL they were referred to a specialized 
dietician. Even with all of these efforts made, no patient was able to maintain the 
same weight.  Although patients were invited for their post-operative visits on a 
yearly basis, only 53% of patients attended on a regular basis. Among these were 
all of the patients that eventually underwent a second procedure. This alone proves 
the importance of regular post-operative visits. More importantly, physicians 
should actively counsel their patients on expected weight gain after LAGB 
removal. The mechanisms that led to morbid obesity did not disappear after band 
removal, even when the LAGB was highly successful. Some patients hope for a 
resetting of weight influencing factors after successful weight loss. However, in the 
context of an adjustable band this does not seem to be the case.  
Van Nieuwenhove et al. [3] showed in a series of LAGBs that removal in 
54 patients lead to weight regain, but EWL was only 11% less than patients who 
still had their band in place. Also, Lanthaler et al. [12]  reported on 41 patients who 
either had their band removed or deflated and also showed a decrease in EWL over 
time; 5 Patients (4 band desuflations) were able to maintain their weight. These 
results are different to those found in our series as a number of patients seem to be 
able to maintain or hold their EWL at an acceptable level. 
Although the number of patients in this study is limited, the results are 
uniform. In particular, the difference in %EWL between patients that eventually 
underwent secondary surgery compared to patients that only had their band 
removed is highly significant, with 67 vs. -11% (P<0.001), respectively, at the time 
of their last post-operative visit. Even with regain of weight after LAGB removal, 
these patients seem to do well after a second bariatric procedure. 
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Conclusion 
 
Patients who have their gastric band removed will surely regain their 
weight to pre-surgery levels in most cases. It is inadvisable to  remove the LAGB 
without performing a second bariatric procedure when deemed technically feasible 
and safe. In this study no patient was able to maintain the weight loss achieved 
with the LAGB after its removal. Best efforts should be made to inform patients of 
the long-term expectancy of weight development. Surgeons should hold a low 
threshold for patients that eventually change their mind. 
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Abstract          
 
Background  
With a prevalence of 1% band migration is an uncommon complication after gastric 
banding. Migrated bands can be removed using a gastrointestinal endoscopic approach 
which has, according to the current literature, a low complication rate. In our series we 
show that this procedure is not without risk.  
 
Patients and Methods  
From June 2006 till June 2010, in eight patients endoscopic removal was attempted. 
Afterwards patients were followed in time.  
 
Results  
In four patients removal was performed without complications. In two patients extracting 
the cleaved gastric band into the stomach appeared impossible. The two remaining patients 
presented with acute hematemesis and melena. One of these patients was readmitted with  
hematemesis. The other patient started bleeding during the gastroscopy and was converted 
to a laparoscopy in which one of the branches of the left gastric artery was oversewn. 
 
Conclusion  
Band migration after gastric banding can be life threatening. Gast rointestinal endoscopic 
removal is a feasible technique that holds the promise of fast reconvalescence. However, 
there is a risk for fulminant hemorrhage from the extract ion site, even a few weeks after the 
procedure. It is inadvisable to postpone re-intervention when bleeding is suspected when a 
patient presents with hematemesis or melena.       
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Introduction 
 
Laparoscopic Adjustable Gastric Banding (LAGB) is one of the surgical 
treatment modalities for morbid obesity. Over the years popularity for this 
treatment increased it has been by far the most performed bariatric procedure for 
years in Europe and increasingly so in the US. LAGB combines moderate excess 
weight loss with low post-operative morbidity and mortality. Despite low 
complication rates, some failures do occur and as the total number of patients 
increase, so does its complications [1,2].  
Complications after LAGB are not uncommon and consist mainly of 
hernias, gastroesophageal reflux disease, pouch dilatation and leakage of the band 
[1-3]. Intragastric migration of the band is perhaps one of the gravest 
complications. Migration is regularly reported in literature and prevalence ranges 
from 0.3 to 4.8% and in one study even in 11% within the first 2 years after surgery 
[4-12]. When migration occurs, band removal is mandatory to prevent intra-
abdominal infection, gastrointestinal obstruction or life threatening hemorrhage. 
Although the introduction of the pars flaccid technique might have lowered the risk 
for developing band migration, the increased number of LAGB procedures 
worldwide makes migration a complication to be reckoned with [1,2,5]. 
In our hospital the removal of migrated LAGB is most often performed by 
gastrointestinal endoscopy. During this procedure the band is cut and removed 
transoraly. Gastrointestinal endoscopic removal is promoted as a relatively safe 
alternative for laparoscopic removal of the band and mortality has not yet been 
reported [11,13]. We present  twelve patients with migrated gastric bands in whom 
gastrointestinal endoscopic removal was attempted.  
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Abstract 
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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Patients and methods 
 
From January 2006 to October 2010, on a total of 1823 LAGB placements, 
nine patients developed intragastric band migration. Three additional patients that 
were included had received their LAGB in a different hospital. In all patients 
gastrointestinal endoscopic removal of the band was attempted by two 
gastroenterologists, performing the removal together. Clinical signs of band 
migration were: persisted nausea, abdominal pain, weight gain, (recurrent) 
infection of the port and tubing system, unexplained anemia, heartburn and 
hematemesis. Demographics and preoperative data are shown in Table 1. 
 
Preoperative 
When an LAGB migration was suspected all patients underwent an upper 
gastrointestinal (UGI) gastrograffin study and a gastroscopy. In most cases the 
LAGB has to be completely migrated into the stomach to reveal a migrated band 
on a UGI. Therefore a gastroscopy is imminent in most cases to diagnose a 
possible migration, so that when suspicion is high, the gastrograffin swallow can be 
left out [14]. When migration was confirmed, proton pump inhibitors were 
prescribed and the patient was scheduled for gastrointestinal endoscopic removal of 
the LAGB. Before the endoscopic procedure patients signed an informed consent. 
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Operative technique 
The gastrointestinal endoscopic removal of a migrated gastric band is an 
interdisciplinary procedure in our hospital. Although the procedure was carried out 
under general anesthesia in all cases, conscious sedation for gastrointestinal 
endoscopic band removal and local anesthesia for port removal is possible. The 
removal of the LAGB is divided into two stages: Firstly the removal of the port and 
the connecting tube and secondly the gastrointestinal endoscopic removal of the 
band. 
After insertion of the gastroscope and insufflation of the stomach the 
migrated band is identified. A metal cutting wire is guided in between the 
protruded portion of the band and the stomach wall. Then the tip of the wire is 
retracted outside the patient so that the wire is looped around the band with both 
ends coming out by mouth. A flexible metal overtube is inserted over the wires to 
provide counterforce to the band. When wire-ends pulled tight using the special 
Toggle device, the band is easily cut through (Gastric Band Cutter System Surgical 
Company). The loose end of the cutted band can now be caught with a polipectomy 
loop and pulled free into the stomach and out by mouth. The migration defect in 
the stomach wall is not closed.  
 
Postoperative 
All patients were reexamined gastroscopiccally a few days after the 
removal of their LAGB to confirm adequate closure of the migration defect and to 
exclude apparent bleeding. While these patients received their LAGB to achieve 
weight loss, removing the LAGB will lead to weight gain in most cases [8]. All 
patients were evaluated to decide which bariatric procedure was most appropriated 
to replace the LAGB and were followed in time for at least twelve months.  
 
 
 
125 
 
Results 
 
All twelve patients agreed on attempting a gastrointestinal endoscopic 
removal of their AGB. Results are shown in Table 2.  
Seven patients had their bands removed gastroscopiccally without any 
complications. Almost all complaints caused by the migrated band vanished 
immediately and patients could leave the following day. These patients received a 
different bariatric procedure after a mean of eight months (3-12). Eight patients 
eventually received a Gastric Bypass, one patient received a Gastric Sleeve and one 
received a BilioPancreatic Division with Duodenal Switch (BPD-DS). 
In two patients, numbers one and twelve, the LAGB was cut, but 
dislocation into the stomach failed. The surgeon performed a laparoscopy and 
found that tissue had grown into the buckle of the LAGB making gastrointestinal 
endoscopic extraction impossible in both cases. The tissue capsule in which LAGB 
was located was cleaved and the LAGB removed. 
Gastrointestinal endoscopic removal in patient number seven also failed. In 
this case the band had only partially migrated and the gastroenterologists were 
unable to loop the guide wire over the band. Eventually this procedure was 
converted to an uncomplicated laparoscopic removal of the band. 
Two patients suffered from melena and hematemesis prior to the 
procedure. Both patients did not use any medication. In patient number four, no 
complications occurred during the initial gastrointestinal endoscopic removal of the 
LAGB. This patient was readmitted after four days with significant hematemesis. 
Gastroscopy revealed an ulcer with signs of recent bleeding just below the 
migration site. After coagulation no more bleeding occurred and the patient was 
discharged after six days. This patient refused further operations for the treatment 
of her morbid obesity, and currently has reached her initial BMI. 
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In patient number six bleeding occurred when the band was dislocated into 
the stomach and this procedure was converted to laparoscopy while the bleeding 
site could initially not be located. The bleeding arose from a branch of the left 
gastric artery and was oversewn. Follow up gastroscopy after a few days showed 
no more signs of bleeding and this patient was discharged after three days without 
any symptoms. However nine weeks thereafter she was acutely readmitted in 
another hospital with hematemesis and hypovolemic shock. Urgent gastroscopy 
showed a large blood clot inside the stomach, but an active bleeding could not be 
located. This patient was transferred to a university hospital to attempt 
angiographic embolization. However, one day later the patients situation suddenly 
worsened during another gastroscopy and a CT was made, which showed an active 
bleeding on the site were the LAGB had been located. Unfortunately the patient 
developed an abdominal compartment syndrome and died during an emergency 
laparotomy. The true origin is still unclear, also because autopsy was refused.  
 
Discussion 
 
Migration of the AGB is a complication which can occur shortly after 
placement, but is more often a long-term complication. Incidences of band 
migration greatly vary in literature, with a range from 0.3 to 11%. However, larger 
series describe an average rate as low as 1% or even less [4-12,15,16]. The 
percentage of migrated bands is possibly higher, as a prospective study showed a 
great number of migrated gastric bands (7.5%) when patients were screened 
routinely during the first years after placement [17]. The prevalence of migration 
increases over time because patients often remain asymptomatic for long periods or 
even will never become symptomatic. For this reason a great number of migrated 
bands will not be discovered unless a gastroscopy is performed routinely [14,17]. 
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There are several possible mechanisms for band migration into the gastric 
lumen. The first is early erosion or trauma of the gastric wall during the 
laparoscopic insertion of the band. More specifically during canulation of the 
retrogastric route or when the band is pulled behind the stomach using a hooked 
retraction device, the dorsal serosal portion of the cardia is easily lacerated. This 
may be the cause of early perforation and subsequent migration.  
Secondly, chronic shear stress of the band on the stomach wall due to 
physiological movement of the gastric wall and diaphragm can lead to 
microperforation and infection. These infections are most likely due to a 
microperforation of the gastric wall, giving microorganisms a chance to colonize 
the gastric band and migrate to the port site. An infected port is therefore always a 
reason to perform a gastroscopy [2]. Another factor is the pressure applied by 
simply filling the adjustable band in order to get enough restriction to meals. 
Chronic overfilling of the band or inclusion of too much gastric wall within the 
gastric band during placement can add to this pressure problem. The fourth 
mechanism for migration lies in the fact that a gastric band is recognized by the 
immune system as a foreign body leading to a rejection reaction against the silicon 
material. This causes formation of a fibrous capsule that leads to contraction 
[1,2,7,13,18]. The suggested mechanisms can play a role in LAGB migration. It is 
however likely in our opinion that the etiology of most migrations is multifactorial.  
Due to the tissue capsule formed around the band most patients are 
asymptomatic, because it seals of the peritoneal cavity. However, a number of 
clinical signs and symptoms can occur when a gastric band has migrated. These 
include the inability to regulate the stomach diameter with inflation, a sudden stop 
in weight loss or even weight regain, recurrent port size infection and life-
threatening gastrointestinal bleeding [4,9-11,13]. When a band has completely 
eroded into the gastric lumen it may lead to life threatening complications such as 
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peritonitis or upper intestinal hemorrhage [3,19,20]. Even acute bowel obstruction 
or thrombophlebitis of the portal vein after migration have been reported [21-23]. 
A number of endoscopic and surgical methods for removing a (partially) 
migrated band have been described in published articles. The first is a perigastric 
laparoscopic division [2,6,24,25], the second a transgastric approach [4,8,15]. 
These techniques have the advantage of being relative safe, allow gastric wall 
repair and omental patching. Several other groups have reported endoscopic 
methods using traditional endoscopic devices or the Gastric Band Cutter (A.M.I., 
Agency for Medical Innovation) first published by Lattuada et al [7,11,18,26,27]. 
The latter has the advantage to be minimal invasive, but is only advised when 
performed by experienced surgeons or gastroenterologists. 
The ideal momentum of endoscopic extraction of the migrated band is 
matter of debate. Some articles using the gastrointestinal endoscopic technique 
advise to wait until complete migration, so that the band can be easier removed 
[13,18]. Other authors stress the serious risk of peritonitis and advise to remove the 
band rapidly after an endoscopic confirmation of migration [6,9,10,21,27,28]. In 
our hospital the migrated LAGB is removed shortly after the diagnosis to minimize 
the risk of complications. This implicates that removal in some cases is performed 
when the LAGB has only partially migrated, which makes the procedure more 
difficult.  
A number of complications occurred during and after gastrointestinal 
endoscopic removal of the LAGB. Gastrointestinal endoscopic extraction failed in 
three patients (25%) due to tissue overgrowth into the buckle in two cases, and 
minimal migration of the LAGB in a third. This is a known complication and has 
been described earlier in 20% of patients were gastrointestinal endoscopic removal 
is attempted [7]. 
Although LAGB is a relatively safe procedure with mortality rates less 
than 0.1% there are two major complications leading to grave morbidity and the 
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risk of death. One is early or late perforation leading to peritonitis, sepsis and organ 
failure. The other is massive bleeding due to iatrogenic trauma or erosion of a 
vessel by the band. Band migration holds the risk of both [5,19-21]. In our series 
we had two patients with significant bleeding after the gastrointestinal endoscopic 
removal. One of them was easily controlled, in the second case a conversion to 
laparoscopy was necessary to locate and stop the hemorrhage. Although both 
patients were discharged in good health, one patient eventually died due to a 
massive rebleeding at the LAGB location two months after the gastrointestinal 
endoscopic removal.  
 
Conclusion 
 
Band migration is a serious complication after LAGB that can be 
potentially life threatening and should be treated accordingly. Gastrointestinal 
endoscopic removal of the migrated Laparoscopic Adjustable Gastric Band is a 
feasible technique that holds the promise of fast reconvalescence. However, there 
is a serious risk for fulminant hemorrhage from the extraction site, even a few 
weeks after the procedure. It is inadvisable to postpone re-intervention when 
bleeding is suspected or to try a gastrointestinal endoscopic approach when a 
patient presents with hematemesis or melena. 
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Abstract          
 
Background 
Access-Port (AP) complicat ions after Laparoscopic Adjustable Gastric Banding (LA GB) 
are often seen but seldom reported in scientific literature. AP complicat ions requiring 
additional surgery is reported in 3.6 to 24% of LA GB patients. We evaluated the effect of 
fixing the AP on the left pectoral fascia using the Velocity ™  Injection Port on complication 
and re-operation rate.  
 
Methods 
From January 2005 till October 2007, 619 LA GB procedures were performed for the 
treatment of morbid obesity using the SAGB QuickClose™ . AP’s were placed on the fascia 
of the left pectoral muscle using an infra-mammary incision. The AP device was fixed on 
the fascia using the Velocity™  Injection Port and Applier. Data was obtained retrospectively 
and 619 consecutive patients were reviewed for access -port related complicat ions.  
 
Results 
Access-port related complications were observed in 68 patients. Complications could b e 
divided in four categories. Discomfort was reported in 30 patients of which seven needed 
additional surgery. Infection contributed in 11 patients in which surgical removal of the 
device was needed. 14 Patients with superficial infect ion were treated cons ervatively. Nine 
patients had inaccessible AP’s. Due to inaccessibility of the AP, ult rasound guided access 
was required in three patients. The remainder needed surgical relocation of the AP. Leakage 
of the tube was observed in four patients all of which needed revisional surgery. 
 
Conclusion 
Our experience shows that fixation of the AP on the left pectoral fascia using the Velocity™ 
leads to a readily accessible AP with good anaesthetic and aesthetic results. 68 (11%) 
Patients developed AP related complication, of which 28 (4.5%) needed additional surgery. 
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Introduction 
 
Laparoscopic adjustable gastric banding (LAGB) is one of the most often 
performed bariatric procedure in Europe. Its objective is to induce weight loss by 
restricting food intake [1-10]. It involves relative safe and simple laparoscopic 
surgery. Substantial and sustained weight loss is obtained in approximately 50% of 
all patients [11]. However, patients with a LAGB are susceptible for complications 
and there is a high re-operation rate. Other patients just fail to respond to the 
restrictive procedure, despite thorough selection [12, 13]. Insufficient weight loss 
and even weight gain is reported in up to 30% of all LAGB patients. Insufficient 
weight loss can be due to pouch dilatation or slippage of the gastric band. Pouch 
formation attributes approximately 5% to these so-called non-responders, and these 
patients need additional surgery. Often considered minor but second in frequency 
are the AP-related complications. These complications can be divided in four 
different categories; discomfort, infection of the AP and/or LAGB, inability to 
puncture the reservoir due to dislocation and disconnection/leakage of the tubing 
[14]. So far, only few papers have addressed these specific LAGB associated 
complications [15-17]. In order to reduce the number of AP-related complications 
an alternative location for the AP, analogue to the fixation site of the Port-a-Cath 
system, was evaluated in our hospital. This new technique was retrospectively 
evaluated. A total number of 619 consecutive patients were treated with LAGB and 
had their AP fixed on the left pectoral fascia using the Velocity™ Injection Port 
and Applier. 
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Abstract          
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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postoperative years. 
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conversion results in a good EWL of 65% after two years, however proper patient selection 
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Materials and Methods 
 
Since 1995, minimally invasive gastric banding was implemented in the 
Rijnstate Hospital in Arnhem. From January 2005 till November 2007, the Swedish 
Adjustable Gastric Band (SAGB) was combined with the Velocity™ Injection Port 
and Applier which was fixed on the left pectoral fascia. A prophylactic dose of 2 g 
cefazoline IV was given 30 min before the onset of surgery. All bariatric 
procedures were performed by three experienced and dedicated surgeons. All 
patients agreed to participate in a standardised follow-up used for evaluating the 
effectiveness of the SAGB. Follow-up procedure was performed by a dedicated 
nurse, and included an appointment 2 and 8 weeks post-operative. Thereafter, 
patients were seen annually for the first 5 years. After 8 weeks the gastric band was 
filled with 2 ml saline independently to weight loss. Later adjustments were done 
according to individual weight loss characteristics. Data on post-operative AP 
complications and re-operation rates were collected retrospectively from this 
database. Patients were evaluated for AP-related symptoms such as pain, infection, 
orientation of the port, inability to gain excess to the AP and leakage and/or 
disconnection of the tubing.  
All LAGB devices were placed using a standard five port laparoscopic 
technique as described by Belachew [18, 19] and positioned using the pars flaccida 
technique. In order to gain access to the pectoral fascia, the sub-xiphoid incision 
was made just left of the midline and extended laterally to approximately 3 cm in 
the inframammary fold. Blunt and electrocautery dissection was performed to 
create a pocket large enough to fit the AP (see Figures 1a–d). The AP was then 
connected to the tube. Fixation of the AP on the pectoral fascia was obtained using 
the four retractable hooks of the Velocity™. Data was statistically analysed using 
SPSS 16.0®. All data is reported as mean±95% confidence interval (95%CI). 
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Patients with less than 6 months of post-operative follow-up were contacted by 
telephone and/or by mail.  
 
Results 
 
From January 2005 till October 2007, a total of 619 patients underwent a 
LAGB procedure in our hospital all of which are included in this study. Patient 
characteristics are summarised in Table 1. Total follow-up was 14.4± 10.0 months. 
Reduction in BMI was found to be significant (p<0.001) from time of operation 
(BMI 44.1 kg/m2) till date of last follow-up (BMI 36.3 kg/m2). From this group 
seven (1.1%) patients received a revision of an earlier placed LAGB. These 
revision were done for pouch dilatation and/or slippage. These were included in 
this study.  
 
Table 1. Patient Characteristics 
Male/Female  102 (16.5%)/517 (83.5%) 
Age (Years) 40.1 ± 9.6 
Duration of surgery (minutes) 63.4 ± 18.1 
Total Follow-up (years) 14.4 ± 10.0 
BMI at the start (kg/m2) 44.1 ± 5.0* 
BMI at last follow-up (kg/m2) 36.3 ± 5.7* 
* Paired t-test; p<0.001 
 
Our AP complications could be stratified in four different categories: 
discomfort, infection, inaccessibility of the AP device and leakage/disconnection of 
the tubing (see Table 2). 
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Table 2. Complications stratified in four categories  
 Discomfort 
 
n (%) 
Infection 
 
n (%) 
Inaccessibility  
 
n (%) 
Leakage/ 
disconnection 
n (%) 
Total 
 
n (%) 
Conservative 23 (3.7%) 14 (2.3%) 3 (0.5%) 0 (0%) 40 (6.4%) 
Surgery 7 (1.0%) 11 (1.7%) 6 (1.0%) 4 (0.6%) 28 (4.5%) 
Total 30 (4.8%) 25 (4.0%) 9 (1.5%) 4 (0.6%) 68 (11.0%) 
 
 Post-operative pain was reported in 30 (4.8%) patients but usually 
subsided within 6 months (23 (3.7%) cases). Seven cases had ongoing chest pain 
oblivious to conservative treatment and required surgery in which the AP was 
moved to the left hypochondrial port site. After this intervention, pain resolved in 
all cases. 
 Infection was reported in 25 (4.0%) patients. Fourteen (2.3%) patients had 
just superficial wound infections and could be treated conservatively. Eleven 
(1.7%) patients required additional surgery. In eight (1.3%) patients only the AP 
was removed and the tubing was left to rest in the abdominal cavity, while patients 
received oral antibiotics for a period of 6 weeks. After approximately 6 months, the 
tubing was recollected laparoscopically and a new AP was placed at the same spot. 
Three (0.5%) patients had the whole system removed due to infection of the gastric 
band and the AP. In all three cases this complication manifested itself at least 4 
months after primary surgery. Two (0.3%) of these patients underwent additional 
bariatric surgery and received a laparoscopic Roux-en-Y gastric bypass. One 
(0.2%) patient renounced from further bariatric procedures and had only the SAGB 
system removed. 
 Inaccessibility of the AP was seen in nine (1.5%) patients. This resulted in 
revisional surgery in six (1.0%) patients. Revision was done in day care since it 
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required only superficial surgery. The remaining three (0.5%) patients had their 
LAGB adjusted using ultrasound guiding.  
Four (0.6%) patients were found to have leaks of the tubing from AP to the 
gastric band. In two (0.3%) patients leakage of the band was found to be intra-
abdominally most likely due to damaging of the tubing during implantation. Two 
tubes were damaged on the spot where the tube passed through the abdominal wall 
and these lesions were considered to be a result from wear and tear from the fascia 
on the tube (see Figure 2). All four (0.6%) patients needed additional surgery in 
order to reconnect the LAGB to the access-port.  
 
Figure 1a. Infra-mammary incision facilitating the AP placement. 
 
147
2
Results of bariatric surgery
 
139 
 
Table 2. Complications stratified in four categories  
 Discomfort 
 
n (%) 
Infection 
 
n (%) 
Inaccessibility  
 
n (%) 
Leakage/ 
disconnection 
n (%) 
Total 
 
n (%) 
Conservative 23 (3.7%) 14 (2.3%) 3 (0.5%) 0 (0%) 40 (6.4%) 
Surgery 7 (1.0%) 11 (1.7%) 6 (1.0%) 4 (0.6%) 28 (4.5%) 
Total 30 (4.8%) 25 (4.0%) 9 (1.5%) 4 (0.6%) 68 (11.0%) 
 
 Post-operative pain was reported in 30 (4.8%) patients but usually 
subsided within 6 months (23 (3.7%) cases). Seven cases had ongoing chest pain 
oblivious to conservative treatment and required surgery in which the AP was 
moved to the left hypochondrial port site. After this intervention, pain resolved in 
all cases. 
 Infection was reported in 25 (4.0%) patients. Fourteen (2.3%) patients had 
just superficial wound infections and could be treated conservatively. Eleven 
(1.7%) patients required additional surgery. In eight (1.3%) patients only the AP 
was removed and the tubing was left to rest in the abdominal cavity, while patients 
received oral antibiotics for a period of 6 weeks. After approximately 6 months, the 
tubing was recollected laparoscopically and a new AP was placed at the same spot. 
Three (0.5%) patients had the whole system removed due to infection of the gastric 
band and the AP. In all three cases this complication manifested itself at least 4 
months after primary surgery. Two (0.3%) of these patients underwent additional 
bariatric surgery and received a laparoscopic Roux-en-Y gastric bypass. One 
(0.2%) patient renounced from further bariatric procedures and had only the SAGB 
system removed. 
 Inaccessibility of the AP was seen in nine (1.5%) patients. This resulted in 
revisional surgery in six (1.0%) patients. Revision was done in day care since it 
 
140 
 
required only superficial surgery. The remaining three (0.5%) patients had their 
LAGB adjusted using ultrasound guiding.  
Four (0.6%) patients were found to have leaks of the tubing from AP to the 
gastric band. In two (0.3%) patients leakage of the band was found to be intra-
abdominally most likely due to damaging of the tubing during implantation. Two 
tubes were damaged on the spot where the tube passed through the abdominal wall 
and these lesions were considered to be a result from wear and tear from the fascia 
on the tube (see Figure 2). All four (0.6%) patients needed additional surgery in 
order to reconnect the LAGB to the access-port.  
 
Figure 1a. Infra-mammary incision facilitating the AP placement. 
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Figure 1b. Tunnelling of the tube in order to reduce wear and tear of the tube. 
 
 
Figure 1c. Placement of the AP device on the pectoral fascia. 
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Figure 1d. Cosmetic result at termination of the LAGB procedure
 
 
Figure 2. Blue dye shows leakage of the tubing due to wear and tear on the fascia  
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Figure 1d. Cosmetic result at termination of the LAGB procedure
 
 
Figure 2. Blue dye shows leakage of the tubing due to wear and tear on the fascia  
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Discussion 
 
After approximately 11 years of experience with LAGB surgery we 
concluded that AP-related complications are frequent and most often due to 
technical failure. Some of these complications are caused by the chosen location of 
the AP and thus it is only logic to try to identify the ideal site for AP fixation. In 
order to appoint a new location for the AP we considered multiple factors for 
optimal placement. First of all, the location must be readily accessible for the 
required and frequent adjustments of the LAGB. One must be able to firmly secure 
the AP on the designated spot. 
This fixation should give no or little discomfort and should provide 
acceptable cosmetic characteristics. In the long run, wear and tear on the devices’ 
tubing should be minimised in order to reduce the change of leakage of the system 
and inducing a failure. To minimise infection rates, antibiotic prophylaxis should 
be given 30 min before the onset of surgery.  
Different port locations are commonly used and include: the anterior rectus 
sheath, under the anterior rectus sheath, within the subcutaneous fat, sub-xiphoid 
and left subcostal margin. Ports can be fixed by sutures or with retractable hooks, 
our even non-fixed. APs seem to be well tolerated by most patients regardless of 
position and fixation. Subfascial placement may give some more pain complaints 
during access and may be more difficult to palpate. Ports placed in the 
subcutaneous fat may become very prominent once a patient has lost weight. 
Rotation of the port is thought to occur more often making the ports inaccessible. 
Fixation of the port on the fascia is time consuming and may give pain 
complaints. Infra-mammary placement is cosmetically favourable, and makes the 
AP easy to palpate. By using the mechanical port fixation method, operation time 
and post-operative discomfort complaints can be reduced. 
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We choose the left pectoral fascia analogue to years of experience with the 
port-a-cath system. In order to create a pouch for the AP, we elongated our sub-
xiphoid incision laterally in the infra-mammary fold for the best aesthetic result 
possible. When placing the infra-mammary incision in female patients we made 
sure it did not interfere with wearing a brassiere, since scar tissue might give rise to 
irritation of the skin in the infra-mammary fold. The AP was fixed just lateral of 
the sternum in order to make needle access to the AP relatively safe and simple. 
The device was firmly attached on the chest wall in order to prevent friction 
between connection tube and fascia. In our study population, two early patients had 
leakage of the tubing due to wear and tear of the device on the fascia (see Figure 
2). The technique used was adjusted by tunnelling our tube parallel to and direct on 
the fascia in order to minimise mechanical wear. Two other patients were shown to 
have intra-abdominal leakage using water-soluble contrast. These were considered 
technical failures, probably due to incorrect handling of the tube during initial 
placement of the access-port. 
 Thoracic pain complaints were seen in some of our earlier patients, two of 
which were even referred to the cardiologist by their family doctor. Complaints 
were most often short lived and regressed spontaneously. After we started using 
local anaesthetics (Ropivacaine® 7.5 mg/ml, 10 ml) on the AP fixation site and 
placed our APs a little laterally of the sternum, pain complaints receded. Thoracic 
pain is probably due to damaging the periost lining of the sternum and costae with 
our suturing device. Dislodgement of the AP was seen in nine (1.5%) patients. 
Revisional surgery to relocate and fixate the dislocated AP was required in six 
(1.0%) of our cases.  
Overall, we had an 11% complication rate of which only 4.5% needed 
additional surgery. In literature, a 3.6–24% reoperation rate for AP-related 
complications is reported [1– 9]. We conclude that besides being fast, fixation of 
the AP on the left pectoral fascia is safe and simple. If the reservoir is firmly 
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attached to the fascia, it lies rather superficial which makes percutaneous access 
easy. No additional incision is needed since the incision below the xiphoid is 
extended laterally in the infra-mammary fold, thereby giving good cosmetic results. 
Discomfort is minimised by using local anaesthetic preoperative. Mechanical wear 
and tear was minimised by lining the tubing parallel to the fascia and thus reducing 
the angle in which the tube passed through the fascia. Whether our system can 
stand up to the wear and tear of time needs yet to be seen since our follow up is 
relatively short.  
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Abstract          
 
Background 
Anemia associated with deficiencies in iron, folic acid and, vitamin B12 are very common 
after Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) surgery for morbid  obesity. This 
study was conducted to evaluate the prevalence of anemia and its associated deficiencies in 
the first year after LRYGB. 
 
Patients and methods 
From January 2005 till October 2009 a total of 377 morb id obese  patients were included in 
our study. All patients were scheduled for a LRYGB. Hematologic parameters were 
obtained prior to surgery and on standardized time intervals after  surgery. 
 
Results 
After LRYGB, anemia was present  in 21 (p=0.02) patients The percentage of patients with 
iron, folic acid and vitamin B12 deficiencies were 66%, 15% and 50% respectively. In 86% 
of patients anemia was accompanied by one of these deficiencies. Patients who did lose less 
than 70%  of their excess weight within the first year after surgery were at greater risk for 
developing a vitamin B12 deficiency (p=0.03).  
 
Conclusion 
These results show that anemia and deficiencies for iron, folic acid deficiency and vitamin 
B12 are very common within the first year after LRYGB. We advise a minimal daily intake 
of  65 mg of iron in male and 100 mg in female patients,  350 μg of vitamin B12 an d 400 
μg of folic acid. Patients undergoing LRYGB must be closely monitored for deficiencies 
pre- and postoperative and supplemented when deficiencies occur.  
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Introduction 
 
Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) is one of the most 
commonly performed bariatric procedures to establish weight loss in morbid obese 
patients. A sustained Excess Weight Loss (EWL) of 50-70% is obtained in at least 
50% of the patients by combining restrictive and malabsorption techniques. 
Sustained weight loss is associated with a decrease in obesity related morbidity and 
mortality and an increase in quality of life [1-5]. 
However, due to malabsorption and insufficient intake, LRYGB patients 
are prone to develop deficiencies in many macro- and micronutrients.  Most 
common are deficiencies in iron, folate and vitamin B12, all of which can lead to 
anemia. Once these deficiencies are present they can be difficult to treat by oral 
vitamin and mineral supplements. Therefore, patients who undergo RYGB should 
be evaluated prior to surgery for deficiencies, and treated accordingly. After 
surgery supplementation and close monitoring is warranted [1,2,6-8].  
A number of possible risk factors for developing anemia have been 
previously researched. Differences in sex as well as length of Roux-en-Y limb are 
described as contributing factors for the development of certain deficiencies [3]. 
Also we researched whether the amount of weight loss or an Adjustable Gastric 
Band (AGB) prior to the LRYGB influenced the amount of deficiencies. 
Although weight loss effects of RYGB are well established, the number of 
studies addressing  nutrient deficiencies and  anemia is limited. Furthermore, the 
studies conducted so far often include only a small number of patients and are 
incongruent in their findings [1,7]. For this reason we conducted a prospective 
study to investigate the prevalence of anemia and deficiencies in iron, folate and 
vitamin B12 in the first year after LRYGB in our patients . 
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Patients and methods 
 
Between January 2005 and October 2009 a total of 416 patients underwent a 
LRYGB in our hospital. All patients were screened by a multidisciplinary team 
preoperatively and met the criteria stated by the NIH Consensus Development 
Conference Panel for bariatric surgery1. Patients who were unable to attend our 
standardized follow-up protocol were excluded. Also excluded were patients with 
laboratory evaluations which surpassed the six and 12 months evaluation with two 
and three months respectively. Research nurses assured a minimum of data loss. 
Hence being part of our standard intake  protocol, all patients were informed about 
this study. A total number of 377 (91%) patients scheduled for LRYGB were 
included in this study. We included 102 (27%) male patients and 275 (73%) female 
patients with a mean age of 43 (18-63) years. Medium follow up time was 13.7 
months. Demographics are shown in Table 1. 
In our clinic the proximal gastric volume is reduced by stapling of a 30cc 
proximal gastric pouch and connecting a 100 or 150 cm roux-en-y limb as an 
entero-enterostomie to the jejunum 40 cm from the ligament of Treitz. Limb length 
was based on the patients BMI between 2005 and 2007.  Patients with a BMI 
>40kg/m2  received a 100cm limb. Patients with a BMI >50 kg/m2  or a failing 
gastric band were treated with a 150cm limb. Since 2007 all patients received a 
150cm limb. After surgery patients were followed up at 1,3,6, and 12 months.  
Standard laboratory evaluation was performed preoperatively consisting of a 
complete blood count, a mean cell volume (MCV) and kidney function. After six 
and twelve months, laboratory evaluation was repeated along with plasma levels 
for iron, Total Iron Binding Capacity (TIBC), serum folate levels, and serum 
vitamin B12 levels.  
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Table 1. Demographics 
Parameter Values (Standard deviation) 
Number of patients 377 
Male 102 (27.1%) 
Female 275 (72.9%) 
Age 43.4 (18-63) 
      Age male      46.0 (20-63) 
      Age female      42.5 (18-62) 
Initial weight in kg 137.5 (± 22.6) 
      Male      151.4 (± 22.1) 
      Female      132.4 (± 20.6) 
Initial BMI in kg/m2 46.8 (± 6.3) 
      Male      47.0 (± 6.4) 
      Female      46.7 (± 6.2) 
 
Patients were instructed to take a standard multivitamin tablet three times 
daily. These tablets contained at least 7mg of iron, 100 µg of folic acid and 0.5 µg 
of vitamin B12 per tablet. Our standard postoperative medication consisted of a 
CaD 1000/880® sachet to prevent bone loss, Omeprazol® 40mg once daily to 
prevent ulceration of the staple line and the remaining stomach and 5700U of 
Fraxiparine® once daily for six weeks postoperative for preventing thrombosis. 
During each visit patients were asked about their medication use so as to estimate 
their compliance to our described medication. 
Anemia was defined as a hemoglobin (Hb) level < 8.4mmol/L in men and 
< 7.4 mmol/L in women. MCV was defined normal between 80 and 100fL. Iron 
deficiency was defined by serum levels < 9.0µmol/L. Total Iron Binding Capacity 
was defined as high when >80%. Folate deficiency was defined by serum levels     
Para eter Values (Standard deviation) 
Number of patients 377 
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Female 275    (72.9%) 
Age 43.4   (18-63) 
      Age male 46.0   (20-63) 
      Age female 42.5   (18-62) 
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      ale 151.4 (± 22.1) 
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Initial B I in kg/m2 46.8   (± 6.3) 
      ale 47.0   (± 6.4) 
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< 9.0nmol/L. Cobalamin deficiency was defined by serum levels < 150pmol/L.  
Once a deficiency was identified treatment was started  accordingly.  
 
Statistics 
Data were prospectively collected and evaluated using SPSS16® for 
Windows. All data are reported as mean ± standard error of the mean. To evaluate 
the results between groups, logistic regression was used. Evaluation of laboratory 
results was performed using a paired T-tests. P<0.05 was considered significant.  
Patients who were anemic preoperative were excluded for the 12 months 
evaluation (Table 3 N=350) and were evaluated  separately (Table 4 N=27).  
 
Results 
 
Before surgery anemia was present in 27 (7%) patients. After twelve 
months 66 (19%) patients had developed anemia de novo, of which 19 (29%) were 
microcytic. In these patients mean Hb levels dropped from 8.2mmol/L to 
7.1mmol/L (p<0.001). Total prevalence of anemia diagnosed in the first year, 
including preoperative anemic patients, was 25%. Preoperative laboratory results 
are shown in Table 2. 
 
Table 2. Laboratory outcomes before RYGB 
 Level Number of patients (%) 
Low 27 (7,9%) of which 9 microcytic Hb 
Normal 350 (92,9%) of which 13 microcytic and 5 
macrocytic Microcytic 22 (5,8%) 
Normocytic 350 (92,9%) 
MCV 
Macrocytic 5 (1,3%) 
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 A total of 93 patients were diagnosed with or developed anemia during the 
first postoperative year.  The percentage of deficiencies in patients with anemia are 
separately shown in Table 3. The percentage of patients with iron, folic acid and 
vitamin B12 deficiencies were 66%, 15% and 50% respectively. In 86% of patients 
anemia was accompanied by one of these deficiencies. 
Analysis of deficiencies in all patients is shown in Table 4. Iron deficiency 
after one year was identified in 33% of patients and in 61% of our patients with 
anemia de novo (p<0.001). The percentage of patients with folic acid and vitamin 
B12 deficiency were 14% and 40% respectively. Three patients developed 
macrocytic red blood cells, and in two cases a vitamin B12 deficiency was found. 
Of all patients 239 (63%) were diagnosed with at least one of the deficiencies 
mentioned above. 
Risk factor analysis is presented in Table 5. Many differences between 
male and female patients were found in the prevalence of iron (38% vs. 17%, 
p=0.02), and vitamin B12 (42% vs. 21% p=0.03) deficiencies. However, the 
percentage for developing anemia in these groups was similar, 20%. Male patients 
had  a 45% risk of being diagnosed with an iron, folic acid or vitamin B12 
deficiency whereas female patients had  a 68 % risk (p=0.004). 
Further analysis was done to investigate the role of  Roux-en-Y limb length 
the onset of deficiencies. No significant differences were found. A number of 
patients were treated with a AGB prior to RYGB surgery. A significant difference 
(24% vs. 39% p=0.03) in vitamin B12 deficiencies between these groups was 
found. Surprisingly the percentages for anemia, folic acid and vitamin B12 
deficiencies were lower in the group who had a previous AGB placement. 
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Table 4. 12 Month evaluation of all RYGB patients  
 Month 6 (%) Month 12 
(%) 
Total (%) 
Anemia 50 (13.3%) 71 (18.8%) 93 (24,7%) 
MCV 
Micro 24 (6.4%) 20 (5.3%) 34 (9.0%) 
Macro 4 (1.1%) 6 (1.6%) 8(2.1%) 
Elevated TYBC 17 (4.5%) 26 (6.9%) 32 (8.5%) 
Iron deficiency 79 (21%) 78 (20.7%) 124 (32.9%) 
Folic acid deficiency 34 (9.0%) 25 (6.6%) 51 (13.6%) 
Vitamin B12 deficiency 89 (23.6%) 71 (18.8%) 152 (40.2%) 
Total deficiency 175 (46.4%) 150 (39.8%) 239 (63.4%) 
T6= laboratory findings (%) at 6 months T12= laboratory findings (%) at 12 
months.  N=377 
 
Patients who lost over 70% of their excess weight in one year were less 
likely to develop anemia and deficiencies for folic acid and vitamin B12 compared 
to patients below 70% EWL. 
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Patients who lost over 70% of their excess weight in one year were less 
likely to develop anemia and deficiencies for folic acid and vitamin B12 compared 
to patients below 70% EWL. 
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Discussion 
 
Bypassing the duodenum and proximal jejunum leads to a decrease in 
absorption surface for specific nutrients and causes a reduction in the absorptive 
capacity. After a LRYGB the most common reported are iron and vitamin B12 
deficiencies. Deficiencies in these micronutrients are well known causes for 
anemia [1,7,9]. Published reports on metabolic deficiencies after RYGB with 
different follow-up periods found anemia varying from 18 to 35 %. Iron deficiency 
was reported in 20-49% in these studies. Folate deficiency was found in 0- 18% of 
the cases. Vitamin B12 deficiency varied from 26-70% [12,13, 25-28]. Although a 
relative short follow-up of only one year, we found high percentages in folic acid 
and vitamin B12 deficiencies, of  19 and 36% respectively. 
Iron deficiency after RYGB is due to a combination of factors and is the 
main cause for developing anemia after a RYGB [14,15]. Absorption is dependent 
of the  pH of the stomach. Acid reduces iron from a ferric state (Fe3+) to a ferrous 
state (Fe2+) which is readily absorbed in the duodenum and proximal jejunum. 
Due to the RYGB configuration,  iron passes through the small gastric pouch 
without being reduced to the ferrous state.  This effect is further enhanced by the 
prescribed protonpump inhibitors and calcium. After ingestion, iron bypasses the 
absorptive surface of the duodenum and jejunum. Iron intake is further reduced by 
the frequently found intolerance for red meat [9,10]. A normal individual requires 
1-2mg of iron daily as a minimum. Especially premenopausal female are prone for 
developing iron deficiency [3,12-14].  
Preoperative 8% of our patients were anemic and another 5% had micro-or 
macrocytic red blood cells. These findings are most likely due to an unvaried 
intake of macro- and micronutrients by these patient [9,10]. This shows that testing 
patients for anemia and deficiencies in iron, folate and vitamin B12 preoperative is 
needed to achieve the best medical care for the bariatric patient. Patients should be 
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Discussion 
 
Bypassing the duodenum and proximal jejunum leads to a decrease in 
absorption surface for specific nutrients and causes a reduction in the absorptive 
capacity. After a LRYGB the most common reported are iron and vitamin B12 
deficiencies. Deficiencies in these micronutrients are well known causes for 
anemia [1,7,9]. Published reports on metabolic deficiencies after RYGB with 
different follow-up periods found anemia varying from 18 to 35 %. Iron deficiency 
was reported in 20-49% in these studies. Folate deficiency was found in 0- 18% of 
the cases. Vitamin B12 deficiency varied from 26-70% [12,13, 25-28]. Although a 
relative short follow-up of only one year, we found high percentages in folic acid 
and vitamin B12 deficiencies, of  19 and 36% respectively. 
Iron deficiency after RYGB is due to a combination of factors and is the 
main cause for developing anemia after a RYGB [14,15]. Absorption is dependent 
of the  pH of the stomach. Acid reduces iron from a ferric state (Fe3+) to a ferrous 
state (Fe2+) which is readily absorbed in the duodenum and proximal jejunum. 
Due to the RYGB configuration,  iron passes through the small gastric pouch 
without being reduced to the ferrous state.  This effect is further enhanced by the 
prescribed protonpump inhibitors and calcium. After ingestion, iron bypasses the 
absorptive surface of the duodenum and jejunum. Iron intake is further reduced by 
the frequently found intolerance for red meat [9,10]. A normal individual requires 
1-2mg of iron daily as a minimum. Especially premenopausal female are prone for 
developing iron deficiency [3,12-14].  
Preoperative 8% of our patients were anemic and another 5% had micro-or 
macrocytic red blood cells. These findings are most likely due to an unvaried 
intake of macro- and micronutrients by these patient [9,10]. This shows that testing 
patients for anemia and deficiencies in iron, folate and vitamin B12 preoperative is 
needed to achieve the best medical care for the bariatric patient. Patients should be 
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treated for their deficiencies preoperative to prevent symptomatic anemia, 
deficiencies and possible complications during and after surgery. In case of 
preoperative deficiencies, patients in our clinic are treated with high doses of iron 
(200mg a day), vitamin B12 injections (3000 μg every week) and folic acid (2mg a 
day). These amounts are used until an adequate serum level is reached. 
  In our study 56% of the patients who developed anemia de novo 
also had an  iron deficiency and 42% had microcytic red blood cells. Of the 
patients who did not develop anemia within the first year another 32% appeared to 
be iron deficient and may develop anemia in the near future if not treated. In our 
study we prescribed all patients Omeprazol® tablets and CaD 1000/880® sachets. 
This may increase the percentage of iron deficiencies because Omeprazol® reduces 
acid secretion and subsequent iron absorption. Calcium can, when taken around the 
same time as iron, decrease the uptake of iron up to 60% [16]. The amount of iron 
(21mg daily) supplemented did not prevent iron deficiency in a large number of 
patients.  Most recent recommendations in literature advise a daily intake of 40 to 
65 mg of elemental iron per day for male and 100mg per day for female patients. 
Vitamin C added to this regimen may also improve absorption [10,15,27].  
Folic acid is present in food as polyglutamates and must be hydrolyzed to 
monoglutamates by the intestinal brush border. Folic acid absorption 
predominantly takes place in the upper third of the small intestine, but can be 
absorbed throughout the small intestine [15]. Absorption is pH dependent and 
therefore partially facilitated by hydrochloric acid. Additionally, vitamin B12 acts 
as a coenzyme in converting folic acid to an absorbable form thus a vitamin B12 
deficiency may result in a folate deficiency [16,17]. Due to the low acid production 
of the proximal pouch and the bypassing of the upper third of the small intestine, 
RYGB patients are at risk for developing folic acid deficiency [17,18]. 
Enterohepatic recirculation is an important factor in preserving the body pool of 
folate [10]. Another contributing factor for developing a folic acid deficiency may 
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be due to the malabsorption and the short bowel in RYGB patients . Despite these 
apparent mechanisms for folate deficiency, decreased dietary intake of folic acid 
seems the dominant cause. Since folic acid reserves are low with an average of 
10mg, a daily requirement of 50μg and a deficit absorption, deficiency can occur 
rapidly [16,19].  
In this study 19% of the patients were diagnosed with folic acid deficiency. 
A number of studies found a substantial decrease in folic acid deficiencies over the 
years. An explanation for this decrease may be that folic acid absorption in the 
distal small intestine compensates for the reduced absorption capacity. Another 
mechanism might by the based on  bacteria in the upper small bowel who produce 
more folic acid over time [22,30].  
The 300µg of folic acid prescribed per day appears not to be sufficient to 
avoid a deficiency in the first year. A sufficient quantity of folic acid should be at 
least 400μg per day while most authors prescribe 1 mg of folic acid a day [13,16]. 
Folic acid deficiency may be of great concern in female patients who want to 
became pregnant in the near future after RYGB. Although uncommon, reports of 
neural tube defects have been reported in infants after RYGB surgery[13,29]. 
Woman of reproductive age should be monitored closely, bearing in mind that one 
of the reasons for undergoing a RYGB is decreased fertility due to morbid obesity.  
Vitamin B12 in food is bound to proteins and first needs to be released by 
pepsin and hydrochloric acid before it can be bound by Intrinsic Factor (IF). When 
the released vitamin B12 in a normal individual enters the duodenum it is bound to 
IF released from the parietal cells of the stomach facilitated by pepsin and 
pancreatic enzymes. In this state the bound vitamin B12 is eventually absorbed in 
the terminal ileum. After RYGB vitamin B12 cannot be released from the food and 
is hardly bound to IF due to the bypassing of the stomach and duodenum and the 
reduced amount of IF released [20,21]. The frequently found intolerance for red 
meat and milk might also play a role, as these products are rich in vitamin B12. In 
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healthy subjects a daily minimal dose of  2µg vitamin B12 per day is needed. A 
normal individual has a vitamin B12 reserve of 2000µg which should last for a 
minimum of two years [10,22-24]. .  
LRYGB patients appear to have much lower vitamin B12 reserves than 
healthy individuals, probably due to inadequate dietary intake preoperatively. The 
multivitamins prescribed contains 1,5 µg of vitamin B12 per day. Several studies 
have shown that a 300-500µg dose of vitamin B12 is sufficient. Others recommend 
sublingual administration or intramuscular injections of 1000-3000µg every month 
to every six months and report similar outcomes for resulting vitamin B12 levels 
[13,21,27,31-33]. In the case of vitamin B12 the prescribed Omeprazol® may also 
decrease absorption [16]. Although none of our patients became symptomatic for 
B12 deficiency, there have been reports of patients developing Wernicke’s 
encephalopathy and megaloblastic anemia years after RYGB [34-39]. 
The risk factors  studied for developing metabolic deficiencies showed  a 
number of interesting results. A number of studies reported a difference for 
developing anemia and iron deficiency between male and female patients who had 
underwent RYGB [12-14]. Anemia and iron deficiency are thought to be higher 
among woman, because premenopausal women lose iron during menstruation 
every month and often have no iron reserves [11-14]. This study did not find a 
significant difference in the prevalence for anemia between the sexes. In fact the 
prevalence was identical at 20%. This shows that the first year after LRYGB the 
risk for developing anemia is equal between male and female patients after RYGB 
surgery for morbid obesity. We did however find significant higher percentages for 
iron and vitamin B12 deficiencies in female patients. From these data one could 
conclude that on the long run female patients may have a higher risk for developing 
anemia. The difference in iron deficiencies between males and females can be 
explained by the average lower iron reserves of females, combined with the loss of 
iron during menstruation. The difference in vitamin B12 might be explained by the 
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average lower daily intake of vitamin B12 by female patients compared to male 
patients (4µg vs. 7µg). Of all the patients who developed anemia 71% were female. 
This greater number is due to the fact that a  greater number of patients undergoing 
RYGB were female. 
The different lengths of the Roux-en-Y limb did not show any significant 
outcomes. Although the 150cm limb group showed a 6% higher prevalence for 
anemia and lower values for folic acid and vitamin B12 deficiencies these values 
were not significant. Brolin et al also found lower deficiency rates for vitamin B12 
with an increase of the Roux-en-Y limb length.  
Patients with a AGB prior to a RYGB had a lower prevalence’s for anemia, 
folic acid deficiency and even a significant lower risk of vitamin B12 deficiency 
(p=0.03). These patients were already used to taking multivitamin tablets during 
the period they had a AGB. Thus resulting in higher baseline values and  a better 
compliance (92 vs. 76%). These differences may explain the unexpected 
differences in deficiencies found. 
We expected the group who lost >70% of their EWL to have higher 
prevalence’s of deficiencies due to a decreased intake of macro- and 
micronutrients. The prevalence of iron deficiency was as expected higher in the 
>70% group, but all the other prevalence’s where lower in this group. The 
difference in vitamin B12 deficiency was almost significant (p=0.07)., and might 
be explained by the release of vitamin B12 from the shrinking liver and fatty tissue. 
This mechanism will only protect these patients during the rapid weight loss. After 
this period the micronutrient stores will be depleted. 
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Conclusion 
 
Our  results show that anemia and deficiencies for iron, folic acid and 
vitamin B12 are very common the first year after LRYGB. Women are at risk for 
developing iron deficiency and vitamin B12 deficiency and have a greater overall 
risk for developing one of the deficiencies researched. Our standard policy for 
supplementation of multivitamin tablets after LRYGB failed to prevent 
deficiencies. We advise a minimal daily intake of  65mg of iron in male and 100mg 
in female patients,  350 μg of Vitamin B12 and 400 μg of folic acid .With this 
article we want to create awareness for screening RYGB patients for deficiencies 
and correcting these within the first year. Furthermore, supplementing these 
patients with multivitamins should only be regarded as a base upon which a 
patient-specific regimen for micronutrients should be build.  
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Abstract          
 
Background 
 Recently the Laparoscopic Sleeve Gastrectomy (LSG) has become popular as a single -
stage procedure for the treatment of morbid obesity and its co -morbidit ies. However, the 
incidence of micronutrient deficiencies after LSG have hardly been researched. 
 
Methods  
From January 2005 to October 2008, 60 patients underwent LSG. All patients were 
instructed to take daily vitamin supplements. Patients were tested for micronutrient 
deficiencies six and twelve months after surgery. 
 
Results  
Anemia was diagnosed in 14 (26%) patients. Iron, folic acid and vitamin B12 deficiency 
was found in 23 (43%), 8 (15%) and 5 (9%) patients respectively. Vitamin D and albumin 
deficiency was diagnosed in 21 (39%) and 8 (15%) patients. Hypervitaminosis A, B1 and 
B6 were d iagnosed in 26 (48%), 17 (31%) and 13 (30%) patients respectively. 
 
Conclusion  
Due to inadequate in-and uptake of micronutrients, patients who underwent LSG are at 
serious risk for developing micronutrient deficiencies. Moreover, some vitamins seem to 
increase to chronic elevated levels with possible complications in the long term. 
Multivitamins and calcium tablets should be regarded only as a min imum and supplements 
especially for iron, vitamin B12, v itamin D and calcium  should be added to this regimen 
based on regular blood testing.  
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Introduction 
 
A Laparoscopic Sleeve Gastrectomy (LSG) is often used as a first-stage 
procedure followed either by Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) 
or Duodenal Switch (DS). LSG is performed to obtain weight loss and co-
morbidity reduction by restricting the food capacity of the stomach. Currently LSG 
is performed less often than Laparoscopic Gastric Banding (LAGB) and LRYGB, 
but reports of LSG used as a single procedure in morbid obese patients are 
increasing [1-8]. Deficiencies in micronutrients after bariatric procedures are a 
known threat if not corrected appropriately [9-13]. Surprisingly, reports on anemia 
and micronutrient deficiencies specifically in patients who underwent LSG are 
scarce. As part of our standard follow up care we conducted this prospective study 
to evaluate the deficiencies in the first year following LSG.  
 
Patients and Methods  
 
From January 2005 to October 2008, 60 morbid obese patients were treated 
with a LSG by two surgeons as a first-stage procedure towards a DS. This group of 
patients consisted of 36 males and 24 females with a mean age of 44 (18-70) years. 
Mean initial weight and BMI were 178 (±33.9) kg and 56,8 (±10.9) kg/m2 
respectively. Demographics are shown in Table 1. 
All patients underwent a LSG as a first step in order to reduce operative 
risks (ASA score) of the DS in the second-stage. In our clinic the gastric volume is 
reduced by stapling the gastric fundus and greater curvature parallel to a 36 French 
boogie, which is inserted in the stomach through the esophagus. Stapling starts 
from a distance of 3 to 5 cm from the pylorus at the greater curvature side towards 
 
90 
 
Abstract          
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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the angle of His. This results in a tube-like stomach made from the lesser curvature 
only. 
 
Table 1. Demographics 
Parameter Values (Standard 
deviation) Number of patients 60 
Male 34 (56,6%) 
Female 26 (43,3%) 
Age 43,6 (18-70) 
Initial weight in kg 178,4 (± 33,9) 
Initial BMI in 
kg/m2 
56,8 (± 10,9) 
 
 Standard laboratory evaluation was performed preoperatively consisting of 
a complete blood count, a mean cell volume (MCV) and kidney function. Results 
are shown in Table 2. After six and twelve months, the laboratory evaluation was 
repeated along with plasma iron, total iron binding capacity (TIBC), calcium, 
serum calcidiol (vitamin D3), parathyroid (PTH), serum retinol (vitamin A), serum 
thiamin (vitamin B1), serum pyridoxine (vitamin B6), serum folate (vitamin B11) 
and serum cobalamin (vitamin B12).  
Patients were instructed to take multivitamin tablets three times daily 
(150% RDA). Other postoperative medication consisted of a CaD 1000/880® 
sachet for one year to prevent bone loss, Omeprazol® 40mg once daily for 6 
months to prevent ulceration of the staple lines and the remaining stomach and 
5700U of fraxiparine® once daily for six weeks postoperative to prevent 
thrombosis.  
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Table 2. Preoperative laboratory outcomes 
 Level Number of patients (%) 
Hb Low 5 (8,3%) of which 1 microcytic 
Normal 55 (91,7%) of which 2 microcytic  
MCV Microcytic 3 (5,0%) 
Normocytic 57 (95,0%) 
Macrocytic 0 (0%) 
 
During the first year of follow up 6 patients, none of which were anemic 
before surgery, underwent a DS as the second stage for the treatment for their 
morbid obesity. These patients were excluded for the 12 month laboratory 
evaluation.  
Laboratory results were evaluated according to the values mentioned in 
Table 3. Once a deficiency was identified it was treated accordingly. Data were 
prospectively collected and processed using SPSS16®. All data are reported as 
mean ± standard error of the mean unless otherwise specified. P<0,05 was 
considered significant.  
 
Results 
 
Preoperatively 5 (8.3%) patients were anemic of which one had microcytic 
red blood cells. Additionally, two patients without anemia were diagnosed with 
microcytic red blood cells. 
Perioperative complications occurred in two patients. One patient had a 
staple line leakage that was oversewn during reoperation. A second patient 
developed a leakage in the staple line at the esophageal-gastric junction which was 
clipped endoscopically and resolved after a few months. 
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One year after surgery mean weight loss and excess BMI loss were 51 kg 
and 16.4 kg/m2 respectively. Mean excess weight loss was 52% (22.1%-84.3%) 
after the first year. All patients adhered to the multivitamin supplements advised in 
the first year. Laboratory results are shown in Table 3. 
Anemia de novo developed in ten patients during the first year. Only one 
patient who was anemic before surgery reached a normal Hb level with suppletion 
of the deficiencies found. From all new anemic patients only two developed 
microcytic red blood cells. In total 14 (26%) patients where anemic after one year. 
Iron deficiency was found in 23 (43%) patients. From these patients only 
three were diagnosed with a raised TIBC and six developed microcytic red blood 
cells.  
Calcium levels corrected for albumin remained between acceptable levels. 
Two patients had slightly raised levels, with a maximum of 2.58mmol/L. More 
concerning were the high PTH levels and low levels of vitamin D found. 21 (39%) 
Patients had elevated PTH levels and 21 (39%) patients were diagnosed with low 
serum vitamin D levels also. This shows a fast change in bone metabolism after a 
LSG, despite the specific medication that was prescribed for preventing bone loss. 
 In a number of patients vitamin levels were above normal range. 
Vitamin A appeared to be high in 26 (48%) patients, vitamin B1was high in 17 
(31%) patients and vitamin B6 was high in 13 (30%) patients. Vitamin B1 however 
was also low in 6 (11%) patients. 
Folic acid deficiency was found in 8 (15%) patients and vitamin B12 
deficiency in 5 (9%) patients. No patients developed macrocytic red blood cells 
during the first year. 
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Table 3. Postoperative laboratory outcomes 
 Normal values Mean value (±SD) Total (%) 
Hb Male >8,4 
mmol/L 
8,5mmol (±0,9) Anemia 14/54 
(26%) Female >7,4 
mmol/L MCV 80-100fL 87fL (±6) Micro 8/54 (15%) 
Macro 0/54 (0%) 
Iron 9-31µmol/L 13,2µmol/L (±5,6)  Low 23/54 (43%) 
High 0/54 (0%) 
TIBC 45-81nmol/L 58nmol/L (±14) Low 0/54 (0%) 
High 3/54 (6%) 
Calcium 2,10-2,55mmol/L 2,34mmol/L (±0,10) Low 0/54 (0%) 
High 2/54 (4%) 
PTH 1,3-6,8pmol/L 5,7pmol/L (±3,0) Low 0/54 (0%) 
High 21/54(39%) 
Albumin  35-50G/L 38,7G/L (±4,0) Low 8/54(15%) 
High 0/54(0%) 
Vitamin A 1,05-2,80µmol/L 2,59µmol/L (±0,9)  Low 2/54 (4%) 
High 26/54 (48%) 
Vitamin B1 95-175nmol/L 153nmol/L (±41) Low 6/54 (11%) 
High 17/54 (31%) 
Vitamin B6 25-100nmol/L 115nmol/L (±129) Low 0/44 (0%) 
High 13/44 (30%) 
Folic acid 9-36nmol/L 178,0nmol/L (±9,4)  Low 8/54 (15%) 
High 2/54 (4%) 
Vitamin B12 150-640pmol/L 296pmol/L (±106) Low 5/54 (9%) 
High 1/54 (2%) 
Vitamin D 30-100nmol/L 47nmol/L (±23) Low 21/54(39%) 
High 0/54 (0%) 
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One year after surgery mean weight loss and excess BMI loss were 51 kg 
and 16.4 kg/m2 respectively. Mean excess weight loss was 52% (22.1%-84.3%) 
after the first year. All patients adhered to the multivitamin supplements advised in 
the first year. Laboratory results are shown in Table 3. 
Anemia de novo developed in ten patients during the first year. Only one 
patient who was anemic before surgery reached a normal Hb level with suppletion 
of the deficiencies found. From all new anemic patients only two developed 
microcytic red blood cells. In total 14 (26%) patients where anemic after one year. 
Iron deficiency was found in 23 (43%) patients. From these patients only 
three were diagnosed with a raised TIBC and six developed microcytic red blood 
cells.  
Calcium levels corrected for albumin remained between acceptable levels. 
Two patients had slightly raised levels, with a maximum of 2.58mmol/L. More 
concerning were the high PTH levels and low levels of vitamin D found. 21 (39%) 
Patients had elevated PTH levels and 21 (39%) patients were diagnosed with low 
serum vitamin D levels also. This shows a fast change in bone metabolism after a 
LSG, despite the specific medication that was prescribed for preventing bone loss. 
 In a number of patients vitamin levels were above normal range. 
Vitamin A appeared to be high in 26 (48%) patients, vitamin B1was high in 17 
(31%) patients and vitamin B6 was high in 13 (30%) patients. Vitamin B1 however 
was also low in 6 (11%) patients. 
Folic acid deficiency was found in 8 (15%) patients and vitamin B12 
deficiency in 5 (9%) patients. No patients developed macrocytic red blood cells 
during the first year. 
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Table 3. Postoperative laboratory outcomes 
 Normal values Mean value (±SD) Total (%) 
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mmol/L 
8,5mmol (±0,9) Anemia 14/54 
(26%) Female >7,4 
mmol/L MCV 80-100fL 87fL (±6) Micro 8/54 (15%) 
Macro 0/54 (0%) 
Iron 9-31µmol/L 13,2µmol/L (±5,6)  Low 23/54 (43%) 
High 0/54 (0%) 
TIBC 45-81nmol/L 58nmol/L (±14) Low 0/54 (0%) 
High 3/54 (6%) 
Calcium 2,10-2,55mmol/L 2,34mmol/L (±0,10) Low 0/54 (0%) 
High 2/54 (4%) 
PTH 1,3-6,8pmol/L 5,7pmol/L (±3,0) Low 0/54 (0%) 
High 21/54(39%) 
Albumin  35-50G/L 38,7G/L (±4,0) Low 8/54(15%) 
High 0/54(0%) 
Vitamin A 1,05-2,80µmol/L 2,59µmol/L (±0,9)  Low 2/54 (4%) 
High 26/54 (48%) 
Vitamin B1 95-175nmol/L 153nmol/L (±41) Low 6/54 (11%) 
High 17/54 (31%) 
Vitamin B6 25-100nmol/L 115nmol/L (±129) Low 0/44 (0%) 
High 13/44 (30%) 
Folic acid 9-36nmol/L 178,0nmol/L (±9,4)  Low 8/54 (15%) 
High 2/54 (4%) 
Vitamin B12 150-640pmol/L 296pmol/L (±106) Low 5/54 (9%) 
High 1/54 (2%) 
Vitamin D 30-100nmol/L 47nmol/L (±23) Low 21/54(39%) 
High 0/54 (0%) 
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Discussion 
 
Deficiencies in micronutrients in morbid obese patients are frequently 
diagnosed. Due to a limited diet for certain micronutrients, a great number of 
patients already develop these deficiencies prior to a bariatric procedure [14,15]. 
Because LSG is a restrictive procedure and therefore lacks the malabsorptive 
component of for example a RYGB, the risk for developing deficiencies after 
surgery is considered low and therefore often not tested.  However, because of the 
resection of the fundus a number of micronutrients like iron and vitamin B12 are 
less likely to be absorbed and the low risk status for developing deficiencies can be 
questioned [11,16-18].  
In the past a number of publications presented data on micronutrient 
deficiencies found after partial gastrectomy for the treatment for ulcer disease. 
Iron, folate and vitamin B12 deficiencies were most frequently reported. Long term 
follow up was advised to identify anemia, vitamin and mineral deficiencies [19-
23]. 
During the first year of follow up we found that anemia was identified in 
almost a third of patients. This implicates that preventing and screening for anemia 
and possible deficiencies leading to anemia should be one of the priorities in 
postoperative care. Although only eight patients developed abnormal MCV’s it is 
likely that, with 23 (43%) patients developing iron deficiency and 8 (15%) patients 
developing folate deficiency, these two deficiencies eventually contribute to the 
number of anemic patients. The iron deficiencies found can be partially explained 
by pre-existing shortage [14], but also by the LSG itself. Iron needs to be 
transformed to an absorbable form by hydrochloric acid in the normal stomach 
[11,14]. The quantity of hydrochloric acid produced in the stomach is reduced and 
nutrients may pass the stomach faster after a LSG, thus making it more difficult to 
absorb iron [5]. Folic acid stores deplete quickly when intake is insufficient. This is 
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also the most likely explanation for the 8 patients (15%) who were found to have 
folate deficiency [24]. A normal individual has an average store of 2mg of vitamin 
B12 that should last for two years when intake is insufficient. Morbid obese 
patients have a higher risk of having a preexisting vitamin B12 deficiency or lower 
storage levels, due to insufficient intake. Vitamin B12 uptake after LSG can 
become inadequate due to the lower production of hydrochloric acid which is 
needed to release bounded vitamin B12 in food [16,17]. In the first year five 
patients were diagnosed with a vitamin B12 deficiency, but it can be expected that 
this number will increase over the years when vitamin B12 stores have depleted.  
Bone metabolism can change during the first year after LSG. Part of this 
change is explained by the weight loss itself due to the loss of pressure on the 
weight bearing bones, thus losing a potent stimulant for bone preservation. 
Furthermore, normal levels of vitamin D are essential for an adequate intestinal 
calcium uptake. A shortage in vitamin D eventually leads to a negative calcium 
balance and causes a compensatory rise in PTH to promote bone resorption 
[25,26]. Although calcium levels were almost all within acceptable margins, 39% 
of the patients were diagnosed with elevated PTH levels and 39% were diagnosed 
with vitamin D deficiency. Suboptimal vitamin D levels (<50nmol/L) occurred in 
30 (55.5%) patients. The rise in PTH is in some cases most likely due to secondary 
hyperparathyroidism, and not solely explained by a decreased uptake of calcium by 
insufficient calcium intake or low vitamin D levels. Albumin levels dropped in the 
first year resulting from protein malnutrition especially in the first months after the 
LSG. This is a second explanation for these results. Clearly these patients are at 
risk for osteoporosis in the long term when not corrected or treated for their 
calcium, vitamin D and albumin deficiencies.  
Another phenomenon arises when patients who underwent LSG are 
supplemented with multivitamins. Some vitamins showed a significant rise in 
serum levels. Serum vitamin A was elevated most frequently (48%). It is known 
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Discussion 
 
Deficiencies in micronutrients in morbid obese patients are frequently 
diagnosed. Due to a limited diet for certain micronutrients, a great number of 
patients already develop these deficiencies prior to a bariatric procedure [14,15]. 
Because LSG is a restrictive procedure and therefore lacks the malabsorptive 
component of for example a RYGB, the risk for developing deficiencies after 
surgery is considered low and therefore often not tested.  However, because of the 
resection of the fundus a number of micronutrients like iron and vitamin B12 are 
less likely to be absorbed and the low risk status for developing deficiencies can be 
questioned [11,16-18].  
In the past a number of publications presented data on micronutrient 
deficiencies found after partial gastrectomy for the treatment for ulcer disease. 
Iron, folate and vitamin B12 deficiencies were most frequently reported. Long term 
follow up was advised to identify anemia, vitamin and mineral deficiencies [19-
23]. 
During the first year of follow up we found that anemia was identified in 
almost a third of patients. This implicates that preventing and screening for anemia 
and possible deficiencies leading to anemia should be one of the priorities in 
postoperative care. Although only eight patients developed abnormal MCV’s it is 
likely that, with 23 (43%) patients developing iron deficiency and 8 (15%) patients 
developing folate deficiency, these two deficiencies eventually contribute to the 
number of anemic patients. The iron deficiencies found can be partially explained 
by pre-existing shortage [14], but also by the LSG itself. Iron needs to be 
transformed to an absorbable form by hydrochloric acid in the normal stomach 
[11,14]. The quantity of hydrochloric acid produced in the stomach is reduced and 
nutrients may pass the stomach faster after a LSG, thus making it more difficult to 
absorb iron [5]. Folic acid stores deplete quickly when intake is insufficient. This is 
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also the most likely explanation for the 8 patients (15%) who were found to have 
folate deficiency [24]. A normal individual has an average store of 2mg of vitamin 
B12 that should last for two years when intake is insufficient. Morbid obese 
patients have a higher risk of having a preexisting vitamin B12 deficiency or lower 
storage levels, due to insufficient intake. Vitamin B12 uptake after LSG can 
become inadequate due to the lower production of hydrochloric acid which is 
needed to release bounded vitamin B12 in food [16,17]. In the first year five 
patients were diagnosed with a vitamin B12 deficiency, but it can be expected that 
this number will increase over the years when vitamin B12 stores have depleted.  
Bone metabolism can change during the first year after LSG. Part of this 
change is explained by the weight loss itself due to the loss of pressure on the 
weight bearing bones, thus losing a potent stimulant for bone preservation. 
Furthermore, normal levels of vitamin D are essential for an adequate intestinal 
calcium uptake. A shortage in vitamin D eventually leads to a negative calcium 
balance and causes a compensatory rise in PTH to promote bone resorption 
[25,26]. Although calcium levels were almost all within acceptable margins, 39% 
of the patients were diagnosed with elevated PTH levels and 39% were diagnosed 
with vitamin D deficiency. Suboptimal vitamin D levels (<50nmol/L) occurred in 
30 (55.5%) patients. The rise in PTH is in some cases most likely due to secondary 
hyperparathyroidism, and not solely explained by a decreased uptake of calcium by 
insufficient calcium intake or low vitamin D levels. Albumin levels dropped in the 
first year resulting from protein malnutrition especially in the first months after the 
LSG. This is a second explanation for these results. Clearly these patients are at 
risk for osteoporosis in the long term when not corrected or treated for their 
calcium, vitamin D and albumin deficiencies.  
Another phenomenon arises when patients who underwent LSG are 
supplemented with multivitamins. Some vitamins showed a significant rise in 
serum levels. Serum vitamin A was elevated most frequently (48%). It is known 
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for its function in cell differentiation and phototransduction. An excess in serum 
vitamin A can lead to ataxia, alopecia, dry skin, hepatotoxia, hepatomegalie and 
might have an effect on bone metabolism by increasing bone resorption [27,28]. 
Furthermore, high serum levels of vitamin A can be harmful in pregnant women 
due to the teratogenic effects on the fetus [13,29,30]. The serum levels in our 
patients did however not exceed 4µmol/L after one year. 
Vitamin B1 was low in 6 (11%) patients, but was found too high in 17 
(31%) patients with a maximum of 230 nmol/L. Neurological abnormalities like 
Wernicke-Korsakoff can occur when thiamin levels are below the adequate level 
[11]. There even has been a report on Wernicke’s encephalopathy after a LSG [31]. 
Reports on anaphylactic shock after intake of high doses of vitamin B1 have been 
published, but complications due to high levels seem rare [32,33]. 
As vitamin B6 plays a role in amino acid metabolism, gluconeogenesis and 
neurotransmitter synthesis it is important to ensure adequate serum levels [32]. No 
patients had deficient serum vitamin B6, which is less than after a RYGB [34]. 
During this study one patient developed neuropathy in hands and feet, which can 
be a symptom of high levels of vitamin B6 [35]. This patient had taken extra 
vitamin B6 on own initiative and serum levels had risen to 7 times the maximum 
normal serum level. Supplements were stopped and the symptoms vanished after a 
few weeks.  
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Conclusion 
 
Supplementing patients is a very important part of patient care after every 
bariatric procedure. Balancing between low and high levels of micronutrients is a 
challenging part of postoperative care. In this study a quarter of our patients were 
diagnosed with anemia, over 40% with iron deficiency and almost 40% with 
secondary hyperparathyroidism in the first year postoperative. We want to stress 
the risk of developing certain deficiencies after LSG, but also the risk of 
developing undesirable high levels of micronutrients. Our concern is that due to the 
use of multivitamin tablets after LSG in the long term the serum levels of some 
potential harmful vitamins will be chronically elevated or rise towards toxic levels. 
The multivitamin and CaD regiment used in this study is insufficient for 
supplementing patients after LSG. We therefore advise to prescribe multivitamins 
and calcium tablets only as a minimum and to withdraw or add supplements to this 
regimen based on regular blood testing, especially for iron, vitamin B12, vitamin D 
andcalcium. 
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for its function in cell differentiation and phototransduction. An excess in serum 
vitamin A can lead to ataxia, alopecia, dry skin, hepatotoxia, hepatomegalie and 
might have an effect on bone metabolism by increasing bone resorption [27,28]. 
Furthermore, high serum levels of vitamin A can be harmful in pregnant women 
due to the teratogenic effects on the fetus [13,29,30]. The serum levels in our 
patients did however not exceed 4µmol/L after one year. 
Vitamin B1 was low in 6 (11%) patients, but was found too high in 17 
(31%) patients with a maximum of 230 nmol/L. Neurological abnormalities like 
Wernicke-Korsakoff can occur when thiamin levels are below the adequate level 
[11]. There even has been a report on Wernicke’s encephalopathy after a LSG [31]. 
Reports on anaphylactic shock after intake of high doses of vitamin B1 have been 
published, but complications due to high levels seem rare [32,33]. 
As vitamin B6 plays a role in amino acid metabolism, gluconeogenesis and 
neurotransmitter synthesis it is important to ensure adequate serum levels [32]. No 
patients had deficient serum vitamin B6, which is less than after a RYGB [34]. 
During this study one patient developed neuropathy in hands and feet, which can 
be a symptom of high levels of vitamin B6 [35]. This patient had taken extra 
vitamin B6 on own initiative and serum levels had risen to 7 times the maximum 
normal serum level. Supplements were stopped and the symptoms vanished after a 
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Conclusion 
 
Supplementing patients is a very important part of patient care after every 
bariatric procedure. Balancing between low and high levels of micronutrients is a 
challenging part of postoperative care. In this study a quarter of our patients were 
diagnosed with anemia, over 40% with iron deficiency and almost 40% with 
secondary hyperparathyroidism in the first year postoperative. We want to stress 
the risk of developing certain deficiencies after LSG, but also the risk of 
developing undesirable high levels of micronutrients. Our concern is that due to the 
use of multivitamin tablets after LSG in the long term the serum levels of some 
potential harmful vitamins will be chronically elevated or rise towards toxic levels. 
The multivitamin and CaD regiment used in this study is insufficient for 
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Abstract          
 
Background 
Obesity is associated with nutritional deficiencies. Bariatric surgery could worsen these 
deficiencies. Fewer nutrit ional deficiencies would be seen after sleeve gastrectomy 
compared to the Roux-en-Y Gastric Bypass, but sleeve gastrectomy would also cause 
further deterioration of the deficiencies. The aim of this study was to determine the amount 
of preoperative nutrient deficiencies in sleeve gas trectomy patients and assess the evolution 
of the nutritional status during the first postoperative year. 
 
Methods 
407 Sleeve gastrectomy patients were assigned to a standardized fo llow-up program. Data 
of interest were weight loss, preoperative nutrient status and evolution of nutrient 
deficiencies during the first post-operative year. Deficiencies were supplemented when 
found. 
 
Results   
200 Patients completed blood withdrawal preoperatively and in the first postoperative year. 
Preoperatively, 5% of the patients were anemic, 7% had low serum ferrit in and 24% had 
low folic acid. Hypovitaminosis D was present in 81%. Vitamin A had excessive levels in 
72%. One year postoperatively, mean excess weight loss was 70%. Anemia was found in 
6%. Low ferritin levels were found in 8% of the patients. Folate deficiency decreased 
significantly and hypovitaminosis D was still found in 36%.  
 
Conclusions 
In this study, a considerable amount of patients suffered from a deficient micronutrient 
status preoperatively. One year after surgery, micronutrient deficiencies persisted or were 
found de novo in a considerable amount of patients, despite significant weight loss and 
supplementation. Only for fo late and vitamin D significant reduction was seen. 
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Introduction 
 
 Over the past years, the sleeve gastrectomy (SG) has become accepted as a 
stand-alone treatment modality for morbid obesity.[1] Early results of the SG show 
the safety and effectiveness of this procedure in terms of weight loss and remission 
of comorbidities.[2-5] Although long-term results of the SG are scarce, this 
technique seems to be a promising procedure.[4,5] Obesity is associated with 
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between 100 and 200% of the recommended daily intake. Furthermore, Dalteparin 
5000IU injections were addressed to all patients for five weeks to prevent for 
thrombosis. A proton pump inhibitor (PPI) was prescribed for at least 3 months to 
prevent for ulceration of the gastric staple line and to reduce the risk of staple line 
leakage, as the staple line is exposed to higher pressure and secretion of gastric 
acids is only slightly decreased, leading to higher risk of gastro-esophageal reflux 
disease.[18] All patients were assigned to a standard follow-up program consisting 
of four visits to the outpatient clinic at 6 weeks, 3 months, 6 months and 1 year 
postoperatively and annual consultation until the fifth postoperative year. Standard 
laboratory evaluation, consisting of a complete blood count, mean cell volume 
(MCV) and mineral and vitamin status, was performed for preoperative 
assessment, at 6 months and 12 months after surgery and annually until the fifth 
postoperative year.  
 Nutrient deficiencies were diagnosed by blood analysis. Laboratory values 
were regarded as deficient when they did not meet the reference values determined 
by our clinical laboratory (see table 2). Nutrient deficiencies were scored as de 
novo when they were newly diagnosed postoperatively. There was anemia in case 
of reduced hemoglobin and hematocrit values according to local laboratory 
reference values. Deficiencies that were found either preoperatively or 
postoperatively were supplemented. In case of iron levels <10 µmol/L and ferritin 
concentrations <20 µg/L, Ferrofumarate 200mg was prescribed once or twice daily 
in combination with 500 milligram Vitamin C once per day. When deficient levels 
of calcium were found preoperatively, 1000 mg calcium citrate was supplemented 
once a day in combination with 800IU vitamin D. Preoperative vitamin D levels < 
50 nmol/L were restored by supplementation of 1 milliliter vitamin D liquid 
(50,000 IU/ml) weekly during the first 4 weeks and monthly afterwards. In case of 
folate deficiency, 5mg folic acid daily was prescribed for 3 months. Vitamin B12 
levels <140 pmol/L were corrected by injecting 2 mL of Hydroxocobalamine 
 188 
500Ug/ml once per 2 weeks in the first two months, and once per three months 
afterwards. Vitamin B1 levels <70 nmol/l were restored by supplementation of 50-
100mg thiamin daily for a period of three months. All laboratory values were 
evaluated after twelve months of treatment.  
 For this study, only those patients who completed a preoperative blood test 
and at least one blood withdrawal during the first postoperative year were included. 
Patients who did not complete blood testing, or those who had a revision to RYGB, 
were excluded from the study. Data were analyzed retrospectively using a 
prospectively collected database. Data of interest were weight loss, preoperative 
nutrient status and evolution of nutrient deficiencies during the first post-operative 
year.  
 
Statistics 
 Excess Weight Loss (EWL) was calculated using the formula %EWL = 
Weight Loss (kg) / Excess Weight (kg). Excess weight was based on the patients’ 
ideal weight with a BMI of 25 kg/m2. IBM® Statistical Package for the Social 
Sciences® (SPSS®) 18.0 was used for processing. The normality of distribution 
was checked using the skewness and kurtosis calculation, showing normal 
distribution when values were between -1.00 and 1.00. In case of normal 
distribution mean values and ±SD were given, median values and range were given 
for non-normally distributed data. For calculation of nominal data the chi-square 
test was used. For trend analysis of the deficiencies the McNemar Test was used. A 
p-value <0.05 was regarded as statistically significant. 
 
Results 
 
 Two-hundred patients completed preoperative blood withdrawal and blood 
sampling in the first postoperative year. Their mean age was 43 years. Seventy-one 
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per cent of the patients were female. The mean preoperative BMI in this group was 
46 Kg/m2. Table 1 shows the baseline characteristics.  
 
Table 1. Baseline Characteristics  
Number of patients 200 
Male:Female 59 : 141 
Age (yrs) 42.7± 10.8 
T2DM 63 (31.5%) 
          Insulin use 23 (36.5%) 
Weight (Kg) 136.0 ± 27.2 
BMI (Kg/m2) 46.2   ± 7.9 
EW (Kg) 67.7  ± 24.8 
 
 Preoperatively, 10 patients were anemic. Of them, 20% had microcytic 
anemia and 20% had low ferritin levels. There was no difference in distribution of 
anemia between both sexes (8.5% vs. 3.5%; p = 0.145 X2-test). Low serum iron 
was present in high rates (38%). Low ferritin levels were present in 7% of the 
patients and all were female. The mean serum concentration was 78.51 µg/L. 
Decreased levels of serum folate were found in 24% of the patients. At 
preoperative evaluation, a disturbed vitamin status was seen frequently. 
Remarkably, vitamin A and B6 levels were elevated in a high number of patients 
(72% and 21% respectively). The mean serum concentration of vitamin A was 
even 2.62 µmol/L. A vitamin B12 deficiency was found in 23 patients (11.5%) and 
low levels of vitamin B1 were present in 5.5%. Hypovitaminosis D was present in 
a great majority of the patients (81%), and 55% of them even had a severe 
deficiency (<30 nmol/L). The mean preoperative serum concentration of vitamin D 
was 36.13 nmol/L. In 29% of the patients with low vitamin D, elevated levels of  
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Table 2. Laboratory values at assessment 
 Normal values Laboratory values Number of deficiencies 
      Mean       ± SD                      N         % 
Hemoglobin (mmol/L) M 8.5-11.0 9.4 ± 0.82 deficient 5 2.5 
  F 7.5-10 8.6 ± 0.59 deficient 5 2.5 
Hematocrit    (L/L)  M 0.40 – 0.50 0.44 ± 0.04 deficient 5 2.5 
  F 0.35 – 0.45 0.41 ± 0.03 deficient 5 2.5 
MCV    (fL) 80.0 – 100.0 87.28 ± 4.89 microcytic 11 5.5 
 macrocytic 1 0.5 
Iron    (µmol/L)  M 14.0 – 35.0 13.6 ± 4.33 deficient 31 15.5 
  F 10.0 – 55.0 12.3 ± 5.21 deficient 45 22.5 
Ferritin    (µg/L)  M 30.0 – 400.0 198.92 ± 135.34 deficient 0 - 
  F 20.0 – 400.0 78.51 ± 58.00 deficient 14 7.0 
Albumin    (g/L) 35.0 – 50.0 43.82 ± 2.43 deficient 0 - 
Calcium    (mmol/L) 2.10 – 2.55 2.30 ± 0.07 deficient 1 0.5 
Magnesium     (mmol/L) 0.7 – 1.0 0.82 ± 0.07 deficient 4 2.0 
Phosphate    (mmol/L) 0.8 – 1.5 0.97 ± 0.17 deficient 28 13.9 
Zinc    (µmol/L) 8.4 – 24.0 12.32 ± 2.02 deficient 0 - 
Folic Acid    (nmol/L) > 10.4 15.57 ± 8.21 deficient 48 23.9 
Vitamin A    (µmol/L) 0.7 – 2.1 2.62 ± 0.76 deficient 0 - 
 excess  144 71.6 
Vitamin B1    (nmol/L) 70.0 – 200.0 132.65 ± 32.90 deficient 11 5.5 
 excess  5 2.5 
Vitamin B6    (nmol/L) 35.1 – 110.0 79.31 ± 40.64 deficient 6 3.0 
 excess  42 20.9 
Vitamin B12    (pmol/L) 140.0 – 700.0 252.43 ± 102.77 deficient 23 11.5 
 excess  2 1.0 
Vitamin D    (nmol/L) > 50.0 36.13 ± 19.27 <30* 87 43.5 
 30-50** 75 37.5 
PTH    (pmol/L) 1.6 – 6.9 6.91 ± 3.80 low 1 0.5 
 high 57 28.4 
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Parathyroid Hormone (PTH) were found at assessment, and serum calcium levels 
corrected for albumin were between acceptable values. In patients with normal 
serum vitamin D concentration, 5.3% had elevated PTH-levels. The mean 
preoperative laboratory values are listed in Table 2.  
 One year postoperatively, a mean excess weight loss of 69.8% was 
achieved and the mean BMI decreased significantly from 46.2 Kg/m2 to 32.7 
Kg/m2 (see Table 3).  
 
Table 3. Weight Loss 
 Assessment 1yr. Post-Op  
mean SD/(%) mean SD/(%) P-value 
Weight (Kg.) 136.0 ± 27.2 96.3 ± 21.7 <0.001*  
BMI (Kg/m2) 46.2 ± 7.9 32.7 ± 6.7 <0.001*  
T2DM n 63 (31.5%) 22 (11.0%) <0.001**  
EW (Kg.) 67.7 ± 24.8 22.5 ± 19.6 <0.001*  
EWL (%)  69.8 ± 20.7  
BMIL (%) 13.5 ± 4.7 
* Paired Samples T-test 
** Mc. Nemar’s Test 
BMI : Body Mass Index (Kg./m2), T2DM : type 2 Diabetes Mellitus, EW : Excess 
Weight (Kg.), EWL:ExcessWeight Loss (%), BMIL : BMI Loss (Kg/m2) 
 
Twelve months after surgery, laboratory results were assessed (see Table 4). 
Postoperative anemia was found in 6.5% of the patients. The number of patients 
with Low serum iron decreased significantly to 37 patients (18.5%). The number of 
patients with low ferritin levels increased from 14 to 16 patients (8.0%). Still, all 
were female. Their mean serum ferritin concentration increased from 78.51 µg/L 
preoperatively to 112.14 µg/L one year after surgery. Low levels of folate 
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recovered significantly in 35 patients, postoperatively 25 patients had folate 
deficiency. Table 5 shows the evolution of the most common deficiencies.  
Although the presence of hypervitaminosis A had significantly decreased, excess 
of Vitamin A was still found in over half the patients. The mean serum 
concentration decreased to 2.32 µmol/L, which is still excessive. The number of 
patients with hypervitaminosis B6 had even doubled (47.5%). Vitamin B12 was 
still deficient in 11.5% of the patients. Deficiency of vitamin B1 was more frequent 
one year after surgery (9.0 vs. 5.5%). In the meantime, Vitamin D deficiency had 
disappeared in over half the cases and the mean serum concentration increased to 
58.11 nmol/L. Recovery of elevated PTH-levels occurred in more than one third 
(37%) of the affected patients. Still, the corrected calcium level remained within 
normal range. Elevated levels of PTH were found in 12.5% of the patients with a 
normal serum vitamin D concentration one year postoperatively.   
*
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Parathyroid Hormone (PTH) were found at assessment, and serum calcium levels 
corrected for albumin were between acceptable values. In patients with normal 
serum vitamin D concentration, 5.3% had elevated PTH-levels. The mean 
preoperative laboratory values are listed in Table 2.  
 One year postoperatively, a mean excess weight loss of 69.8% was 
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Kg/m2 (see Table 3).  
 
Table 3. Weight Loss 
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mean SD/(%) mean SD/(%) P-value 
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T2DM n 63 (31.5%) 22 (11.0%) <0.001**  
EW (Kg.) 67.7 ± 24.8 22.5 ± 19.6 <0.001*  
EWL (%)  69.8 ± 20.7  
BMIL (%) 13.5 ± 4.7 
* Paired Samples T-test 
** Mc. Nemar’s Test 
BMI : Body Mass Index (Kg./m2), T2DM : type 2 Diabetes Mellitus, EW : Excess 
Weight (Kg.), EWL:ExcessWeight Loss (%), BMIL : BMI Loss (Kg/m2) 
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Table 4. 1 Year post-operative 
 Normal values Laboratory values Number of deficiencies 
      Mean       ± SD                      N         % 
Hemoglobin (mmol/L) M 8.5 – 11.0 9.26 ± 0.57 deficient 5 2.5 
  F 7.5 – 10.0 8.53 ± 0.64 deficient 5 4.0 
Hematocrit    (L/L) M 0.40 – 0.50 0.44 ± 0.03 deficient 5 2.5 
  F 0.35 – 0.45 0.41 ± 0.03 deficient 8 4.0 
MCV    (fL) 80.0 – 100.0 89.68 ± 4.62 microcytic 4 2.0 
 macrocytic 1 0.5 
Iron    (µmol/L)  M 14.0 – 35.0 18.7 ± 6.5 deficient 12 6.0 
  F 10.0 – 25.0 15.4 ± 5.8 deficient 25 12.5 
Ferritin    (µg/L)  M 30.0 – 400.0 200.4 ± 99.7 deficient 0 - 
  F 20.0 – 200.0 112.1 ± 79.3 deficient 16 8.0 
Albumin    (g/L) 35.0 – 50.0 43.27 ± 2.89 deficient 1 0.5 
 excess  43 21.4 
Calcium    (mmol/L) 2.10 – 2.55 2.29 ± 0.09 deficient 4 2.0 
Magnesium     (mmol/L) 0.7 – 1.0 0.83 ± 0.07 deficient 6 3.0 
Phosphate    (mmol/L) 0.8 – 1.5 1.08 ± 0.15 deficient 7 3.5 
Zinc    (µmol/L) 8.4 – 24.0 11.28 ± 2.10 deficient 10 5.0 
Folic Acid    (nmol/L) > 10.4 22.64 ± 11.24 deficient 25 12.4 
Vitamin A    (µmol/L) 0.7 – 2.1 2.32 ± 0.76 deficient 0 - 
 excess  144 71.6 
Vitamin B1    (nmol/L) 70.0 – 200.0 139.88 ± 38.36 deficient 4 2.0 
 excess  5 2.5 
Vitamin B6    (nmol/L) 35.1 – 110.0 102.74 ± 56.67 deficient 71 35.5 
 excess  42 20.9 
Vitamin B12    (pmol/L) 140.0 – 700.0 283.91 ± 150.60 deficient 1 0.5 
 excess  2 1.0 
Vitamin D    (nmol/L) > 50.0 283.91 ± 150.60 <30* 4 2.0 
 30-50** 52 25.9 
PTH    (pmol/L) 1.6-6.9 0.5 ± 2.18 low 1 0.5 
 high 36 17.9 
 
 194 
Table 5. Evolution of deficiencies and excess 
 Preoperative Postoperative  De novo 
N  % N % N % 
Hemoglobin 10 5.0 13 7.5 7 3.5 
Iron  76 38.0 37 18.5 15 7.5 
Ferritin  14 7.0 16 8.0 4 2.0 
Folic Acid  48 23.9 25 12.4 12 6.0 
Vitamin A  (E) 144 71.6 111 55.2 12 6.0 
Vitamin B1 11 5.5 18 9.0 16 8.0 
Vitamin B6 
(E) 
42 20.9 95 47.3 70 35.0 
Vitamin B12   23 11.5 23 11.5 14 7.0 
PTH   (E) 57 28.4 36 17.9 13 6.5 
Vitamin D  162 81.0 72 36.0 30 15.0 
(E) = Excess of 
 
MCV = Mean Cell Volume  
PTH = Parathyroid Hormone   
 
Discussion 
 
 This study shows that in the morbidly obese, micronutrient deficiencies are 
frequently found preoperatively. Deficiencies can be attributed to a non-varied, 
high-caloric and high-fat diet. Previous studies already showed the importance of 
pre- and postoperative assessment of the nutritional status of patients undergoing a 
bariatric intervention.[6-8,10] Few studies reported on the nutritional status before 
and after sleeve gastrectomy.[9,14-16] All recommend adequate supplementation 
based on laboratory values. 
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 Anemia is a condition that can be caused by micronutrient deficiencies. 
Anemia was determined based on low hemoglobin and hematocrit levels. 
Preoperatively, anemia was found in 5% of the patients, and 20% of them had an 
iron deficiency with low serum ferritin levels. A recent study reporting pre- and 
postoperative deficiencies in laparoscopic RYGB candidates found 7.9% 
preoperative anemia. [20] Other studies found anemia rates between 12 and 22%. 
[10,21-23] The number of anemic patients doubled postoperatively. Literature 
describes iron deficiency rates varying between 17% and 44%. [10,24,25] Serum 
iron levels alone are a poor marker for iron deficiency. Serum ferritin is more 
specific. [25-27] We found low ferritin levels in 7% of the patients before surgery. 
One year after the SG the number of affected patients had not significantly 
changed, iron deficiency persisted in the preoperatively affected patients. However, 
the mean serum ferritin concentration increased significantly. This could be the 
result of supplementation. By resecting the fundus during the SG procedure and by 
administration of proton pump inhibitors after surgery, the production of HCl is 
reduced, which may reduce the iron uptake, as Fe3+ conversion to Fe2+ is 
diminished. The uptake of haem iron is also disrupted and iron rich red meat is less 
well tolerated after stomach reduction. These factors could also contribute to a 
disturbed iron status. The findings implicate that preoperative supplementation was 
not sufficient.  
 A disturbed bone metabolism with secondary hyperparathyroidism was 
found in more than one fifth of the patients preoperatively. However, calcium 
levels were between normal values. The prevalence of preoperative 
hypovitaminosis D was considerably high (81%). These high rates have been 
reported in other studies. [17, 28-30] Hypovitaminosis D is associated with 
malnutrition, but also with less exposure to sunlight due to reduced physical 
activity. Several studies have shown that there is increased uptake of vitamin D in 
adipose tissue, reducing the serum concentrations of this vitamin.[31,32] Twelve 
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months after surgery the number of patients with vitamin D deficiency had 
decreased significantly. This might be related to the loss of adipose tissue after 
surgery, but serum levels may also have risen because of adequate supplementation 
of vitamin D. Although the duodenum and jejunum are not bypassed and uptake of 
vitamin D is not disturbed, almost one fifth of the patients developed a deficiency 
newly during the first postoperative year. This could be caused by accelerated food 
passage, a topic that should be further investigated. Adequate monitoring and 
supplementation of this vitamin is highly recommended.  
 Remarkably, in a considerable number of patients vitamin A and vitamin 
B6 were found in excessive serum concentrations prior to surgery. The number of 
patients with hypervitaminosis B6 had doubled in the first post-operative year. This 
might be the effect of multivitamin supplementation, as the prescribed 
multivitamins contained pyridoxine. Severe excessive serum concentrations of 
vitamin B6 can cause neurologic symptoms. These symptoms were not reported in 
this cohort and in none of the patients toxic serum levels of vitamin B6 were found. 
Excessive levels of vitamin A can cause nausea, vomiting, headaches and altered 
mental status, but also anemia, hepatotoxia and osteoporosis in case of chronic 
elevated serum levels. Moreover, hypervitaminosis A has a strong teratogenic 
effect. Vitamin A Intoxication has been described from a level of >100 µg/dL 
(>3.49 µmol/L), [33] but there are no data on long term effects of elevated vitamin 
A levels. None of the patients in our cohort reported signals of intoxication. 
Vitamin B1 (thiamine) deficiency was present in 5.5% of the patients at 
assessment. This prevalence is lower than earlier studies have reported.[21,34] 
After surgery, de novo hypovitaminosis B1 was found in 8% of the patients. 
Chronic deficiency of thiamine can cause neurological disorders.[35,36] The 
deficiency can be caused by a non-varied diet or by chronic alcohol abuse. 
Moreover, major surgery increases vitamin requirements. After bariatric surgery, 
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thiamine levels must be monitored as rapid weight loss and loss of distributional 
area after bariatric surgery can cause severe deficiencies.  
 Vitamin B12 (cobalamin) is present in fish, meat and dairy products. It 
plays a vital role in DNA synthesis and in neurologic functioning, and is absorbed 
in the terminal ileum when bound to intrinsic factor (IF).[7] The glycoprotein IF is 
produced in the parietal cells in the antrum of the stomach and in the duodenum. 
These parts are bypassed after the RYGB, but are preserved after the sleeve 
gastrectomy. Therefore, cobalamin deficiencies are expected to be less common 
after sleeve gastrectomy. However, by resecting two thirds of the stomach during 
SG a considerable reduction in the number of parietal cells occurs, and less IF 
might be produced.[7,36] Literature reports deficiency rates between 3% and 18% 
preoperatively, supporting our findings.[6,7,21,37] After sleeve gastrectomy, a 
vitamin B12 deficiency was newly diagnosed in 8.0%.  Frequently, vitamin B12 
deficiency is accompanied by low levels of serum folate and they can cause 
hyperhomocysteinemia, creating a risk factor for atherosclerosis. Low levels of 
serum folate were already present in a quarter of the patients preoperatively. This 
deficiency is mainly associated with reduced intake of folate rich food, such as 
lettuce and vegetables.[37] Adequate multivitamin intake might have contributed to 
the resolution of the deficiency in half of the affected patients. Deficient serum 
levels of the minerals magnesium and zinc were found in a small amount of 
patients. Zinc levels were adequate in all patients preoperatively. Zinc plays a role 
in the immune system and in wound healing and it plays a key role in the synthesis 
of insulin. Deficiency of zinc can be associated with hair loss. Deficiency of zinc 
was newly diagnosed in 5% of the patients postoperatively. This is lower than the 
prevalence reported in other studies.[6,38] Magnesium deficiency can cause 
neurological and cardiovascular complaints. Magnesium is considered a key factor 
in development of the metabolic syndrome.[39,40] The unvaried high caloric diet 
of the obese patient often does not contain adequate amounts of magnesium. We 
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found a magnesium deficiency in 2% of the patients preoperatively. After surgery 
levels rose in 3 of them, but deficient levels were diagnosed newly in 5 patients.  
 This study has some limitations. First of all, more than half of the cohort 
did not complete pre- and postoperative blood withdrawal. This is a large drop-out, 
however still 200 patients were analyzed. It is difficult to distinguish between the 
remission in deficiencies based on supplementation and remission based on weight 
loss after the sleeve gastrectomy. We only asked patients whether they were 
compliant toward taking their multivitamins. We did not further assess the patients’ 
compliance, which could be a major factor in remission of the nutrient deficiencies. 
Neither did we check the patients’ dietary intake at 12 months postoperatively. 
This may also have had an important influence on the postoperative micronutrient 
status. At last, the supplements were dosed based on the local protocol. The 
optimal dose for the micronutrient supplements in the bariatric patient should be 
subject to further investigation, as this might also be an influence on the patients’ 
micronutrient status.  
 
Conclusion 
 
 In this study, the pre- and post-operative nutrient status of 200 morbidly 
obese patients undergoing a sleeve gastrectomy, were analyzed. A considerable 
amount of patients suffered from a deficient micronutrient status preoperatively. 
One year after surgery, micronutrient deficiencies persisted or were found de novo 
in a considerable amount of patients, despite significant weight loss and 
supplementation. Only for folate and vitamin D significant deficiency reduction 
was seen. The question remains whether preoperative supplementation was 
inadequate and what was the direct effect of the sleeve gastrectomy. Another point 
of interest is the patients’ compliance of supplement intake and this should be 
subject to further research. At last, the optimal duration of supplementation and the 
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optimal dosage should be determined for adequate treatment of the nutrient 
deficiencies.   
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Introduction 
 
The Roux-en-Y Gastric Bypass (RYGB) is very effective in inducing 
weight loss in morbid obesity [1]. However, it is also associated with several 
undesirable side effects such as the loss of bone mass. A 10% reduction of bone 
mineral density in the first two years after RYGB is not uncommon [2]. 
 
The aetiology of post-RYGB bone loss is multi-factorial [3]. Some loss 
may occur as a result of reduced mechanical loading of the skeleton because of 
massive weight loss [4]. This is probably unavoidable, but other risk factors are 
preventable and should be addressed appropriately. Vitamin D deficiency, defined 
as a serum level less than 50 nmol/L, is very common in morbidly obese patients, 
even in those awaiting bariatric surgery [5]. The reported prevalence of vitamin D 
deficiency prior to surgery ranges between 54 - 80% [6 - 8]. These low vitamin D 
levels before surgery have been attributed to inadequate intake, a lifestyle of 
limited sun exposure, and decreased bioavailability of vitamin D due to 
sequestration of the fat soluble vitamin in excess adipose tissue [9]. As RYGB will 
impair intestinal vitamin D absorption it will further increase the risk of developing 
vitamin D deficiency. The degree of RYGB induced vitamin D malabsorption is 
presently not known. However, it appears that the length of the limb bypass is one 
of the determinants of postoperative vitamin D deficiency, i.e. vitamin D levels are 
lower after long-limb than after short-limb RYGB [10]. 
 
Preoperative normalization of calcium and vitamin D metabolism, 
individualized postoperative supplementation regimens and rapid treatment of 
calcium and vitamin D deficits detected after surgery should become the corner 
stones for the prevention of bone loss after RYGB. To date, however, rational 
guidelines for preoperative correction of vitamin D deficits in morbid obese 
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Abstract          
 
Background  
Severe vitamin D deficiency is a common finding in morbid obesity, and the incidence 
increases markedly after RYGB. Normalisation of vitamin D levels after RYGB is difficult 
to achieve because the degree of surgery-induced malabsorption is not known.  
 
Methods 
 Absorption characteristics of cholecalciferol were studied in 14 morbidly obese, 
premenopausal women before and 4 weeks after laparoscopic RYGB. Serum 
cholecalciferol levels were measured at baseline, and 1, 2, 3 and 14 days after a single oral 
dose of 50.000 IU of solubilised cholecalciferol.  
 
Results 
Peak serum cholecalciferol levels were observed on day 1 in all patients. They were 26.6 ± 
3.7% lower after GBS (P = 0.02). Inter-individual variability was high. 
 
Conclusion 
Peak cholecalciferol levels are reduced by about 25% after GBS. Further analysis suggested 
that the timing of sampling in the current study was not optimal. This may have caused an 
underestimation of the true decrease in cholecalciferol absorption induced by RYGB.  
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Abstract          
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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patients are not available [11,12]. Correction of post-operative vitamin D deficits is 
even more difficult to achieve because the dose adjustments that are needed to 
overcome malabsorption are presently not known. This lack of knowledge hampers 
the development of rational guidelines to correct post-operative calcium and 
vitamin D deficits. The present study is focused on intestinal cholecalciferol 
absorption and attempts to quantify the changes induced by RYGB. Two non-
invasive approaches are available to quantify intestinal cholecalciferol absorption: 
by measuring fractional fecal excretion of an oral dose of radiolabeled 
cholecalciferol, or by measuring serum cholecalciferol levels after a single oral 
dose of unlabelled cholecalciferol [13]. The former method is cumbersome, time 
consuming, not readily available in most institutions, and not suitable for outpatient 
use. As we wished to develop a diagnostic tool that would be applicable on an 
individual basis in a large numbers of patients, we chose to quantify cholecalciferol 
bioavailability based on measuring post-absorptive plasma levels.  
 
Patients and Methods  
 
Patients 
The study included 14 obese premenopausal women 20 - 50 years of age, 
with a BMI of 35 - 50 kg/m2, and scheduled for laparoscopic RYGB (LRYGB) in 
the winter period of 2008 - 2009. Two patients had undergone a cholecystectomy 
previously. The time schedule was chosen to prevent any bias caused by the 
seasonal variation of cutaneous cholecalciferol production. The use of a solarium 
was not allowed. Exclusion criteria for participation were: liver disease (liver 
enzymes > 2 times the upper normal limit), kidney disease (GFR < 60 ml/min), 
gastrointestinal disorders suggestive of malabsorption, granulomatous disorders, 
diabetes mellitus > 10 years or clinical suspicion of diabetic gastroenteropathy, and 
 207 
medication known to affect vitamin D and bone metabolism (e.g. corticosteroids, 
anti-convulsive medication).  
LRYGB was performed in a single centre by 2 dedicated bariatric surgeons 
who used the same techniques. All subjects received a 100 cm alimentary limb and 
a 40 cm biliopancreatic limb. Postoperatively, each patient was recommended to 
take multivitamins daily equivalent to 150% of the recommended daily allowance 
(RDA), omeprazole 40 mg once a day and a combination of calcium carbonate 500 
mg and vitamin D3 400 IU three times a day (Calcichew 500/400 tid). Low 
molecular weight heparin was given subcutaneously once daily, for 6 weeks 
postoperatively. The study was approved by the Regional Institutional Review 
Board. Written informed consent was obtained from all patients. 
 
Methods 
Vitamin D status was checked at baseline. When the serum 25-OHD level 
was less than 75 nmol/L the deficit was corrected with oral, solubilised 
cholecalciferolFNA 50.000 IU/ml, as described previously (14). Calculation of the 
loading dose needed to raise serum 25-OHD to the target level of 75 nmol/L was 
based on the equation: 
        
Loading Dose(IU) = 40 x [75-actual serum 25-OHD3 level] x body weight  
 
The prescribed loading dose was equal to the calculated dose rounded off 
upwards to a multiple of 25.000 IU. The calculated dose was administered in 
divided portions of 50.000 IU/ml and, if necessary, a final portion of 25.000 IU. 
The gifts were administered on Monday, Wednesday and Friday, until the total 
loading dose was reached. To check the results of vitamin D supplementation, 
serum 25-OHD levels were measured 14 days after the final dose.  
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Methods 
Vitamin D status was checked at baseline. When the serum 25-OHD level 
was less than 75 nmol/L the deficit was corrected with oral, solubilised 
cholecalciferolFNA 50.000 IU/ml, as described previously (14). Calculation of the 
loading dose needed to raise serum 25-OHD to the target level of 75 nmol/L was 
based on the equation: 
        
Loading Dose(IU) = 40 x [75-actual serum 25-OHD3 level] x body weight  
 
The prescribed loading dose was equal to the calculated dose rounded off 
upwards to a multiple of 25.000 IU. The calculated dose was administered in 
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The cholecalciferol absorption test was performed 4 weeks before and 4 
weeks after LRYGB. The protocol required that a cholecalciferol absorption test 
should be scheduled at least two weeks after the completion of treatment for pre-
existent vitamin D deficiency. After an overnight fast, a test dose of 50.000 IU was 
administered orally at 9.00h a.m., in combination with 100 ml vanilla flavoured 
custard. Serum cholecalciferol levels were measured over a period of 15 days, 
starting one day before the ingestion of the test dose (T = -1), just before the 
ingestion of cholecalciferol (T = 0), and 1, 2, 3 and 14 days after (T = 1, 2, 3 and 
14). In each subject the timing (Tmax) and the serum level of the peak 
cholecalciferol concentration (Cmax) was assessed, and the cholecalciferol area 
under the curve over day 0 - 3 (AUC) was calculated, before and after surgery. 
 
Measurements 
All blood samples were taken in the fasting state, between 8.00 and 9.00h 
a.m. Serum cholecalciferol was measured by high-pressure liquid chromatography 
/ ultraviolet light absorption analysis as described previously [15]. This technique 
has a detection limit of 1.25 nmol/L, and an intra- and inter-assay coefficient of 
variation (CV) of  8.3% and 11.4%, respectively. Serum 25-OHD levels were 
measured by radioimmunoassay (DiaSorin, Stillwater, Minnesota, USA), with a 
total imprecision of 11%. Serum 1.25-OHD levels were measured by 
radioimmunoassay (Immunodiagnostic Systems GmbH, Frankfurt am Main, 
Germany), with an intra- and interassay precision of < 12% and < 14%, 
respectively.  The analytical detection limits of the 25-OHD and 1.25-OHD assay 
(defined as the concentration corresponding to the mean minus 2 standard 
deviations of 10 replicates of the zero calibrator) were 3.75 nmol/L and 8 pmol/L 
respectively. Serum intact PTH was measured by a solid-phase, two-site 
chemoluminiscent enzyme-labeled immunometric assay (Immulite 2500, Siemens, 
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Los Angeles, CA, USA), with an intra- and interassay precision of < 6% and < 9% 
respectively. The analytical sensitivity of this PTH assay was 0.3 pmol/l. 
 
Statistics 
Results are shown as mean values ± standard error (SE). Power analysis 
was based on the study of Armas et al [16]. This study showed that a single dose of 
50.000 IU cholecalciferol briefly raised serum cholecalciferol by 30 nmol/L in 10 
healthy volunteers with a standard deviation of 12 nmol/L. A postoperative decline 
in Cmax > 25% was defined as clinically relevant, because a change of this 
magnitude was likely to require a dose adjustment. To be able to detect a 25% 
difference between pre- and post-operative Cmax with α = 0.05 (one-sided) and β = 
0.10, and assuming a correlation coefficient of 0.70 between pre- and postoperative 
measurements, 14 patients needed to be tested. Pre- and postoperative results were 
compared by paired t-test. A P-value < 0.05 was considered to be statistically 
significant.  
 
Results 
 
Fourteen premenopausal women participated in the study. Their mean age 
was 37.0 ± 2.1 years, and they had a BMI of 44.9 ± 1.7 kg/m2 (range 36.7 - 61.2 
kg/m2). Mean serum 25-OHD at screening was 38.0 ± 4.0 nmol/L. Serum total 
calcium, phosphate albumin and PTH levels were within the normal range. Mean 
urinary calcium excretion was 3.4 ± 0.5 mmol/24h. Nine patients had reduced 
urinary calcium excretion rates, i.e. a calcium excretion of less than 4 mmol/24h. 
As shown in figure 1, twelve patients had a 25-OHD level < 50 nmol/L, and two 
had a level between 50 - 75 nmol/L. The calculated vitamin D deficit ranged from 
16,000 to 305,000 IU, with a mean of 188,366 ± 22,022 IU. All patients received 
oral cholecalciferol supplementation as described, the doses ranged from 25,000 IU 
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Statistics 
Results are shown as mean values ± standard error (SE). Power analysis 
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healthy volunteers with a standard deviation of 12 nmol/L. A postoperative decline 
in Cmax > 25% was defined as clinically relevant, because a change of this 
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0.10, and assuming a correlation coefficient of 0.70 between pre- and postoperative 
measurements, 14 patients needed to be tested. Pre- and postoperative results were 
compared by paired t-test. A P-value < 0.05 was considered to be statistically 
significant.  
 
Results 
 
Fourteen premenopausal women participated in the study. Their mean age 
was 37.0 ± 2.1 years, and they had a BMI of 44.9 ± 1.7 kg/m2 (range 36.7 - 61.2 
kg/m2). Mean serum 25-OHD at screening was 38.0 ± 4.0 nmol/L. Serum total 
calcium, phosphate albumin and PTH levels were within the normal range. Mean 
urinary calcium excretion was 3.4 ± 0.5 mmol/24h. Nine patients had reduced 
urinary calcium excretion rates, i.e. a calcium excretion of less than 4 mmol/24h. 
As shown in figure 1, twelve patients had a 25-OHD level < 50 nmol/L, and two 
had a level between 50 - 75 nmol/L. The calculated vitamin D deficit ranged from 
16,000 to 305,000 IU, with a mean of 188,366 ± 22,022 IU. All patients received 
oral cholecalciferol supplementation as described, the doses ranged from 25,000 IU 
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to 300,000 IU. This regimen increased the mean 25-OHD level from 38.0 ± 4.0 
nmol/L to 76.5 ± 3.1 nmol/L (P < 0.001). The post-supplementation level was > 50 
nmol/L in all patients, five patients had a level between 50 - 75 nmol/L and nine 
had a level between 75 - 100 nmol/L. 
 
The main parameters of interest for this study, assessed on T = 0 of the pre- 
and post-operative absorption tests are summarized in table 1. Mean weight 
decreased from 127.2 ± 6.5 kg to 115.0 ± 6.2 kg (P < 0.001). Baseline serum 
cholecalciferol was significantly higher preoperatively then postoperatively (18.8 ± 
3.0 nmol/L versus 5.8 ± 1.3 nmol/L, P < 0.001), whereas all other parameters were 
not different on the two occasions. All patients had received cholecalciferol 
treatment preoperatively to correct the pre-existent vitamin D deficit. The interval 
between the final dose of cholecalciferol supplementation and the preoperative 
baseline measurement of serum cholecalciferol varied from 11 to 16 days and it 
was less than 14 days in 2 subjects. All patients received the standardized 
postoperative supplementation regimen as described above, until T = -1 of the 
postoperative cholecalciferol absorption test.  
The mean changes in serum cholecalciferol levels in response to a single 
dose of 50,000 IU are shown in figure 2a on the left. In all patients, peak levels 
were observed on the first day after the oral dose, before as well as after surgery. 
The maximal change in serum cholecalciferol (∆-Cmax), defined as the difference 
between baseline and the highest postabsorptive level, varied markedly between 
patients. Preoperatively ∆-Cmax ranged from 43.3 to 118.5 nmol/L, and 
postoperatively from 10.0 to 142.3 nmol/L, i.e. the range widened after surgery 
(from 75.2 nmol/L preoperatively to 132 nmol/L postoperatively). The mean ∆-
Cmax decreased from 92 ± 6.5 nmol/L to 63.5 ± 10.3 nmol/L after surgery, i.e. a 
decrease of 26.6 ± 3.7% (P = 0.02). As shown in figure 2b, ∆-Cmax did not decrease 
in all subjects. Three patients demonstrated a post-surgery increase in ∆-Cmax > 
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10%. The AUC-cholecalciferol measured over 3 days, and corrected for the 
difference in baseline (∆-AUC), did not change significantly (59.0 ± 4.4 to 45.3 ± 
6.7 nmol/L/day, P = 0.09). 
 
Table 1. Comparison of baseline characteristics at T = 0 of the pre- and post-
operative cholecalciferol absorption tests, shown as mean values ± standard error.   
 
 Pre-op Post-op P-value 
Weight  (kg) 127.2  6.5 115.0 ± 6.2 < 0.001 
Creatinine  (µmol/L) 64.8  1.8 68.1 ± 2.4 NS 
Albumin  (g/L) 39.2  0.6 40.4 ± 0.6 NS 
Total Calcium (mmol/L) 2.29  0.03    2.33 ± 0.02 NS 
Phosphate  (mmol/L) 1.02 ± 0.04 0.99 ± 0.05 NS 
Cholecalciferol (nmol/L) 18.8 ± 3.0 5.8 ± 1.3 < 0.001 
25-OHD3  (nmol/L) 77.3  3.4 74.4 ± 4.2 NS 
1.25-OHD3 (pmol/L) 136 ± 13 138 ± 10 NS 
PTH (pmol/L) 3.5 ± 0.5 4.1± 0.6 NS 
 
Discussion 
 
The aim of this study was to quantify the changes in intestinal 
cholecalciferol absorption induced by RYGB to serve as a starting point for the 
development of rational and individualized guidelines for dose adjustments to 
correct post-operative vitamin D deficits.  
 
Preoperatively, all patients received solubilised cholecalciferol orally 
according to a recently published guideline to achieve a target level of 75 nmol/L 
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[14]. According to this guideline the required loading dose can be calculated based 
on the basal serum 25-OHD level and body weight. The latter is important to adjust 
the vitamin D requirements for differences in distribution volume. Differences in 
distribution volume and sequestration of vitamin D in adipose tissue explain why 
peak serum levels after an oral dose of vitamin D are lower in obese than in non-
obese subjects [9]. Although the guideline referred to above was developed for 
subjects weighing less than 125 kg, it performed very well in the obese women 
with body weights ranging from 98 - 177 kg (Figure 1). The result of treatment 
was very close to the target level of 75 nmol/L. Although very promising, a further 
validation in a larger number of obese subjects will be necessary before this 
loading dose equation can be safely  recommended for the rapid correction of 
vitamin D deficiency in morbid obesity. It may be of interest to examine whether 
correction for fat mass, as assessed by dual energy X-ray absorptiometry or bio-
impedance analysis, may serve to improve the accuracy of the loading dose 
equation in morbidly obese subjects.   
Cholecalciferol absorption was studied by means of AUC cholecalciferol 
(∆-AUC) and by assessing the peak change in serum cholecalciferol (∆-Cmax). In 
this particular study design ∆-AUC was less sensitive to detect changes in 
cholecalciferol absorption than ∆-Cmax. The mean ∆-Cmax decreased by about 25% 
after surgery. This was less than expected. Clinical practice has taught us that the 
individual needs of post-RYGB patients vary greatly and that they may require a 
weekly dose between 25,000 – 50,000 IU cholecalciferol to maintain their 25-OHD 
levels between 50 - 100 nmol/L (unpublished observations). In our experience, this 
is about 4 - 8 times the amount required to maintain 25-OHD levels in normal 
weight subjects. Based on these findings we expected to find a decrease in 
cholecalciferol absorption of at least 50 - 75%.  
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Figure 1. Pre-operative serum 25-OH vitamin D3 levels before and after 
correction of the calculated vitamin D deficit by means of oral, solubilized 
cholecalciferol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
In theory, there are several explanations for the relatively small decrease in 
peak absorption.  First, although we planned to do the postoperative absorption test 
as early as 4 weeks after surgery, the patients had already lost a mean of 12 kg in 
weight at that time. This reduces the distribution volume which will cause a rise in 
Cmax and the AUC and thus masks the postoperative decrease in cholecalciferol 
absorption. Second, the timing of the sampling schedule may not be optimal and 
thus lead to an underestimation of the decrease in cholecalciferol bioavailability. 
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As all subjects had their Tmax (the point of time that Cmax occurs) after 24 hours and 
all serum cholecalciferol levels were lower at 48 hours, it is most likely that the 
true Tmax must be somewhere in the first 24 hours. If that is the case, the C max will 
be higher than the level measured after 24 hours. In addition, the individual’s T max 
may change after surgery. These issues will affect the estimated cholecalciferol 
bioavailability. We therefore conclude that more frequent sampling will be 
required during the first 48 hours to determine the optimal sampling times, 
preoperatively as well as postoperatively.  
 
Information regarding the cholecalciferol transport time from intestinal 
lumen to the blood compartment is essential to optimize the sampling times. 
Unfortunately, the literature is very scarce on this subject. Lymphatic transport is a 
major contributor of oral cholecalciferol bioavailability [17]. After uptake into the 
enterocyte, cholecalciferol associates with intracellular lipoproteins that are 
subsequently exocytosed and taken up into the intestinal lymphatic system. Further 
transport occurs as chylomicrons through the intestinal lymphatic system to the 
systemic circulation. In rats, the appearance of orally administered C14-labelled 
cholecalciferol in the intestinal lymphe starts after about 4 hours with a rapid 
increase in recovery during the next 16 hours, and then a subsequent decline [18]. 
These observations support the expectation that the preoperative Tmax in humans 
will occur somewhere within the first 24 hours. Only two studies have described 
the first 24-hour response to a single oral dose of 50,000 IU vitamin D in healthy 
humans [9,19]. Both studies used ergocalciferol (vitamin D2) instead of 
cholecalciferol (vitamin D3), which we used. In the first study the 50,000 IU oral 
dose was given to 7 healthy volunteers, with samples taken at baseline, and 4, 8, 
12, 24, 48 and 72 hours afterwards. Peak ergocalciferol levels were observed at 12 
hours, with lower values at 24 hours [19]. In the second study a single oral dose of 
50,000 IU was given to 11 healthy subjects, and blood was sampled at baseline, 
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and 5, 10 and 25 hours. Maximal serum ergocalciferol levels were found at 10 
hours [9]. In both studies, the time interval between the sample with the peak 
concentration and the next sample was rather large, i.e. 12 -14 hours, and it is 
conceivable that the true Tmax is somewhere between 12 and 24 hours after a single 
oral dose. The Tmax after gastric bypass is not known. 
 
Initially we assumed that the increased postoperative dose requirements to 
normalize serum 25-OHD levels were exclusively due to a decrease in 
cholecalciferol absorption. This may have been an oversimplification. Loss of 
cholecalciferol or 25-OHD as a result of an interrupted entero-hepatic cycle could 
also have been a factor. The hypothesis on entero-hepatic circulation of vitamin D 
was generated in the seventies based on observations in humans showing that 
considerable amounts of intravenously administered H3-labelled cholecalciferol or 
25-OHD derivates appeared in the bile [20]. Subsequent studies, however, revealed 
that vitamin D was mainly excreted as biologically inactive polar degradation 
products and that the amount of intact cholecalciferol or 25-OHD was negligible 
[21,22]. It is now commonly concluded that the entero-hepatic circulation of 
vitamin D is nihil.  
In theory, the postoperative increase in cholecalciferol requirements could 
also be due to changes in vitamin D metabolism. Poorer hydroxylation of 
cholecalciferol, lowering of vitamin D binding protein, or increased breakdown of 
hydroxylated vitamin D would increase the required amount of cholecalciferol to 
maintain normal 25-OHD levels. So far, these issues have not been studied. 
 
Two unexpected observations in this study deserve comments. First, the 
preoperative basal serum cholecalciferol levels were found to be significantly 
higher than postoperatively (18.8 ± 3.0 versus 5.8 ± 1.3 nmol/l, P < 0.001). The 
interval of two weeks between the loading dose of cholecalciferol and the basal 
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serum sample of the test may have been too short. Estimations are that about 14 
days are required to convert the administered cholecalciferol into 25-OHD, 
however, in severely obese subjects this interval may be longer [23]. 
Postoperatively, the time span between the latest cholecalciferol loading dose and 
the basal measurements was about 80 days, which is more than long enough to 
achieve steady state.  
In contrast to our expectations, and despite the carefully controlled 
cholecalciferol ingestion procedure during the absorption test, three subjects 
demonstrated a postoperative peak ∆-cholecalciferol that was more than 10% 
higher than preoperatively (figure 2). Apart from a measurement error, this 
unexpected observation may be related to changes in T max after surgery. This is 
another argument to repeat the study with more frequent sampling during the first 
48 hours after the ingestion of the oral dose.  
 
In conclusion, this study has shown that RYGB reduces the peak 
cholecalciferol levels by about 25 %. Substantial inter-individual variability was 
observed, and a methodical underestimation of the true decrease in cholecalciferol 
absorption is suspected. A repeat study with an optimized sampling time schedule 
is considered necessary to obtain a more reliable estimate of the change in 
cholecalciferol availability after RYGB. If that can be achieved the cholecalciferol 
absorption test may become a useful instrument to predict the patient’s 
cholecalciferol requirements early after bypass surgery. It is conceivable that in the 
long-term intestinal adaptation may change fractional cholecalciferol absorption 
and that it could be useful to repeat the test when weight loss is completed and 
body weight has stabilized.  
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Figure 2. Changes in serum cholecalciferol level in response to a single dose of 
50.000 IU, before (open circles) and after gastric bypass (black dots). On the left: 
mean response, top right ∆-Cmax cholecalciferol, bottom right ∆-AUC 
cholecalciferol.  
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Abstract          
 
Background 
Weight loss surgery includes various surgical techniques to restrict food intake and reduce 
absorption of calories. Calcium malabsorption may be harmful to skeletal health in the 
long term. Optimal skeletal management post-surgery is highly recommended. 
 
Methods 
 103 Patients were evaluated retrospectively at 12 months after surgery. The evaluation 
included the results of a standard questionnaire to quantify stool frequency and consistency 
and laboratory assessments prior to surgery and 12 months after surgery.  
 
Results 
 103 Patients, 27 males and 76 females were included in a retrospective study. 83 Patients 
had a alimentary limb of 100 cm and 20 patients one of 150 cm. At 12 months post -surgery, 
77.7% of the included group reported changes of bowel habits, albumin adjusted calcium 
levels were normal in all but 1 patient and PTH levels were increased in 35% of the 
patients. Correlations between semi-quantified bowel scores (fecal scores) and data from 
the laboratory demonstrated increasing PTH values along with more frequent and 
softer/watery stools (RR 30.5, CI 6.2–149.2, p<0.001). There was a trend for higher PTH 
levels in patients with an alimentary limb of 150 cm.  Relatively more patients who were 
compliant in  using 1 g of a calcium and 800 IU v itamin D3 formulat ion had normal PTH 
levels than non-compliant users (RR 14.3, CI 3.6-56.5, P<0.001). 
 
Conclusion 
The current study demonstrates interrelationships between semi-quantified fecal scores, 
PTH levels and the compliance calcium/vitamin D3 suppletion.  However, prospective 
randomized intervention studies are necessary to elucidate the causality of these 
relationships and are critical to optimize patient management.    
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Introduction 
 
Bariatric surgery still remains the most effective treatment for morbid 
obesity, leading to a reduction of co-morbidities in the long term [1]. Roux-en-Y-
Gastric Bypass (RYGB) is one of the most frequently performed procedures in the 
United States and is also widely practiced in Europe [2-4]. Calcium and vitamin D 
deficiencies, which frequently arise after surgery, may be overlooked because of 
their slow development. However, they may give rise to secondary 
hyperparathyroidism (2°HPT) as the body attempts to counter the deficits [5]. 
Obviously, sufficient dietary calcium and vitamin D is necessary to prevent this 
condition, which  can be difficult to achieve because of the bypassed proximal part 
of the small intestine.  This is the obvious reason for the recommendation of 
supplying adequate amounts of dietary calcium and vitamin D after surgery [6-8]. 
Long lasting 2°HPT for years is believed to be an important contributing factor for 
increased bone turnover and consequent bone loss. Indeed, epidemiologic data 
have shown that gastric surgery can lead to a state of 2°HPT with an increased risk 
of osteoporotic fractures [9-11]. 
Besides inadequate dietary intake of  calcium to compensate for 
suboptimal calcium absorption, changes of bowel habits after gastrointestinal 
surgery may also interfere. It is of note that morbidly obese patients frequently 
have fecal incontinence due to a rise in intra-abdominal pressure with compression 
and stretch of the pelvic floor and of the muscles and nerves around the anal 
sphincter complex and in the vicinity of the supporting endopelvic fascia [12]. 
After bariatric surgery, many patients initially experience less fecal incontinence 
due to substantial weight loss and associated improvements of intra-abdominal 
mechanics [13,14]. For obvious reasons, patients may even have a lowered 
frequency and hardened consistency of defecation in comparison to the situation 
prior to the operation. Nevertheless, more frequent and looser stools are common in 
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Abstract  
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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operated patients [15-17].  Studies in laboratory animals elaborating on intestinal 
calcium absorption have shown that intestinal calcium kinetics depends on 
intestinal transit time [18]. Similar observations were found after RYGB due to the 
inability of the small intestine to bind and absorb calcium [19].  
 To our knowledge, no previous studies were published about interactions 
between bowel habits after surgery and changes of calcium metabolism. The aim of 
the present study is to investigate relationships between semi-quantified stools 
scores according to patient reports, compliance for the daily use of extra calcium 
and calcium metabolism.     
   
Patients and methods 
 
During a period of 3 years, 423 morbidly obese patients underwent 
laparoscopic RYGB. Patients were eligible for the study if laboratory data were 
available at baseline and at 11 to 13 months after surgery. A total of 103 patients, 
27 males and 76 females were eligible and these were invited to discuss the 
purpose of the study; all consented  to participate. The objectives of the study were 
1. to evaluate bowel habit changes after surgery; 2. to evaluate relationships 
between 1. and laboratory assessments and 3. to evaluate relationships between 1. 
and 2. with the daily use of a formulation, containing 1 g of elementary calcium 
and 880 to 1000 IU Vitamin D3.  The medical ethical committee of Rijnstate 
Hospital, Arnhem, The Netherlands, approved the study.  
All patients were planned for surgery All patients underwent surgery in a 
single centre for bariatric surgery (Hospital Rijnstate Alysis Zorggroep, The 
Netherlands). Laparoscopic RYGB was performed by 2 dedicated bariatric 
surgeons who used standard techniques. According to protocol, patients with a 
BMI >40 kg/m2 received a 45 cm biliopancreatic limb and a 100 cm alimentary 
limb, while patients with a BMI >50 kg/m2 received a 150 cm alimentary limb. 20 
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Patients received a 150 cm limb and 83 patients received a 100 cm limb..22.2% Of 
all males received a 150 cm limb vs. 18.8% of all females, meaning no statistical 
difference in sex distribution.  Patients were advised to take daily multivitamins in 
addition to omeprazole 40mg (once daily for 6 months) [20] and low molecular 
heparin SC (fraxiparine® 5700 IU once daily for 6 weeks), patients were advised 
to take a daily calcium/vitamin preparation (CaD 1000/880® sachets, containing 
calcium citrate and vitamin D3) or, if they refused to take CaD, to try a different 
formulation containing calcium carbonate and vitamin D3 (Calcichew® 500/400 
chewing tablets b.i.d.) 
After written informed consent, each participant was requested to complete 
a questionnaire about his/her bowel habits prior to and at 12 months after surgery. 
Fecal frequency was scored on a five-point scale ranging from less than twice a 
week (1 point), every two days (2 points), once a day (3 points), twice a day (4 
points) to more than twice a day (5 points). In addition, fecal consistency was 
scored on a five-point scale ranging from watery stools (5 points), watery to solid 
stools (4 points), normal stools (3 points), firm stools (2 points) to hard stools with 
concomitant constipation (1 point). Summation of fecal consistency and frequency 
scores yielded a ‘fecal score’ (FS). Compliance in taking additional calcium and 
vitamin D3 was arbitrarily defined as daily use with the maximal exception of one 
day per week. Patients who reported taking the supplement for 5 or less days a 
week were categorized as non-compliant. For the current analysis, we recorded 1. 
compliance with regular use of calcium and vitamin D3 containing formulations, 2. 
the number of patients who requested to switch from liquid formulations (sachets) 
to chewing tablets and 3. the number of patients who used laxatives or constipating 
agents, at least weekly. Calcium, albumin, vitamin D and PTH at baseline (before 
surgery) and at 12 months after surgery, were used in the final analysis of the 
study. 
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Statistical Analysis 
The datasheet was analysed using SPSS16®, statistical software. All data 
are reported as mean±1SD unless otherwise specified; p0.05 was considered 
significant. Results were compared using independent sample t-tests, Chi square-
tests, relative risk calculation and one-way ANOVA. Logistic regression was used 
to differentiate between variables.  
 
Results 
 
Demographic data of the included 103 patients, prior to surgery are listed 
in Table 1. There were 27 males and 76 females (P<0.05).  All patients were 
Caucasians.  8 Patients (7.7%) were regular tobacco users, 12 patients were on 
antidiabetic drugs (11.6%) and 1 patient used prednisone. 6 Females were 
postmenopausal, 1 of them was on hormonal replacement therapy.   
2 Patients were diagnosed with a leakage at the gastro-jejunostomy and 
were over sewn successfully, respectively on the first and third postoperative day. 
Both patients were discharged within a week after the second operation. Another 2 
patients had their gallbladder removed at 6 and 8 months post-surgery.  There were 
no other surgical complications.  
The Excess Weight Loss (EWL) was >25% for the entire group of 103 
patients and exceeded more than half in 83 participants (81%). EWL of the total 
group at 12 months had decreased with (mean±1SD) 63.5±19.5%. The BMI of the 
whole group decreased from 48.2±6.2 kg/m2 before surgery to 33.9±5.5 kg/m2 at 12 
months. 
Serum calcium concentrations corrected for albumin were normal in 101 
patients (98%), vitamin D insufficiency (<50nmol/L) was demonstrated in 63 
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patients of whom 32 patients (31%) had vitamin D deficiency (<30nmol/L). PTH 
levels were increased (>6.8pmol/L) in 36 patients (35%), see Table 2. 
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Age (yr)     42.3 ± 9.7  
BMI (Kg/m2)      48.6 ± 6.2  
Bodyweight (Kg) 144.3 ± 21.9  
Alimentary limb 
Patient no. with  100cm 83 
Patient no. with  150cm 20 
 Patients  with abnormal lab. values  
Calcium (mmol/L) ²         2.31±0.07                            2 ³
Vitamin D (nmol/L)           50.4±22.4      
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18 (17%)
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PTH (pmol/L)                   5.1±1.0                                 10 (10%)
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²Serum calcium was adjusted for albumin concentrations. ³1 Patient had a corr. 
serum calcium of 2.63 and 1 patient of 2.10 mmol/L.  
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Statistical Analysis 
The datasheet was analysed using SPSS16®, statistical software. All data 
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Table 2. Biochemical data categorized according to normal or increased PTH 
levels at 12 months post gastric bypass surgery. 
Lab. results are represented as (mean ±1SD). *Significant by one-way ANOVA 
with p<0.0001. 
 
Notably, none of the patients were regular laxative users and 79 out of 103 
patients (77.7%) reported permanent changes of their bowel habits.  Each patient 
estimated stool frequency and consistency on two 5 point-scales ranging from 
stools less than twice a week to more than twice a day and from watery to hard 
stools.  The summation of each score (frequency plus consistency scores) yielded a 
fecal score (FS). Memorized stool frequency and consistency data before surgery 
and at 12 months are listed in Table 3a and the distribution of fecal scores (FS) 
(from 2 to 10 points) in Table 3b.  Each score disclosed a significant change 
comparing frequency of stools (F), consistency of stools (C), and the fecal score 
(FS).  In general, there was a significant shift towards more frequent and less 
consistent stools, which overall had resulted in higher fecal scores (for: F: P<0.05, 
C: P<0.0001, and FS: P <0.01).   
Laboratory assessments disclosed no significant changes of corrected 
calcium and vitamin D levels (calcium before surgery 2.31 mmol/L and at 12 
PTH (pmol/L) PTH≤6.8 PTH>6.8 Normal  
Patient no.   67 36  
Calcium 2.34 ± 0.08 2.31 ± 0.11 2.10 - 2.55 mmol/L 
Vitamin D 47.5 ± 27.5 40.3 ± 20.3 30 - 100 nmol/L 
Albumin 38.6 ± 3.0 38.6 ± 4.0 35 - 50 g/L 
PTH 4.3 ± 1.4 * 9.5 ± 2.8* 1.3 - 6.8 pmol/L 
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months 2.34 mmol/L, vitamin D before surgery 50.4 nmol/L and at 12 months 45.0 
nmol/L), while mean PTH levels increased from 5.1 to 6.1 pmol/L (P=0.02).   
 
Table 3a. Changes of bowel habits according to frequency and  consistency scores 
before and after gastric bypass surgery. 
Time baseline 
frequency 
12 mo. 
frequency 
baseline 
consistency 
12 mo. 
consistency 
Patient no. 103 103 103 103 
Frequency/Consistency  
< 2 per week /constipated 9 6 12 8 
3 times per week / firm 23 19 26 14 
1 day / normal 55 44 62 48 
2 per day / solid to watery 13 19 2 27 
> 2 per day / liquid 3 15 1 6 
Number of patients with frequency and consistency scores ranging from 1-5 points. 
 
Before surgery, 10 patients had increased PTH levels, while 4 of them 
(40%) had also increased PTH levels at 12 months.  Before surgery, 32 out of 93 
patients had normal PTH levels but developed raised PTH levels at 12 months 
(34.4%)  (NS).  PTH levels compared for each domain of stool habits [frequency 
(F), consistency(C), fecal score (FS)] per tertile at 12 months, showed no 
significant changes for F and C.  However, PTH levels rose significantly along 
with tertile FS (RR 30.5, CI 6.2-149.2, p<0.001), see Table 4.     
At 12 months, calcium and vitamin D levels were similar between patients 
with an alimentary limb of 100 cm (n=83) and 150 cm (n=20) (100 cm: calcium: 
2.31 mmol/L, vitamin D 46 nmol/L and 150 cm: calcium: 2.33 mmol/L, vitamin D 
42 nmol/L.  In addition, there was a trend towards higher PTH levels after 
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inclusion of all patients using two-sided Student-t test: 100 cm: PTH: 5.6 pmol/L 
and 150 cm: PTH 7.9 pmol/L (P=0.001).  PTH levels were not significantly 
significant after inclusion of compliant calcium/vitamin D3 users (logistic 
regression) (RR 3.2, CI 0.9-11.8, P=0.08).  At 12 months, there were 36 patients 
(35%) with increased PTH levels. 24 Of these patients had a 100 cm alimentary 
limb (67%) and 12 patients had a 150 cm alimentary limb (33%). 
 
Table 3b. Fecal scores before and after gastric bypass surgery 
Fecal score Baseline 12 Months 
2 7 8 
3 4 8 
4 12 17 
5 29 27 
6 39 17 
7 8 12 
8 4 9 
 9       0  4 
    10 0  1 
Fecal scores are the summation of stool frequency and consistency ranging from 2-
10 points and disclosed a significant increase post-surgery (γ 2-test: P<0.01).   
 
According to the definition used in the current study, there were 82 
compliant calcium/vitamin D3 users (80%).  High PTH levels (PTH >6.8 pmol/L) 
were found in 21 patients who belonged to this group compliant for suppletion 
(26%) against 15 patients who belonged to the 21 remaining non-compliant 
suppletion users (71%)  (RR 14.3, CI 3.6-56.5, P<0.001).  In the subgroup of 36 
patients with high PTH levels, 21 patients (58%) were compliant suppletion users 
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(PTH: 9.2±2.8 pmol/L) and 15 patients (42%) were not compliant (PTH: 9.9±2.7 
pmol/L) (NS).   
 
Table 4. Laboratory results according to fecal scores calculated for each tertile  
Fecal score Low Intermediate High P-value 
Patient no. 
(Point range per tertile FS)  
33 
(2-4) 
44 
(5-6) 
26  
(7-10) 
 
Calcium (mmol/L)  
(Patient no. with hypocalcemia)   
2.35 ±0.09  
(0) 
2.32 ±0.09 
(1) 
2.34 ±0.11 
(1) 
0.43 
VitaminD    
(<30 nmol/L/<50 nmol/L)  
41 ±21.0 
(11/22) 
51 ±29.8 
(11/25) 
39.5 ±20.4 
(10/16) 
0.12 
PTH  
(≥6.8 pmol/L) 
4.9 ±2.3 
(4) 
5.8 ±3.2 
(13) 
8.0 ±3.4 
(19) 
<0.001 
Patients with AL  of 150 cm  
(% of total)                   
3  
(9) 
10  
(23) 
7  
(26) 
0.17* 
*= p value by γ2-test, all other comparisons were performed by one-way ANOVA. 
AL: Alimentary Limb FS: Fecal Score 
 
The reasons for non-compliant suppletion use were; being principally 
against regular use of any prescribed drug, frequently forgetting, and taste aversion 
against calcium formulations.  69 Of the 82 compliant suppletion users (84%) had 
decided to switch from sachets (liquid formulation) to chewing tablets, while the 
remaining 13 patients (16%) continued to take sachets.  The main reasons for 
changing from sachets to tablets was non-palatability reported by 54 patients (78%) 
and/or the inability to drink large volumes reported by 30 patients (43%). There 
were 6 reports on dumping-like symptoms with sachets. 
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inclusion of all patients using two-sided Student-t test: 100 cm: PTH: 5.6 pmol/L 
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Discussion 
 
The results of the current study showed significant changes of bowel habits 
after surgery, which went into the direction of a higher stool frequency, less 
consistency and consequent higher fecal scores. There were no correlations with 
either frequency or consistency and PTH levels, while fecal score and PTH levels 
were positively correlated.  There was also an interaction between compliance for 
calcium/vitamin D3 suppletion and PTH levels but it should be emphasized that the 
current results are nothing but associations, which implicates that prospective 
intervention studies are needed to clarify how these factors interact.  Moreover, it is 
entirely unclear whether additional calcium and vitamin D supplements are 
beneficial in suppressing PTH levels and ultimately affect incident osteoporotic 
fractures in later life. An additional uncertainty is the effect of omeprazole 40mg 
(once daily for 6 months) on calcium metabolism after surgery.  Indeed, proton 
pump inhibitor therapy increases the risk to skeletal fracture in the long-term, 
possibly by inhibiting intestinal calcium absorption [21, 22].  Obviously, 
prospective randomized clinical trials should be long lasting as osteoporotic 
fractures usually occur much later in life.   
Elevation of PTH, even in the presence of unchanged corrected calcium 
and vitamin D levels is compatible with 2°HPT [5].  In fact, RYGB serves as a 
model for 2°HPT exclusively due to inadequate calcium absorption. A study on 
calcium metabolism of patients who had undergone RYGB and matched controls 
showed that the patients needed an extra amount of 750 mg calcium per day to 
maintain similar PTH levels [23].  These calculations were made at 9 months post-
surgery, meaning that calcium metabolism was still influenced by skeletal calcium 
effluxes due to high bone turnover [23,24]. Yet, no calcium balance studies have 
been published that deal with operated patients with a stable body weight to 
provide information on the optimal amount of dietary calcium.  Notably, too much 
 232 
extra dietary calcium may be harmful because of calcium-related constipation.  It 
has been shown previously that calcium salts bind to free fatty acids and fecal bile 
acids in the colonic lumen, forming calcium soaps.  In other words, calcium 
suppresses intestinal motility indirectly through binding at the colon level leading 
to less free fatty acids and to bile acids that are toxic to the colonic mucosa to 
provoke frequent and watery stools [25].  
It is an open question whether increased PTH levels due to chronic calcium 
malabsorption after RYGB are relevant to future skeletal health.  Bone loss after 
bariatric surgery can be partly ascribed to the direct and secondary effects of rapid 
weight loss and partly to 2°HPT-related bone loss.  Moreover, shortly after 
bariatric surgery there will be substantial bone loss, which is obviously driven by 
the catabolic state of the ongoing weight reduction and not by 2°HPT.  Most of this 
type of rapid bone loss occurs at the hip and ceases with stabilization of body 
weight.  The loss of bone mineral density after surgery occurs mainly at the hip and 
pelvis, varying between 5 to 10% [23, 24, 26].  However, these analyses were 
performed around 12 months after surgery, during rapid bone loss.  Thus far, there 
are no data, for example, after a decade available in the literature.  Most of the 
available data come from histological studies of operated patients with a jejunoileal 
bypass, showing that full-blown osteomalacia was common after this particular 
procedure [27].  However, jejunoileal bypass surgery is fraught with many long-
term complications, among which is vitamin D deficiency, and the operation has 
therefore been abandoned. Since no histology data are available from obese 
patients after Roux-en-Y bypass surgery, the jejunoileal bypass bone samples are 
unique and could help to understand some of the skeletal health issues that should 
be dealt with.  In a comparative histomorphometry study in 21 patients 3-14 years 
after intestinal bypass surgery for obesity, osteomalacia was found in one-third of 
all patients. Biopsies of those without osteomalacia disclosed a marked reduction 
of trabecular thickness, partly as the result of 2°HPT and partly because of 
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weight.  The loss of bone mineral density after surgery occurs mainly at the hip and 
pelvis, varying between 5 to 10% [23, 24, 26].  However, these analyses were 
performed around 12 months after surgery, during rapid bone loss.  Thus far, there 
are no data, for example, after a decade available in the literature.  Most of the 
available data come from histological studies of operated patients with a jejunoileal 
bypass, showing that full-blown osteomalacia was common after this particular 
procedure [27].  However, jejunoileal bypass surgery is fraught with many long-
term complications, among which is vitamin D deficiency, and the operation has 
therefore been abandoned. Since no histology data are available from obese 
patients after Roux-en-Y bypass surgery, the jejunoileal bypass bone samples are 
unique and could help to understand some of the skeletal health issues that should 
be dealt with.  In a comparative histomorphometry study in 21 patients 3-14 years 
after intestinal bypass surgery for obesity, osteomalacia was found in one-third of 
all patients. Biopsies of those without osteomalacia disclosed a marked reduction 
of trabecular thickness, partly as the result of 2°HPT and partly because of 
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insufficient osteoblastic synthesis. This picture differs from that of age-related 
bone loss and post-menopausal osteoporosis which share loss of density rather than 
thickness of trabecular plates [28].  Biopsies from 16 middle-aged males after 
partial gastrectomy with Billroth II anastomosis revealed high bone turnover 
(leading to bone loss) due to body weight reduction post-surgery and/or 2°HPT 
[11]. Finally, there is histological proof for insufficient osteoblastic recruitment and 
activity, probably due to deficits of unidentified nutrients resulting from the 
malabsorption caused by bypassing critical parts of the small intestines [28].  In a 
bone biopsy study among 41 patients after partial or total biliopancreatic bypass, it 
was found that defective mineralization and a decrease of bone formation rate were 
present in spite of serum 25-hydroxyvitamin D concentrations being normal [29].  
These biopsy data underscore the concept that in one way or another essential 
nutrients are needed to support   bone formation.  
This study has several limitations, mainly related to its retrospective and 
cross-sectional design.  However, it underlines the need for more prospective 
intervention studies in gastric bypass patients, even though this procedure is 
considered the gold standard, suggesting safety. In the meantime it remains 
advisable to consider bone mineral density in the assessments of risk factors prior 
to surgery, particularly in women.    
In conclusion, 12 months after gastric bypass surgery, there was a positive 
relationship between bowel habits (i.e. the summation of stool frequency and 
consistency scores) and PTH levels with an interaction for the compliance with 
calcium/Vitamin D suppletion. This finding is based on fecal score and an 
arbitrarily chosen definition of compliance. The current study underscores the 
importance of professional management of bowel habits and tailor made 
calcium/vitamin D suppletion. Long-term prospective intervention studies are 
critical to evaluate efficacy as well as side effects and should be undertaken in the 
near future.    
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Abstract          
 
Background 
Iron, vitamin B12 and folic acid deficiencies are among the most common 
deficiencies occurring after Laparoscopic Roux-en-Y Gastric Bypass (LRYGB). The 
present study evaluates the effectiveness of a specially designed multivitamin supplement 
(WLS Forte®) specifically developed for LRYGB patients. 
 
Methods 
A double-blind, randomized, 12-month study was conducted comparing WLS 
forte® with a standard multiv itamin supplement (sMVS) containing approximately 100% of 
recommended daily allowance (RDA) for iron, vitamin B12 and folic acid. WLS Forte ® 
contains vitamin B12 14000% RDA, iron 500% RDA, and fo lic acid 300% RDA.  
 
Results  
In total 148 patients (74 in each group) underwent a LRYGB procedure. Baseline 
characteristics were similar for both groups. Per protocol analysis demonstrated that sMVS 
treatment was associated with a decline in ferrit in ( - 24.4 ±70.1 ug/L) and vitamin B12 (-
45.9 ±150.3 pmol/L), whereas in W LS Forte® patients ferrit in remained stable (+ 3.2±93.2 
ug/L) and vitamin B12 increased significantly (+ 55.1±144.2 pmol/L). The number of 
patients developing ferritin or vitamin B12 deficiency was significantly lower with WLS 
Forte® compared to sMVS (p<0.05). Iron deficiency (ID) was reduced with 88% after WLS 
Forte® compared to sMVS. Adverse events related to supplement usage did not occur. 
 
Conclusion 
An optimized multiv itamin supplement is safe and results in less ferrit in and 
vitamin B12 deficiencies after LRYGB.  
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Introduction 
 
 Bariatric surgery has proven itself as an effective treatment to establish 
sustained weight loss, and reduce obesity-related co-morbidities like type 2 
diabetes mellitus, hypertension and sleep apnea syndrome, in morbidly obese 
patients [1-6]. The Roux-en-Y Gastric Bypass (RYGB) is worldwide one of the 
most performed surgical procedures to induce weight loss [7]. However, the 
restricted intake and partial bypass of the upper intestinal tract increases the risk for 
nutritional deficiencies. Most commonly diagnosed postsurgical deficiencies are 
iron (47-66%), vitamin B12 (37-50%), folic acid (15-38%), vitamin D (20-51%) 
and calcium (±10%) [8-23, 27, 28]. To prevent postsurgical deficiencies, daily use 
of multivitamin and mineral supplements are generally recommended [25], 
however, guidelines vary and RYGB specific, multivitamin supplements (MVS) 
are currently not available [8, 11,14, 24].  
Based on the literature and pilot studies performed in our hospital, a 
customized MVS for RYGB patients was developed (WLS Forte®, FitForMe, 
Rotterdam, the Netherlands). The present study evaluates the effectiveness and 
safety of WLS Forte® compared to standard MVS (sMVS, commercially available 
tablets) after RYGB in a double-blind randomized controlled trail.   
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Abstract 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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Patients and Methods  
 
Patient selection 
Between June 2011 and March 2012 a total of 150 patients who were 
scheduled for a primary laparoscopic RYGB (LRYGB) were randomized for 
postoperative multivitamin supplementation for a duration of twelve months. All 
patients met the criteria for bariatric surgery according to NIH Consensus 
Development Conference Panel for bariatric surgery [26]. Patients were 
randomized to receive either standard multivitamin supplements (sMVS, FitForMe, 
Rotterdam, The Netherlands) or RYGB specif ic multivitamin supplements (WLS 
Forte®, FitForMe, Rotterdam, The Netherlands). A computer-generated variable 
block schedule was used for randomization. Patients, surgeons and researchers 
were blinded for the supplements. Both supplements were similar for color, size, 
and packaging, and both were dosed as one capsule daily. The composition of both 
supplements is shown in Table 1. The sMVS served as control and contained the 
compounds of interest in a dose  equivalent to the recommended daily allowance 
(RDA), whereas WLS Forte contained much higher doses, in particular, of iron (5 
times RDA), folic acid (3 times RDA) and vitamin B12 (140 times RDA).  All 
patients also received calcium carbonate/ cholecalciferol (CaD) 500/400 tablets 
three times daily (a total of 1500mg calcium en 1200 IU vitamin D). 
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Table 1. Dosages of supplement ingredients  
Ingredients StandardMVS   WLS Forte®  
 Dosage ADH (%) Dosage ADH (%) 
Biotin (μg) 25.00 50.0 600.00 1200.0 
Calcium (mg) 91.43 11.4 0.0 0.0 
Chloride (mg) 0.14 0.0 0.54 0.1 
Chrome (μg) 40.00 100.0 160.00 400.0 
Copper (μg) 999.60 100.0 3000.20 300.0 
Folic acid (μg) 200.00 100.0 600.00 300.0 
Iodine (μg) 153.70 102.5 225.04 150.0 
Iron (mg) 14.00 100.0 70.00 500.0 
Manganese (mg) 2.00 100.1 3.00 150.0 
Magnesium (mg) 30.00 8.0 0.0 0.0 
Molybdenum (μg) 50.00 100.0 112.40 224.8 
Selenium (μg) 55.00 100.0 105.00 190.9 
Vitamin A (μg) 599.70 75.0 1000.38 125.0 
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Patients and Methods  
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Surgical procedure 
All procedures were performed by one of 3 bariatric surgeons all beyond 
their learning curve (> 750 procedures each). They performed an antecolic 
antegastric LRYGB, with a proximal gastric pouch of 30 ml, a biliopancreatic limb 
(BPL) of 50 cm and a Roux limb of 150 cm. All patients received low-molecular 
heparin (Nadroparin 5700IU daily) for 6 weeks and proton-pump inhibitor 
(Omeprazol 40mg daily) for 6 months, as a part of our standard postoperative 
protocol.  
 
Follow-up and outcome 
All patients followed a strict postoperative schedule consisting of 17 visits 
in the first year, and on each visit patients were encouraged to keep taking their 
supplements. Standard laboratory blood test were performed at baseline, 6 and 12 
months. This included a complete blood count (CBC, (normal range (NR) 
hemoglobin: females: 7.4 - 9.9 mmol/L, males: 8.4 - 10.8 mmol/L), mean cell 
volume (MCV, [NR: 80 – 100 fL]), creatinine [NR: 45 – 90 μmol/L], sodium [NR: 
135 – 145 mmol/l], potassium [NR: 3.5 – 4.7 mmol/l], calcium [NR: 2.10 – 2.55 
mmol/l], phosphate [NR: 0.87 – 1.45 mmol/l], magnesium [NR: 0.71 – 0.93 
mmol/l], zinc [NR 9.2 – 18.4 μmol/L], albumin [35 – 50 g/l], fasting glucose (FG, 
[NR: 4.0 – 5.6 mmol/l]), Hb1Ac [NR: 20 – 42 mmol/mol], total cholesterol [NR 
<6.50 mmol/l] , HDL-cholesterol [NR >1.10 mmol/l], LDL-cholesterol [NR: 3.50 – 
4.50 mmol/l], and triglycerides [NR: 0.8 – 2.0 mmol/l]), iron [NR: 9.0 – 31.0 
μmol/l], total-iron-binding-capacity (TIBC, [NR: 45.0 – 81.0 μmol/L]), ferritin 
[NR 20 -200 μg/L], folic acid [NR: 9.0 – 36.0 nmol/l], vitamin B12 [NR: 150 – 640 
pmol/l], 25-hydroxyvitamin D (25-OHD, [NR: >50 nmol/L]), parathyroid hormone 
(PTH, [NR: 1.3 – 6.8 pmol/l]),  vitamin B1 [NR: 95 – 175 nmol/L], vitamin B6 
[NR: 25 – 100 nmol/L].  
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Primary outcome variables were the percentage of iron, folic acid and 
vitamin B12 deficiencies developed during the 12 month after LRYGB. Iron 
Deficiency (ID), was defined as a serum ferritin < 20 μg/L, folic acid deficiency if 
the level was < 9.0 nmol/L, and vitamin B12 deficiency if the level was <150 
pmol/L). Vitamin D deficiency was diagnosed if 25-OHD < 50 nmol/L, 
hypocalcemia if serum calcium <2.1 mmol/L), and zinc deficiency of the serum 
level was <9.2 μmol/L. Calcium data are shown as calcium levels corrected for 
albumin (Cacorr), according to the following equation: Cacorr = Total Calcium – 
(0.025 x albumin) + 1. 
 
Correction of deficiencies 
Preoperative deficiencies for iron, folic acid, vitamin B12 and vitamin D 
were treated with predefined medication until 2 months pre-operatively so that it 
would not intervene with the post-operative multivitamin supplements. If a 
postoperative deficiency occurred it was recorded for the purpose of this study. 
Subsequently the deficiency was corrected. 
ID with or without anemia was treated with ferrous gluconate 695 mg 3 
times daily for 3 months. Vitamin B12 deficiency was corrected with intramuscular 
injection of 1000μg hydroxocobalamin once every 2 months for 12 months. 
Vitamin D deficiency was corrected with oral solubilized cholecalciferolFNA 50 000 
IU/ml. First, a loading dose (IU) was calculated with the formula: 40 x (75 – actual 
serum 25-OHD level) x body weight in kilograms, as described previously [29,30]. 
Thereafter, a maintenance dosage of 25 000 IU cholecalciferolFNA per week was 
prescribed for a period of 3 months. For other deficiencies the endocrinologist was 
consulted. 
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Ethics 
Written informed consent was obtained from each patient before 
participating the study. The study protocol was approved by the National Medical 
Ethics Review Committee of the Radboud University Nijmegen Medical Centre 
(RUNMC) and Local Ethical Committee of the Rijnstate Hospital Arnhem. The 
study protocol was registered at ClinicalTrials.gov register (identifier 
NCT01609387).  
 
 
Statistical analysis and sample size calculation 
Sample size calculation was performed by the epidemiologist of the 
Research Department of Rijnstate Hospital Arnhem using Openepi.com. Sample 
size calculation was based on the number of patients developing ID. To detect a 
25% reduction of ID 12 months after surgery, with a confidence interval 95% and a 
power of 90%, a minimum of 56 patients per group were needed. Taking into 
account a 10% drop-out and 15% deficiency of iron at 6 months which will be 
supplemented at that time, it was decided to include 75 patients per treatment 
group.  
All data were analyzed using IBM® SPSS® Statistics 20 for Windows. Data 
were expressed in mean (± standard deviation), unless otherwise specified. 
Difference between groups were calculated using student-t test for continuous data 
and chi-square test for ordinal/ nominal data. A P-value < 0.05 was considered 
statistically significant. 
 
Results 
 
Two patients were excluded after randomization: one patient in the WLS 
Forte® group because he underwent a sleeve gastrectomy instead of a LRYGB 
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because of multiple adhesions during surgery, and one patient in the sMVS group 
because he cancelled the scheduled operation procedure. In total 148 patient (74 in 
each group) underwent a LRYGB and were included for analysis. Baseline patient 
characteristics are shown in Table 2. Both groups were similar with respect to age, 
sex, weight, body mass index (BMI) and preoperative deficiencies. However, 
dyslipidaemia was twice as frequent in the WLS Forte® group as compared to the 
sMVS group (P = 0.04).  
 
Table 2. Baseline characteristics of patients  
 Standard MVS WLS Forte®  P-value  
Age (yrs) 43.4 ±10.0 45.3 ±10.2 0.26 
Weight (kg) 132.1  ±17.7 134.8  ±20.7 0.39 
BMI (kg/m2) 44.8  ±4.8 44.8  ±6.4 1.00 
Male/ Female (N,%) 24/51 32%/68% 22/53 29%/71% 0.86 
Co-morbidities (N,%) 
T2DM 24 32% 25 33.3% 0.86 
Hypertension 33 44% 28 37.3% 0.41 
Dyslipidemia 10 13.3% 20 26.7% 0.04 
OSAS 11 14.7% 14 18.7% 0.51 
Preoperative deficiencies (N,%) 
Folic acid 1 1.4% 1 1.4% 0.90 
Vitamin B12 5 6.8% 4 5.4% 0.23 
Iron 17 23% 13 20.3% 0.42 
Ferritin 5 6.7% 3 4.0% 0.19 
Vitamin D 46 63% 50 67.6% 0.56 
MVS: Multivitamin Supplement, T2DM: Type 2 Diabetes Mellitus, OSAS: 
Obstructive apnea syndrome 
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Weight loss 
The degree of weight loss over 12 months was similar in both groups. 
Weight dropped to 90.6±17.4 kg compared 93.8±16.9 kg in sMVS versus WLS 
Forte® (p=0.24), respectively. Percentage Excess Weight Loss (%EWL), defined as 
weight loss divided by excess weight based on ideal body weight at BMI 25 kg/m2 , 
were after 12 months 72.5±20.9 kg/m2 versus 72.1±23.2 kg/m2 for MVS and WLS 
Forte® (p=0.92), respectively.  
 
Iron, vitamin B12 and folic acid deficiency 
In Table 3 laboratory serum levels of hemoglobin metabolism are shown. 
Mean hemoglobin levels at baseline were 8.5±0.7 mmol/L (sMVS) and 8.6±0.7 
mmol/L (WLS Forte®) (p=0.24), and did not change over 12 months. MCV’s also 
did not change (data not shown). In total, 10 (6.8%) patients had anemia pre-
operatively, 6 (8.1%) patients in the sMVS and 4 (5.4%) in the WLS Forte® group 
(p=0.50), respectively. Three of them (1.4%), 2 in sMVS and 1 in WLS Forte®, had 
ID anemia. After 12 months post-operatively, 3 patients (4.3%) versus 5 patients 
(7.4%) had anemia (p=0.75), respectively. Of these patients, 2 patients had anemia 
the novo in both groups. Two patients (1.5%), one patient in each group, had ID 
anemia.  
The total number of patients developing ferritin deficiency during follow-
up were 8 (10.7%) patients in sMVS and 1 (1.3%) patients in WLS Forte® 
(p=0.03). In total 55 (37.2%) patients, 28 (37.8%) in sMVS and 27 (36.5%) in 
WLS Forte® group, received additional iron medication at any time during the 12 
month follow-up. Results after exclusion of these patients are shown in Table 4. 
Mean serum ferritin decreased by 18.4±61.8 ug /L in the sMVS group, but 
remained stable in the WLS Forte® group (p = 0.08).  At baseline, vitamin B12 
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deficiency was diagnosed in 9 (6.1%) patients, i.e. 5 (6.8%) patients in the sMVS 
group, and 4 (5.4%) patients in the WLS Forte® group. 
Table 3. Laboratory blood tests of hemoglobin metabolism  
Serum levels Standard MVS WLS Forte ® P-value  
Hemoglobin (mmol/L)  
Baseline  8.5 ±0.7 8.6 ±0.7 0.24 
6 months 8.6 ±0.7 8.5 ±0.7 0.56 
12 months 8.5 ±0.8 8.6 ±0.7 0.50 
Δ 0 – 12 months 0.029 ±0.7 -0.063 ±0.5 0.40 
MCV (fL)   
Baseline  88.8 ±4.6 88.6 ±4.1 0.79 
6 months 90.2 ±4.5 89.4 ±6.5 0.41 
12 months 90.6 ±4.1 91.4 ±3.7 0.22 
Δ 0 – 12 months 1.96 ±3.2 2.55 ±2.7 0.24 
Iron (μmol/L)  
Baseline  13.1 ±5.9 12.5 ±4.0 0.43 
6 months 15.1 ±4.3 14.7 ±4.9 0.66 
12 months 16.0 ±5.3 16.8 ±5.5 0.42 
Δ 0 – 12 months 2.9 ±6.9 4.5 ±5.2 0.14 
Ferritin (μg/L)  
Baseline  114.3 ±101.6 142.5 ±122.7 0.13 
6 months 94.3 ±92.5 119.9 ±89.1 0.10 
12 months 89.8 ±88.5 130.7 ±99.1 0.10 
Δ 0 – 12 months -23.4 ±70.1 -18.4 ±105.3 0.74 
TIBC (μmol/L)  
Baseline  66.7 ±9.8 64.4 ±10.6 0.18 
6 months 62.4 ±10.4 59.4 ±9.8 0.09 
12 months 63.8 ±11.2 59.1 ±9.3 0.01 
Δ 0 – 12 months -3.8 ±11.7 -5.35 ±8.3 0.41 
Folic acid (nmol/L)  
Baseline  17.6 ±7.3 17.9 ±7.4 0.83 
6 months 21.8 ±9.0 27.7 ±10.7 0.001 
12 months 22.9 ±8.0 29.3 ±11.5 <0.001 
Δ 0 – 12 months 5.7 ±7.3 11.2 ±11.9 0.002 
Vitamin B12 (pmol/L)  
Baseline  350.4 ±211.1 311.8 ±115.1 0.17 
6 months 285.0 ±176.5 418.1 ±250.4 <0.001 
12 months 348.3 ±297.9 421.9 ±250.4 0.12 
Δ 0 – 12 months -4.9 ±353.8 112.8 ±270.3 0.03 
Numbers are mean (±SD), MVS: Multivitamin Supplement, MCV: mean cell 
volume, TIBC: total iron-binding capacity 
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Baseline  8.5 ±0.7 8.6 ±0.7 0.24 
6 months 8.6 ±0.7 8.5 ±0.7 0.56 
12 months 8.5 ±0.8 8.6 ±0.7 0.50 
Δ 0 – 12 months 0.029 ±0.7 -0.063 ±0.5 0.40 
MCV (fL)   
Baseline  88.8 ±4.6 88.6 ±4.1 0.79 
6 months 90.2 ±4.5 89.4 ±6.5 0.41 
12 months 90.6 ±4.1 91.4 ±3.7 0.22 
Δ 0 – 12 months 1.96 ±3.2 2.55 ±2.7 0.24 
Iron (μmol/L)  
Baseline  13.1 ±5.9 12.5 ±4.0 0.43 
6 months 15.1 ±4.3 14.7 ±4.9 0.66 
12 months 16.0 ±5.3 16.8 ±5.5 0.42 
Δ 0 – 12 months 2.9 ±6.9 4.5 ±5.2 0.14 
Ferritin (μg/L)  
Baseline  114.3 ±101.6 142.5 ±122.7 0.13 
6 months 94.3 ±92.5 119.9 ±89.1 0.10 
12 months 89.8 ±88.5 130.7 ±99.1 0.10 
Δ 0 – 12 months -23.4 ±70.1 -18.4 ±105.3 0.74 
TIBC (μmol/L)  
Baseline  66.7 ±9.8 64.4 ±10.6 0.18 
6 months 62.4 ±10.4 59.4 ±9.8 0.09 
12 months 63.8 ±11.2 59.1 ±9.3 0.01 
Δ 0 – 12 months -3.8 ±11.7 -5.35 ±8.3 0.41 
Folic acid (nmol/L)  
Baseline  17.6 ±7.3 17.9 ±7.4 0.83 
6 months 21.8 ±9.0 27.7 ±10.7 0.001 
12 months 22.9 ±8.0 29.3 ±11.5 <0.001 
Δ 0 – 12 months 5.7 ±7.3 11.2 ±11.9 0.002 
Vitamin B12 (pmol/L)  
Baseline  350.4 ±211.1 311.8 ±115.1 0.17 
6 months 285.0 ±176.5 418.1 ±250.4 <0.001 
12 months 348.3 ±297.9 421.9 ±250.4 0.12 
Δ 0 – 12 months -4.9 ±353.8 112.8 ±270.3 0.03 
Numbers are mean (±SD), MVS: Multivitamin Supplement, MCV: mean cell 
volume, TIBC: total iron-binding capacity 
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These patients received vitamin B12 injections by protocol. In total 27 (18.2%) 
additional patients were treated vitamin B12 injections any time during the twelve 
month follow up, 17 (23%) in the sMVS group and 10 (13.5%) in the WLS Forte® 
group (p=0.14). The results obtained after exclusion of these patients receiving 
vitamin B12 injections are shown in Table 4. Mean vitamin B12 serum levels 
decreased by -38.9±141.3 pmol/L in the sMVS group and increased by 44.1±138.8 
pmol/L in the WLS Forte® group (<0.001) after 12 months, and as a result mean 
vitamin B12 blood serum levels at 6 months and 12 months were significant higher 
with WLS Forte® compared to sMVS (p<0.05). After 12 months, vitamin B12 
deficiency had developed in 5 (7.9%) patients receiving sMVS versus 1 (1.6%) in 
WLS Forte® group (p=0.207).  
 
Mean serum folic acid levels were similar at baseline, 17.6±7.3 nmol/L and 
17.9±7.4 nmol/L (p=0.83) for sMVS and WLS Forte® respectively. In both groups, 
one patient (1.4%) had folic acid deficiency at baseline. During the study period 
folic acid deficiency developed in 5 (6.8%) in sMVS and 2 (2.7%) in WLS Forte® 
group (p=0.441). After 6 and 12 months, mean serum folic acid levels were 
significant higher in WLS Forte® group (p<0.05).  
 
Vitamin D metabolism 
 In total 96 (65.3%) patients, 46 (63.0%) in sMVS and 50 (67.6%) patients 
in WLS Forte® (p=0.56), had vitamin D deficiency before surgery. Mean serum 
vitamin D levels were 42.5±17.9 nmol/L and 44.3±20.6 nmol/L at baseline 
(p=0.58), respectively. Vitamin D deficiencies were corrected according to 
protocol and this resulted in mean 25-OHD levels close to the target of 75 nmol/L 
in both groups. The mean loading dose was 226.087±60.442 IU with a 
maintenance dose of 25.000 IU/month. At 12 months, 7 (10.1%) patients in the 
sMVS and 12 (18.5%) patients in the WLS Forte® group had vitamin D deficiency 
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(p=0.168). Excluding the patients who received extra vitamin D supplementation 
additional to the standard suppletion, mean vitamin D levels at baseline were 
61.8±10.8 versus 66.8±19.3 nmol/L (p=0.29) for sMVS and WLS Forte® ; after 12 
months 84.6±20.8 nmol/L versus 83.4±24.8 nmol/L (p=0.87), respectively.  
 
Table 4.  Laboratory blood tests of hemoglobin metabolism excluding patient with 
additional iron and/ or vitamin B12 medication 
Serum levels Standard MVS 
 
WLS Forte® 
 
P-value  
Hemoglobin (mmol/L)   
Baseline 8.5 ±0.6 8.6 ±0.7 0.38 
6 months 8.6 ±0.7 8.4 ±0.7 0.25 
12 months 8.5 ±0.8 8.5 ±0.6 1.00 
Δ 0 – 12 months 0.029 ±0.7 -0.063 ±0.5 0.64 
Ferritin (μg/L)  
Baseline  103.0 ±86.1 102.1 ±71.0 0.95 
6 months 84.5 ±73.2 97.8 ±66.7 0.29 
12 months 80.8 ±71.0 108.3 ±83.1 0.05 
Δ 0 – 12 months -18.4 ±61.8 4.9 ±81.3 0.08 
Vitamin B12 (pmol/L)   
Baseline  305.4 ±107.1 302.8 ±100.9 0.88 
6 months 249.9 ±85.6 351.3 ±135.6 <0.001 
12 months 267.2 ±100.1 349.8 ±122.1 <0.001 
Δ 0 – 12 months  -38.9 ±141.3 44.1 ±138.8 0.002 
Numbers are mean (±SD),  MVS: Multivitamin Supplement 
 
There were no differences in parathyroid hormone (PTH) levels and calcium levels 
between the two groups (p≥0.05), although PTH levels rose with 1.26±2.39 and 
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(p=0.168). Excluding the patients who received extra vitamin D supplementation 
additional to the standard suppletion, mean vitamin D levels at baseline were 
61.8±10.8 versus 66.8±19.3 nmol/L (p=0.29) for sMVS and WLS Forte® ; after 12 
months 84.6±20.8 nmol/L versus 83.4±24.8 nmol/L (p=0.87), respectively.  
 
Table 4.  Laboratory blood tests of hemoglobin metabolism excluding patient with 
additional iron and/ or vitamin B12 medication 
Serum levels Standard MVS 
 
WLS Forte® 
 
P-value  
Hemoglobin (mmol/L)   
Baseline 8.5 ±0.6 8.6 ±0.7 0.38 
6 months 8.6 ±0.7 8.4 ±0.7 0.25 
12 months 8.5 ±0.8 8.5 ±0.6 1.00 
Δ 0 – 12 months 0.029 ±0.7 -0.063 ±0.5 0.64 
Ferritin (μg/L)  
Baseline  103.0 ±86.1 102.1 ±71.0 0.95 
6 months 84.5 ±73.2 97.8 ±66.7 0.29 
12 months 80.8 ±71.0 108.3 ±83.1 0.05 
Δ 0 – 12 months -18.4 ±61.8 4.9 ±81.3 0.08 
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Baseline  305.4 ±107.1 302.8 ±100.9 0.88 
6 months 249.9 ±85.6 351.3 ±135.6 <0.001 
12 months 267.2 ±100.1 349.8 ±122.1 <0.001 
Δ 0 – 12 months  -38.9 ±141.3 44.1 ±138.8 0.002 
Numbers are mean (±SD),  MVS: Multivitamin Supplement 
 
There were no differences in parathyroid hormone (PTH) levels and calcium levels 
between the two groups (p≥0.05), although PTH levels rose with 1.26±2.39 and 
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1.75±3.1 pmol/L. Table 5 shows serum blood tests of the vitamin D metabolism at 
fixed time moments.  
 
Table 5. Laboratory blood tests of vitamin D metabolism  
Serum levels Standard MVS WLS Forte ® P-value  
Vitamin D (nmol/L)  
Baseline  42.5 ±17.9 44.3 ±20.6 0.58 
6 months 74.0 ±21.3 73.6 ±26.1 0.92 
12 months 76.7 ±24.6 70.4 ±25.4 0.92 
Δ 0 – 12 months 33.0 ±27.2 25.0 ±27.0 0.09 
PTH (pmol/L)  
Baseline  3.46 ±2.0 3.88 ±3.7 0.40 
6 months 4.10 ±1.9 4.38 ±2.1 0.41 
12 months 4.81 ±2.4 5.80 ±3.4 0.052 
Δ 0 – 12 months 1.26 ±2.39 1.75 ±3.1 0.31 
Calcium (mmol/L)  
Baseline  2.31 ±0.08 2.32 ±0.09 0.28 
6 months 2.32 ±0.10 2.31 ±0.09 0.48 
12 months 2.32 ±0.21 2.32 ±0.10 1.00 
Δ 0 – 12 months 0.009 ±0.21 0.001 ±0.09 0.77 
Albumin (g/l)  
Baseline  39.0 ±2.9 38.4 ±5.0 0.43 
6 months 39.9 ±3.7 38.4 ±3.1 0.008 
12 months 40.0 ±2.7 38.1 ±3.3 <0.001 
Δ 0 – 12 months 1.04 ±2.8 -0.015 ±5.1 0.14 
Phosphate (mmol/L)  
Baseline  0.99 ±0.19 0.98 ±0.19 0.86 
6 months 1.03 ±0.22 1.00 ±0.20 0.44 
12 months 1.08 ±0.21 1.03 ±0.17 0.14 
Δ 0 – 12 months 0.09 ±0.24 0.05 ±0.25 0.38 
Numbers are mean (±SD), MVS: Multivitamin Supplement, PTH: parathyroid 
hormone 
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Other vitamins and minerals 
 Vitamin B6 levels were at baseline 68.6±22.1 nmol/L versus 74.9±22.8 
nmol/L for sMVS and WLS Forte® group (p=0.13), respectively. There were no 
vitamin B6 deficiencies observed at baseline. In total 15 (10.1%) patients, 5 (6.8%) 
patients in sMVS versus 10 (13.5%) patients in WLS Forte® (p=0.173), 
respectively, had elevated serum vitamin B6 levels at baseline. After 12 months, 
there were no deficiencies in both groups and elevated serum vitamin B6 levels 
were observed in total 52 (40.6%) patients, 21 (31.8%) patients in sMVS group and 
31 (50%) patients in WLS Forte® group. In one patient, an extreme high level of 
vitamin B6 of 2777 nmol/L (without any neurological symptoms) was detected in 
the WLS Forte® group, however, this patient had used additional multivitamin 
supplements on advice of his general practitioner additionally to the study 
multivitamin tablets. This level dropped to 110 nmol/L after withdrawal of these 
additional vitamin B6 tablets after 2 months. 
 For vitamin B1, zinc, phosphate and magnesium, no differences were 
observed between the groups. Laboratory blood tests are shown in Table 6. 
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Other vitamins and minerals 
 Vitamin B6 levels were at baseline 68.6±22.1 nmol/L versus 74.9±22.8 
nmol/L for sMVS and WLS Forte® group (p=0.13), respectively. There were no 
vitamin B6 deficiencies observed at baseline. In total 15 (10.1%) patients, 5 (6.8%) 
patients in sMVS versus 10 (13.5%) patients in WLS Forte® (p=0.173), 
respectively, had elevated serum vitamin B6 levels at baseline. After 12 months, 
there were no deficiencies in both groups and elevated serum vitamin B6 levels 
were observed in total 52 (40.6%) patients, 21 (31.8%) patients in sMVS group and 
31 (50%) patients in WLS Forte® group. In one patient, an extreme high level of 
vitamin B6 of 2777 nmol/L (without any neurological symptoms) was detected in 
the WLS Forte® group, however, this patient had used additional multivitamin 
supplements on advice of his general practitioner additionally to the study 
multivitamin tablets. This level dropped to 110 nmol/L after withdrawal of these 
additional vitamin B6 tablets after 2 months. 
 For vitamin B1, zinc, phosphate and magnesium, no differences were 
observed between the groups. Laboratory blood tests are shown in Table 6. 
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Table 6. Laboratory blood tests of other vitamins or minerals 
Serum levels Standard MVS WLS Forte® P-value  
Vitamin B1 (nmol/L)  
Baseline 154.4 ±23.3 160.6 ±29.7 0.16 
6 months 154.4 ±27.6 154.4 ±30.8 1.00 
12 months 147.3 ±31.8 151.2 ±31.3 0.49 
Δ 0 – 12 months  -7.05 ±30.1 -11.2 ±35.4 0.47 
Vitamin B6 (nmol/L)  
Baseline 68.6 ±22.1 74.9 ±28.8 0.13 
6 months 90.6 ±38.5 116.7 ±77.1 0.01 
12 months 96.0 ±37.5 111.5 ±57.8 0.07 
Δ 0 – 12 months  28.0 ±36.8 39.2 ±58.1 0.20 
Zinc (μmol/L)  
Baseline 11.73 ±1.73 11.23 ±1.74 0.08 
6 months 11.61 ±1.96 12.10 ±2.56 0.21 
12 months 12.31 ±3.12 12.52 ±2.20 0.66 
Δ 0 – 12 months  0.35 ±3.38 1.36 ±2.44 0.06 
Magnesium (mmol/L)  
Baseline 0.78 ±0.06 0.78 ±0.06 0.85 
6 months 0.81 ±0.07 0.79 ±0.07 0.17 
12 months 0.89 ±0.52 0.81 ±0.06 0.29 
Δ 0 – 12 months 0.11 ±0.52 0.03 ±0.05 0.25 
Numbers are mean (±SD), MVS: Multivitamin Supplement  
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Discussion 
 
 The present study illustrates that a multivitamin supplement specifically 
developed to prevent deficiencies in LRYGB patients has advantages over standard 
supplementation. sMVS was associated with a substantial decline in serum ferritin 
and vitamin B12 levels, whereas in patients on WLS Forte® ferritin remained stable 
and vitamin B12 increased significantly. Moreover, the numbers of patients 
developing ferritin or vitamin B12 deficiencies were significantly smaller with the 
LRYGB specific multivitamin. These results were achieved by raising the iron 
content from 1 tot 5 times RDA and vitamin B12 from 1 to 140 times RDA. No 
benefit was found with respect to folic acid, despite a difference between the 
supplements in folic acid content of 1 and 3 times RDA. 
 
Iron deficiency 
Decreased acid production in the small gastric pouch, exclusion of the 
duodenum and proximal part of the jejunum, use of protonpump inhibitors during 
the first months of surgery, and intolerance for iron-rich food such as red meat are 
the main factors increasing the risk of iron deficiency [24, 31]. ID in the first year 
after LRYGB has been reported to occur in 44 - 66% of patients not using 
supplements. These figures should be interpreted with caution because of marked 
differences in the definition of iron deficiency between these studies. Sometimes 
serum iron levels are erroneously used to diagnose iron deficiency. Serum iron 
levels do not reflect the body iron store. In the absence of inflammation, serum 
ferritin is the gold standard. Standardized supplementation of 14 mg iron daily 
reduced the incidence of iron deficiency in the first year after LRYGB to 11%. The 
American Society of Metabolic and Bariatric Surgery (ASMBS) guidelines advise 
a minimum of 18 mg iron per day for patients after RYGB. An additional 
minimum of 18-27 mg per day elemental iron is advised for high risk patients 
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a minimum of 18 mg iron per day for patients after RYGB. An additional 
minimum of 18-27 mg per day elemental iron is advised for high risk patients 
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including menstruating women [34]. However, Vargas-Ruiz et al. [17] 
demonstrated that 18mg iron/day was insufficient in LRYGB patients. ID was 
diagnosed in 20% of the patients after 12 months and rose to 55% after 3 years. 
This is in line with the observation of Aarts et al. where ID was diagnosed in 21% 
of the patients despite of daily intake of a minimum of 21 mg iron [16]. In addition, 
female patients had a higher risk to develop ID than men (38% versus 17%, 
p=0.02). Brolin et al. [18] demonstrated in a double-blind, randomized controlled 
trial the effectiveness of 320 mg ferrous sulfate twice daily (total of 130 mg 
elemental iron) in young women who underwent a RYGB for prevention of ID.  
Based on the literature that advises 40 to 65 mg intake of iron in man and 
100 mg in female patients after RYGB, the iron content in WLS Forte® was 
increased to 70 mg, i.e. to 5 times RDA  [11, 16, 35, 36], In the present study with 
a male to female ratio of 1:2.3, this was sufficient to maintain serum ferritin at 
baseline level, whereas in patients on sMVS ferritin steadily decreased over the 
year. The fact that the difference in ferritin levels at 12 months did not reach 
statistical significance is attributed to a lack of power in this study.  
 
Vitamin B12 deficiency 
Vitamin B12 in food is bound to proteins, and needs to be liberated by the 
action of hydrochloric acid, pepsin and pancreatic enzymes. This process is 
compromised after RYGB. In addition, IF release is reduced which further 
compromises vitamin B12 absorption. Finally, preoperative vitamin B12 
deficiencies are not uncommon in the morbidly obese, probably due to their dietary 
habits. In the present study, 9% of patients had vitamin B12 deficiency pre-
operatively. Published data of post-operative vitamin B12 deficiencies diagnosed 
after variable periods of time vary from 10% - 50% [17, 18, 27, 38]. Vargas-Ruiz 
et al. [17] reported a post RYGB incidence of vitamin B12 deficiency of 10% after 
12 months and 18% after 3 years, despite the use of a multivitamin containing 
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cobalamin 6 μg daily. Brolin et al. [18] reported 37% of the patients with vitamin 
B12 deficiency after a mean follow-up period of 42 months. ASMBS guidelines 
advise vitamin B12 supplements of 350-500 μg daily, eventually addition 
intramuscular injections of 1000 μg per month [34]. WLS Forte® contains high 
doses of 350 μg vitamin B12, which is 14.000% ADH. After 12 months, in 9 
patients hypervitaminosis of vitamin B12 was observed in WLS Forte® compared 
to 7 patients in sMVS (p=0.575). No adverse events of hypervitaminosis were 
observed during the study period.  
ID, vitamin B12 deficiency and folic acid deficiencies are associated with 
anemia after LRYGB [16-18]. A previous study of our group demonstrated high 
incidence of deficiencies for iron (66%), vitamin B12 (50%) and folic acid (15%) 
in patients with anemia after LRYGB [16].  Therefore, minimal daily intake of 65 
mg of iron in male and 100 mg in female patients, 350 μg of vitamin B12, and 400 
μg of folic acid were advised after LRYGB. In our current study, anemia was 
present in total 11.7% after 12 months, 4.3% versus 7.4% after sMVS and WLS 
Forte® (p=0.75). However, only 1 patient had a ID anemia in the sMVS group. The 
fact that 23% of the patients received additional oral iron medication at baseline 
and 10% received vitamin B12 injections at baseline or 6 months, may resulted in 
lower nutrient related anemia.  Previous study of Brolin et al. [37] showed also 
reduction in ID with additional iron supplements, however, incidence of anemia 
was not reduced compared to placebo. Other pathophysiological aspects play 
probably a role in anemia after RYGB surgery.   
 
Vitamin D 
 Vitamin D, a fat-soluble vitamin, can be absorbed from sunlight, diet (e.g. 
certain fish and milk products) and dietary supplements  [39, 40]. It is metabolized 
in the liver to 25-OH-D, the best parameter for patients’ vitamin D status [9, 36]. 
Several studies claimed high incidence of vitamin D (34 – 73%) deficiency after 
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RYGB [52-54], however, mechanisms of post-operative vitamin D deficiency is 
not cleared yet. On the other hand, obesity itself seems to be a risk factor to 
develop vitamin deficiency.  
Despite of high incidence of post-operative vitamin D deficiency, optimal 
prevention strategies are lacking. The ASMBS guidelines advise daily intake of 
2000 IU vitamin D, but no specific recommendation was provided regarding intake 
strategies. In addition, 1500 – 2000 mg per day of calcium was recommended [34]. 
In contrast to these guidelines, in the literature advised post-operative vitamin D 
supplements varied between 320 IE and 2000 IE per day [8, 24, 43, 44], and lower 
doses of calcium intake of 1000 – 1500 mg daily were recommended [24, 35, 44].  
Goldner et al. conducted a prospective, randomized controlled trial 
comparing three different doses of vitamin D supplementation of 800 IU, 2000 IU 
and 5000 IU daily following RYGB [43]. Post-operative increase of mean serum 
vitamin D level at 12 months was higher with higher doses (800 – 5000 IU) of 
vitamin D supplement. Therefore, a minimum of 2000 IU daily intake of vitamin D 
was advised. Signori et al. reported that  daily use of prophylactic vitamin D of 
1200 – 2000 IU do not prevents post-operative vitamin D deficiency [45]. 
Furthermore, Carlin et al. [46] demonstrated that despite of daily intake of 800 IU 
vitamin D, 44% of the population still remained insufficient for vitamin D.  
In the current study, in all patients total calcium carbonate of 1500 mg and 
vitamin D of 1200 IU daily were prescribed as standard post-operative protocol. 
Furthermore, sMVS (control group) contained 160 IU (4 μg) vitamin D, while 
WLS Forte® had 500 IU (12.5 μg). In total, 29% of the cohort had vitamin D 
deficiency after 12 months, being not significant different between groups. After 
12 months, 10% and 19% patients had vitamin D deficiency (p=0.168) in sMVS 
and WLS Forte® group, respectively. 
Earlier study from our group demonstrated 25% reduction of peak 
cholecalciferol levels after intake of oral cholecalciferol of 50 000 IU, 
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corresponding with impaired uptake [30]. Furthermore, we found that a minimum 
dosage of 25 000 IU per week of oral cholecalciferol is necessary to achieve 
adequate response [29]. The dosages in the multivitamin supplements are less than 
a quarter than we used. These results in combination with previously reported 
studies suggest that vitamin D deficiency after LRYGB is difficult to prevent with 
standard multivitamin supplement, hence higher doses of vitamin D may be needed 
for prophylaxis.  
 
Other vitamin and minerals 
 In our study, no differences were found in vitamin B1, vitamin B6, zinc, 
magnesium, or phosphate serum levels between standard MVS and WLS Forte®. 
Notable finding is the high incidence (10%) of hypervitaminosis of vitamin B6 
prior to the surgery. In addition, in total 41% had high levels of vitamin B6, while 
no deficiencies were observed in both groups after 12 months. Increased level of 
vitamin B6 was also observed in the limited literature [47-49], but no adverse 
events were reported. Since 100% ADH of vitamin B6 is associated with increased 
serum levels after surgery and no deficiencies, no higher concentrations were 
needed as in WLS Forte®. Therefore, vitamin B6 doses is decreased to 0.98 mg 
(70%) RDA in the WLS Forte® supplements.  
 
Compliance 
 Vitamin and mineral deficiencies are common both prior and after LRYGB 
surgery. Therefore additional supplements are advised after weight loss surgery. 
However, lifelong compliance of daily supplement intake is hard to achieve. To 
measure adequate intake of MVS, one can monitor the serum concentration of 
highly absorbable vitamins. Navarro et al. [51] demonstrated a serum folic acid 
concentration of fivefold compared to baseline, 4 hours after oral intake of standard 
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MVS containing 1.6 mg folic acid. Therefore, folic acid can be used as a marker 
for compliance of MVS intake.  
 The capsules in both groups had cherry flavor with powder, nevertheless, 
several patients complaint about vitamin B aftertaste for a period of 30 minutes 
after ingestion. This had no influence for the compliance of the patients. After the 
end of the study, commercially available capsules have bubble gum taste with 
micro-capsulation to prevent this aftertaste.  
 
Limitations 
 Despite of the double-blind, prospective, randomized character of the 
study, few limitations of the study should be considered. High prevalence of 
preoperative nutritional and mineral deficiencies, which accompany obesity, made 
additional treatment necessary. Therefore,  part of the population received next to 
the multivitamin supplements medication during a part of the follow-up and were 
excluded during analysis as described.  However, nutritional deficiencies could 
induce physical damage and not treating patients can be harmful and was 
considered unethical. The compliance of patients was inquired during the follow-
up interviews, however, the answers depended on the honesty of the patients and 
could only be compared to their folic acid levels. On the other hand, patients were 
blinded for the nature of their supplements  and thus it is plausible that any non-
compliant patients were equally distributed in both groups.  
Because of adequate reserves in the human body, many vitamin and 
nutrient deficiencies only occur after a few years. Although a significant difference 
in the first year has been shown in this study, we expect an even greater effect of 
optimized supplements compared to standard supplements in the long term. It is 
still uncertain whether customized multivitamin supplements can completely 
prevent post-surgical deficiencies. The effectiveness and safety on the long-term of 
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high doses multivitamin supplement should be corroborated with longer follow-up, 
since patients need life-long supplements after bariatric surgery [55]. 
 
Conclusion 
 
In summary, prevention of mineral and vitamin deficiencies after LRYGB 
is hard to achieve with standard multivitamin supplements, especially when deficits 
prior to the operation are present. WLS Forte® is introduced as a customized 
multivitamin supplement for post-RYGB intake, including 4000% RDA (350 μg) 
vitamin B12, 500% RDA (70 mg) iron, and 300% RDA (600 μg) folic acid. Using 
WLS Forte® after LRYGB surgery results in less iron, vitamin B12 and folic acid 
deficiencies compared to sMVS. Despite of decreased risk for vitamin deficiencies 
with WLS Forte® supplements after LRYGB, a strict follow-up regime remains 
necessary to prevent patients to become vitamin deficient.   
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Abstract          
 
Background 
Obesity-related hypogonadotropic hypogonadism (OrHH) occurs in over 40% of morb idly 
obese men. OrHH may reduce the beneficial effects of bariatric surgery. This study was 
performed to assess the impact of OrHH on the outcome of bariatric surgery in men.  
 
Methods 
Observational study with measurement of serum gonadal hormones, and assessment of 
body composition, glucose, lipid and bone metabolis m during the first year after bariatric 
surgery in 13 men with OrHH (free testosterone (free T) < 225 pmol/L) and 11 age-
matched eugonadal morb idly obese men (free T > 225 pmol/L).  
 
Results 
Serum free T was inversely related to body weight (R = -0.65, P < 0.0001) and rose 
gradually after bariat ric surgery, in eugonadal as well as in OrHH men, by 30 pmol/L for 
every 10 kg loss of weight. In 3 patients serum free T remained within the hypogonadal 
range despite substantial weight loss. Gonadal hormone status prior to surgery did not 
affect the 1-year outcome of surgery.  
 
Conclusion 
OrHH is a reversible condition in the majority of obese men. It does not reduce the efficacy 
of bariatric surgery. Preoperative weight-adjusted normal values are recommended to avoid 
an incorrect diagnosis of hypogonadism in obese men.   
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Introduction 
 
 Bariatric surgery effectively reduces excess weight, decreases blood 
pressure, improves glucose and lipid metabolism, and reduces morbidity and 
mortality in severely obese subjects [1,2]. These results mainly apply to women, as 
women usually comprise up to 80% of patients in studies evaluating the effects of 
bariatric surgery [1-3]. Knowledge about the outcome of bariatric surgery in men is 
still very limited [4,5]. There is ample reason to perform a separate analysis in 
men, and also in subgroups of men. Men may respond differently to bariatric 
surgery then women, and there also may be a difference in response among obese 
men. It is now well established that a subgroup of obese men has markedly reduced 
serum testosterone levels, and this subgroup with diminished androgen action may 
respond differently to bariatric surgery than men with testosterone levels within the 
normal range [6-8].  
 
 Obesity-related hypogonadotropic hypogonadism (OrHH) is characterized 
by the combination of reduced serum testosterone (T) levels, relatively high 
estradiol (E2) levels, and inappropriately low levels of luteinizing hormone (LH) 
and follicle stimulating hormone (FSH) [8-10]. This reduction in gonadotropic 
hormone secretion has been attributed to the inhibitory effects of oestrogen and 
leptin excess at the pituitary and hypothalamic level. Nocturnal hypothalamic-
pituitary dysfunction induced by obstructive sleep apnoea may also have 
contributed [11,12].  
 
 Overproduction of E2 with an increased negative feedback on LH secretion 
probably is the most important mechanism explaining the development of OrHH in 
men. E2 is mainly produced in the adipocyte by the aromatase enzyme that is 
responsible for the conversion of T into E2. Aromatase activity increases in paralle l 
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With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
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Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
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Conclusion 
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conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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with the increase in fat mass. This raises blood E2 levels, which causes suppression 
of LH secretion and secondarily, a reduction in testosterone. It has been shown that 
aromatase inhibitors can completely reverse this process and normalize blood E2 
and T levels [13,14].  
 
 It is currently not known whether OrHH should be regarded as a separate 
disease entity or as a clinically unimportant condition associated with obesity that 
should be treated by weight loss interventions only, and not by (anti)hormonal 
therapy. It is also not known whether OrHH adversely affects the results of 
bariatric surgery. These considerations are relevant issues because OrHH is present 
in at least 40% of men with a BMI ≥ 40 kg/m [8].  In theory, a chronic lack of 
testosterone could reduce post-surgery fat loss, potentiate the catabolic effects of 
surgery on muscle and bone, and attenuate the positive effects of surgery on insulin 
resistance, dyslipidaemia, decreased libido and sexual dysfunction [15-17]. To 
study these aspects we evaluated the effects of bariatric surgery in obese men with 
normal preoperative free T levels and in a group with reduced free T levels.   
  
Patients and Methods  
 
Subjects 
 Twenty-four morbidly obese men were enrolled in this study. Selection 
was based on gonadal hormone status as assessed during the screening procedure 
for bariatric surgery. General inclusion criteria were: Age 20 - 55 years, BMI > 40 
kg/m2, or a BMI > 35 kg/m2 with obesity-related co-morbidity such as diabetes 
mellitus type 2 (DM2) or hypertension, but otherwise healthy. Thirteen subjects 
had a diagnosis of OrHH, defined as a serum free testosterone (free T) < 225 
pmol/L with a serum LH within the normal range (2.0 - 9.0 U/L), i.e. 
inappropriately low for the reduction in testosterone levels. Eleven obese age-
 270 
matched men with a serum free T > 225 pmol/L and a BMI as close as possible to 
that of the OrHH subjects served as controls (NT, normal T). Exclusion criteria 
were: presence of additional pituitary hormone deficiencies, metabolic disorders or 
medications known to affect the gonadal axis, evidence of chronic inflammatory 
disease, serum creatinine levels over 150 micromole/L, liver enzymes over 2 times 
the upper limit of normal, or psychiatric disorders. The study was approved by the 
medical ethics committee, and was registered at clinicaltrials.gov as 
NCT00624624. All patients signed an informed consent before entering the study.  
 
Surgical procedures  
 Bariatric procedures consisted of laparoscopic adjustable gastric banding 
(LAGB) or a laparoscopic Roux-en-Y gastric bypass (LRYGB) depending on the 
degree of obesity and other patient characteristics. A team of two surgeons 
specialized in bariatric surgery executed all operations. 
 
Hormone evaluation 
 All blood samples were taken in the morning between 08.00 and 10.00 
A.M., after an overnight fast. Screening included a complete pituitary profile: TSH, 
free T4, T3, LH, FSH, prolactin, E2 , total T, free T, cortisol, ACTH and IGF-I. 
Gonadal hormone follow-up included serum levels of LH, FSH, total E2, total T, 
free T, SHBG and albumin at baseline and 1, 3, 6, 9 and 12 months after bariatric 
surgery. Normalization of testosterone was defined as a rise in free T to a level > 
225 pmol/L. A patient with OrHH was classified as a non-responder if serum free 
T remained < 225 pmol/L.  
 
Assays and calculations  
 Serum LH was measured by solid-phase, two site chemoluminescent 
immunometric assay (CLIA) on the Immulite 2500 analyser (Siemens – Diagnostic 
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Products Corporation, Los Angeles, USA, male reference range 1 - 8 IU/L). FSH 
was measured with a CLIA on the Immulite 2500 analyser (Siemens – Diagnostic 
Products Corporation, Los Angeles, USA, male reference range 1 - 11 IU/L).  E2 
was measured with an ECLIA assay on an E170 analyser (Roche Diagnostics 
GmbH, Mannheim, Germany, male reference range 40 - 160 pmol/L, analytical 
sensitivity 18.4 pmol/L, validated against isotopic dilution gas chromatography - 
mass spectrometry). Total T was measured with a solid-phase, competitive CLIA 
on an Immulite 2500 analyser (Siemens – Diagnostic Products Corporation Los 
Angeles, USA, male reference range (>21 year) 10.0 – 30.0 nmol/L, analytical 
sensitivity 0.5 nmol/L, validated against a Siemens calibrator). SHBG was 
measured with an ECLIA assay on the E-module of a COBAS 6000 system (Roche 
Diagnostics GmbH, Mannheim, Germany, male (17-65 year) reference range 14.5 - 
48.4 nmol/L). Calculation of free T was based on the approach described by 
Vermeulen et al.i Free E2 was calculated using the method of Sodergard et al 
(normal range: 1.1 – 4.7 pmol/L) [20]. The ratio of total E2 versus total 
testosterone (E/T ratio) was used to assess aromatase activity. Intact N-terminal 
propeptide of type 1 procollagen (PINP, a marker for bone formation), and C-
terminal telopeptide of type 1 collagen (ICTP, a marker for bone resorption) were 
measured by radioimmunoassay (Orion Diagnostica, Espoo, Finland, male 
reference range 22 - 87 µg/l and 2.1 - 5.0 µg/l respectively).  
 
Measurement of body composition 
 CT scans were performed using the Philips Brilliance 40 Channel CT and 
Extended Brilliance Workspace (Philips Electronics, Eindhoven, The Netherlands). 
A 1cm horizontal coupe was scanned midway of the line connecting the top of the 
major trochanter and the most distal surface of medial condyle of the right femur. 
The anatomical boundaries between bone, muscle and subcutaneous fat tissue were 
 272 
drawn by hand. The surfaces of bone, muscle and fatty tissue were measured by the 
computer, and expressed in mm2. 
Bone density of the lumbar spine and both femoral necks were measured by Dual 
Energy X-ray Absorptiometry (Lunar DXA, GE Healthcare, Madison, WI, USA). 
 
Statistics 
 Data are shown as mean values ± standard error of the mean (SEM), unless 
stated otherwise. Data were evaluated by general linear model for repeated 
measures and paired t-tests. Correlation was calculated using Pearson’s test if 
distributed normally, or by Spearman’s test in case of a non-normal distribution. P 
values below 0.05 were considered to be statistically significant. Statistical analysis 
was performed by SPSS version 18.0 (Chicago, IL, USA) 
 
Results  
 
Baseline 
 Baseline characteristics of the 24 men participating in the study are 
summarized in the first column of table 1 and 2. All were severely obese, with 
body weights ranging from 105 - 205 kg, and BMI’s varying from 35.6 to 59.3 
kg/m2. Eight patients had diabetes mellitus type 2 (T2DM), i.e. 6 in the OrHH and 
2 in the NT group.  The mean HbA1c in T2DM patients was 6.6 ± 0.5%. Three 
patients had an HbA1c > 7.5%. Nine patients were treated for hypertension, 7 in 
the OrHH and 2 in the NT group. Serum TSH, fT4, T3, FSH, prolactin, ACTH, 
cortisol, and IGF-1 were within the normal range in all men (data not shown). 
 
One-year results of surgery 
 The overall results of bariatric surgery, irrespective of gonadal status, are 
shown in the first column of table 1 and 2.  
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Table 1. Patient characteristics at baseline (T0) and results of serum hormone level 
one year after bariatric surgery (T12).  
 All Eugonadal OrHH P* 
Number of patients 24 11 13  
Age (years)  43.1 ± 1.5 43.5 ± 2.0 0.46 
Gastric Bypass 15 5 10 0,21 
Body weight (kg)         T0 
                                     T12 
                                     ∆ 
152.0 ± 4.8 
   114.9 ± 3.5(1) 
   - 37.0 ± 3.3(1) 
141.4 ± 6.0 
   110.2 ± 5.8(3) 
   - 31.2 ± 4.2(3) 
160.9 ± 6.5 
   118.9 ± 4.0(3) 
   - 42.0 ± 4.5(3) 
0.04 
0.35 
0.09 
BMI (kg/m2)                T0 
                                     T12 
                                     ∆ 
  46.1 ± 1.3 
     34.8 ± 0.8(1) 
   -11.3 ± 1.0(1) 
43.1 ± 1.7 
33.5 ± 1.4(1) 
-9.7 ± 1.4(1) 
  48.7 ± 1.7 
     36.0 ± 1.0(1) 
    -12.7 ± 1.4(1) 
0.03 
0.15 
0.13 
LH (U/L)                      T0 
                                     T12 
                                     ∆ 
3.6 ± 0.3 
   5.1 ± 0.6(3) 
   1.5 ± 0.5(3) 
4.3 ± 0.4 
5.6 ± 0.9 
1.4 ± 0.8(P=0.12) 
2.9 ± 0.4 
   4.6 ± 0.9(4) 
   1.7 ± 0.5(4) 
0.03 
0.43 
0.73 
FSH (U/L)                   T0 
                                     T12 
                                     ∆ 
5.2 ± 0.8 
   6.4 ± 1.2(3) 
   1.2 ± 0.5(3) 
6.2 ± 1.4 
7.5 ± 2.2 
1.3 ± 0.9(P=0.23) 
4.4 ± 0.9 
5.4 ± 1.1(5) 
1.0 ± 0.3(5) 
0.19 
0.32 
0.47 
Total E2 (pmol/L)       T0 
                                     T12 
                                     ∆ 
123 ± 6.0 
   109 ± 7.8(5) 
 -14.5 ± 6.1(5) 
130 ± 6.0 
   104 ± 8.4(5) 
-26.1 ± 9.1(5) 
117 ± 9.8 
113 ± 12.7 
-4.6 ± 7.5 
0.28 
0.58 
0.08 
Free E2 (pmol/L)         T0 
                                     T12 
                                     ∆ 
3.5 ± 0.1 
   2.9 ± 0.2(1) 
  -0.6 ± 0.1(1) 
3.6 ± 0.1 
2.8 ± 0.2 
-0.8 ± 0.2(5) 
3.4 ± 0.2 
3.0 ± 0.3(1) 
-0.4 ± 0.1(1) 
0.69 
0.65 
0.14 
Total T (nmol/L)          T0 
                                     T12 
                                     ∆ 
 9.6 ± 0.8 
  17.3 ± 1.6(1) 
    7.6 ± 1.3(1) 
12.6 ± 0.9 
   20.5 ± 2.4(3) 
     7.9 ± 2.0(3) 
7.1 ± 0.7 
 14.5 ± 2.1(3) 
   7.4 ± 1.9(3) 
<0.001 
0.07 
0.85 
Free T (pmol/L)           T0 
                                     T12 
                                     ∆ 
                                     ∆* 
212 ± 15 
   349 ± 31(1) 
   137 ± 24(1) 
   167 ± 23(1) 
275 ± 12 
   431 ± 42(3) 
   156 ± 38(3) 
   171 ± 37(3) 
159 ± 13 
   280 ± 35(3) 
   121 ± 30(3) 
   163 ± 27(2) 
<0.0001 
<0.02 
0.48 
0.86 
SHBG (nmol/L)           T0 
                                    T12 
                                    ∆ 
28.2 ± 2.6 
35.7 ± 4.0 
7.5 ± 4.2 
29.9 ± 4.3 
35.0 ± 3.9 
5.1 ± 3.8 
26.7 ± 3.1 
36.3 ± 6.7 
9.6 ± 7.1 
0.55 
0.86 
0.58 
Albumin (g/L)             T0 
                                    T12 
41.0 ± 0.6 
41.6 ± 0.6 
42.0 ± 1.1 
42.5 ± 0.8 
40.2 ± 0.7 
40.9 ± 0.9 
0.20 
0.67 
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                                    ∆   0.6 ± 0.7 0.5 ± 0.8 0.7 ± 1.1 0.87 
E/T  ratio                      T0 
                                    T12 
                                    ∆ 
14.8 ± 1.5 
7.8 ± 0.9(2) 
-7.0 ± 1.1(2) 
10.6 ± 0.6 
6.0 ± 1.0(1) 
-4.6 ± 0.6(1) 
18.4 ± 2.3 
9.3 ± 1.3(2) 
-9.1 ± 1.9(2) 
< 0.005 
0.03 
0.09 
Statistical significances of within group changes are shown as superscripts: 
(1) P < 0.0001, (2) P < 0.001, (3) P < 0.005, (4) P < 0.01, (5) P < 0.05 
 
 P* : Statistical significances of differences between eugonadal and OrHH 
 patients 
∆   : Within group change after 12 months of treatment 
∆* : Within group change after 12 months of treatment, after removal of the 3 
 non-responders 
 
 
LABG was performed in 9 patients, and 15 had a LRYGB. Body weight decreased 
by 37.0 ± 3.3 kg, which is equivalent to a weight reduction of 23.9 ± 1.8% (P < 
0.0001). The main change occurred during the first 6 months with a decrease of 
29.7 ± 2.7 kg (P < 0.0001), and a further decrease of 7.3 ± 1.1 kg (P < 0.0001) 
during the next 6-months. Leg fat area decreased by 33.2 ± 2.9% (P < 0.001), and 
leg muscle area by 15.7 ± 1.8% (P < 0.001). Bone density of the lumbar spine 
increased by 2.0 ± 1.0% (P = 0.04) and decreased in the left and right hip by 4.0 ± 
0.9% (P <0.001), and 4.6 ± 1.3% (P < 0.001), respectively. Surgery was also 
associated with a gradual increase in serum LH, FSH, total T, and free T. The 
largest changes in serum hormone levels were observed during the first 6 months 
of the study, in parallel with the changes in body weight. Free T rose by 116 ± 18.2 
pmol/L during the first 6 months (P < 0.0001), and only by 16.6 ± 23.5 pmol/L (P 
= 0.49) during the second half year.  
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LABG was performed in 9 pat ents, nd 15 ha a LRYGB. Body weight decreased 
by 37.0 ± .3 kg, which is equival nt to a weight reduc ion of 23.9 ± 1.8% (P < 
0.0001). The main change occurred d ing the firs  6 mon hs with a decre se of 
29.7 ± .7 kg (P < 0.0001), and a further decr ase of 7.3 ± 1.1 kg (P < 0.0001) 
during the ex  6-months. Leg fat area dec sed by 33.2 ± 2.9% (P < 0.001), and 
leg muscle area by 15.7 ± .8% (P < 0.001). Bone density of the lumbar spine 
increased by 2.0 ± 1.0% (P = 0.04) and decreased in th  left and right hip by 4.0 ± 
0.9% (P <0.001), and 4.6 ± 1.3% (P < 0.001), respectiv ly. Surgery was also 
associated with a gradu l incre se in serum LH, FSH, total T, and free T. Th
largest changes in serum ho mone levels w r  obs ved during the firs  6 mon hs 
of the study, in parallel with the chang s in body weight. Fr e T ros by 116 ± 18.2 
pmol/L during the firs  6 months (P < 0.0001), and only by 16.6 ± 23 5 pmol/L (P 
= 0.49) during the second half year.  
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Table 1. Patient characteristics at baseline (T0) and results of serum hormone level 
one year after bariatric surgery (T12).  
 All Eugonadal OrHH P* 
Number of patients 24 11 13  
Age (years)  43.1 ± 1.5 43.5 ± 2.0 0.46 
Gastric Bypass 15 5 10 0,21 
Body weight (kg)         T0 
                                     T12 
                                     ∆ 
152.0 ± 4.8 
   114.9 ± 3.5(1) 
   - 37.0 ± 3.3(1) 
141.4 ± 6.0 
   110.2 ± 5.8(3) 
   - 31.2 ± 4.2(3) 
160.9 ± 6.5 
   118.9 ± 4.0(3) 
   - 42.0 ± 4.5(3) 
0.04 
0.35 
0.09 
BMI (kg/m2)                T0 
                                     T12 
                                     ∆ 
  46.1 ± 1.3 
     34.8 ± 0.8(1) 
   -11.3 ± 1.0(1) 
43.1 ± 1.7 
33.5 ± 1.4(1) 
-9.7 ± 1.4(1) 
  48.7 ± 1.7 
     36.0 ± 1.0(1) 
    -12.7 ± 1.4(1) 
0.03 
0.15 
0.13 
LH (U/L)                      T0 
                                     T12 
                                     ∆ 
3.6 ± 0.3 
   5.1 ± 0.6(3) 
   1.5 ± 0.5(3) 
4.3 ± 0.4 
5.6 ± 0.9 
1.4 ± 0.8(P=0.12) 
2.9 ± 0.4 
   4.6 ± 0.9(4) 
   1.7 ± 0.5(4) 
0.03 
0.43 
0.73 
FSH (U/L)                   T0 
                                     T12 
                                     ∆ 
5.2 ± 0.8 
   6.4 ± 1.2(3) 
   1.2 ± 0.5(3) 
6.2 ± 1.4 
7.5 ± 2.2 
1.3 ± 0.9(P=0.23) 
4.4 ± 0.9 
5.4 ± 1.1(5) 
1.0 ± 0.3(5) 
0.19 
0.32 
0.47 
Total E2 (pmol/L)       T0 
                                     T12 
                                     ∆ 
123 ± 6.0 
   109 ± 7.8(5) 
 -14.5 ± 6.1(5) 
130 ± 6.0 
   104 ± 8.4(5) 
-26.1 ± 9.1(5) 
117 ± 9.8 
113 ± 12.7 
-4.6 ± 7.5 
0.28 
0.58 
0.08 
Free E2 (pmol/L)         T0 
                                     T12 
                                     ∆ 
3.5 ± 0.1 
   2.9 ± 0.2(1) 
  -0.6 ± 0.1(1) 
3.6 ± 0.1 
2.8 ± 0.2 
-0.8 ± 0.2(5) 
3.4 ± 0.2 
3.0 ± 0.3(1) 
-0.4 ± 0.1(1) 
0.69 
0.65 
0.14 
Total T (nmol/L)          T0 
                                     T12 
                                     ∆ 
 9.6 ± 0.8 
  17.3 ± 1.6(1) 
    7.6 ± 1.3(1) 
12.6 ± 0.9 
   20.5 ± 2.4(3) 
     7.9 ± 2.0(3) 
7.1 ± 0.7 
 14.5 ± 2.1(3) 
   7.4 ± 1.9(3) 
<0.001 
0.07 
0.85 
Free T (pmol/L)           T0 
                                     T12 
                                     ∆ 
                                     ∆* 
212 ± 15 
   349 ± 31(1) 
   137 ± 24(1) 
   167 ± 23(1) 
275 ± 12 
   431 ± 42(3) 
   156 ± 38(3) 
   171 ± 37(3) 
159 ± 13 
   280 ± 35(3) 
   121 ± 30(3) 
   163 ± 27(2) 
<0.0001 
<0.02 
0.48 
0.86 
SHBG (nmol/L)           T0 
                                    T12 
                                    ∆ 
28.2 ± 2.6 
35.7 ± 4.0 
7.5 ± 4.2 
29.9 ± 4.3 
35.0 ± 3.9 
5.1 ± 3.8 
26.7 ± 3.1 
36.3 ± 6.7 
9.6 ± 7.1 
0.55 
0.86 
0.58 
Albumin (g/L)             T0 
                                    T12 
41.0 ± 0.6 
41.6 ± 0.6 
42.0 ± 1.1 
42.5 ± 0.8 
40.2 ± 0.7 
40.9 ± 0.9 
0.20 
0.67 
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                                    ∆   0.6 ± 0.7 0.5 ± 0.8 0.7 ± 1.1 0.87 
E/T  ratio                      T0 
                                    T12 
                                    ∆ 
14.8 ± 1.5 
7.8 ± 0.9(2) 
-7.0 ± 1.1(2) 
10.6 ± 0.6 
6.0 ± 1.0(1) 
-4.6 ± 0.6(1) 
18.4 ± 2.3 
9.3 ± 1.3(2) 
-9.1 ± 1.9(2) 
< 0.005 
0.03 
0.09 
Statistical significances of within group changes are shown as superscripts: 
(1) P < 0.0001, (2) P < 0.001, (3) P < 0.005, (4) P < 0.01, (5) P < 0.05 
 
 P* : Statistical significances of differences between eugonadal and OrHH 
 patients 
∆   : Within group change after 12 months of treatment 
∆* : Within group change after 12 months of treatment, after removal of the 3 
 non-responders 
 
 
LABG was performed in 9 patients, and 15 had a LRYGB. Body weight decreased 
by 37.0 ± 3.3 kg, which is equivalent to a weight reduction of 23.9 ± 1.8% (P < 
0.0001). The main change occurred during the first 6 months with a decrease of 
29.7 ± 2.7 kg (P < 0.0001), and a further decrease of 7.3 ± 1.1 kg (P < 0.0001) 
during the next 6-months. Leg fat area decreased by 33.2 ± 2.9% (P < 0.001), and 
leg muscle area by 15.7 ± 1.8% (P < 0.001). Bone density of the lumbar spine 
increased by 2.0 ± 1.0% (P = 0.04) and decreased in the left and right hip by 4.0 ± 
0.9% (P <0.001), and 4.6 ± 1.3% (P < 0.001), respectively. Surgery was also 
associated with a gradual increase in serum LH, FSH, total T, and free T. The 
largest changes in serum hormone levels were observed during the first 6 months 
of the study, in parallel with the changes in body weight. Free T rose by 116 ± 18.2 
pmol/L during the first 6 months (P < 0.0001), and only by 16.6 ± 23.5 pmol/L (P 
= 0.49) during the second half year.  
  
 274 
                                    ∆   0.6 ± 0.7 0.5 ± 0.8 0.7 ± 1.1 0.87 
E/T  ratio                      T0 
                                    T12 
                                    ∆ 
14.8 ± 1.5 
7.8 ± 0.9(2) 
-7.0 ± 1.1(2) 
10.6 ± 0.6 
6.0 ± 1.0(1) 
-4.6 ± 0.6(1) 
18.4 ± 2.3 
9.3 ± 1.3(2) 
-9.1 ± 1.9(2) 
< 0.0 5 
0.03 
0.09 
Statistical significances of within group changes are shown as superscripts: 
(1) P < 0.0 1, (2) P < 0.0 1, (3) P < 0.0 5, (4) P < 0.01, (5) P < 0.05 
 
 P* : Statistical significances of dif erences betwe n eugonadal and OrHH 
 patients 
∆ : ithin group change after 12 months of treatment 
∆* : ithin group change after 12 months of treatment, after removal of the 3 
 non-responders 
 
 
LABG was performed in 9 patients, and 15 had a LRYGB. Body weight decreased 
by 37.0 ± 3.3 kg, which is equivalent to a weight reduction of 23.9 ± 1.8% (P < 
0.0 1). The main change occur ed during the first 6 months with a decrease of 
29.7 ± 2.7 kg (P < 0.00 1), and a further decrease of 7.3 ± 1.1 kg (P < 0.0 1) 
during the next 6-months. Leg fat area decreased by 3 .2 ± 2.9% (P < 0.0 1), and 
leg muscle area by 15.7 ± 1.8% (P < 0.0 1). Bone density of the lumbar spine 
increased by 2.0 ± 1.0% (P = 0.04) and decreased in the left and right hip by 4.0 ± 
0.9% (P <0.0 1), and 4.6 ± 1.3% (P < 0.0 1), respectively. Surgery was also 
as ociated with a gradual increase in serum LH, FSH, total T, and free T. The 
largest changes in serum hormone levels were observed during the first 6 months 
of the study, in paral el with the changes in body weight. Free T rose by 1 6 ± 18.2 
pmol/L during the first 6 months (P < 0.00 1), and only by 16.6 ± 23.5 pmol/L (P 
= 0.49) during the second half year. 
  
 274 
                ∆   0.6 ± 0.7 0.5 ± 0.8 0.7 ± 1.1 0.87 
E/T  ratio                T0 
                T12
                ∆ 
14.8 ± 1.5 
7.8 ± 0.9(2) 
-7.0 ± 1.1(2) 
10.6 ± 0.6 
6.0 ± 1.0(1) 
-4.6 ± 0.6(1) 
18.4 ± 2.3 
9.3 ± 1.3(2) 
-9.1 ± 1.9(2) 
< 0.005 
0.03 
0.09 
Statistical s gn ficances of within group changes are shown a  super cripts: 
(1) P < 0.0001, (2) P < 0.001, (3) P < 0.005, (4) P < 0.01, (5) P < 0.05
 
 P* : Statistical s gn ficances of differences b tw en ugonadal a d OrHH 
 patients 
∆   : Within group change after 12 months of treatment 
∆* : Within group change after 12 months of treatment, ft r removal of the 3 
 non-resp d r  
 
 
LABG was performed in 9 pat ents, nd 15 ha a LRYGB. Body weight decreased 
by 37.0 ± .3 kg, which is equival nt to a weight reduc ion of 23.9 ± 1.8% (P < 
0.0001). The main change occurred d ing the firs  6 mon hs with a decre se of 
29.7 ± .7 kg (P < 0.0001), and a further decr ase of 7.3 ± 1.1 kg (P < 0.0001) 
during the ex  6-months. Leg fat area dec sed by 33.2 ± 2.9% (P < 0.001), and 
leg muscle area by 15.7 ± .8% (P < 0.001). Bone density of the lumbar spine 
increased by 2.0 ± 1.0% (P = 0.04) and decreased in th  left and right hip by 4.0 ± 
0.9% (P <0.001), and 4.6 ± 1.3% (P < 0.001), respectiv ly. Surgery was also 
associated with a gradu l incre se in serum LH, FSH, total T, and free T. Th
largest changes in serum ho mone levels w r  obs ved during the firs  6 mon hs 
of the study, in parallel with the chang s in body weight. Fr e T ros by 116 ± 18.2 
pmol/L during the firs  6 months (P < 0.0001), and only by 16.6 ± 23 5 pmol/L (P 
= 0.49) during the second half year.  
  
286
Chapter 4
 275 
Table 2. Body composition and metabolic characteristics at baseline (T0) and one 
year after bariatric surgery (T12).  
 All Eugonadal OrHH P* 
Number of patients 24 11 13  
ASAT  (U/L)               T0 
                                     T12 
                                     ∆12 
35.8 ± 2.1 
27.3 ± 2.1 
-8.5 ± 2.2(1) 
40.4 ± 3.0 
27.0 ± 3.2 
-13.4 ± 2.7(1) 
31.9 ± 2.5 
27.5 ± 3.0 
-4.5 ± 2.9 
P=0.043 
P=0.916 
P=0.039 
ALAT  (U/L)               T0 
                                     T12 
                                     ∆12 
55.6 ± 4.8 
32.1 ± 4.1 
-23.5 ± 4.6(1) 
63.2 ± 6.8 
33.5 ± 7.0 
-29.6 ± 7.0(2) 
49.2 ± 6.5 
30.9 ± 4.9 
-18.3 ± 6.0(2) 
P=0.153 
P=0.758 
P=0.230 
-GT  (U/L)                  T0 
                                     T12 
                                     ∆12 
42.3 ± 4.1 
28.4 ± 3.9 
-13.9 ± 2.5(1) 
51.0 ± 7.7 
35.7 ± 7.4 
-15.3 ± 4.7(2) 
35.0 ± 3.0 
22.2 ± 2.9 
-12.8 ± 2.5(1) 
P=0.052 
P=0.084 
P=0.628 
 
HbA1c  (%)                 T0 
                                    ∆12 
 6.6 ± 1.4 
-0.9 ± 0.2(1) 
 6.9 ± 0.6 
-1.1 ± 0.4(3) 
 6.3 ± 0.3 
-0.7 ± 0.2(3) 
P=0.325 
P=0.212 
HDL (mmol/L)           T0 
                                    ∆12 
0.98 ± 0.04 
0.15 ± 0.04(2) 
0.90 ± 0.07 
0.11 ± 0.05 
1.05 ± 0.04 
0.18 ± 0.06(3) 
P=0.061 
P=0.392 
LDL (mmol/L)            T0 
                                    ∆12 
2.90 ± 0.18 
-0.41 ± 0.11(1) 
2.80 ± 0.32 
-0.14 ± 0.14 
2.98 ± 0.22 
-0.63 ± 0.14(1) 
P=0.624 
P=0.022 
Triglycerides               T0 
(mmol/L                      ∆12 
2.01 ± 0.18 
-0.52 ± 0.19(3) 
2.41 ± 0.35 
-0.65 ± 0.39 
1.68 ± 0.12 
-0.40 ± 0.15(3) 
P=0.047 
P=0.529 
 
Calcium  (mmol/L)       T0 
                                      ∆12 
2.31 ± 0.02 
-0.01 ± 0.02 
2.30 ± 0.04 
0.01 ± 0.04 
2.31 ± 0.02 
-0.01 ± 0.03 
P=0.853 
P=0.678 
PO4  (mmol/L)            T0 
                                     ∆12 
0.92 ± 0.04 
0.11 ± 0.04(3) 
0.85 ± 0.05 
0.09 ± 0.08 
0.98 ± 0.05 
0.13 ± 0.05(3) 
P=0.069 
P=0.644 
ICTP                            T0 
                                     T12 
                                     ∆% 
4.5 ± 0.4 
7.9 ± 1.2 
74.1 ± 15.2%(2) 
4.3 ± 0.6 
8.0 ± 2.4 
77.2 ± 27.0%(3) 
4.7 ± 0.5 
7.9 ± 1.1 
71.5 ± 17.4%(2) 
P=0.680 
P=0.986 
P=0.866 
PINP                            T0 
                                     T12 
                                     ∆% 
48.8 ± 3.1 
85.3 ± 10.0 
81.1 ± 20.0%(2) 
51.1 ± 4.3 
74.7 ± 14.9 
43.5 ± 20.3%(3) 
46.9 ± 4.5 
94.3 ± 13.6 
112.9 ± 30.8%(2) 
P=0.508 
P=0.343 
P=0.215 
25-OH Vitamin D        T0 
(nmol/L)                       ∆12 
57.0 ± 4.2 
-3.4 ± 7.7 
56.9 ± 7.3 
-0.2 ± 12.0 
57.2 ± 5.1 
-6.2 ± 10.4 
P=0.978 
P=0.709 
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PTH  (pmol/L)             T0 
                                     T12 
                                     ∆ 
5.0 ± 0.7 
5.1 ± 0.8 
0.1 ± 0.4 
5.6 ± 1.4 
5.7 ± 1.5 
0.2 ± 0.6 
4.5 ± 0.5 
4.6 ± 0.7 
0.1 ± 0.6 
P=0.428 
P=0.477 
P=0.963 
Urinary Calcium          T0 
(mmol/24h)                  ∆12 
3.5 ± 0.6 
0.4 ± 0.8 
3.1 ± 0.9 
-0.1 ± 0.5 
3.9 ± 0.8 
0.8 ± 1.4 
P=0.803 
P=0.404 
 
Leg Fat area (cm2)       T0 
                                     T12 
                                     ∆12 
205.7 ±20.4 
133.7 ± 12.8 
-72.1 ±10.3(1 
163.6 ±25.0 
112.0 ±17.4 
-51.6 ± 9.7(1) 
241.4 ± 28.2 
152.0 ±17.4 
          -89.3 ± 16.2(1) 
P=0.055 
P=0.120 
P=0.069 
Leg Muscle area (cm2) T0 
                                     T12 
                                     ∆12 
214.0 ± 5.4 
180.1 ±5.6 
-33.8 ± 4.1(1) 
219.0 ± 6.9 
184.0 ± 9.9 
-34.4 ±6.6(1) 
210.1 ±8.0 
176.8 ± 6.2 
-33.3 ± 5.4(1) 
P=0.449 
P=0.532 
P=0.892 
Lumbar spine density   T0 
                                     T12 
                                     ∆12 
1.24 ± 0.04 
1.26 ± 0.04 
0.02 ± 0.01(3) 
1.25 ± 0.05 
1.29 ± 0.05 
0.04 ± 0.01(2) 
1.23 ± 0.06 
1.24 ± 0.05 
0.01 ± 0.02 
P=0.838 
P=0.447 
P=0.070 
Left Hip                        T0 
                                     T12 
                                     ∆12 
1.19 ± 003 
1.14 ± 0.03 
-0.05±0.01(1) 
1.18 ± 0.05 
1.13 ± 0.05 
-0.05±0.02(3) 
1.21 ± 0.05 
1.16 ± 0.05 
-0.05±0.01(1) 
P=0.667 
P=0.639 
P=0.910 
Right Hip                     T0 
                                     T12 
                                     ∆12 
1.18±0.03 
1.13±0.04 
-0.05±0.01(1) 
1.17±0.06 
1.10±0.06 
-0.07±0.0(3) 
1.19±0.05 
1.15±0.05 
-0.04±0.02(3) 
P=0.701 
P=0.486 
P=0.353 
Within group changes: (1) P < 0.001, (2) P < 0.01, (3) P < 0.05 
 
  P* : Differences between hypogonadal and eugonadal groups  
∆   : Change after 12 months of treatment 
 
Over 12 months, there was a slight decrease in serum TE2 from 123  6.0 pmol/L 
to 109  7.8 pmol/L (P < 0.05). Free E2 decreased from 3.5 ± 0.2 pmol/L to 3.0 ± 
0.2 pmol/L (P < 0.01) during the first month of the study, and stayed at this level 
during the remaining study period. Serum SHBG rose from 28.2  2.6 nmol/L to 
35.7  4.0 nmol/L (P = 0.09). The E2/T ratio, a marker of aromatase activity, 
decreased by about 50%. Of note, free E2, SHBG and the E2/T ratio showed the 
most pronounced changes during the first month after surgery.  
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112.0 ±17.4 
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219.0 ± 6.9 
184.0 ± 9.9 
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1.25 ± 0.0  
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0.04 ± . 1(2)
1.23 ± 0.06 
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Table 2. Body composition and metabolic characteristics at baseline (T0) and one 
year after bariatric surgery (T12).  
 All Eugonadal OrHH P* 
Number of patients 24 11 13  
ASAT  (U/L)               T0 
                                     T12 
                                     ∆12 
35.8 ± 2.1 
27.3 ± 2.1 
-8.5 ± 2.2(1) 
40.4 ± 3.0 
27.0 ± 3.2 
-13.4 ± 2.7(1) 
31.9 ± 2.5 
27.5 ± 3.0 
-4.5 ± 2.9 
P=0.043 
P=0.916 
P=0.039 
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                                     T12 
                                     ∆12 
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32.1 ± 4.1 
-23.5 ± 4.6(1) 
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33.5 ± 7.0 
-29.6 ± 7.0(2) 
49.2 ± 6.5 
30.9 ± 4.9 
-18.3 ± 6.0(2) 
P=0.153 
P=0.758 
P=0.230 
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                                     ∆12 
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-15.3 ± 4.7(2) 
35.0 ± 3.0 
22.2 ± 2.9 
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P=0.084 
P=0.628 
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-1.1 ± 0.4(3) 
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P=0.212 
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                                    ∆12 
0.98 ± 0.04 
0.15 ± 0.04(2) 
0.90 ± 0.07 
0.11 ± 0.05 
1.05 ± 0.04 
0.18 ± 0.06(3) 
P=0.061 
P=0.392 
LDL (mmol/L)            T0 
                                    ∆12 
2.90 ± 0.18 
-0.41 ± 0.11(1) 
2.80 ± 0.32 
-0.14 ± 0.14 
2.98 ± 0.22 
-0.63 ± 0.14(1) 
P=0.624 
P=0.022 
Triglycerides               T0 
(mmol/L                      ∆12 
2.01 ± 0.18 
-0.52 ± 0.19(3) 
2.41 ± 0.35 
-0.65 ± 0.39 
1.68 ± 0.12 
-0.40 ± 0.15(3) 
P=0.047 
P=0.529 
 
Calcium  (mmol/L)       T0 
                                      ∆12 
2.31 ± 0.02 
-0.01 ± 0.02 
2.30 ± 0.04 
0.01 ± 0.04 
2.31 ± 0.02 
-0.01 ± 0.03 
P=0.853 
P=0.678 
PO4  (mmol/L)            T0 
                                     ∆12 
0.92 ± 0.04 
0.11 ± 0.04(3) 
0.85 ± 0.05 
0.09 ± 0.08 
0.98 ± 0.05 
0.13 ± 0.05(3) 
P=0.069 
P=0.644 
ICTP                            T0 
                                     T12 
                                     ∆% 
4.5 ± 0.4 
7.9 ± 1.2 
74.1 ± 15.2%(2) 
4.3 ± 0.6 
8.0 ± 2.4 
77.2 ± 27.0%(3) 
4.7 ± 0.5 
7.9 ± 1.1 
71.5 ± 17.4%(2) 
P=0.680 
P=0.986 
P=0.866 
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                                     T12 
                                     ∆% 
48.8 ± 3.1 
85.3 ± 10.0 
81.1 ± 20.0%(2) 
51.1 ± 4.3 
74.7 ± 14.9 
43.5 ± 20.3%(3) 
46.9 ± 4.5 
94.3 ± 13.6 
112.9 ± 30.8%(2) 
P=0.508 
P=0.343 
P=0.215 
25-OH Vitamin D        T0 
(nmol/L)                       ∆12 
57.0 ± 4.2 
-3.4 ± 7.7 
56.9 ± 7.3 
-0.2 ± 12.0 
57.2 ± 5.1 
-6.2 ± 10.4 
P=0.978 
P=0.709 
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5.6 ± 1.4 
5.7 ± 1.5 
0.2 ± 0.6 
4.5 ± 0.5 
4.6 ± 0.7 
0.1 ± 0.6 
P=0.428 
P=0.477 
P=0.963 
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3.5 ± 0.6 
0.4 ± 0.8 
3.1 ± 0.9 
-0.1 ± 0.5 
3.9 ± 0.8 
0.8 ± 1.4 
P=0.803 
P=0.404 
 
Leg Fat area (cm2)       T0 
                                     T12 
                                     ∆12 
205.7 ±20.4 
133.7 ± 12.8 
-72.1 ±10.3(1 
163.6 ±25.0 
112.0 ±17.4 
-51.6 ± 9.7(1) 
241.4 ± 28.2 
152.0 ±17.4 
          -89.3 ± 16.2(1) 
P=0.055 
P=0.120 
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-33.8 ± 4.1(1) 
219.0 ± 6.9 
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210.1 ±8.0 
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0.02 ± 0.01(3) 
1.25 ± 0.05 
1.29 ± 0.05 
0.04 ± 0.01(2) 
1.23 ± 0.06 
1.24 ± 0.05 
0.01 ± 0.02 
P=0.838 
P=0.447 
P=0.070 
Left Hip                        T0 
                                     T12 
                                     ∆12 
1.19 ± 003 
1.14 ± 0.03 
-0.05±0.01(1) 
1.18 ± 0.05 
1.13 ± 0.05 
-0.05±0.02(3) 
1.21 ± 0.05 
1.16 ± 0.05 
-0.05±0.01(1) 
P=0.667 
P=0.639 
P=0.910 
Right Hip                     T0 
                                     T12 
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1.18±0.03 
1.13±0.04 
-0.05±0.01(1) 
1.17±0.06 
1.10±0.06 
-0.07±0.0(3) 
1.19±0.05 
1.15±0.05 
-0.04±0.02(3) 
P=0.701 
P=0.486 
P=0.353 
Within group changes: (1) P < 0.001, (2) P < 0.01, (3) P < 0.05 
 
  P* : Differences between hypogonadal and eugonadal groups  
∆   : Change after 12 months of treatment 
 
Over 12 months, there was a slight decrease in serum TE2 from 123  6.0 pmol/L 
to 109  7.8 pmol/L (P < 0.05). Free E2 decreased from 3.5 ± 0.2 pmol/L to 3.0 ± 
0.2 pmol/L (P < 0.01) during the first month of the study, and stayed at this level 
during the remaining study period. Serum SHBG rose from 28.2  2.6 nmol/L to 
35.7  4.0 nmol/L (P = 0.09). The E2/T ratio, a marker of aromatase activity, 
decreased by about 50%. Of note, free E2, SHBG and the E2/T ratio showed the 
most pronounced changes during the first month after surgery.  
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 Before surgery 15 out of 24 men reported severe erectile dysfunction. 
Twelve months after surgery nine of these patients were able to achieve an 
erection. The liver enzymes ASAT, ALAT and GT decreased significantly (table 
2). HbA1c decreased from 6.6 to 5.7% (P < 0.001), HDL cholesterol increased by 
15.3 ± 4.6% (P < 0.005), LDL cholesterol decreased by 14.1 ± 3.7% (P < 0.005), 
and triglycerides decreased by 25.8%) ± 8.1% (P = 0.01). The bone turnover 
marker ICTP (marker for bone resorption) rose by 74.1  15.2% ( P < 0.005), and 
PINP (marker for bone formation) increased by 81.1  20.0% (P < 0.005).  
Correlation of hormone levels and body weight 
 The serum LH, FSH, SHBG, total and free T levels were inversely 
correlated with body weight: LH: R = -0.41, P < 0.001; FSH: R = -0.50, P < 
0.0001; total T: R = -0.55, P < 0.0001; free T: R = -0.65, P < 0.0001; SHBG: R = -
0.28, P < 0.001. Serum total and free E2 showed a weak positive correlation with 
body weight: R = +0.25, P < 0.01, and R = +0.34, P < 0.0001, respectively. The 
linear regression line describing the relation between body weight and serum free 
testosterone over the one-year study period is shown as solid blue line in figure 2. 
The interrupted blue lines represent the + 2 SD and -2 SD limits. All NT men, and 
10/13 OrHH men had a marked rise in serum free T over the year. Three men in the 
OrHH group (marked in red, orange and green) did not demonstrate an increase in 
free testosterone, despite marked weight loss. They were classified as non-
responders (NR). Their data have not been included in the calculation of the 
regression line. The line is defined by a slope of -3.3  0.3 (95% CI: -4.0 to -2.6), 
and an intercept of 740  45 (95% CI: 650 - 820), with an SD of 90 pmol/L. To 
facilitate its use in clinical practice these numbers can be simplified to numbers 
that remain within the 95% confidence interval of prediction. This results in the 
following equation, to be used a rule of the thumb:  
Predicted Free Testosterone = 700 – (3 x body weight), SD 90 pmol/L  
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Free T is expressed in pmol/L, body weight in kg. This simplified regression line is 
shown in figure 2 as a red line, and it is not significantly different from its original. 
The equation predicts which free testosterone can be expected for a specific body 
weight in obese but otherwise healthy men. The Z-score is obtained by dividing the 
difference between observed and predicted free testosterone by the SD of 90 
pmol/L. This approach may be useful to classify patients preoperatively. Some 
examples may serve to illustrate the clinical value of this nomogram. The red open 
circles represent the date of a patient with a preoperative body weight of 205 kg 
and a free testosterone of 114 pmol/L who would have been classified as 
hypogonadal if the conventional cut-off of 225 pmol/L had been used. However, 
looking at the weight adjusted prediction his preoperative free T is well within the 
expected normal range (+ 0.3 SD), and this remained so during the study period, 
with free testosterone rising as expected in proportion to the decrease in body 
weight. Non-responder 1 (NR-1, body weight 128 kg, free testosterone 70 pmol/L, 
Z-score -2.7) is a patient with true hypogonadism who would have been correctly 
diagnosed preoperatively with this nomogram, and would then have received 
appropriate and timely follow-up diagnostic care and treatment. NR-2 (body 
weight 147 kg, free T 144 pmol/L) and 3 (body weight 140 kg, free T 204 pmol/L) 
would not have been detected preoperatively since their free T levels were within 
the weight-adjusted normal range. They illustrate the inherent difficulty and 
uncertainty of correctly classifying the gonadal state in obese men. They also 
illustrate the need and value of follow-up measurements.  
Figure 2 is also helpful to predict the change in free T levels after weight loss. 
However, this information is more easily obtained by using the linear equation 
defining the change in free T (∆ free T) as a function of the degree of weight loss 
(∆ Body weight). This line is defined by a slope of 2.9  0.6 pmol/kg (95% CI: 1.8 
– 4.1), which implies that the predicted rise in free T is about 30 pmol/L for every 
10 kg weight loss.  
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shown in figure 2 as a red line, and it is not significantly different from its original. 
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shown in figure 2 as a red line,  it is not significantly differ nt from its original. 
The equation predicts which fre te toster ne can be exp c ed for a specific body 
weight in obese but otherwise h althy men. The Z-score is btained by dividing the 
d fference between observed nd predicted free t stosterone by the SD of 90 
pmol/L. This approach may be useful t  classify patients preoperatively. Som  
examples may serve t  illustrate the clinical value of this nomogram. The red open 
circles represent the d te of a pati nt with a preoperative body weight of 205 kg
and a free testosterone of 114 pmol/L who would have been classified as 
hypogonadal if the convention l cut-off of 225 pmol/L had been us d. However, 
looking at the weight adjusted prediction his preoperative free T is well within the 
expect d normal range (+ 0.3 SD), and this remained s  during the study period,  
 
 
 
 
weight-adjusted normal range. They illustrate the in rent difficulty and 
of cor ectly classifying the gonadal state in obese men. They also 
Figure 2 is also helpful to predict the cha ge in free T evels after weight 
loss. However, this informat on is more easily obtained by using the linear 
 i  free T (∆ fre  T) as a function of the degree of weight loss 
i i  fi   slo  of 2.9 ± 0.6 pmol/kg (95% CI: 1.8 
i i li  t t t  predicted rise in fre  T is about 30 pmol/L for every 
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 Before surgery 15 out of 24 men reported severe erectile dysfunction. 
Twelve months after surgery nine of these patients were able to achieve an 
erection. The liver enzymes ASAT, ALAT and GT decreased significantly (table 
2). HbA1c decreased from 6.6 to 5.7% (P < 0.001), HDL cholesterol increased by 
15.3 ± 4.6% (P < 0.005), LDL cholesterol decreased by 14.1 ± 3.7% (P < 0.005), 
and triglycerides decreased by 25.8%) ± 8.1% (P = 0.01). The bone turnover 
marker ICTP (marker for bone resorption) rose by 74.1  15.2% ( P < 0.005), and 
PINP (marker for bone formation) increased by 81.1  20.0% (P < 0.005).  
Correlation of hormone levels and body weight 
 The serum LH, FSH, SHBG, total and free T levels were inversely 
correlated with body weight: LH: R = -0.41, P < 0.001; FSH: R = -0.50, P < 
0.0001; total T: R = -0.55, P < 0.0001; free T: R = -0.65, P < 0.0001; SHBG: R = -
0.28, P < 0.001. Serum total and free E2 showed a weak positive correlation with 
body weight: R = +0.25, P < 0.01, and R = +0.34, P < 0.0001, respectively. The 
linear regression line describing the relation between body weight and serum free 
testosterone over the one-year study period is shown as solid blue line in figure 2. 
The interrupted blue lines represent the + 2 SD and -2 SD limits. All NT men, and 
10/13 OrHH men had a marked rise in serum free T over the year. Three men in the 
OrHH group (marked in red, orange and green) did not demonstrate an increase in 
free testosterone, despite marked weight loss. They were classified as non-
responders (NR). Their data have not been included in the calculation of the 
regression line. The line is defined by a slope of -3.3  0.3 (95% CI: -4.0 to -2.6), 
and an intercept of 740  45 (95% CI: 650 - 820), with an SD of 90 pmol/L. To 
facilitate its use in clinical practice these numbers can be simplified to numbers 
that remain within the 95% confidence interval of prediction. This results in the 
following equation, to be used a rule of the thumb:  
Predicted Free Testosterone = 700 – (3 x body weight), SD 90 pmol/L  
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Hypogonadal versus eugonadal obese men 
 The study included 11 NT men (free T > 225 pmol/L) and 13 OrHH men 
(free T < 225 pmol/L). OrHH men had a higher baseline body weight (160.9 ± 6.5 
kg/141.4 ± 6.0 kg, P = 0.04) and BMI (48.7 ± 1.7 versus 43.1 ± 1.7 kg/m2, P = 
0.03) than NT men (table 1). In addition, their mean serum LH, total T, and free T 
were significantly lower than in NT men. The E/T ratio was also significantly 
higher in OrHH than in NT men (P<0.01). Other parameters (pituitary hormones, 
metabolic data) were not significantly different at baseline (data not shown). 
Erectile dysfunction (ED) was reported by 77% (10/13) of the OrHH subjects 
compared to 36% (4/11) in the NT men, P = 0.09). One year after gastric bypass 
ED had resolved in 8/10 OrHH men and in 1/4 NT men, respectively. 
 
 During the 12 months after surgery body weight gradually decreased in 
both groups but somewhat faster in the OrHH group than in the NT group (Figure 
1). The decrease in body weight was 10.8 kg greater in the OrHH group (P = 0.09). 
As a result, the initial difference in body weight between the two groups gradually 
decreased, and after the 6th month the differences in body weight between the two 
groups were no longer statistically significant (Figure 1). Total T rose significantly 
in both groups, and the absolute increase was of the same magnitude in NT and 
OrHH subjects (7.5  2.1 nmol/L versus 7.4  1.9 nmol/L, P = 0.99). The rise in 
free T tended to be somewhat greater in NT than in OrHH subjects (156  38 
pmol/L versus 121  30 pmol/L, P = 0.48) , however, this difference could be fully 
attributed to the three non-responders (NR’s) within the hypogonadal group. Their 
baseline free T levels were 70, 144 and 204 pmol/L, and at 12 months levels had 
remained less than 225 pmol/L, i.e. 92, 153 and 124 pmol/L, respectively, despite a 
weight loss of 14, 48 and 34 kg in twelve months. After exclusion of the 3 NR’s 
the rise in free T was similar in both groups (156  38 pmol/L versus 163  27 
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pmol/L, P = 0.44). Serum total E2 and SHBG levels did not change significantly in 
either group. The E/T ratio decreased substantially in both groups, and it tended to 
be greater in OrHH than in NT patients. Nevertheless, at 12 months the difference 
in E/T ratio’s between the NT and OrHH men remained significant (6.0  1.0 
versus 9.3  1.3, P = 0.025) despite a near equilibration of body weights. Figure 3 
illustrates that E/T responses in OrHH men were markedly different from those in 
NT men. The connected dots represent the E/T ratio at baseline and at 12 month, 
expressed as a function of body weight. The blue lines are the mean ± 2 SD lines 
describing this relation in NT men. At baseline 7 out of 13 OrHH men had a 
weight-adjusted E/T ratio > + 2 SD of NT men. The slope of the line defining the 
change in E/T ratio over 12 months was about 3-fold steeper in OrHH men then in 
NT men (0.22 ± 0.027 versus 0.066 ± 0.017, P < 0.001). 
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illustrates that E/T responses in OrHH men were markedly different from those in 
NT men. The connected dots represent the E/T ratio at baseline and at 12 month, 
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describing this relation in NT men. At baseline 7 out of 13 OrHH men had a 
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change in E/T ratio over 12 months was about 3-fold steeper in OrHH men then in 
NT men (0.22 ± 0.027 versus 0.066 ± 0.017, P < 0.001). 
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Figure 1. Changes in body weight, serum total and free testosterone and serum 
estradiol levels in morbidly obese eugonadal (blue) and hypogonadal (red) men 
after bariatric surgery. Dashed lines represent the upper normal limit for serum 
estradiol, or the lower normal limit for total and free testosterone. *, P < 0.05, for 
the comparison between groups at various points of time. The interrupted green 
line represents the change in free testosterone in responders who were hypogonadal 
at baseline.  
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Figure 2. Correlation between body weight and serum free testosterone, in. The 
three non-responders (NR’s) are shown in red, orange and green. Two example 
patients (Expl 1 and 2) are discussed in the results section.  
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Figure 3. Changes in E/T ratio’s induced by bariatric surgery. The blue lines 
reflect the mean ± SD of E/T ratio’s in men who had preoperative testosterone 
levels within the normal range. The red dots represent men with reduced 
preoperative testosterone levels.  
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Discussion  
 
 This study confirms that OrHH in men can be corrected by weight loss 
induced by bariatric surgery, and it is shown that changes in serum testosterone 
levels are directly related to the degree of weight loss. Ten out of 13 OrHH subjects 
showed complete normalization of free T within 12 months, which indicates that 
OrHH is a reversible condition, responsive to weight loss in the majority of obese 
men. However, there also were 3 non-responders, and this illustrates that the group 
of severely obese men with reduced testosterone levels is heterogeneous. Some 
may have irreversible pituitary dysfunction not related to obesity. This observation 
does have two implications. First, an attempt should be made to correctly diagnose 
this subgroup preoperatively, and secondly, testosterone levels should be checked 6 
to 12 months after surgery to detect those with an insufficient rise in testosterone, a 
finding that will warrant further evaluation of the gonadal axis. 
 Correctly diagnosing hypogonadism in obese men is notoriously difficult. 
It has been shown previously that the use of total T levels will lead to an 
overestimation of hypogonadism [8]. Calculated free T is a better instrument 
because it corrects for the confounding effects of reduced SHBG levels in obese 
men. However, the absolute cut-off levels of free testosterone are not sufficient to 
avoid over diagnosing hypogonadism, because obesity also affects the setting of 
the gonadal axis. As shown in figure 2, the impact of body weight on free T leve ls 
is substantial, and thus weight-corrected free testosterone levels will be needed to 
further improve diagnostic accuracy. We propose that only those with a free T 
below -2 SD of the weight-predicted level should have a further analysis to rule out 
pituitary disease. This procedure will greatly reduce the number of false positive 
diagnoses of hypogonadism in obese men. Although weight-correction may protect 
against false-positive diagnosis of hypogonadism, it does not protect against false-
negative diagnoses. It should be noted that a low free T that is within the normal 
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range after weight-adjustment may represent OrHH, but it does not exclude the 
possibility that there may be a second condition present that is responsible for the 
low free T. Observations in two patients may serve to illustrate this diagnostic 
uncertainty (figure 2). Their low free T levels were within the weight-corrected 
normal range but did not rise after substantial weight loss. We therefore 
recommend to check free testosterone levels in all men with preoperatively reduced 
testosterone levels 6 - 12 months after bariatric surgery.  
 The interpretation of total T and total E2 in obese men is complex because 
the levels and changes of these levels do not always parallel the changes in the 
unbound fraction. This is caused by the changes in SHBG levels. In case of 
testosterone, both free testosterone and SHBG move in the same direction, they 
both increase after weight loss, and this results in an increase in total testosterone. 
For total E2 there is a confounding effect: weight loss decreases free E2 but 
increases SHBG, and these opposite changes tend to neutralize the effects of 
weight loss on total E2 suggesting that there is not much happening with respect to 
estradiol dynamics. For a better understanding of the changes in estradiol and 
testosterone balance in obese men we therefore recommend to primarily use the 
calculated free levels of these hormones.   
 The response in free E2 after bariatric surgery is the result of opposite 
changes. Loss of fat mass will tend to reduce aromatase activity and estradiol 
production whereas the rise in serum LH will stimulate testosterone production and 
increase substrate availability for the production of estradiol. The net effect on 
serum estradiol may vary between individuals depending on inter-individual 
differences in aromatase activity. Aromatase activity, as reflected by the E/T ratio, 
was markedly higher in OrHH men compared to NT men, and this difference 
remained after correction for body weight and also did not disappear after surgery-
induced weight reduction. These findings are illustrated in figure 3 showing the 
E/T ratio’s of NT and OrHH men at baseline and after 12 months. Defining the NT 
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group as the reference population, the OrHH men had excessively high E/T ratio’s 
preoperatively. Moreover they responded differently to weight loss. The slope of 
the line defining the decrease in E/T ratio was much steeper than in NT men. It is 
tempting to conclude that the difference between NT and OrHH obese men is 
primarily determined by the degree of the individual’s expression of aromatase 
activity in the adipocyte. In case of high expression, obesity will result in OrHH, 
whereas testosterone will remain within the normal range in men with adipocytes 
of low aromatase expression [19].    .  
 The present study is one of the few to study the metabolic effects of 
bariatric surgery in a separate group of men [4,5] The results are encouraging. 
Bariatric surgery induced a marked excess weight loss of 53 %, a decrease in 
HbA1c from 6.6% to 5.7%, and a substantial increase in HDL cholesterol of 17%, 
with a decrease in LDL cholesterol of 14%. The magnitudes of changes are 
comparable to those described for studies that mainly comprised women [1,2] The 
main adverse effects were substantial loss of muscle (15.7% ± 1.8% and hip bone 
(4.6 ± 0.1%). Prevention of these latter effects warrants further attention in future 
studies.  
 In contrast to our expectations, preoperative gonadal status did not 
adversely affect the beneficial effects of bariatric surgery. Excess weight loss was 
even greater in OrHH than in NT men. The catabolic effects on leg muscle and 
bone density were similar in both groups, and there also was no difference in the 
degree of improvement in HbA1c and lipid levels. Finally, bone turnover activity 
increased to a similar extent in both groups. It is therefore concluded that the 
changes induced by bariatric surgery are not affected by preoperative testosterone 
levels and that there is no evidence to suggest that preoperative correction of 
testosterone levels may be beneficial in obesity-related OrHH. 
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Conclusion 
 
 In conclusion, the results of this study indicate that the disturbance in 
testosterone/estradiol balance in obese men is markedly different among 
individuals, probably as a reflection of differences in the degree of adipocyte 
aromatase activity. Weight loss reduces excess aromatase activity and this leads to 
a normalization of the estradiol/testosterone balance in the majority of men. 
However, in a subset of men, obesity may have masked the presence of a second 
condition that has contributed to the development of low testosterone levels. To 
diagnose these patients properly it is recommended to repeat measuring serum 
testosterone level 6 - 12 months after surgery.  
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Abstract          
 
Background 
This study was performed to evaluate whether preoperative measurement of fasting plasma 
C-peptide levels is useful to predict diabetes outcome after Roux-en-Y-gastric bypass 
surgery (RYGB).  
 
Methods  
Diabetes outcome after RYGB was evaluated in 126 obese patients: 41 non -diabetic 
controls (NDC), 29 with impaired glucose tolerance (IGT) and 56 had Type 2 Diabetes 
Mellitus (T2DM). Body weight, fasting plasma glucose, fasting C-peptide levels, and 
HbA1c were measured at baseline and 3.6 ± 0.16 years after GBS. Complete resolution of 
diabetes was defined as: fasting glucose < 7.0 mmol/L, HbA1c < 6.5%, achieved without 
anti-diabetic medication.  
 
Results  
Patients with complete resolution of diabetes had a more recent diagnosis of T2DM, lower 
preoperative HbA1c levels and lower daily dos es of metformin and insulin use. These were 
related to postoperative HbA1c levels but failed to mark the patients who had not reached 
resolution of T2DM. Fasting preoperative C-peptide levels had better predictive power: 
90% of T2DM patients with preoperative fasting C-peptide levels > 1.0 nmol/L ach ieved a 
HbA1c < 6.5%, and 74% ach ieved complete resolution of their diabetes. In contrast, none 
of the T2DM patients with a fasting C-peptide < 1.0 nmol/L reached these goals.  
 
Conclusion  
A preoperative fasting plasma C-peptide level < 1.0 nmol/L in  severely obese T2DM 
patients indicates partial ß-cell failure, and is associated with a markedly reduced chance of 
complete resolution of T2DM after RYGB.  We therefore advocate measuring C-peptide 
levels in all diabetic patients up for bariatric surgery to improve the prediction of outcome.  
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Introduction 
 
Obesity has increased dramatically in the last decades. Close to half the 
European population is overweight and about 30% is considered obese (BMI > 30 
kg/m²) [1]. It is a major risk factor for the development of type 2 diabetes mellitus 
(T2DM). Over 80% of T2DM is causally linked to excess weight [2-4]. So far, no 
medical cure has been found for this disease. It is slowly progressive despite the 
use of anti-diabetics and ultimately results in micro- and macrovascular 
complications that increase mortality and affect the quality of life [5-7].  
 
Bariatric surgery has been shown to improve and in many cases to resolve 
T2DM. The Roux-en-Y Gastric bypass (RYGB) is the most successful surgical 
technique to improve glucose control in T2DM [8,9]. It reduces nutrient absorption 
by restricting food intake and bypassing part of the small intestine. The additional 
anti-diabetic effect of RYGB is related to changes in gut hormone release that lead 
to improved insulin secretion and insulin sensitivity [1,4]. Together these changes 
induce durable weight loss and improved glucose homeostasis in many patients. 
Current guidelines indicate that T2DM patients with a BMI > 35 kg/m2 should be 
offered RYGB [10]. The RYGB’s rate of success is so impressive that there is a 
trend to reduce the weight limits for bariatric surgery in T2DM [8].  
 
To balance the risks of surgery against its benefits, tools will be needed to 
accurately predict diabetes outcome after surgery. Although it is known that the 
success of surgery is inversely related to the duration of T2DM, the preoperative 
HbA1c level and the dose of oral anti-diabetics and insulin, the predictive accuracy 
of these parameters on an individual level is limited [7,9,11-13]. 
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Abstract          
 
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patients were retrospectively selected using a prospectively collected database. The AGB 
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
Converting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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Progressive ß-cell failure is a natural development in T2DM, and in case of 
severe ß-cell failure it is unlikely that bariatric surgery will lead to complete 
resolution of T2DM. Therefore, a preoperative assessment of insulin secretion 
capacity could prove to be useful to assess the stage and severity of T2DM and to 
predict diabetes outcome after RYGB surgery. Measurement of fasting C-peptide 
levels is a commonly accepted tool to assess insulin secretion. Insulin is stored as 
pro-insulin, and when this pro-insulin is split C-peptide and insulin are released in 
a 1:1 ratio [6,7,12]. In patients on insulin therapy insulin assays have the 
disadvantage that they will detect the insulin secreted by the -cell as well as the 
insulin injected. Therefore, measurement of C-peptide levels is preferred because 
C-peptide levels purely reflect endogenous insulin production. The aim of the 
present study was to evaluate the potential of preoperative fasting plasma C-
peptide levels as predictor of diabetes outcome after a RYGB  
 
Patients and Methods  
 
Patient selection 
Between 2003 and 2008 a laparoscopic Roux-en-Y Gastric Bypass 
procedure was performed in 582 morbidly obese patients. The Roux-limb length 
had been set at 100 cm for patients with a BMI < 50 kg/m2, and at 150 cm for those 
with a BMI ≥ 50 kg/m2 [11]. Preoperative fasting glucose, C-peptide and HbA1c 
levels were available in 145 patients with a follow-up of at least one year. They 
were recalled for re-evaluation 1 to 5 years after surgery. Fifteen were lost to 
follow-up, and 126 patients agreed to participate and gave their informed consent. 
The patients were categorized into three groups, based on preoperative fasting 
glucose and HbA1c levels: 1. non-diabetic controls (NDC) if fasting glucose levels 
were < 6 mmol/L and HbA1c was < 6.0%, 2. patients with impaired glucose 
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tolerance (IGT) if fasting glucose was > 6.0 and < 7.0 mmol/L and/or HbA1c was 
6.0 - 6.5%, and 3. patients with T2DM: fasting glucose ≥ 7.0 and/or HbA1c ≥ 6.5% 
and/or on medication for T2DM.  
Medical history, age, height (cm), weight (kg), BMI (kg/m2) and 
medication were recorded before and after surgery. Fasting glucose, fasting C-
peptide and HbA1c were measured in all 126 patients, pre- and postoperatively. A 
complete response, i.e. a complete resolution of T2DM, was defined as a 
postoperative decline in HbA1c to a level ≤ 6.5% without the need of anti-diabetic 
medication. A partial response was defined as a decline in dose of anti-diabetics > 
50% combined with an improvement of HbA1c of at least 25% when compared to 
preoperative levels. 
 
Assays  
Glucose was measured by standard laboratory method (hexokinase method 
Roche Modular, normal fasting plasma glucose 4.0 – 6.0 mmol/L). C-peptide was 
measured with a ECLIA assay on a E170 analyser (Roche Diagnostics GmbH, 
Mannheim, Germany, reference range, 0.27 – 1.28 nmol/ in non-obese subjects). 
HbA1c was measured by HPLC analysis (Menarini, former reference range 4.0 - 
6.0%). 
 
Statistical analysis  
Results are summarized as mean values ± standard error. Changes in 
glucose, HbA1c and C-peptide levels were analysed by student t-test for normally 
distributed data, Mann-Whitney U test for data with a non-normal distribution, and 
by Chi-Square test for proportions. Relationships between parameters were 
examined by Pearson’s Correlation Test. All data were analysed using SPSS 16.01 
statistical software. Differences were considered statistically significant if P < 0.05.  
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Results 
 
Baseline characteristics 
A complete set of pre- and post-operative data on glucose metabolism was 
available in 126 patients. The mean follow-up after surgery was 3.6 ± 0.16 years. 
Forty-one patients were classified as non-diabetic controls (NDC), 29 had impaired 
glucose tolerance (IGT), and 56 had T2DM. Prior to the screening for surgery, 36 
patients (25%) already had a diagnosis of T2DM: 35 were on anti-diabetics, one 
patient had refused medication. Their mean HbA1c was 8.1± 1.5 %. Oral 
medication consisted of metformin in 26/35 patients (mean dose 1710 ± 818 
mg/day), and sulfonylurea in 10/35 patients (Glimepiride N = 8, mean dose 4.8 
±1.6 mg/day; Tolbutamide N = 1, 1000 mg/day; Gliclazide N = 1, 60 mg/day). 
None were on thiazolidinediones (TZD), DPP-4 inhibitors or GLP-1 analogs. 
Nineteen patients only used oral anti-diabetics, 14 used a combination of oral anti-
diabetics and short plus long-acting insulin (short-acting insulin 66 ± 30 IU/day + 
long-acting insulin 31 ± 38 IU/day), and 2 patients only used a combination of 
short and long-acting insulin without oral anti-diabetics (short-acting insulin 47 ± 
54 IU/day, long-acting insulin 55 ± 35 IU/day). The mean insulin requirements 
were about 100 IU/day. The mean duration of T2DM for patients on tablets alone 
was 4.8 ± 5.0 years, and 8.7 ± 6.1 years for those on insulin with or without oral 
anti-diabetics. During preoperative screening 20 patients were newly diagnosed 
with T2DM. This raised the total number of T2DM from 36 to 56. The mean 
HbA1c in these newly diagnosed T2DM was 6.8 ± 0.8%, i.e. significant lower than 
the 8.1± 1.5 % observed in patients on anti-diabetic patients (P <0.001).  
The preoperative patient characteristics are summarized in Table 1 and 2. 
On average, the patients with T2DM were 6 years older than IGT patients (P < 
0.001) and 10 years older than NDC subjects (P < 0.001). The T2DM group also 
contained a higher percentage of males (P < 0.01). Mean body weight and BMI did 
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not differ between the three groups. Preoperative fasting glucose levels ranged 
from 4.3-5.8 mmol/L in NDC, from 4.8 – 6.9 mmol/L in IGT and from 5.1- 17.6 
mmol/L in T2DM. Preoperative fasting plasma C-peptide levels > 1.0 nmol/L were 
observed in 27/29 (93%) IGT patients, and in 48/56 (86%) T2DM patients, 
irrespective of their fasting glucose levels. All 21 (100%) T2DM patients not on 
medication (100%), 17 out of 19 (83%) T2DM patients on oral anti-diabetics alone, 
and 10/16 (63%) patients on insulin therapy had C-peptide levels > 1.0 nmol/L, 
(Figure 1). All 8 patients who had C-peptide levels < 1.0 nmol/L had concomitant 
fasting glucose levels > 7.0 mmol/L, thereby ruling out lack of -cell stimulation as 
a cause for their low C-peptide levels.  
 
Table 1. Preoperative characteristics in morbidly obese non-diabetic controls 
(NDC), patients with impaired glucose tolerance (IGT), and patients with type 2 
diabetes (T2DM) 
 
 NDC IGT T2DM 
Number of patients 41 29 56 
Mean Age  (years) 37 ± 9.5 41 ± 7.3 47 ± 7.3* 
Male  (%) 27% 14% 50%* 
Body weight  (kg) 145 ± 26.5 146 ± 19.0 146 ± 23.3 
BMI  (kg/m²) 48.0 ± 6.9 50.8 ± 5.8 48.1 ± 6.3 
(* p < 0.01) 
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Postoperative weight loss and glucose control  
Most patients had a marked excess weight loss (EWL), only two patients 
had an EWL < 25%. Twelve months after surgery the mean BMI had dropped from 
48.5 ± 6.8 kg/m2 to 38.3 ± 6.2 kg/m². At the time of reevaluation the BMI had 
further decreased to 33.5 ± 5.8 kg/m² with a mean EWL of 66 ± 21% (P < 0.001). 
Weight loss was comparable in NDC, IGT and T2DM patients (Table 2). 
Normalization of glucose metabolism, defined as a fasting glucose level < 6.0 
mmol/L and an HbA1c < 6.0%, occurred in 90% of IGT patients and in 43% of 
T2DM. Improvement from T2DM to IGT occurred in 32% of the patients with 
T2DM (Table 2). 
 
Changes in T2DM medication 
The overall postoperative results on glucose metabolism and diabetes 
medication are summarized in Tables 2 and 3. Preoperatively 35 out of 56 T2DM 
patients were on anti-diabetics, either oral treatment alone (N= 19), oral treatment 
in combination with insulin (N =14), or insulin alone (N=2). Eighteen out of 19 
patients on oral anti-diabetics (95%) could decrease their daily dose by at least 
50%, and 15 out of 16 users of insulin (94%) could reduce their daily insulin dose 
by at least 50%. A complete response was observed in 26 out of 35 (74%) patients 
who previously had needed anti-diabetics. Oral treatment was discontinued in 17 
out of 19 (89%) patients, and insulin in 9 out of 16 patients (56%). In the group 
that could stop diabetes medication, BMI had decreased from 47.5 ± 5.4 to 31.4 ± 
6.0 kg/m2 (P < 0.001), and HbA1 from 7.5 ± 1.1 to 6.0 ± 0.8% (P < 0.001). The 
group of patients still needing anti-diabetics had a decrease in BMI from 47.3 ± 4.2 
to 34.1 ± 5.4 kg/m2 (P < 0.001), and a decline in HbA1c from 8.7 ±1.6 to 7.1% ± 
1.2 (P < 0.001). Their postoperative decline in weight and HbA1c was significantly 
less than in the group of patients who could stop their anti-diabetics, (P < 0.02 and 
P < 0.001, respectively).  
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Postoperative weight loss and glucose control  
Most patients had a marked excess weight loss (EWL), only two patients 
had an EWL < 25%. Twelve months after surgery the mean BMI had dropped from 
48.5 ± 6.8 kg/m2 to 38.3 ± 6.2 kg/m². At the time of reevaluation the BMI had 
further decreased to 33.5 ± 5.8 kg/m² with a mean EWL of 66 ± 21% (P < 0.001). 
Weight loss was comparable in NDC, IGT and T2DM patients (Table 2). 
Normalization of glucose metabolism, defined as a fasting glucose level < 6.0 
mmol/L and an HbA1c < 6.0%, occurred in 90% of IGT patients and in 43% of 
T2DM. Improvement from T2DM to IGT occurred in 32% of the patients with 
T2DM (Table 2). 
 
Changes in T2DM medication 
The overall postoperative results on glucose metabolism and diabetes 
medication are summarized in Tables 2 and 3. Preoperatively 35 out of 56 T2DM 
patients were on anti-diabetics, either oral treatment alone (N= 19), oral treatment 
in combination with insulin (N =14), or insulin alone (N=2). Eighteen out of 19 
patients on oral anti-diabetics (95%) could decrease their daily dose by at least 
50%, and 15 out of 16 users of insulin (94%) could reduce their daily insulin dose 
by at least 50%. A complete response was observed in 26 out of 35 (74%) patients 
who previously had needed anti-diabetics. Oral treatment was discontinued in 17 
out of 19 (89%) patients, and insulin in 9 out of 16 patients (56%). In the group 
that could stop diabetes medication, BMI had decreased from 47.5 ± 5.4 to 31.4 ± 
6.0 kg/m2 (P < 0.001), and HbA1 from 7.5 ± 1.1 to 6.0 ± 0.8% (P < 0.001). The 
group of patients still needing anti-diabetics had a decrease in BMI from 47.3 ± 4.2 
to 34.1 ± 5.4 kg/m2 (P < 0.001), and a decline in HbA1c from 8.7 ±1.6 to 7.1% ± 
1.2 (P < 0.001). Their postoperative decline in weight and HbA1c was significantly 
less than in the group of patients who could stop their anti-diabetics, (P < 0.02 and 
P < 0.001, respectively).  
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Table 3. Postoperative outcome in three categories of T2DM: those who were 
preoperatively without medication, those on tablets alone, and those on insulin with 
or without tablets.  
 No Medication 
N = 21 
Tablets 
N = 19 
Insulin 
N = 16 
Free of Tablets 100% 90% 57% (8/14) 
Free of Insulin 100%    - 69% 
Free of all Anti-diabetics 100% 90% 56% 
Dose reduction(1)    - 5% 38% 
Overall Improvement(2)    - 95% 94% 
    
Glucose < 7.0 mmol/L 90% 79% 33% 
HbA1 < 6.5% 95% 79% 44% 
(1),  Dose reduction is defined as a decrease in dose of at least 50% of 
preoperative T2DM medication 
(2)   Overall improvement is defined as the use of less medication (50% dose 
reduction or more) and/or lower HbA1c levels (reduction of 0.5% of more 
 
Changes in fasting C-peptide levels  
Postoperatively, C-peptide levels decreased in most patients (Figure 2). 
The overall pattern was similar in the three groups, but most pronounced decreases 
occurred in those with high preoperative C-peptide levels. In the group of T2DM 
patients, the magnitude of the decrease was inversely related to the preoperative 
plasma C-peptide concentration (R2 = -0.85, P <0.0001, Figure 3, left), and this is 
described by the equation:  
 
∆-Cpept = - 0.91 x (preoperative Cpept) + 0.71, SEE 0.30 nmol/L 
 300 
 
This equation not only describes that those with highest preoperative 
fasting C-peptide levels showed the greatest decrease in C-peptide levels after 
surgery, it also describes that those with C-peptide levels around 0.78 (95% CI: 
0.61 – 0.92 nmol/L) did not show a decrease in C-peptide levels. As a result, C-
peptide levels converged from a very wide range preoperatively to a relatively 
small range postoperatively (Figure 2). Figure 3B illustrates the pre- and 
postoperative fasting C-peptide levels in patients with complete resolution of 
T2DM after surgery (open circles), and those still on tablets (blue dots) or insulin 
(red diamonds). Of note: all patients with complete resolution of T2DM had 
preoperative fasting C-peptide levels > 1.0 nmol/L.  
 
Prediction of diabetes outcome 
Retrospective analysis showed that patients with complete resolution of 
T2DM had a more recent diagnosis of T2DM (1.5  2.8 versus 8.1  6.5 years, P < 
0.01), had lower preoperative HbA1c levels (6.6  0.8 versus 8.7  1.5%, P < 
0.01), and had lower daily doses of metformin (470 ± 843 mg versus 1232 ± 956 
mg, P < 0.01) and insulin (5 ± 19 IU versus 59 ±69 IU, P < 0.001). These 
parameters were statistically significant related to postoperative HbA1c levels (all 
P < 0.05), however they failed to mark the specific patients who had not reached 
complete resolution of T2DM.  
The predictive value of preoperative C-peptide levels in T2DM patients is 
shown in figure 3. Forty-eight out of 56 T2DM patients had preoperative C-peptide 
levels > 1.0 nmol/L. Forty-three of these patients (90%) achieved postoperative 
HbA1c levels < 6.5%, with only 4 (9%) needing anti-diabetics to achieve this, 
although at a much reduced dose compared to preoperatively. All 8 T2DM patients 
with preoperative C-peptide levels < 1.0 nmol/L were unable to achieve 
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postoperative HbA1c levels < 6.5%, and none of them could completely 
discontinue their diabetes medication.  
 
Figure 1. Preoperative fasting C-peptide levels in patients with T2DM without 
medication (open circles), on oral anti-diabetics alone (blue dots) and those on 
insulin (red diamonds), expressed as a function of fasting plasma glucose level.
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Figure 2. Pre-and postoperative fasting C-peptide levels in T2DM subjects, IGT 
patients and non-diabetic controls. 
 
 
Figure 3. Postoperative changes in fasting C-peptide level in patients with T2DM, 
as a function of the preoperative fasting C-peptide level (left figure), and C-peptide 
levels in patients cured for their T2DM (open circles), T2DM patients on oral anti-
diabetics only (blue dots) and those still on insulin (right figure). 
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Figure 4.  Preoperative C-peptide levels correlated to postoperative HbA1c% 
outcome in T2DM patients. Open circle: no anti-diabetic medication, blue dot: only 
tablets, red diamond: insulin with or without oral anti-diabetics.
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Discussion 
 
This study confirms that RYGB is very effective to improve glucose 
metabolism in T2DM [2,3,9,11,15]. Ninety percent of our T2DM patients 
responded with a major decline in HbA1c to a value < 6.5%, and 74% of the 
T2DM patients on anti-diabetic medication achieved a complete resolution of their 
T2DM, i.e. they no longer needed anti-diabetics to keep their HbA1c < 6.5%. 
These figures are comparable to the results of previous studies with similar 
outcome criteria: complete resolution of T2DM was observed in 72 - 86% of these 
patients [9-11,17]. The average excess weight loss of 66% in our T2DM patients is 
also consistent with the reported range of 60 – 67% [3,9-11,17,18].  
 
A new finding is that preoperative fasting C-peptide levels may be helpful 
to predict T2DM outcome after RYGB. In this retrospective analysis all 20 patients 
with newly diagnosed T2DM had C-peptide levels > 1.0 nmol/L, and all but one 
experienced a complete resolution of T2DM. In addition, all 17 patients on oral 
anti-diabetics with fasting C-peptide levels > 1.0 nmol/L also experienced 
complete resolution of T2DM. In contrast, none of the 8 patients on oral anti-
diabetics or insulin with preoperative fasting C-peptide levels < 1.0 nmol/L had a 
complete resolution of their T2DM (Figure 3). They did benefit from the RYGB as 
reflected by the decrease in mean HbA1c from 8.6 to 7.4%, but their benefit was 
obviously not as large as in those who had fasting C-peptide levels > 1.0 nmol/L. 
Their postoperative HbA1c levels remained higher than 6.5%, and all still needed 
their anti-diabetics, although at a much lower dose.  
 
The results of his study suggest that a preoperative fasting C-peptide level 
less than 1.0 nmol/L is a critical value in T2DM patients with a BMI > 35 kg/m2. 
As shown in figure 3, all patients who had a complete resolution of T2DM had 
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fasting C-peptide levels > 1.0 nmol/L. Values less than 1.0 nmol/L in T2DM 
patients with a concomitant fasting plasma glucose > 7.0 mmol/L appear to be 
indicative of irreversible ß-cell failure of a degree that precludes complete 
resolution of T2DM after substantial weight loss. We hypothesize that fasting C-
peptide levels in severely obese T2DM patients reflect maximal -cell activity, and 
if this generates C-peptide levels less than 1.0 nmol/L insulin production is 
apparently insufficient to achieve normoglycemia after successful weight loss, i.e. 
a condition with markedly improved insulin sensitivity and reduced insulin 
requirements.  
 
The natural course of T2DM is progressive ß-cell failure. Currently 
available anti-diabetics won’t alter that. Insulin treatment will help only 
temporarily to regain control of their diabetes, often at the cost of additional weight 
gain. The findings in this study support the notion that one should not wait too long 
before considering RYGB or any other form of metabolic surgery in severely obese 
T2DM patients. Waiting until ß-cell failure has occurred will worsen the outcome 
of surgery. “Early” RYGB surgery is therefore recommended. This is also 
supported by the observation that the benefit of bariatric surgery is greater in 
patients T2DM of shorter duration or limited severity. Lower preoperative HbA1c 
levels, a shorter duration of T2DM or a shorter duration of medication use and 
lower daily insulin doses have been associated with a higher rate of success of 
bariatric surgery [4,9]. The accuracy of these factors as predictors of outcome is 
limited. We hypothesize that measurement of preoperative fasting C-peptide levels 
may have more accurate predictive power, because it is a more physiological and 
more direct tool to assess ß-cell function. One potential pitfall should be noted. In 
T2DM patients with severe renal failure the relation between fasting C-peptide 
levels and insulin secretion is disturbed because of a decrease in C-peptide 
excretion [19].   
 306 
The results of the present study should be regarded as preliminary because 
number of subjects was limited. In particular, the number of T2DM patients with 
fasting C-peptide levels  < 1.0 nmol/L was rather small and thus future studies are 
needed to increase these numbers to strengthen the predictive value C-peptide 
measurements in this subset of patients. Future studies may also benefit by further 
standardization of the sampling conditions. It seems prudent to pre-specify the 
degree of -cell stimulation by requiring a fasting glucose level > 7.0 mmol/L to 
avoid underestimation of insulin secretion capacity. To achieve that in tightly 
controlled obese T2DM patients it may be necessary to reduce the daily dose of 
oral anti-diabetics or long-acting insulin on the day prior to sampling. Another 
issue of interest is to sort out whether the most simple test, i.e. the measurement of 
fasting C-peptide, is as informative as the glucagon-stimulated C-peptide level. A 
direct comparison of the two tests as predictor of diabetes outcome after RYGB is 
currently not available.  
 
In conclusion, the results of this retrospective analysis suggest that 
preoperative measurement of fasting C-peptide level in severely obese T2DM 
could become a useful tool to predict the outcome of T2DM after RYGB. It may 
help to further improve the indications for bariatric surgery. Validation of this 
concept on a larger scale is warranted. 
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4.3 
 
Hepatic steatosis in morbidly obese patients 
undergoing gastric bypass surgery: assessment 
with open-system 1H-MR spectroscopy.	  
	  
J.R. van Werven, T.C.M.A. Schreuder, E.O. Aarts, A.J. 
Nederveen, J. W.R. Meijer, F.J. Berends, I.M.C. Jansen, 
C.J. Mulder, P.L.M. Jansen, J. Stoker	  
	  
Published in American Journal of Roentgenology	  
(Am J Roentgenol. 2011;196:W736-42) 
322
Chapter 4
 
 
 310 
Abstract          
 
Background 
The purpose of this study was to assess hepatic steatosis in morbidly obese patients 
undergoing gastric bypass surgery using open magnet 1.0T 1H-MRS with histopathological 
control. 
 
Methods 
Patients underwent 1H-MRS for the assessment of steatosis before and three months after 
surgery. Liver biopsy was performed during surgery. Hepatic steatosis was expressed as a 
ratio of the fat peak area over the cumulative water and fat peak areas. Histopathological 
percentages of steatosis were graded as follows: none (0-5%), mild (5-33%), moderate (33-
66%) and severe (>66%). Spearman’s correlation and accuracy was assessed. Differences 
between groups were assessed with the Wilcoxon signed ranks and Mann-Whitney U 
analysis. 
 
Results 
We included 38 patients, with mean age and BMI of 45.6 years and 47.9 kg/m2 
respectively. Before surgery mean steatosis measured with 1H-MRS was 10.3%. 1H-MRS 
showed an accuracy of 32/36 (89%) and significantly correlated with histopathological 
assessment of steatosis (r=0.85,p<0.001). 1H-MRS was able to discriminate none from mild 
steatosis (p=0.011), mild from moderate steatosis (p<0.001) and moderate from severe 
steatosis (p=0.037). Th ree months after surgery steatosis decreased to 5.2% (p<0.001). The 
prevalence of hepatic steatosis measured by 1H-MRS decreased from 53% to 33%. 
 
Conclusions 
1H-MRS for assessment of hepatic steatosis and changes in steatosis after gastric bypass 
surgery is feasible in morbidly obese patients using an open 1.0T MR scanner. 1H-MRS 
measurements of hepatic fat are accurate and correlate with histopathology results. 1H-MRS 
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using an open 1.0T MR scanner should be considered when morbidly obese patients do not 
fit in cylindrical MR scanners. 
           
 
Introduction 
 
Non-alcoholic fatty liver disease (NAFLD) is characterized by lipid 
accumulation in the liver. The disease spectrum ranges from simple hepatic 
steatosis to more severe non-alcoholic steatohepatitis (NASH), fibrosis, and 
cirrhosis, which can lead to end-stage liver failure or development of hepatocellular 
carcinoma [1]. NAFLD is present in approximately 85–95% of morbidly obese 
persons [2, 3], and the prevalence is expected to increase owing to the current 
obesity epidemic [4]. Bariatric surgery (metabolic surgery) is increasingly 
performed to treat patients with morbid obesity. In 2008, 344,221 bariatric surgical 
procedures (including 168,597 Roux-en-Y gastric bypass operations) were 
performed worldwide, most (220,000) in North America [5]. Most patients with 
type 2 diabetes, NAFLD, dyslipidemia, and hypertension had marked improvement 
after bariatric surgery [6–8]. 
Percutaneous liver biopsy is the only available reference standard for 
histopathologic evaluation of NAFLD but carries the risk of complications, 
interobserver variability, sampling error, and patient discomfort [9–11]. 
Furthermore, liver biopsy is technically difficult in morbidly obese patients. 
Consequently there is a need for a noninvasive diagnostic tool for the detection, 
quantification, and monitoring of hepatic steatosis. The imaging techniques used to 
detect hepatic steatosis include ultrasound, CT, MRI, and 1H MR spectroscopy 
(1H-MRS) [12, 13]. MRI and 1H-MRS are considered the most accurate 
noninvasive techniques for detecting hepatic fat [14, 15].  
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Abstract          
Background 
The most performed restrictive bariatric procedure is the Adjustable Gastric Band (A GB). 
With large number of patients receiving a A GB so will inevitably the number of 
complications. For many complications revisional bariatric surgery is necessa ry. In this 
study the outcomes of one stage AGB conversions to a Roux-en-Y Gastric Bypass from our 
institution are presented. 
 
Methods 
Patient  were retrospectively selected using a prospectively coll cted database. The AGB
had to be in situ for at least one year and minimum postoperative follow up had to be 12 
months. The RYGB had to be performed as a one-step procedure. 
 
Results 
195 Pat ients were included. In total 175 (90%) procedures were performed without 
perioperative complications, and only 8 (4%) patients required re-operation within 30 days. 
Mean  EW L increased from 25% (±26/-50-120%) to 60% (±21.2/0-130), 65% (±23.5/0-
131), 63% (±24.2/2-132), 60% (±24.1/0-111) and 53% (±28.7/-39-109) in the first five 
postoperative years. 
 
Conclusion 
v rting a AGB to a RYGB in a one stage procedure is a safe and feasible procedure 
with acceptable complication rates when performed in a specialized institution. The RYGB 
conversion results in a good EWL of 65% after two years, however proper patient selection 
is of the utmost importance. 
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With respect to precision, 1H-MRS is a reproducible method for 
quantifying hepatic fat content [16], having a coefficient of variation of 9.5% over 
time and 14.5% for within-liver variability at 3 T. Previous studies in which 
cylindric MRI systems were used for 1HMRS showed a beneficial effect of 
bariatric surgery on hepatic steatosis [17–20]. Histopathologic confirmation was 
obtained in one study [19] and showed good correlation with the 1H-MRS findings 
(r = 0.77, p < 0.001). Because of the obesity epidemic, an increasing number of 
patients have problems fitting in the bore of a standard cylindric MRI unit. 
Although some morbidly obese patients do fit in this type of unit and more fit in 
the newer large-bore clinical 70-cm 1.5- and 3-T cylindric systems, the relatively 
short diameter and long bore make it uncomfortable for these patients and increase 
the tendency to induce a squeezing effect and claustrophobia [21]. Therefore, 1H-
MRS measurements of hepatic fat content can be problematic even though the 
patients are at high risk of NAFLD and NASH. 
For the morbidly obese population, 1H-MRS in an open MRI system may 
be an alternative to imaging with a cylindric system. Open MRI units have been 
available since the introduction of MRI in the 1980s, but most operate at low field 
strength, impeding 1H-MRS measurement. However, high-field-strength open 1-T 
MRI units have become available for clinical use, making good-quality 1H-MRS 
possible. The purpose of this study was to measure hepatic steatosis in morbidly 
obese patients before and after laparoscopic Roux-en-Y gastric bypass surgery with 
1H-MRS in an open 1-T MRI system. Histopathologic confirmation was obtained 
during surgery.  
 
Subjects and Methods 
Study Design and Subjects 
 This prospective study was approved by the institutional review board. All 
patients gave written informed consent. From January to September 2008, all 
325
Co-morbidities
4
 
 
 312 
With respect to precision, 1H-MRS is a reproducible method for 
quantifying hepatic fat content [16], having a coefficient of variation of 9.5% over 
time and 14.5% for within-liver variability at 3 T. Previous studies in which 
cylindric MRI systems were used for 1HMRS showed a beneficial effect of 
bariatric surgery on hepatic steatosis [17–20]. Histopathologic confirmation was 
obtained in one study [19] and showed good correlation with the 1H-MRS findings 
(r = 0.77, p < 0.001). Because of the obesity epidemic, an increasing number of 
patients have problems fitting in the bore of a standard cylindric MRI unit. 
Although some morbidly obese patients do fit in this type of unit and more fit in 
the newer large-bore clinical 70-cm 1.5- and 3-T cylindric systems, the relatively 
short diameter and long bore make it uncomfortable for these patients and increase 
the tendency to induce a squeezing effect and claustrophobia [21]. Therefore, 1H-
MRS measurements of hepatic fat content can be problematic even though the 
patients are at high risk of NAFLD and NASH. 
For the morbidly obese population, 1H-MRS in an open MRI system may 
be an alternative to imaging with a cylindric system. Open MRI units have been 
available since the introduction of MRI in the 1980s, but most operate at low field 
strength, impeding 1H-MRS measurement. However, high-field-strength open 1-T 
MRI units have become available for clinical use, making good-quality 1H-MRS 
possible. The purpose of this study was to measure hepatic steatosis in morbidly 
obese patients before and after laparoscopic Roux-en-Y gastric bypass surgery with 
1H-MRS in an open 1-T MRI system. Histopathologic confirmation was obtained 
during surgery.  
 
Subjects and Methods 
Study Design and Subjects 
 This prospective study was approved by the institutional review board. All 
patients gave written informed consent. From January to September 2008, all 
	  
	  
	   9	  
Subjects and Methods 
 
Study Design and Subjects 
 This prospective study was approved by the institutional review board. All 
patients gave written informed consent. From January to September 2008, all 
patients 18 years and older who were scheduled to undergo laparoscopic Roux-en-
Y gastric bypass surgery were consecutively invited to participate in this study. 
Because of long waiting lists for bariatric surgery, the preoperative and 
postoperative 1H-MRS measurements were performed up to June 2010. The 
indication for laparoscopic Roux-en-Y gastric bypass surgery was morbid obesity, 
defined as a body mass index (BMI; weight in kilograms divided by the square of 
height in meters) greater than 40 or greater than 35 with comorbidity related to 
morbid obesity, such as cardiovascular, metabolic, and pulmonary complications. 
All patients included in this study met the criteria stated by the U.S. National 
Institutes of Health consensus panel for bariatric surgery [22]. 
The patients underwent 1H-MRS for the assessment of hepatic steatosis 4 
weeks before surgery and 3 months after surgery. Demographic characteristics and 
anthropometric measurements were recorded and blood analyses performed on the 
same day that 1H-MRS was performed. Exclusion criteria were pregnancy, 
contraindications to MRI, other causes of chronic liver disease, and the presence of 
alcoholic fatty liver disease. 
 
Clinical Evaluation 
Within 4 weeks before surgery, age, sex, medical history, and use of 
alcohol (normal defined as < 140 g/wk for men and < 70 g/wk for women) were 
recorded for all patients. Physical examination included blood pressure, weight, 
height, waist and hip circumference, and calculation of BMI and waist-to-hip ratio 
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(WHR). A WHR greater than 1.0 for men and greater than 0.9 for women is 
associated with increased risk of cardiovascular disease and insulin resistance [23]. 
Blood was collected after an overnight fast. Fasting plasma glucose and insulin 
were analyzed, and the concentrations were used for homeostasis model 
assessment (HOMA) of the severity of insulin resistance [24]. Insulin resistance 
was diagnosed when the HOMA value was greater than 2.5. Diabetes was defined 
with internationally accepted criteria [25]. Other causes of chronic liver disease 
were excluded if serologic results were negative for hepatitis B surface antigen and 
hepatitis C virus antibodies, autoimmunity test results were negative for antinuclear 
antibodies and smooth muscle antigens, and results of tests for iron and copper 
storage diseases were normal. This clinical evaluation was repeated 3 months after 
laparoscopic Roux-en-Y gastric bypass surgery. 
 
1-T 1H–MR Spectroscopy 
With the patient supine and breathing freely on an open 1-T MRI system 
(Panorama HFO, Philips Healthcare) with a 160-cm-wide patient aperture and a 
height of 45 cm, 1H-MRS measurements were performed with the quadrature body 
coil (acquisition time, 30 minutes). No respiratory triggering or outer-volume 
suppression was used. After T1-weighted coronal and axial localizer images were 
acquired, a 20 × 20 × 20 mm voxel was positioned in the right liver lobe, avoiding 
overlap with extrahepatic structures and intrahepatic vascular and biliary structures. 
Spectra (Fig. 1) were acquired with pencil beam second-order shimming in a 
predefined volume (shim box) in the liver, a point-resolved spectroscopic sequence 
(PRESS) with TR/TE of 35/2000 and 64 signal acquisitions. Receiver bandwidth 
was 1500 Hz, and the number of data points was 2048. Data were processed with 
jMRUI software [26] by a research fellow blinded to study results under direct 
supervision of an experienced MR physicist (5 years of experience). Signal 
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resonances from water and fat located at 4.65 and 1.3 ppm were analyzed (Fig. 1). 
Prior knowledge was used for peak localization by use of soft constraints.  
 Signal resonances were fitted with lorentzian line shapes. Phase variation 
(40°) was allowed around a manually selected optimum. Relative fat content was 
expressed as a ratio of the fat peak area over the cumulative water and fat peak 
areas: 1.3 ppm / (1.3 ppm + 4.65 ppm). No correction for T1 relaxation was 
performed because no T1 weighting is present at a TR of 2000 ms. Calculated peak 
areas of water and fat were corrected for T2 relaxation. The T2 measurements in 
five patients were performed by use of a multiecho point-resolved spectroscopic 
sequence (TE, 35, 65, 95, 125, and 155 ms). Measured T2 values appeared to be 
stable in this subset: T2water, 69.3 ms (SD, 2.3 ms); T2fat, 59.5 ms (SD, 5.0 ms). 
These measurements were used for calculating the percentage hepatic fat content 
according to Szczepaniak et al. [27]. 
 
Surgical Technique 
Laparoscopic Roux-en-Y gastric bypass surgery was performed by two 
experienced bariatric surgeons (10 and 15 years of experience). During surgery, the 
gastric volume was reduced by stapling off a 30-mL proximal gastric pouch and 
connecting the antecolic alimentary limb in a gastroenterostomy. The 
biliopancreatic limb with a length of 45–50 cm from the ligament of Treitz was 
connected to this alimentary limb at a distance of 100–150 cm as an 
enteroenterostomy. This procedure resulted in a bypass of the distal stomach, 
duodenum, and proximal part of the jejunum. The surgeon chose the alimentary 
limb length on the basis of the patient’s BMI. Patients with a BMI greater than 35 
received a 100- cm limb, and patients with a BMI greater than 50 received a 150-
cm limb for greater weight reduction. During surgery laparoscopic liver biopsy was 
performed for histopathologic assessment of NAFLD. 
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Liver Biopsy and Histopathologic Analysis 
Liver specimens were fixed in 10% buffered formalin for 24 hours, 
dehydrated, and embedded in paraffin. Sections 4 μm thick were treated with H and 
E and periodic acid–Schiff stain with and without diastase. Periodic acid–Schiff 
staining also was used to detect glycogen in tissues. Separate stainings for iron, 
copper, reticulin, and collagen fibers were performed. Sections were scored by an 
experienced hepatopathologist (20 years of experience and blinded to study results) 
for macrovesicular steatosis grade and localization, presence of microvesicular 
steatosis, inflammation, fibrosis, and liver cell injury according to the NASH 
Clinical Research Network scoring system defined by Kleiner et al. [28]. 
Percentage of macrovesicular steatosis was graded as follows: none (0–5%), mild 
(5–33%), moderate (33–66%), and severe (> 66%). Macrovesicular steatosis was 
assessed as percentage of hepatocytes in the microscopic field containing a lipid 
vacuole larger than the diameter of the nucleus and displacing the nucleus. To 
assess the severity of NAFLD (presence of progressive disease, NASH), the 
NAFLD activity score was calculated [28]. The NAFLD activity score is a 
histologic scoring system that represents the sum of scores for macrovesicular 
steatosis, lobular and portal inflammation, fibrosis, and ballooning. This score 
ranges from 0 to 8. NAFLD activity scores of 0–2 are considered not diagnostic of 
NASH; 3 and 4, borderline for NASH; and 5–8, diagnostic of NASH. 
 
Statistical Analysis 
Differences between dependent groups were assessed with the 
nonparametric Wilcoxon signed rank test. Differences between independent groups 
were assessed with nonparametric Mann-Whitney analysis. Correlations between 
hepatic fat content determined with 1H-MRS and clinical and histopathologic 
results (percentage macrovesicular steatosis) before surgery were assessed with 
nonparametric Spearman correlation coefficient. We also performed receiver 
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operator characteristic (ROC) curve analysis to determine the best cutoff value of 
1-T 1H-MRS for predicting the presence of hepatic steatosis. The best cutoff value 
was determined with respect to balancing the best sensitivity with the lowest false-
positive rate. Performance statistics (total accuracy, sensitivity, specificity, positive 
predictive value, negative predictive value) with 95% CI were calculated. For 
statistical analyses, p < 0.05 was considered significant. Post hoc Bonferroni 
correction was used for multiple comparisons. Statistical software (SPSS version 
16.0, SPSS) was used for analysis. 
 
Results 
 
Seventy-two patients were invited to participate in this study. Forty 
patients gave written informed consent, and 38 patients (seven men [18.4%], 31 
women [81.6%]; median age, 45.5 years; range, 22–63 years; median BMI, 47.7; 
range, 40.0–63.9; median waist circumference, 144.0 cm; range, 123–175 cm) were 
included. The median WHR was 1.16 (range, 1.03–1.17) for the men and 0.97 
(range, 0.84–1.17) for the women. Twelve of 38 patients (32%) had a history of 
diabetes. Two patients were excluded: one because of technical failure of the MRI 
system and one who was lost to follow-up 3 months after surgery. No patients were 
excluded for excessive alcohol use.  
Table 1 shows the median change in clinical evaluations before and after 
laparoscopic Roux-en-Y gastric bypass surgery. Compared with baseline weight, 
the median weight loss was 24.0 kg 3 months after surgery (p < 0.001). After 
surgery patients had significant improvement in cardiovascular risk factors: BMI (p 
< 0.001) and WHR (p = 0.002) decreased. When considered, features of metabolic 
syndrome insulin resistance exhibited significant median change (p < 0.001). 
Before surgery, 33 of 38 patients (87%) had insulin resistance. Three months after 
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surgery, only 10 of 38 patients (26%) had insulin resistance, defined as a HOMA 
score greater than 2.5. In a comparison of the values for diabetic and nondiabetic 
patients before surgery, no significant differences were found, except in plasma 
glucose (p = 0.005) and insulin resistance (p = 0.05). 
 
Table 1. Changes in Patient Characteristics 3 Months After Laparoscopic Roux-en-
Y Gastric Bypass Surgery 
 Change  
Parameter  Median Range p 
Weight (kg) 24 13.3 to 38.5 <0.001 
    Men  27.5 24.0 to 38.5 <0.001 
    Woman  22.2 13.3 to 32.5 <0.001 
Body Mass Index 8.5 4.7 to 13.2 <0.001 
    Men  9.4 7.4 to 13.2 0.018 
    Woman  8.5 4.7 to 12.4 <0.001 
Waist-to-hip ratio 0.03 -0.08 to 0.26 0.002 
    Men  0.03 -0.03 to 0.17 0.128 
    Woman  0.04 -0.08 to 0.26 0.007 
Homeostasis model assessment of insulin resistance 3.4 0.2 to 31.9 <0.001 
    Men  5.9 0.7 to 31.9 0.028 
    Woman  3.2 0.2 to 19.8 <0.001 
Hepatic fat content (% ) 2.7 -7.5 to 27.2 <0.001 
    Men  7.1 2.6 to 27.2 0.028 
    Woman  2.1 -7.5 to 14.1 0.001 
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operator characteristic (ROC) curve analysis to determine the best cutoff value of 
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predictive value, negative predictive value) with 95% CI were calculated. For 
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surgery, only 10 of 38 patients (26%) had insulin resistance, defined as a HOMA 
score greater than 2.5. In a comparison of the values for diabetic and nondiabetic 
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Liver Histopathology 
Histopathologic assessment of liver specimens showed hepatic steatosis (> 
5% macrovesicular steatosis) in 22 of 36 of the patients (61.1%). Ten of these 
patients (27.8%) had mild macrovesicular steatosis (5–33%), 10 had moderate 
steatosis (33–66%), and two (5.6%) had severe steatosis (> 66%). Microvesicular 
steatosis was found in six of the 36 patients (16.7%). Other histopathologic 
findings are shown in Table 2. No patients had abnormal accumulation of iron in 
the liver, and therefore hemochromatosis or hemosiderosis could be excluded from 
analysis. For logistic reasons, two liver biopsy samples could not be evaluated. An 
NAFLD activity score of 2 or less was present in 14 of the 36 patients (38.9%), 3–4 
in 10 patients (27.8%), and 4 or greater in 12 patients (33.3%). The median 
NAFLD score at histopathologic examination was 3.0. 
 
1-T 1H–MR Spectroscopic Assessment 
MRS measurements were successful in all 38 patients. No claustrophobia 
was reported. The interval between the first 1H-MRS assessment and surgery was 
7.8 days. Before Roux-en-Y gastric bypass surgery, the median hepatic fat content 
measured with 1-T 1HMRS was 5.8% (range, 0.4–30.5%). Three months after 
surgery, the median hepatic fat content had decreased significantly to 3.1% (range, 
0.1–21.4%; p < 0.001). The median hepatic fat content in diabetic patients was not 
significantly different from that in nondiabetic patients before (p = 0.107) or after 
(p = 0.983) surgery. 
For the 5% upper limit of normal histopathologic macrovesicular steatosis 
threshold value, diagnostic accuracy was determined for 1H-MRS. We performed 
ROC curve fitting for 1H-MRS (area under ROC curve, 0.91) (Figure 2). From the 
ROC curves we found a cutoff value for 1H-MRS of 5.7% hepatic fat. This cutoff 
value was used to calculate diagnostic accuracy. The sensitivity was 85% (17/20); 
specificity, 94% (15/16); positive predictive value, 94% (17/18); negative 
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predictive value, 83% (15/18); and total accuracy, 89% (32/36). Before surgery 20 
of 38 patients (53%) had hepatic steatosis defined by the calculated 1H-MRS cutoff 
of 5.7% hepatic fat content. After Roux-en-Y gastric bypass surgery, the 
prevalence of hepatic steatosis decreased to 32% (12/38). Moreover, a decrease in 
hepatic steatosis was seen in 32 of 38 (84%) patients after surgery. 
 
Figure 2. Receiver operating characteristic curve shows diagnostic accuracy of 1-T 
1H MR spectroscopy in detection of hepatic steatosis in morbidly obese patients. 
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predictive value, 83% (15/18); and total accuracy, 89% (32/36). Before surgery 20 
of 38 patients (53%) had hepatic steatosis defined by the calculated 1H-MRS cutoff 
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Table 2. Histopathologic Assessment According to Nonalcoholic Steatohepatitis 
(NASH) Clinical Research Network Scoring System 
Finding Score or Code No. of Patients (n=36) 
Steatosis grade  
    <5 0 14 (38.9) 
    5-33 1 10 (27.8) 
    33-66 2 10 (27.8) 
    >66 3 2 (5.6) 
Location  
    Zone 3 0 9 (25.0) 
    Zone 1 1 16 (44.5) 
    A zonal 2 8 (22.2) 
    Panacinar 3 3 (8.3) 
Microvasculair steatosis  
    Present 1 6 (16.6) 
    Not present 0 30 (83.3) 
Fibrosis stage  
    None 0 30 (83.3) 
    Perisinusoidal, periportal 1 4 (11.1) 
    Mild, zone 3, perisinusodal 1a 0 (0.0) 
    Moderate, zone 3 , perisinusodal 1b 0 (0.0) 
    Portal, periportal 1c 0 (0.0) 
    Perisinusoidal and periportal/portal 2 1 (2.8) 
    Bridging fibrosis 3 1 (2.8) 
    Cirrhosis 4 0 (0.0) 
Inflammation  
    None 0 30 (83.3) 
    <2 1 4 (11.1) 
    2-4 2 2 (5.6) 
    >4 3 0 (0.0) 
Microgranuloma  
    Present 1 1 (2.8) 
    Not present 0 35 (97.2) 
Lipogranuloma  
    Present 1 8 (22.2) 
    Not present 0 28 (77.8) 
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Finding Score or Code No. of Patients (n=36) 
Liver cell injury  
 Baloning 
    Present 1 4 (11.1) 
    Not present 0 32 (88.9) 
Acidophil bodies  
    Present 1 1 (2.8) 
    Not present 0 35 (97.2) 
Pigmented macrophages  
    Present 1 5 (13.9) 
    Not present 0 31 (85.1) 
Megamitochondria   
    Present 1 0 (0.0) 
    Not present 0 36 (100) 
Other findings  
  Mallory Hyaline bodies 
    Present 1 1 (2.8) 
    Not present 0 35 (97.2) 
  Glycogenated nuclei  
    Present 1 10 (27.8) 
    Not present 0 26 (72.2) 
Diagnostic classification   
    No NASH 0 32 (88.9) 
    Borderline NASH 1 3 (8.3) 
    NASH 2 1 (2.8) 
Nonalcoholic fatty liver disease activity score  
    0-2  14 (38.8) 
    3-4 10 (27.8) 
    4-8 12 (33.3) 
 
Marginal, albeit significant, correlations between WHR (r = 0.48, p = 
0.003), HOMA of insulin resistance ( r = 0.45, p = 0.009), and 1H-MRS 
measurements of hepatic fat content were found (Table 3). Furthermore, 1HMRS 
findings correlated significantly with the histopathologic assessment of 
macrovesicular hepatic steatosis (r = 0.85, p < 0.001) (Figure 3) and NAFLD 
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Marginal, albeit significant, correlations between WHR (r = 0.48, p = 
0.003), HOMA of insulin resistance ( r = 0.45, p = 0.009), and 1H-MRS 
measurements of hepatic fat content were found (Table 3). Furthermore, 1HMRS 
findings correlated significantly with the histopathologic assessment of 
macrovesicular hepatic steatosis (r = 0.85, p < 0.001) (Figure 3) and NAFLD 
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activity score (r = 0.76, p < 0.001) (Figure 4). Moreover, in patients with 
histopathologically proven NASH, hepatic fat content before surgery was 
significantly greater than in patients with NAFLD but not NASH (p < 0.001) 
(Figure 5). 
Figure 6 shows the utility of 1H-MRS in differentiating grades of steatosis 
defined histopathologically. With 1H-MRS measurement of hepatic fat content, it 
was possible to discriminate no steatosis (3.5%) from mild steatosis (6.9%) (p = 
0.011) and mild from moderate steatosis (22.7%) (p < 0.001). There also was a 
trend to differentiation of moderate from severe steatosis (30.0%) (p = 0.021), but 
this finding was not significant after Bonferroni correction. 
 
Table 3. Correlations 
Parameter Compared With 1H MR Spectoscopic 
Hepatic Fat Content 
Spearman Correlation  
Coefficient 
r p 
Waist-to-hip ratio 0.48 0.003 
Homeostasis model assessment of insulin resistance 0.45 <0.001 
Macrovesicular steatosis 0.85 <0.001 
Nonalcoholic fatty liver disease activity score 0.76 <0.001 
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Figure 3. Scatterplot shows correlation (r = 0.85, p <0.001) between hepatic fat 
content determined with 1H MR spectroscopy (MRS) and histopathologic steatosis 
grade (1, < 5%; 2, 5–33%; 3, 33–66%; 4, > 66% hepatic fat). 
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Figure 3. Scatterplot shows correlation (r = 0.85, p <0.001) between hepatic fat 
content determined with 1H MR spectroscopy (MRS) and histopathologic steatosis 
grade (1, < 5%; 2, 5–33%; 3, 33–66%; 4, > 66% hepatic fat). 
  
338
Chapter 4
 
 
 326 
Figure 4. Scatterplot shows correlation (r = 0.76, p < 0.001) between hepatic fat 
content determined with 1H MR spectroscopy (MRS) and histopathologic non-
alcoholic fatty liver disease (NAFLD) activity score 
 
 
 
 
 327 
Figure 5. Box plot shows hepatic fat content determined with 1H MR spectroscopy 
(MRS) in relation to non-alcoholic fatty liver disease activity score of 0–2, no non-
alcoholic steatohepatitis (NASH); 2–4, borderline NASH; and > 4, NASH. 
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Figure 6. Box plot shows hepatic fat content determined with 1H MR spectroscopy 
of morbidly obese patients across histopathologic steatosis grades. 
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Discussion 
 
Using open-unit 1H-MRS with histopathologic confirmation by 
intraoperative laparoscopic liver biopsy, we investigated assessment of hepatic 
steatosis in morbidly obese patients before and after laparoscopic Roux-en-Y 
gastric bypass surgery. Our results show that with an open clinical 1-T MRI 
system, hepatic steatosis in morbidly obese patients can be accurately measured 
with 1H-MRS.  
After laparoscopic Roux-en-Y gastric bypass surgery, the patients had a 
significant decrease in hepatic steatosis. With 1-T 1HMRS we were able to 
differentiate clinically relevant grades of macrovesicular steatosis (none, mild, 
moderate, and severe). This capability is important for monitoring the treatment 
response of morbidly obese patients. Furthermore, the patients had significant 
improvement in almost all investigated clinical parameters after surgery. The 
median change in BMI was 8.5 in 3 months, and the prevalence of insulin 
resistance decreased from 87% to 26%. Our study also showed that hepatic fat 
content was higher in patients with an NAFLD activity score considered diagnost ic 
of NASH.  
To our knowledge, this study is the first noninvasive assessment of hepatic 
steatosis in morbidly obese patients before and after laparoscopic Roux-en-Y 
gastric bypass surgery performed with 1H-MRS on an open 1-T MRI system with 
histopathologic confirmation. Because of the increasing prevalence of obesity and 
the subsequent increasing prevalence of NAFLD, the use of open MRI systems 
may be an attractive alternative in the care of morbidly obese patients. Ultrasound 
and liver biopsy are limited in morbidly obese patients. CT is inaccurate for 
Semiquantitative diagnosis when macrovesicular steatosis is less than 30% [29]. 
The sensitivity and specificity also indicate insufficient diagnostic performance 
[14]. The use of CT also is hampered by exposure to ionizing radiation. The use of 
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standard cylindric MRI systems is limited by an aperture diameter of 60 cm and 
even 55 cm in some 3-T MRI systems. The aperture is decreased by the thickness 
of the table and coils [21], leading to a considerably reduced maximum allowed 
patient circumference in standard cylindric MRI systems. In our study, the median 
waist circumference was 144 cm, and the smallest circumference was 123 cm. Not 
every patient would have fit in a standard cylindric MRI system. However, large-
bore MRI systems have become available for clinical use, allowing more obese 
patients to fit in cylindric MRI systems and offering higher magnetic field strengths 
[21]. 
In four earlier studies [17–20], 1H-MRS of hepatic steatosis in bariatric 
surgery patients was assessed. In three studies, laparoscopic adjustable gastric 
banding and in one study Roux-en-Y gastric bypass surgery was performed. The 
Roux-en-Y bypass study included only seven patients, and the imaging findings 
were not compared with the histopathologic results. The most important 
conclusions that can be drawn from the four studies are as follows: in the early 
phase after Roux-en-Y gastric bypass surgery, rapid lipid mobilization from 
adipose depots to the liver occurs; no significant improvement in insulin resistance 
(HOMA) is found 3 months after gastric banding surgery; and 1H-MRS– assessed 
hepatic steatosis correlates well with the serum γ–glutamyl transpeptidase result. 
Our study did show significant improvement in insulin resistance (HOMA) 3 
months after surgery. This finding can be explained by the far greater weight loss 
accomplished in the 3 months after gastric bypass surgery (24.0 kg) than after 
gastric banding surgery (9.8 kg). In one study [20], 1H-MRS findings were 
compared with histopathologic results. The authors found a correlation of r = 0.77 
(p < 0.001). This finding is comparable to our results (r = 0.86, p < 0.001). The 
four previous studies were performed with standard 60-cmdiameter cylindric MRI 
systems and included only women who had a lower BMI (39–43.7) before surgery 
and a substantially smaller waist circumference (111.6–117.3 cm) than in our 
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study. These patients might have been selected to fit in the cylindric MRI systems. 
In our study, all included patients fit in the open MRI systems, and a large 
proportion of the patients had a waist circumference not suited to a 60-cm standard 
cylindric MRI system. 
This study had limitations. The sample was relatively small with 38 
patients, and only two of the patients had severe steatosis. Intraobserver and 
interobserver variability and reproducibility were not investigated because they 
were not the primary objective of the study. However, 1H-MRS measurements of 
hepatic fat content have been reproducible in previous research [16]. The interval 
between the first 1H-MRS measurements and surgery was 7.8 days. We believe 
this short interval is acceptable and did not influence our study results. In this 
study, 1H-MRS was performed during free breathing. This factor is a potential 
limitation because the volume in the liver examined with 1H-MRS is blurred by 2–
3 cm owing to respiratory excursion. We used an open MRI system for 
spectroscopy of the liver, and imaging with open systems is hampered by 
decreased image quality due to lower magnetic field strength and signal-to-noise 
ratios. Newer large-bore MRI systems allow MR spectroscopy of obese patients 
and operate at high magnetic field strengths of 1.5 T and even 3T. Despite the 
disadvantages, 1H-MRS was performed successfully on all patients.  
Another limitation was that we corrected for T2 relaxation by using fixed 
T2 values from a subset of 10 patients, ignoring the variability in T2 relaxation 
values between individuals. To assess the heterogeneity of hepatic fat, multiple-
voxel measurements or spectroscopic imaging of the whole liver is preferred. 
However, these techniques are time-consuming and pose high demands on 
shimming of the volume of interest. This step is unpractical in daily clinical 
practice and probably impossible with an open 1-T MRI system. Still, the liver 
volume evaluated with 1H-MRS is approximately 400 times larger than the amount 
of liver tissue evaluated by biopsy.  
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spectroscopy of the liver, and imaging with open systems is hampered by 
decreased image quality due to lower magnetic field strength and signal-to-noise 
ratios. Newer large-bore MRI systems allow MR spectroscopy of obese patients 
and operate at high magnetic field strengths of 1.5 T and even 3T. Despite the 
disadvantages, 1H-MRS was performed successfully on all patients.  
Another limitation was that we corrected for T2 relaxation by using fixed 
T2 values from a subset of 10 patients, ignoring the variability in T2 relaxation 
values between individuals. To assess the heterogeneity of hepatic fat, multiple-
voxel measurements or spectroscopic imaging of the whole liver is preferred. 
However, these techniques are time-consuming and pose high demands on 
shimming of the volume of interest. This step is unpractical in daily clinical 
practice and probably impossible with an open 1-T MRI system. Still, the liver 
volume evaluated with 1H-MRS is approximately 400 times larger than the amount 
of liver tissue evaluated by biopsy.  
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Another restriction was that we did not perform the imaging measurements 
at exactly the same location in the liver that was used for histopathologic 
assessment. Because of the heterogeneity of fat in the liver, this limitation might 
have affected the results reported. The difference in prevalence of hepatic steatosis 
with respect to histopathologic findings (61.1%) and literature values (85– 95%) 
[2, 3] can be explained by sampling error. The liver biopsy results in this study 
seem to be underestimates of the prevalence of hepatic steatosis. Finally, only 
hepatic fat content can be measured with 1H-MRS. Although hepatic fat content is 
higher in patients with higher NAFLD activity scores, 1H-MRS does not generate 
information about inflammation or fibrosis and therefore cannot be used to 
differentiate simple steatosis and more severe NASH in NAFLD.  
 
Conclusion 
 
Changes in hepatic fat content before and after laparoscopic Roux-en-Y 
gastric bypass surgery can be measured noninvasively with 1H-MRS on a clinical 
open 1-T MRI system. The 1H-MRS measurements were accurate and correlated 
well with the histopathologic findings in the liver and relevant clinical parameters 
associated with hepatic steatosis. The 1H-MRS measurements of hepatic steatosis 
showed significant improvement 3 months after laparoscopic Roux-en-Y gastric 
bypass surgery. Furthermore, various severity grades of hepatic steatosis were 
differentiated with 1H-MRS. We therefore conclude that 1H-MRS assessment of 
hepatic steatosis in morbidly obese patients is feasible on an open 1-T MRI system. 
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5.1 Summary  
 
 The purpose of the studies presented in this thesis is to provide more 
insight into the results in the short and long term of bariatric surgery.  The focus of 
the various studies is  
 
 - surgical results : complications and impact of surgery on body weight,  
   but also 
 - the impact of operations on vitamin and mineral levels in the blood and       
   its consequences and 
 - diseases caused by obesity and its consequences. 
 
To present these results this thesis is divided into three parts, described in chapters 
2, 3and 4. 
 
 In Chapter 2 the results of different types of bariatric surgeries are 
described. In the nineties, gastric band surgery was the most performed bariatric 
procedure in Europe for the treatment of morbid obesity. The first patients who 
were treated with a gastric band in Rijnstate  Hospital returned after a mean 10 and 
14 years. For a large number of these patients, the long term results were 
disappointing (2.1). A portion of these disappointing results was due to technical 
problems with the first models of gastric bands used. In order to better understand 
these results a second study was started with one of the latest types of gastric band. 
Even though the length of the follow-up was shorter, the same trend was observed 
as with the earlier types of gastric bands (2.2). In Rijnstate Hospital we examined 
the outcomes of placement of the port-a-cath on the pectoralis muscle fascia. 
Compared with data from the literature, fewer complaints and problems caused by 
placement at different body sites were found (2.6). Many patients who were 
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implanted with a gastric band had to deal with complications ranging from 
migration of the band to weight regain, despite good positioning of the band. To 
treat these patients a number of successful follow-up operations have been 
developed. One of these is the Roux -en-Y Gastric Bypass (RYGB), in which the 
gastric band is removed and a small stomach (pouch) is created, resulting in a 
quick 'fullness' sensation. Part of the small intestine is also rerouted and 
reconnected to this little pouch. This rearrangement results in a lower intake and 
less contact between the food and the intestine. This in turn results in less calorie 
uptake from the small intestine into the blood. The outcomes of this second 
operation were good in comparison with the previously placed gastric band. 
Fortunately, there were few complications with this more complex operation, but 
we found that patients who experienced inadequate weight loss after gastric 
banding, even after this second operation, also presented a poor outcome in the 
long term (2.3). In particular, when patients experienced a serious complication 
after gastric band placement such as migration, a portion of these patients refused a 
second bariatric surgery. These patients were still followed in time. They all 
experienced weight regain and half of them requested a second operation in the 
end. In the other half, weight slowly rose to the level before the gastric band (2.4). 
Based on these experiences, we therefore advise replacing a failed gastric band 
with one of the other bariatric procedures. When migration of the gastric band to 
the cavity of the gastrointestinal tract occurred, it was assessed whether removal 
was possible via the mouth (gastroscopic). In many patients this is a good 
alternative to avoid the possible complications of a re-operation. One disadvantage 
of the method, however, is that substantial bleeding may occur. Experience has 
shown that, especially when patients report bleeding due to a migrated band, it is 
unwise to remove it gastroscopically (2.5).  
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Chapter 3 discusses the most common complication of bariatric surgery: 
vitamin and mineral deficiencies. Patients often are on a wrong diet already, 
leading to these deficits preoperatively. In general it can be stated that the higher 
the BMI, the greater the chance of deficiencies. It is therefore very important to 
detect these deficiencies prior to bariatric surgery and treat them accordingly. 
Because patients often eat less after bariatric surgery and their uptake capacity for 
nutrients is often reduced, correcting deficit after surgery is more difficult. One of 
the many consequences of vitamin and iron deficiency is anaemia. A large 
proportion of the patients experience anaemia in the first year after surgery (3.1). 
The literature data suggest that the Gastric Sleeve (GS) operation, in comparison 
with more malabsorptive bariatric procedures like the RYGB, shows fewer 
deficiencies. This theory probably emerged in the past because only a portion of 
the stomach is removed and the rest of the gastrointestinal tract remains intact. 
When treating our patients with a GS, who on average had a high BMI, this proved 
not to be the case and we found numerous deficiencies in iron, vitamin B12 and 
vitamin D. In addition, there are many GS patients with an excess of vitamins A 
and B6. The latter is probably due to the use of standard multivitamins, which 
appear to be excessive for GS patients even though they contain only 100% of the 
RDA for vitamins A and B6 (3.2).  To examine whether these problems are already 
apparent in the first year postoperative in patients with a lower BMI prior to 
surgery, a follow-up study was conducted in collaboration with the Catherina 
Hospital in Eindhoven. In this group of patients the same findings were found, 
although to a somewhat lesser extent, already in the first year after surgery. These 
findings demonstrate that not only routine supplementation but also careful follow 
up of these patients is very important in order to detect deficiencies at an early 
stage (3.3). The most common deficiency in patients with morbid obesity is 
deficiency in vitamin D. This has a negative impact on calcium metabolism and, 
thus, bone density. This is partially due to poor nutrition, as previously mentioned, 
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and possibly also due to the fact that patients with morbid obesity are less exposed 
to sunlight. We investigated how and how much vitamin D (cholecalciferol) should 
be supplemented to correct deficiencies in vitamin D. To this end a formula (Dr De 
Boer et al) for vitamin D supplementation (cholecalciferol) was validated in a 
group of obese patients before and after RYGB (3.4). 
Now it can easily be calculated how much cholecalciferol a patient should 
receive in order to obtain good vitamin D serum levels. It has been found that 
patients often report altered bowel habits after RYGB. We investigated whether 
there was a relationship between these changes and calcium metabolism. It was 
found that patients with a soft and frequent stool experienced higher parathyroid 
hormone (PTH) levels (3.5). A second prospective study on this subject is currently 
being conducted. Given the very frequent deficiencies noted in our clinic after 
bariatric surgery, the  known literature was researched on this topic. Partially based 
on our own previous research and on this literature, the optimal composition of a 
multivitamin (FFM Forte™) was developed. In order to investigate whether this 
optimal multivitamin resulted in fewer deficiencies, a prospective, double-blind 
randomized controlled study was conducted. After just one year the results showed 
that administration of this multivitamin after RYGB surgery resulted in an almost 
complete disappearance of the main deficits. There was, however, an adjustment 
needed in the doses of vitamin A, B1 and B6 (3.6), since most of the patients 
developed a hypervitaminosis for these vitamins. Currently three prospective 
studies on the effects of a multivitamin after GS, RYGB, Scopinaro and Duodenal 
Switch surgery are being conducted. 
 
 Chapter 4 is devoted entirely to the co-morbidities that frequently occur in 
morbidly obese patients. One of these co-morbidities is hypogonadal 
hypogonadism (HH) in morbidly obese men. HH is caused by testosterone being 
converted into oestrogen by the abundant adipocytes. This leads to changes in 
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physical characteristics such as reduced beard growth, erectile dysfunction and 
decreased libido. An earlier article on this subject has already been published from 
Rijnstate Hospital. To investigate whether HH improved or even resolved after 
bariatric surgery, a group of men were followed over time. In many of the patients 
HH resolved completely (4.1). The effect of bariatric surgery on type 2 diabetes 
mellitus (T2DM) has perhaps been published on more than any other co-morbidity. 
In some patients bariatric surgery has virtually no effect on T2DM. In a group of 
patients with T2DM it was therefore examined whether fasting C - peptide in the 
blood could predict the effect of surgery on T2DM outcome. C - peptide is a good 
tool for estimating the function of the pancreas. In a group of T2DM patients 
undergoing RYGB, C - peptide content was measured both pre- and post-
operatively. The study found that when C - peptide levels in the blood before 
surgery were less than 1.0 nmol /L, the RYGB surgery did not resolve the T2DM 
(4.2). Determining C-peptide preoperatively can therefore contribute to 
determining the outcome of T2DM. The last chapter is devoted to the effect of 
surgery on the fatty liver in morbidly obese patients. This study was designed by 
the University Medical Center of Utrecht. Fatty liver disease is common in the 
morbidly obese and is accompanied by enlargement of the liver. This can result in 
a more difficult operation because it is difficult to access. After surgery, with the 
decrease in body weight, the degree of fatty liver often decreases rapidly. The gold 
standard to demonstrate the degree of fatty liver disease is a liver biopsy. This is a 
painful procedure and there is a risk of bleeding after the puncture. MRI can also 
visualize the grade of fatty liver disease. In order to demonstrate the value of MRI 
compared to a liver biopsy for determining the effect of surgery on fatty liver 
disease, an MRI was performed before and after RYGB. A liver biopsy was also 
conducted during the operation. It was found that MR imaging as a non-invasive 
method is as good a measure as liver biopsy for determining the extent of fatty 
liver. 
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5.2 Samenvatting 
 
Bariatrische of metabole, chirurgie is de benaming voor de chirurgische 
ingrepen die uitgevoerd worden ter bestrijding van overgewicht. Het aantal 
bariatrische ingrepen dat wereldwijd wordt uitgevoerd is in de afgelopen jaren snel 
gestegen door de groei van het aantal patiënten met overgewicht. Naar schatting 
heeft momenteel één op de drie Amerikanen overgewicht of is obees, zoals het ook 
wel genoemd wordt. (Body Mass Index (BMI) > 30 kg/m2) In Nederland is dat 
inmiddels al opgelopen naar één op de tien. Deze toename heeft niet alleen 
gevolgen voor de gezondheidszorg, maar heeft ook grote economische 
consequenties. Door al deze gevolgen heeft de World Health Organization obesitas 
gekwalificeerd als een chronische ziekte. In veel gevallen is het niet het 
overgewicht zelf dat zorgt voor een verminderde kwaliteit en duur van leven maar 
de door overgewicht ontstane ziekten (co-morbiditeit), zoals diabetes mellitus type 
2 (DM2), hoge bloeddruk, hoog cholesterol, het slaap apnoe syndroom, hart- en 
vaatziekten, artrose en zelfs bepaalde soorten kanker, zoals borst- en darmkanker. 
Morbide obesitas (BMI > 40 kg/m2) kan bij jonge patiënten betekenen dat de 
levensverwachting met 20 jaar afneemt. 
Veel conservatieve behandelingen zoals diëten falen helaas op de lange 
termijn. Bariatrische chirurgie is een heel ingrijpende behandeling voor morbide 
obesitas, een laatste redmiddel,  maar is tot dusver de enige behandeling met een 
goed resultaat op lange termijn. Gezien de risico’s welke gepaard gaan met een 
operatie moet er een goede afweging gemaakt worden of deze risico’s opwegen 
tegen de te verwachten gunstige effecten. Om deze afweging te kunnen maken 
heeft de National Institute of Health een lijst opgesteld met criteria waar een 
patiënt met obesitas aan moet voldoen om in aanmerking te komen voor operatieve 
behandeling. Een belangrijk criterium is dat alle andere (conservatieve) 
behandelingen gefaald hebben. Een ander belangrijk en objectief criterium is de 
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patiënt met obesitas aan moet voldoen om in aanmerking te komen voor operatieve 
behandeling. Een belangrijk criterium is dat alle andere (conservatieve) 
behandelingen gefaald hebben. Een ander belangrijk en objectief criterium is de 
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mate van overgewicht, uitgedrukt in het de eerder genoemde BMI: (normale 
waarde: tussen de 20 en 24.9 kg/m2), 
 
                                       Gewicht (kg) 
BMI (kg/m2) =            ------------------------------------------ 
   Lengte (meter) x Lengte (meter) 
 
 Er is sprake van overgewicht bij een BMI tussen de 25 en 29.9 kg/m2, van 
obesitas bij een BMI tussen de 30 en 39.9 kg/m2 en van morbide obesitas bij een 
BMI boven de 40 kg/m2. 
Deze laatste groep komt op grond van de BMI direct in aanmerking voor 
bariatrische chirurgie. Wanneer de patiënt aan een, aan overgewicht gerelateerde, 
ziekte lijdt, komt deze al in aanmerking met een BMI vanaf 35 kg/m2. 
 
Het doel van de verrichte studies in dit proefschrift is inzicht geven in de 
resultaten van bariatrische chirurgie op de korte en lange termijn. De nadruk van de 
verschillende onderzoeken ligt op 
- de operatieresultaten: complicaties en effect van operatie op 
lichaamsgewicht, maar ook 
- het effect van de operaties op vitamine en mineralen gehaltes 
in het bloed en de gevolgen hiervan en op 
- de door overgewicht veroorzaakte ziekten en de gevolgen 
hiervan. 
Om deze resultaten overzichtelijk te presenteren is dit proefschrift verdeeld in drie 
delen, respectievelijk beschreven in de hoofdstukken 2, 3 en 4. 
 
 In hoofdstuk 2 wordt beschreven wat de resultaten zijn van verschillende 
typen bariatrische ingrepen. In de jaren negentig was het aanleggen van de 
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maagband de meest verrichte ingreep in Europa voor de behandeling van morbide 
obesitas. De eerste patiënten die in het Rijnstate Ziekenhuis behandeld werden met 
een maagband zijn na 10 en 14  jaar weer terug gezien voor de beoordeling van het 
lange termijn resultaat. Bij een groot aantal van   deze patiënten bleek het resultaat 
niet goed te zijn (2.1). Een deel van deze matige resultaten kwam mogelijk door 
technische problemen met de eerste modellen maagbanden. Om deze aanname 
beter te begrijpen zijn ook de patiënten met één van de nieuwste types maagband 
gecontroleerd. Ook al was de lengte van de follow-up korter, dezelfde trend als bij 
de eerdere types maagbanden werd waargenomen (2.2). In het Rijnstate Ziekenhuis 
werd onderzocht of de plaatsing van de zgn. toegangspoort om de band van buiten 
af aan te prikken en te vullen, verband hield met de klachten na operatie. Hierbij 
bleek, in vergelijking met gegevens uit de literatuur, dat plaatsing onder de huid, op 
de borstspier (2.6) minder klachten en problemen veroorzaakte dan bij implantatie 
op andere plaatsen van het lichaam. Veel patiënten die een maagband 
geïmplanteerd  kregen hadden te kampen met complicaties variërend van migratie 
van de band tot gewichtstoename ondanks een goede positie van de band. Om deze 
patiënten alsnog succesvol te behandelen is een aantal vervolgoperaties 
ontwikkeld. Een daarvan is de Roux-en-Y Gastric Bypass (RYGB), waarbij in één 
operatie de maagband verwijderd wordt en een klein maagje gecreëerd wordt, 
waardoor snel een ‘vol gevoel’ ontstaat. Tevens wordt een deel van de dunne darm 
omgelegd en aangesloten op dat kleine maagje. Deze omlegging resulteert erin dat 
het contact tussen voedsel en darm over een veel  korter deel van de darm 
plaatsvindt en er dus veel minder splitsingsproducten van het voedsel via de darm 
in het bloed wordt opgenomen Bij deze patiënten is in kaart gebracht wat de 
resultaten van deze tweede operatie was, in vergeleken met de eerder geplaatste 
maagband. Er waren gelukkig weinig complicaties van deze meer complexe 
operatie, maar wel bleek dat patiënten die onvoldoende gewichtsverlies 
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mate van overgewicht, uitgedrukt in het de eerder genoemde BMI: (normale 
waarde: tussen de 20 en 24.9 kg/m2), 
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BMI (kg/m2) =            ------------------------------------------ 
   Lengte (meter) x Lengte (meter) 
 
 Er is sprake van overgewicht bij een BMI tussen de 25 en 29.9 kg/m2, van 
obesitas bij een BMI tussen de 30 en 39.9 kg/m2 en van morbide obesitas bij een 
BMI boven de 40 kg/m2. 
Deze laatste groep komt op grond van de BMI direct in aanmerking voor 
bariatrische chirurgie. Wanneer de patiënt aan een, aan overgewicht gerelateerde, 
ziekte lijdt, komt deze al in aanmerking met een BMI vanaf 35 kg/m2. 
 
Het doel van de verrichte studies in dit proefschrift is inzicht geven in de 
resultaten van bariatrische chirurgie op de korte en lange termijn. De nadruk van de 
verschillende onderzoeken ligt op 
- de operatieresultaten: complicaties en effect van operatie op 
lichaamsgewicht, maar ook 
- het effect van de operaties op vitamine en mineralen gehaltes 
in het bloed en de gevolgen hiervan en op 
- de door overgewicht veroorzaakte ziekten en de gevolgen 
hiervan. 
Om deze resultaten overzichtelijk te presenteren is dit proefschrift verdeeld in drie 
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maagband de meest verrichte ingreep in Europa voor de behandeling van morbide 
obesitas. De eerste patiënten die in het Rijnstate Ziekenhuis behandeld werden met 
een maagband zijn na 10 en 14  jaar weer terug gezien voor de beoordeling van het 
lange termijn resultaat. Bij een groot aantal van   deze patiënten bleek het resultaat 
niet goed te zijn (2.1). Een deel van deze matige resultaten kwam mogelijk door 
technische problemen met de eerste modellen maagbanden. Om deze aanname 
beter te begrijpen zijn ook de patiënten met één van de nieuwste types maagband 
gecontroleerd. Ook al was de lengte van de follow-up korter, dezelfde trend als bij 
de eerdere types maagbanden werd waargenomen (2.2). In het Rijnstate Ziekenhuis 
werd onderzocht of de plaatsing van de zgn. toegangspoort om de band van buiten 
af aan te prikken en te vullen, verband hield met de klachten na operatie. Hierbij 
bleek, in vergelijking met gegevens uit de literatuur, dat plaatsing onder de huid, op 
de borstspier (2.6) minder klachten en problemen veroorzaakte dan bij implantatie 
op andere plaatsen van het lichaam. Veel patiënten die een maagband 
geïmplanteerd  kregen hadden te kampen met complicaties variërend van migratie 
van de band tot gewichtstoename ondanks een goede positie van de band. Om deze 
patiënten alsnog succesvol te behandelen is een aantal vervolgoperaties 
ontwikkeld. Een daarvan is de Roux-en-Y Gastric Bypass (RYGB), waarbij in één 
operatie de maagband verwijderd wordt en een klein maagje gecreëerd wordt, 
waardoor snel een ‘vol gevoel’ ontstaat. Tevens wordt een deel van de dunne darm 
omgelegd en aangesloten op dat kleine maagje. Deze omlegging resulteert erin dat 
het contact tussen voedsel en darm over een veel  korter deel van de darm 
plaatsvindt en er dus veel minder splitsingsproducten van het voedsel via de darm 
in het bloed wordt opgenomen Bij deze patiënten is in kaart gebracht wat de 
resultaten van deze tweede operatie was, in vergeleken met de eerder geplaatste 
maagband. Er waren gelukkig weinig complicaties van deze meer complexe 
operatie, maar wel bleek dat patiënten die onvoldoende gewichtsverlies 
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ondervonden na de maagband, ook na deze operatie op lange termijn ook een 
minder goed resultaat boekten (2.3). 
 Met name wanneer patiënten na plaatsing van een maagband ernstige 
complicaties ondervinden, zoals migratie van de maagband, ziet een deel van deze 
patiënten erg op tegen een tweede bariatrische operatie, vaak omdat dan definitief 
het maag-darmstelsel wordt aangepast. Deze patiënten, die afzagen van een tweede 
operatie, zijn gevolgd in de tijd. Hierbij bleken ze allemaal een geleidelijke 
gewichtstoename te ervaren. De helft wenste daarna alsnog een tweede ingreep, bij 
de andere helft steeg het gewicht langzaam weer tot het niveau van voor het 
aanleggen van de maagband (2.4). Op grond van deze ervaringen adviseren we dan 
ook om bij het verwijderen van een maagband, deze, tijdens dezelfde operatie, te 
vervangen door een van de andere bariatrische ingrepen. Bij migratie van de 
maagband naar de holte van het maagdarmkanaal wordt beoordeeld of deze niet via 
de mond, ofwel gastroscopisch, kan worden verwijderd om zo een lastige 
hernieuwde operatie te vermijden. Bij veel patiënten is dit een goed alternatief om 
complicaties van een heroperatie te omzeilen en het herstel van de maag de tijd te 
geven. Een bezwaar van de methode is echter dat forse bloedingen kunnen 
optreden. De ervaring heeft geleerd dat wanneer patiënten zich al melden met een 
bloeding door de gemigreerde band, het niet verstandig is om deze gastroscopisch 
te verwijderen maar dit operatief te doen om beter op een eventuele bloeding te zijn 
voorbereid en dus ook beter te kunnen behandelen (2.5). 
 
 In Hoofdstuk 3 wordt ingegaan op de meest voorkomende complicatie van 
de bariatrische chirurgie, namelijk tekorten aan vitamine en mineralen en de 
mogelijke behandeling ervan. Patiënten hebben vaak voor een operatie een 
eenzijdig eetpatroon, dat leidt tot deze tekorten. Gemiddeld geldt ook dat hoe hoger 
de BMI is, hoe groter de kans op deficiënties, al voor de ingreep. Het is dus zeer 
belangrijk om deze voor een operatie al op te sporen en te behandelen. Doordat 
 
 
 347 
patiënten na een bariatrische operatie vaak minder kunnen eten en bij een groot 
deel van de operaties opname van voedingsstoffen vermindert, is het corrigeren van 
tekorten na operatie lastiger. Een van de belangrijkste gevolgen van vitamine- en 
ijzertekorten is bloedarmoede, ofwel anemie. Een groot deel van de patiënten blijkt 
al in het eerste jaar na operatie een anemie te hebben, eerder is dan tot nu toe is 
beschreven in de literatuur. (3.1). 
De literatuurgegevens suggereren dat de buismaag, ook wel Gastric Sleeve 
(GS) operatie genoemd, in vergelijking met uitgebreidere operaties als de RYGB, 
tot minder deficiënties aanleiding is. Dit komt waarschijnlijk doordat alleen een 
deel van de maag verwijderd wordt en de rest van het maagdarmkanaal intact blijft. 
Bij de door ons behandelde patiënten, echter, die gemiddeld een hoge BMI hadden, 
bleek dit niet het geval te zijn en bleek er wel degelijk veelvuldig sprake te zijn van 
tekorten aan ijzer, vitamine B12, vitamine D. Daarnaast werd er bij veel patiënten 
een te hoge concentratie aan vitamine A en vitamine B6 gevonden. Dit laatste is 
mogelijk het gevolg van het gebruik van standaard multivitaminen, waarin een 
overmaat aan deze vitaminen lijkt te zitten (3.2). 
 Om te onderzoeken of deze bevindingen ook al waarneembaar waren in het 
eerste jaar na operatie bij patiënten met een lagere BMI voor operatie, werd in 
samenwerking met het Catherina Ziekenhuis Eindhoven een vervolgstudie verricht. 
Ook bij deze groep patiënten werden, zij het in mindere mate, dezelfde 
bevindingen gedaan al in het eerste jaar na operatie. Deze bevindingen tonen aan  
dat niet alleen routinematige suppletie, maar ook het zorgvuldig nacontroleren van 
de patiënten die een GS operatie hebben ondergaan, heel belangrijk is (3.3). 
 Het meest voorkomende tekort  bij patiënten  met morbide obesitas  is een 
tekort aan vitamine D. Dit  is van negatieve invloed op de calciumhuishouding en 
daarmee op de stevigheid van bot. Dit is op zichelf weer het gevolg van de al 
eerder genoemde slechte voedselopname en wordt mogelijk nog verergerd doordat 
patiënten met morbide obesitas zich minder blootstellen aan zonlicht, waardoor ze 
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ondervonden na de maagband, ook na deze operatie op lange termijn ook een 
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geven. Een bezwaar van de methode is echter dat forse bloedingen kunnen 
optreden. De ervaring heeft geleerd dat wanneer patiënten zich al melden met een 
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voorbereid en dus ook beter te kunnen behandelen (2.5). 
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patiënten na een bariatrische operatie vaak minder kunnen eten en bij een groot 
deel van de operaties opname van voedingsstoffen vermindert, is het corrigeren van 
tekorten na operatie lastiger. Een van de belangrijkste gevolgen van vitamine- en 
ijzertekorten is bloedarmoede, ofwel anemie. Een groot deel van de patiënten blijkt 
al in het eerste jaar na operatie een anemie te hebben, eerder is dan tot nu toe is 
beschreven in de literatuur. (3.1). 
De literatuurgegevens suggereren dat de buismaag, ook wel Gastric Sleeve 
(GS) operatie genoemd, in vergelijking met uitgebreidere operaties als de RYGB, 
tot minder deficiënties aanleiding is. Dit komt waarschijnlijk doordat alleen een 
deel van de maag verwijderd wordt en de rest van het maagdarmkanaal intact blijft. 
Bij de door ons behandelde patiënten, echter, die gemiddeld een hoge BMI hadden, 
bleek dit niet het geval te zijn en bleek er wel degelijk veelvuldig sprake te zijn van 
tekorten aan ijzer, vitamine B12, vitamine D. Daarnaast werd er bij veel patiënten 
een te hoge concentratie aan vitamine A en vitamine B6 gevonden. Dit laatste is 
mogelijk het gevolg van het gebruik van standaard multivitaminen, waarin een 
overmaat aan deze vitaminen lijkt te zitten (3.2). 
 Om te onderzoeken of deze bevindingen ook al waarneembaar waren in het 
eerste jaar na operatie bij patiënten met een lagere BMI voor operatie, werd in 
samenwerking met het Catherina Ziekenhuis Eindhoven een vervolgstudie verricht. 
Ook bij deze groep patiënten werden, zij het in mindere mate, dezelfde 
bevindingen gedaan al in het eerste jaar na operatie. Deze bevindingen tonen aan  
dat niet alleen routinematige suppletie, maar ook het zorgvuldig nacontroleren van 
de patiënten die een GS operatie hebben ondergaan, heel belangrijk is (3.3). 
 Het meest voorkomende tekort  bij patiënten  met morbide obesitas  is een 
tekort aan vitamine D. Dit  is van negatieve invloed op de calciumhuishouding en 
daarmee op de stevigheid van bot. Dit is op zichelf weer het gevolg van de al 
eerder genoemde slechte voedselopname en wordt mogelijk nog verergerd doordat 
patiënten met morbide obesitas zich minder blootstellen aan zonlicht, waardoor ze 
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ook minder vitamine D aanmaken. Vervolgens is onderzocht langs welke 
toedieningsweg en hoeveel vitamine D (cholecalciferol) er nu eigenlijk gegeven 
moet worden. Voor dit doel werd, in een groep obese patiënten voor en na RYGB, 
een formule (dr. De Boer et al) voor vitamine D suppletie (cholecalciferol) 
gevalideerd (3.4). 
Hiermee kan gemakkelijk berekend worden hoeveel cholecalciferol een 
patiënt toegediend moet krijgen om weer een normaal vitamine D gehalte in het 
bloed te kunnen onderhouden. Ook is het gebleken dat patiënten na de RYGB vaak 
een veranderd ontlastingspatroon hebben. Er is onderzocht of er een relatie bestond 
tussen deze veranderingen en de calciumhuishouding. Daarbij bleek dat patiënten 
met een zachte en frequente ontlasting een hoger parathyreoïdhormoon (PTH) 
spiegel in het bloed hadden en daardoor een calciumtekort (3.5). Een tweede, 
prospectieve, studie naar dit onderwerp wordt momenteel verricht.  
Gezien de zeer veelvuldig beschreven tekorten aan vitaminen, mineralen 
en andere voedingscomponenten na bariatrische chirurgie, werd de bekende 
literatuur over dit onderwerp in kaart gebracht. Mede op basis van eerder door ons 
verricht onderzoek, werd een optimale samenstelling van een multivitamine 
ontwikkeld. Om te onderzoeken of deze samenstelling resulteerde in minder 
deficiënties werd een prospectieve, dubbelblind gerandomiseerde studie verricht. 
Al na een jaar blijkt dat toediening van dit multivitaminepreparaat na de RYGB 
operatie resulteert in een bijna volledig verdwijnen van de belangrijkste tekorten.  
Er bleek eigenlijk alleen aanpassing van de dosering  voor vitamine A, B1 en B6 
nodig te zijn (3.6). Momenteel loopt er nog een drietal prospectieve studies naar 
het effect van  dit multivitaminepreparaat na de GS, RYGB, Scopinaro en 
Duodenal Switch operaties. 
 
Hoofdstuk 4 is volledig gewijd aan de co-morbiditeit die veelvuldig 
voorkomt bij morbide obesitas. Een minder belichte co-morbiditeit is 
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hypogonadaal hypogonadisme (HH) in morbide obese mannen. HH wordt 
veroorzaakt doordat testosteron door de enorme overmaat aan vetcellen wordt 
omgezet in oestrogenen. Dit leidt tot een aantal veranderingen in de uiterlijke 
kenmerken zoals verminderde baardgroei, erectieproblemen en een verminderde 
libido. Over dit onderwerp was al eerder een artikel verschenen vanuit het Rijnstate 
Ziekenhuis. Om te onderzoeken of HH na bariatrische chirurgie verbeterde of 
mogelijk zelfs verdween, werd een groep mannen voor en na RYGB onderzocht en 
hierbij bleek het grootste deel van de geopereerde patiënten volledig te genezen 
(4.1). 
Over het effect van bariatrische chirurgie op diabetes mellitus Type 2, de 
niet-insulineafhankelijke vorm van suikerziekte  (DM2) is misschien wel het meest 
gepubliceerd van alle bijkomende ziekten bij morbide obesitas. Bij een deel van de 
patiënten heeft de operatie nagenoeg geen effect op DM2. In deze groep patiënten 
met DM2 is onderzocht of de nuchtere C-peptidewaarde in het bloed een 
voorspellende waarde voor het effect van operatie op de DM2. C-peptide is een 
splitsingsproduct van insuline en de concentratie in het bloed is een maat voor de 
functie van de alvleesklier. In de groep DM2 patiënten werd pre-operatief dit C-
peptide gehalte gemeten en bekeken wat de relatie was tussen het C-peptide gehalte 
vóór operatie en het effect van operatie op DM2. Uit dit onderzoek bleek dat 
wanneer het C-peptide gehalte in het bloed voor operatie lager dan 1.0 nmol/L was, 
de RYGB operatie niet resulteerde in genezing van de DM2.  het werd dus 
duidelijk dat, met de bepaling van C-peptide voor operatie  voorspeld kan worden 
welke patiënten met DM2 goed en welke minder goed op operatie zullen reageren 
(4.2). 
Het laatste hoofdstuk is gewijd aan het effect van operatie op 
leververvetting bij morbide obese patiënten (4.3). Dit onderzoek werd opgezet 
vanuit het Universitair Medisch Centrum Utrecht. Leververvetting komt veelvuldig 
voor bij morbide obesitas en gaat gepaard met vergroting van de lever. Dit kan 
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ook minder vitamine D aanmaken. Vervolgens is onderzocht langs welke 
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Er bleek eigenlijk alleen aanpassing van de dosering  voor vitamine A, B1 en B6 
nodig te zijn (3.6). Momenteel loopt er nog een drietal prospectieve studies naar 
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hypogonadaal hypogonadisme (HH) in morbide obese mannen. HH wordt 
veroorzaakt doordat testosteron door de enorme overmaat aan vetcellen wordt 
omgezet in oestrogenen. Dit leidt tot een aantal veranderingen in de uiterlijke 
kenmerken zoals verminderde baardgroei, erectieproblemen en een verminderde 
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5.3 Present and Future 
 
Primary prevention of obesity should be pursued in as a matter of policy. 
The government has the difficult task of promoting a healthy lifestyle and warning 
of the consequences of poor nutrition. It seems, however, that governments, 
doctors and patients have completely failed, given the huge increase in obesity in 
recent decades [1,2]. What is responsible for this explosive growth? 
 
  The primary responsibility lies with the consumer who ultimately becomes 
a morbidly obese patient. Ultimately he or she is the one who chooses to eat 
excessively and exercise little [3-5]. In our western society, the trend is to move 
and exercise less and thus burn fewer calories [3-6]. In addition, it has become 
easier to obtain food with a fast-food opportunity on every street corner. In 
addition, morbid obesity is referred to more and more as the result of an addiction 
to eating similar to addiction to smoking or drugs, and is therefore very difficult to 
treat or positively influence on a large scale. 
 
  The main goal of the food industry today is to make as much profit as 
possible. With smart but often misleading advertisements, they know how to 
seduce the consumer to execute unhealthy purchases. Part of the increase in obesity 
is therefore due to the food-industry; however, this industry is also a product of our 
society. The government and its subsidiaries have produced a structure where the 
consumer pays relatively low prices at the cash register for their products. This is 
because farmers and producers are subsidized to the tune of by billions annually. 
As a result, commodity prices are artificially low. On the one hand, the government 
has an interest in a healthy society, while on the other hand it also needs financial 
resources. The increase in obesity has the unfortunate side effect of producing a 
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zorgen dat het operatiegebied lastig toegankelijk wordt, want de maag en de 
overgang van de slokdarm naar de maag (daar waar de operatie moet worden 
uitgevoerd) liggen onder de lever. Na operatie neemt, met het dalen van het 
lichaamsgewicht, de mate van leververvetting vaak snel af. De gouden standaard 
om de mate van leververvetting aan te tonen is de biopsie van de lever. Dit is een 
pijnlijke ingreep en er bestaat een risico op bloeding na de punctie. MRI kan de 
leververvetting ook goed in beeld brengen. Om de waarde van MRI in plaats van 
leverbiopsie voor de bepaling van het effect van operatie op leververvetting aan te 
tonen werd bij een groep patiënten voor en na RYGB operatie een MRI verricht en 
werd tijdens de operatie een leverbiopsie uitgevoerd.  Het bleek dat MRI als niet 
invasieve methode een even goede maat is voor het bepalen van de mate van 
leververvetting als leverbiopsie en dat deze dus de leverbiopsie kan vervangen. 
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sharp rise in healthcare costs, due in particular to increased rates of co-morbidities 
[7]. 
 
  There are simply only two possible strategies to break this vicious circle. 
The first is preventive action, by cutting down on the selling of calorie rich food. 
The second is to accept the increase in obesity and invest in ways to induce weight 
loss. How simple this may sound and how obvious support by most consumers may 
seem initially, support will drop in the second instance.  Real cutting on the selling 
end can only be achieved by such radical choices as product bans or high taxes on 
certain foods. This is alien to the liberal democratic Western world where the myth 
is that every individual is solely his own responsibility. However, the governments 
of, for example, Finland, have taken the first steps with taxes on sweets and 
Denmark, with increased taxes on saturated fats. 
 
In all probability the future of bariatric surgery in terms of numbers, 
therefore, is “favourable”. It is estimated that in the Netherlands at least 250,000 
patients are or will become candidates for bariatric surgery; however, only a few of 
these are actually operated on each year [8,9]. With a current level of only a few 
thousand operations per year, extension of the number per year is desperately 
needed. One trend seen worldwide is that surgical centres are specializing in 
bariatric surgery, so centralization of treatment in these centres is becoming a 
reality. A multidisciplinary approach  (bariatric surgeon, anaesthesiologist, 
endocrinologist, gastrointestinal doctor, radiologist, specialized nurses and general 
staff) and an infrastructure adapted to the needs of the patient and bariatric surgery 
are a must to provide the best care for the patient [10]. 
We must continue to realize that bariatric surgery is currently an option 
only for extremely obese patients and therefore only provides a possible solution 
for a small group of patients who experience overweight. The enormous growth in 
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obesity might, however, make a more drastic approach inevitable, especially now 
that obesity is seen in younger patients. It has even been suggested that these 
paediatric patients should be treated using bariatric surgery [11,12].  
With the development of less invasive methods such as the EndoBarrier™, 
patients with a lesser degree of overweight or T2DM [13] can also be treated in the 
future. This kind of completely reversible method will hopefully be available for 
preventive use in the future, so that obese patients will not become morbidly obese. 
Care must, however, be taken that long term results do not simply vanish as, for 
example, happened with the gastric balloon, by providing continued professional 
guidance and possible re-implantation [14-16]. 
Some bariatric surgeries, like the gastric band, unfortunately result in too 
little weight loss in the long run. This is the reason why the number of gastric 
bands placed in recent years in the Netherlands has been drastically reduced. Most 
patients now receive non-reversible interventions such as the Gastric Sleeve or 
Gastric Bypass. We also expect much of the treatment of T2DM in patients with 
moderate overweight, for example with a Gastric Bypass. In some countries, these 
diabetics form a large percentage of the executed Gastric Bypasses. This is one of 
the reasons why bariatric surgery is more and more referred to as metabolic 
surgery. By inducing rapid weight loss, reducing intake and also by changing the 
route of the food ingested, T2DM seems curable using bariatric surgery [17-21]. 
 
  Thus, the next step is quickly made, which is collaboration with other 
disciplines. With the expanding indications for bariatric surgery, a 
multidisciplinary approach is becoming quite common and offers opportunities for 
combined studies and combined long term evaluation of the outcome of bariatric 
surgery. The pharmaceutical industry is constantly developing new drugs for the 
treatment of obesity. Insights gained from bariatric surgery may contribute to the 
further development of medicines. Already, promising products have been put on 
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the market, but these have often proven to have little effect or excessive side 
effects [22-26]. 
From our perspective the solution should preferably be a global one, and 
surgery will have a place in secondary prevention. The ultimate aim should be to 
turn surgery for morbid obesity into history and hopefully surgeons will, with a 
smile, then look back on bariatric as they do now on B2 gastric resections for 
peptic ulcer, where the treatment paradigm has shifted from surgery to medical 
treatment. 
 
369
5
Summary, present and future, word of gratitude
 
 
 354 
the market, but these have often proven to have little effect or excessive side 
effects [22-26]. 
From our perspective the solution should preferably be a global one, and 
surgery will have a place in secondary prevention. The ultimate aim should be to 
turn surgery for morbid obesity into history and hopefully surgeons will, with a 
smile, then look back on bariatric as they do now on B2 gastric resections for 
peptic ulcer, where the treatment paradigm has shifted from surgery to medical 
treatment. 
 
	  
	  
	   71	  
References 
 
1. York DA, Rossner S, Caterson I, Chen CM, James WP, Kumanyika S, Martorell R & 
Vorster HH. Prevention Conference VII: obesity, a worldwide epidemic related to heart 
disease and stroke: Group I: worldwide demographics of obesity. Circulation 2004; 110: 
e463–e470. 
2. Le Gales-Camus C. Fighting Obesity, clarification from World Health Organization. BMJ, 
2004: 3; 53-4 
3. Bult MJF, van Dalen T, Muller AF. Surgical treatment of obesity. European Jouranl of 
Endocrinology 2008; 158:135-45	  
4. Haslam DW & James WP. Obesity. Lancet 2005; 366: 1197–1209. 
5. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS &Koplan JP. The continuing 
epidemics of obesity and diabetes in the United States. Journal of the American Medical 
Association 2001;286: 1195–1200. 
6. Neumark-Sztainer, D. & Haines, J. (2004) Psychosocial and behavioural consequences of  
obesity. In: J.K.Thomson (Ed.). Handbook of Eating Disorders and Obesity (pp.349-71).  
Hobroken, N.Y: Wiley.        
7. Picot 2009 Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg 
AJ. The clinical-effectiveness and costeffectiveness of bariatric (weight loss) surgery for 
obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1-
190, 215-357 
8. Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg. 2004;14:1157–
64. 
9. Schokker, D.F., Visscher, T.L.S., Nooyens, A.C.J., Van Braak, M.A. & Seidell, J.C. 2007. 
Prevalence of Overweight and Obesity in the Netherlands, Obesity Reviews, 2, 101-7 
10. Buchwald H. Consensus conference statement bariatric surgery for morbid obesity: health 
implications for patients, health professionals, and third party payers. Journal of the 
American College of Surgeons 2004;200:593–604 
11. Inge TH, Xanthakos SA & Zeller MH. Bariatric surgery for pediatric extreme obesity: now 
or later? International Journal of Obesity 2007;31:1–14 
12. Nadler EP, Youn HA, Ginsburg HB, Ren CJ & Fielding GA. Shortterm results in 53 US 
obese pediatric patients treated with laparoscopic adjustable gastric banding. Journal of 
Pediatric Surgery 2007;42:137–141. 
370
Chapter 5
	  
	  
	   372	  
13. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for 
presurgical weight loss prior to bariatric surgery. Schouten R, Rijs CS, Bouvy ND, 
Hameeteman W, Koek GH, Janssen IM, Greve JW. Ann Surg. 2010;251:236-43 
14. Melissas J, Mouzas J, Filis D, Daskalakis M, Matrella E Papadakis JA, Sevrisarianos N & 
Charalambides D. The intragastric balloon – smoothing the path to bariatric surgery. 
Obesity Surgery 2006;16:897–902. 
15. Spyropoulos C, Katsakoulis E, MeadN,Vagenas K& Kalfarentzos F. Intragastric balloon for 
high-risk super-obese patients: a prospective analysis of efficacy. Surgery for Obesity and 
Related Diseases 2007;3:78–83. 
16. Mathus-VliegenEM&TytgatGN. Intragastric balloon for treatmentresistant obesity: safety, 
tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free 
follow-up. Gastrointestinal Endoscopy 2005;61:19–27. 
17. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP & Purnell JQ. 
Plasma ghrelin levels after diet induced weight loss or gastric bypass surgery. New England 
Journal of Medicine 2002;346:1623–30. 
18. Rubino F, Forgione A, Cummings DE, VixM, Gnuli D Mingrone G, Castagneto M & 
Marescaux J. The mechanism of diabetes control after gastrointestinal bypass surgery 
reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. 
Annals of Surgery 2006:244:741–49 
19. Ballantyne GH, Gumbs A & Modlin IM. Changes in insulin resistance following bariatric 
surgery and the adipoinsular axis: role of the adipocytokinese, leptin, adiponectin and 
resistin. Obesity Surgery 2005;15:692–99 
20. Ballantyne GH. Peptide YY(1–36) and peptide YY(3–36). Part II. Changes after 
gastrointestinal surgery and bariatric surgery. Obesity Surgery 2006;16:795–803 
21. Cummings DE. Gastric bypass and nesidioblastosis – too much of a good thing for islets? 
New England Journal of Medicine 2005;353:300–2 
22. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, 
Solomon V, Shekelle PG & Morton SC. Metaanalysis: pharmacologic treatment of obesity. 
Annals of Internal Medicine 2005;142:532–46 
23. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J & Rosenstock J. For the RIO-North 
America study group Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and 
cardiometabolic risk factors in overweight or obese patients: RIO-North America: a 
randomized controlled trial. Journal of the American Medical Association 2006;295:761–
75. 
371
5
Summary, present and future, word of gratitude
	  
	  
	   3	  
24. Scheen AJ, Finer N, Hollander P, Jensen MD & Van Gaal LF. Efficacy and tolerability of 
rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled 
study.Lancet 2006;368:1660–72. 
25. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O & Ro¨ssner S. For the RIO-Europe study 
group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and 
cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe 
study. Lancet 2005;365:1389–97. 
26. Yanovski SZ & Yanovski JA. Obesity. New England Journal of Medicine 2002;346:591–
602. 
372
Chapter 5
373
5
Summary, present and future, word of gratitude	  
	  
	   374	  
 
5.4  Additional published articles on bariatric  surgery 
  
1. Alternations of hormonally active fibroblast growth factor after Roux-
enY Gastric Bypass surgery. 
Janssen PL, van Werven J, Aarts E, Berends F, Janssen I, Stoker J 
Schaap FG.  
Dig Dis. 2011;29:48-51 
2. Esophageal motor responses to increasing adjustment of an implanted 
gastric band 
Burgerhart JS, Aarts EO, van de Meeberg PC, Berends FJ, Siersema 
PD, Smout AJ.  
Neurogastroenterol Motil. 2013 Jul;25:587-e461 
3. Hepatic and peripheral insulin sensitivity do not improve 2 weeks after 
bariatric surgery.  
De Weijer BA, Aarts E, Janssen IM, Berends FJ, van de Laar A, 
Kaasjager K, Ackermans MT, Fliers E, Serlie MJ 
Obesity (Silver Spring). 2013 Jun;21:1143-7 
4. Calorie restriction is a major determinant of the short-term metabolic 
effect of gastric Bypass surgery in obese type 2 diabetic patients. Lips 
MA, de Groot GH, van Klinken JB, Aarts E, Berends FJ, Janssen IM, 
van Ramshorst B, van Wagensveld BA, Swank DJ, van Dielen F, 
Willems van Dijk K, Pijl H. 
Clinical Endocrinology (Oxf) Online 5-2013 
5. The feasibility of delivering a duodenal-jejunal bypass liner 
(endobarrier) endoscopically with patients under conscious sedation 
Koehestanie P, Betzel B, Dogan K, Berends F, Janssen I, Aarts E, 
Groenen M, Wahab P. 
Accepted 12-2013 Surgical Endoscopy 
	  
	  
	   374	  
 
5.4  Additional published articles on bariatric  surge y 
  
1. Alternations f h rm nally active fibroblast growth factor after Roux-
enY Gastric Bypass surgery. 
Janssen PL, van Werven J, Aarts E, Berends F, Janssen I, Stoker J 
Schaap FG.  
Dig is. 2011;29:48-51 
2. Esophage l motor responses to increasing adjustment of an implanted 
gastric band 
Burgerhart JS, Aarts EO, van de M eb rg PC, Berends FJ, Siersema 
PD, Smout AJ.  
Neurogastroenterol Motil. 2013 Jul;25:587-e461 
3. Hepatic and peri heral insulin se sitivity do not improve 2 weeks after 
bariatric surgery.  
De W ijer BA, Aarts E, Janssen IM, Berends FJ, van de Laar A, 
Kaasj ger K, Ackermans MT, Fliers E, Serli  MJ
Obesity (Silver Spring). 2013 Jun;21:1143-7 
4. Calorie rest iction s a m jor determinant of he s ort-term metabolic 
effect of gastric Bypass surgery in obese type 2 diabetic patien s. Lips 
MA, de Groot GH, van Klinke  JB, Aarts E, Berends FJ, Janssen IM, 
van Ramshorst B, van Wagensveld BA, Swank DJ, van Dielen F, 
Willems van Dijk K, Pijl H. 
Clinical Endocrinology (Oxf) Online 5-2013 
5. The feasibility of deliv r ng a duo enal-jejunal bypass liner 
(endobarrier) endoscopically with patien s under conscious sedation 
Koehestanie P, Betzel B, Dogan K, Berends F, Janssen I, Aarts E, 
Groenen M, Wahab P. 
Accepted 12-2013 Surgical Endoscopy 
	  
	  
	   374	  
 
5.4 Additional published articles on bariat ic surgery 
  
1. Alternatio s of hormonal y ctive f broblast growth factor after Roux-
enY Gastric Bypas  surgery. 
Jans e  PL, van Werven J, Aarts E, Berends F, Jans e  I, Stoker J 
Schaap FG.
Dig is. 2011;29:48-51 
2. Esophageal motor respon es to increasing adjustment of an implanted 
gastric band 
Burgerhart JS, Aarts EO, van de Me berg PC, Berends FJ, Siersema 
PD, Smout AJ. 
Neurogastroenterol M til. 2013 Jul;25:587-e461 
3. Hepatic and peripheral insuli  sensitivity do not improve 2 we ks after 
bariatric surgery. 
De Weijer BA, Aarts E, Jans e  IM, Berends FJ, van de Laar A, 
Kaasjager K, Ackermans MT, Fliers E, Serlie MJ 
Obesity (Silver Spring). 2013 Jun;21:1143-7 
4. Calorie restriction is a major determinant of the short-term metabolic 
ef ect of gastric Bypas  surgery in obese typ  2 diabetic patients. Lips 
MA, de Groot GH, van Kli ken JB, Aarts E, Berends FJ, Jans e  IM, 
van R mshor t B, van Wagensv ld BA, Swank DJ, van Dielen F, 
Wil ems van Dijk K, Pijl H. 
Clinical Endocrinology (Oxf) Online 5-2013 
5. The feasibility of delivering a duodenal-jejunal bypas  liner 
(endobar ier) endoscopi al y with patients u der cons ious sedation 
Koehestanie P, Betzel B, Dogan K, Berends F, Jans e  I, Aarts E, 
Groenen M, Wahab P. 
Ac epted 12-2013 Surgical Endoscopy 
374
Chapter 5
375
5
Summary, present and future, word of gratitude	  
	  
	   376	  
 
5.5  Presentations and lectures related to this thesis 
 
1.  Disappointing results after the LAGB.  
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- NOK 2012, Utrecht, The Netherlands 
- Bariatriecongres 2013 MC, Leeuwarden, The Netherlands 
- IFSO 2013, Istanbul, Turkey 
- Expert meeting 2013, The Netherlands 
- Adipositas Symposium 2014, Nordersted, Germany 
- SOFFCO 2014, Versailles, France 
 
10.  Surgical consequences of morbid obesity. 
- Duamutef 2013, Zwolle, The Netherlands 
  
11.  Mixed results of the last generation gastric band (SAGB  VC).  
- IFSO 2011, Hamburg, Germany 
 
12.  Experiences with gastrointestinal endoscopic removal of  migrated 
 adjustable gastric bands.  
- IFSO 2011, Hamburg, Germany 
 
13.  Weight regain after bariatric surgery. 
- Expert meeting 2013, The Netherlands 
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5.6 Dankwoord (Word of gratitude) 
 
Het dankwoord voor dit proefschrift is gedurende vele jaren ontstaan. 
Gedurende de reis die promoveren heet zijn er veel collega’s, vrienden en patiënten 
die hun stempel op deze periode gedrukt hebben. Gelukkig allemaal in positieve 
zin.  
Allereerst wil ik deze laatste groep, alle patiënten die vrijwillig aan deze 
onderzoeken hebben deelgenomen, bedanken. Zonder patiënten die belangeloos 
deelnemen is het verrichten van goed onderzoek niet mogelijk. Met vele patiënten 
heb ik een speciale band opgebouwd wat het verrichten van het onderzoek een 
speciaal tintje gaf. 
Mijn dank gaat uit naar promotor Prof. dr. H.G. Gooszen. Uw begeleiding 
richting het afronden van mijn promotie was onontbeerlijk. Fijn dat ik het gevoel 
kreeg volledig mezelf te kunnen blijven. Met name de rust en ervaring  die u 
uitstraalt is geweldig. 
Dr. F.J. Berends, beste Frits, jij bewijst toch wel hoe moeilijk het is om 
mensen te bedanken in een proefschrift. Je bent gedurende deze jaren veel meer 
een vriend geworden dan een co-promotor. Je combinatie van toegankelijkheid en 
persoonlijke begeleiding maken je een geweldige promotor. De reis die ik vanaf 
2008 heb gemaakt had niet zonder jou gekund. Deze reis heeft meerdere haltes, 
waaronder eerst mijn aanname voor de opleiding chirurgie, nu mijn promotie en 
daarna alles wat in de toekomst nog te wachten staat. Zonder jou zou dit 
proefschrift niet bestaan hebben. Hopelijk kunnen we in de toekomst vele 
promoties tegemoet zien van onze onderzoeksgroep. De basis is gelegd. 
Drs. I.M.C. Janssen, beste Ignace, samen met Frits hebben jullie je nek 
meerdere malen voor mijn uitgestoken. Ik voelde me vereerd als eerste in Arnhem 
structureel onderzoek te mogen gaan doen naar de uitkomsten van de bariatrie. 
Naast een geweldige onderzoeksplaats heb ik er een aantal goede vrienden aan 
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overgehouden waaronder ik je mag scharen. Nu ik alweer een jaar terug in Arnhem 
ben hebben steeds meer  met elkaar te maken.  Met de nieuwe opzet van de 
onderzoeksgroep hoop ik nog veel aan het onderzoek te kunnen bijdragen. Ik kijk 
weer uit naar het volgende congres waar ik samen met jou onze resultaten mag 
presenteren. Dank voor alle begeleiding als mentor, het vertrouwen van nu en het 
vertrouwen in de toekomst. 
De leden van mijn manuscriptcommissie (prof dr. Prof. dr. C.J.J. Tack, 
Prof. dr. J.W.M. Greve, Prof. dr. H. Pijl) en de overige leden van de 
promotiecommissie wil ik hartelijk danken voor het plaatsnemen in de commissie 
en het doornemen van mijn proefschrift. 
Drs. B van Wageningen, beste Bas, met jou is het eigenlijk allemaal 
begonnen. Jij was mijn begeleider tijdens mijn afsluitende  wetenschappelijke stage 
en adviseerde Ignace en Frits me aan te nemen als onderzoeker bariatrie. Sindsdien 
hebben we samen mooi onderzoek verricht en maak jij een groot deel uit van mijn 
proefschrift met vier gezamenlijke publicaties. Los daarvan zijn we nu ook bezig 
met jouw promotie, heel erg leuk! Je bent een heel fijne collega en kundig chirurg.  
Dr. H. de Boer, beste Hans, vanaf het eerste moment dat we samen aan de 
eerste studie werkte heb ik veel aan je gehad. Je liet me verder kijken naar obesitas 
dan je van een ‘simpele’ chirurg zou verwachten met als resultaat een aantal zeer 
endocrinologisch getinte artikelen. Een aantal mooie ideeën voor onderzoek 
kwamen van jouw klant en blijven hopelijk komen. De onderzoeken die we samen 
verricht hebben zijn altijd tot een goed einde gebracht, al koste het soms wat extra 
tijd. Ik hoop ook in de toekomst gebruik te mogen maken van je kennis en goede 
samenwerking. Er ligt in ieder geval nog een hoop op de ‘to do’ stapel. 
Dr. P.J. Wahab, beste Peter, niet voor niets was je een van mijn 
referenties voor mijn sollicitatie voor de opleiding chirurgie. Een ongelooflijke 
duizendpoot die overal tegelijk mee bezig is. We hebben elkaar pas echt leren 
kennen toen we tezamen gastroscopisch vele Endobarriers  hebben geplaatst en 
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verwijderd bij onze patiënten. Je bent een van die mensen die altijd een positieve 
instelling heeft en zijn afspraken nakomt. Heel erg bedankt voor de ontzettend 
prettige samenwerking tot nu toe. 
Dr M.J.M. Groenen, beste Marcel, dank voor je samenwerking en 
correcties van hoofdstuk 2.5 van dit proefschrift. Zonder jouw gastroscopische 
inzichten was dit artikel nooit geworden wat het nu is. 
Dr. D. H. Schweitzer, beste Dave, grappig om te zien waar een mailtje 
naar een auteur van een artikel waarover je vragen hebt  toe kan leiden. Het idee 
voor hoofdstuk 3.5 was nieuw en bracht voor mij onverwachte resultaten. Je 
motiverende houding en geweldige manier van communiceren via Skype hebben 
tot een mooi artikel geleidt en een mooie prospectieve studie waarvan we alweer 
mooie resultaten hebben.  
Parweez (Koehestanie), wat heb je een zware kluif van me gekregen toen 
ik vertrok.  Het is niet makkelijk als je het werk moet overnemen van een eenling 
die zo goed als alles opgezet had naar zijn eigen idee. Gelukkig heb je de kluif niet 
begraven maar met twee handen opgepakt. Je bent er in geslaagd om uiteindelijk 
vat te krijgen op alles en er je eigen draai aan te geven. Ook jouw promotie komt 
dichterbij en zoals je weet vind ik het een eer daar op mijn manier deel van uit te 
maken. Heel veel succes met het afronden en natuurlijk met je opleiding tot MDL 
arts. 
Het volgende hoofdstuk dat toegevoegd werd aan de onderzoeksgroep ben 
jij Kemal (Dogan). Al vele jaren ervaring in het chirurgische vakgebied moest jij 
je waar maken binnen het onderzoek. De eerste versie van je proefschrift ziet er erg 
goed uit en ik heb er alle vertrouwen in je over enige tijd te mogen verwelkomen 
als collega doctor.  
En dan Bark (Betzel), de alweer vierde full-time bariatrisch onderzoeker 
die in Arnhem plaats heeft genomen. Ook voor jou is het de bedoeling om er een 
prachtige promotie van te maken in nog een jaar tijd. Dat je hard kunt werken had 
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je na een paar maanden al bewezen. Hopelijk mag ik je over ongeveer een jaar de 
hand schudden als collega-MDL arts  in opleiding. 
 Jens (Homan), eerst zien en dan geloven is het devies, maar ondanks dat 
je pas net begonnen bent alweer hard op weg een onmisbaar onderdeel te worden 
van de bariatrie onderzoeksgroep. Dank voor je inzet, ook voor het inwerken van 
onze nieuwste collega Wendy Schijns. Heel veel succes en ook voor jullie geldt: 
op naar een mooie promotie over twee of drie jaar! 
Willemien, mijn zeer gewaardeerde partner in crime. Jouw kijk op 
onderzoek en ervaring met patiënten zijn zeer waardevol. Als team hebben we toch 
mooi een hoop voor elkaar gebokst! Altijd in voor een lolletje, maar uiterst 
professioneel tijdens werk. Niet alleen ik ben je dankbaar voor de mooie tijd, maar 
ook al onze patiënten. Toch leuk als zoveel jaren nadien patiënten toch nog naar 
ons vragen. Ik hoop nog jaren met je samen te kunnen werken. 
Lieve Nadine, waar zou een hoop van het onderzoek zijn zonder jou? Als 
gespecialiseerd  bariatrisch verpleegkundige veelal achter de schermen voor ons 
druk bezig om alle patiënten terug te vinden die nog misten in het onderzoek. Dank 
voor je aanvullingen op onze tekortkomingen, je bent een zeer waardevol lid van 
het team. Heel veel geluk met jullie (dus ook voor jou Hans) mooie  dochter Mirte. 
Annemiek, ook jij bent een vaste waarde voor de bariatrisch patiënten. Voor de 
studiepatiënten heb je regelmatig werk moeten verrichten wat nog eens bovenop je 
poli kwam. Grappig dat je met je lifestyle coaching nu al eerder dan ik een eerste 
(kook)boek geschreven hebt samen met twee oud patiënten . Dank voor je inzet en 
meedenken. 
Beste Jochem, wat een kennis, kunde en rust bracht jij mee vanuit het 
Utrechtse. Erg leuk om ook vanuit de ogen van een radioloog naar obesitas te 
kijken. Het is prettig om samen te werken met iemand waarmee je geheel op een 
lijn zit. Succes met je verdere opleiding, hopelijk treffen wij elkaar in de toekomst 
nog vaker. 
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En dan Pim (Rutte), “the best looking guy in bariatrics” en ook nog eens 
een geweldig trompetspeler. Hopelijk volgen er nog vele onderzoeken samen, in 
ieder geval nog één. Heel veel succes met je werkzaamheden en opleiding tot 
chirurg in Heerlen.  
Drs. L. Roovers, lieve Lian, dank voor je hulp bij al het statistische werk 
waar ik af en toe niet meer uit kwam. Je oplossingen en berekeningen maakte een 
groot aantal artikelen tot wat ze geworden zijn.  
Alle andere medeauteurs van de artikelen in dit proefschrift wil ik 
hartelijk danken voor de tijd en moeite die jullie in deze artikelen gestopt hebben.  
Wat een reis hadden jullie al achter de rug voordat ik jullie leerde kennen, 
Simon en Sjoerd, twee vrienden die ooit met een goed idee begonnen en een 
prachtig bedrijf runnen. Na onze inmenging is er voor jullie veel veranderd, sorry 
daarvoor . Dankzij jullie werd een gekoesterde droom waarheid en helpen jullie 
nu veel van de bariatrisch patiënten in Europa deficiënties te voorkomen en te 
behandelen. Let op jullie zelf (en jij Simon ook op je gezin), over tien jaar kijken 
we hopelijk terug op een geslaagd avontuur! 
Lieve dames van Vitalys, wat heb ik jullie toch vaak in problemen 
gebracht door advertenties te zetten voor onderzoeken of in patiënten informatie de 
verkeerde nummers te zetten. Patiënten wisten gelukkig altijd nog dat het de 
afdeling bariatrie was en belden dan naar jullie. Nogmaals sorry voor al deze 
overlast, maar door jullie goede zorgen hebben slechts weinig patiënten afspraken 
gemist. 
Jan (Blokzijl), als er bij het woord’ goedzak’ een foto zou moeten komen 
dan zou die van jou erbij staan. Altijd maar weer lastige vragen over patiënten die 
geopereerd zijn, of moeten worden, ruimtes die gebruikt moeten worden en noem 
zo maar op. Altijd kon ik bij jou terecht en werd het zonder morren geregeld. Heel 
erg bedankt voor al die inzet en interesse in alle onderzoeken. 
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Kirch, beste Martin, toegevoegd aan het Vitalys team als arend in de 
lucht, zoekend naar de beste wegen die bewandeld kunnen worden. Dank voor je 
meedenken bij vele problemen en interessante oplossingen. Hopelijk mogen we 
nog jaren gebruik maken van je expertise. 
Marije, dank voor het openstaan voor het doen van onderzoek onder de 
Vitalys vlag. Toch moeilijk om altijd een afweging tussen kosten en baten te 
maken lijkt me. Je hulp (ook bij de organisatie van he tsymposium) erg wordt 
gewaardeerd! 
Lieve Kurt, Marja en Annelies mijn helden van het lab.  Zonder jullie is 
en was het grootste deel van mijn onderzoek niet mogelijk. Ik snap af en toe nog 
steeds niet waar jullie de tijd vandaan halen om alles zo goed en soepel te laten 
verlopen. Zodra ik weer terug ben op locatie kom ik weer langs om jullie te 
bestoken met moeilijke vragen en onze samenwerking verder te intensiveren. 
Daarnaast mag ik Agnes en alle andere collega’s die mijn patiënten 
opvingen bij de prikpost niet vergeten. Vanaf het moment als coassistent al 
vriendelijk en altijd bereid tijd vrij te maken om mee te denken in oplossingen en 
niet in problemen. Ik weet dat het niet mag, maar ik prik nog steeds het liefst mijn 
patiënten in mijn casual kleding zonder witte jas. 
Mijn helden van de postservice, René, Ruud, Shiva en Nico Hartelijk 
dank jongens voor het verzenden van al die pakketjes en urinebokalen. Wat een 
werk was het inpakken en het versturen toch telkens, desondanks gingen maar 
weinig pakketjes verloren net als alle post richting Amerika. Zonder jullie is een 
hoop van het onderzoek  niet mogelijk! 
Na lange tijd ben ik er sinds een jaar achter gekomen wie er achter de 
naam Frida schuilging van de telefooncentrale. Samen met alle andere telefonisten 
wil ik jullie bedanken voor de vele doorverbindingen die je over de afgelopen jaren 
hebben gemaakt naar andere afdelingen en ziekenhuizen over de hele wereld. De 
“Hoi, met Edo” moet haast wel in jullie geheugen gegrift staan. 
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Graag wil ik ook alle arts-assistenten bedanken van wie ik jarenlang een 
werkplek heb ingenomen (met het beste uitzicht). Jullie interesse in het onderzoek 
wordt zeer gewaardeerd en maakt de soms saaie uren achter de computer vaak toch 
tot een feest. 
Vaak ondergewaardeerd, maar ook mijn nadrukkelijke dank aan de dames 
en heren van de schoonmaak die elke keer na onderzoeken de ruimtes schoon 
hebben gemaakt.  
Alle andere medewerkers van de polikliniek,  de operatiekamers en 
Vitalys wil ik bedanken voor jullie inzet, uitleg en fijne samenwerking. 
Mijn lieve paranimfen, heel veel dank voor jullie steun en organiserend 
vermogen rond mijn promotie. Lieve Luc, broertje van me. Uit hetzelfde gezin en 
zoveel hetzelfde maar ook geheel anders.  De laatste jaren door alle drukte heen 
komen we vaak niet verder dan dat jij alleen of samen met Janna op onze kinderen 
past als we weer eens krap zitten.  Erg jammer, hopelijk in de toekomst anders, als 
je maar weet dat ik heel trots op je ben! Heel veel succes in de schoenen business, 
je komt er wel als je je hart volgt. Janna zorg goed voor hem, ik hou je in de gaten! 
Beste Jeroen, maatje van het eerste uur of in ieder geval al sinds het begin 
van de basisschool. Staat altijd voor mij en ons gezin klaar als er iets moet 
gebeuren. Met name je onvoorwaardelijke trouw is indrukwekkend. Samen met 
Anna, Daan en Maud hebben jullie echt een topgezinnetje en wens ik jullie alle 
goeds voor de toekomst. Niet alleen wij, maar ook onze kinderen zien jullie graag 
komen en hopelijk stapelen de goede herinneringen zich in de toekomst alleen 
maar op.  Je weet, je hoeft maar te bellen en ik sta bij je op de stoep (of regel een 
MRI voor je semi-kapotte knie)! 
Een aantal goede vrienden wil ik in het bijzonder bedanken voor hun 
tomeloze geduld. Opleiding en promotie tegelijk gecombineerd met een gezin zorgt 
er helaas regelmatig voor dat het sociale leven op een laag pitje komt te staan. 
Lieve Marjolein en Niels, ik voelde me vereerd om samen met Daphne (en Bram)  
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jullie ceremoniemeesters te mogen zijn. Ondanks dat we elkaar pas een jaar of 
zeven kennen is onze vriendschap toch echt heel  bijzonder. Mooi te zien dat jullie 
ook goed projecten kunnen afronden (lees Simon en hopelijk ook snel je 1ste 
graad). Geniet van elkaar en, ook samen met ons, van het leven. Zulke vrienden 
zijn veel meer dan goud waard. Laura, echt de grootste schat die er is, nooit een 
kwaad woord over een ander. Heel veel geluk (ook in de liefde) toegewenst. Helaas 
hebben we door alle drukte echt te weinig contact met jullie Suuz en Loekie. 
Moeten we maar eens veranderen toch? 
Lieve Papa en Mama (Piet en Agnes), wat is het toch fijn om als kind met 
liefde omringd te zijn. Dat heeft me voor een groot deel gevormd en dankzij jullie 
goede ouderschap ben ik gekomen waar ik nu ben. Niet alleen in werk maar ook 
privé heb ik alles wat ik me maar kan wensen. Dat jullie trots zijn weet ik echt wel, 
wees maar niet bang. Ik weet dat jullie altijd graag weten waar ik mee bezig ben 
maar dat jullie daar vaak maar weinig van meekrijgen, vandaar dit boekje over de 
afgelopen 4 jaar promotie. Papa en mama, goed gedaan, dank voor jullie 
onvoorwaardelijke steun, ook in moeilijke tijden.  
Lieve Laura, Anne Sofie en Amy Lotte, mijn kleine druiven die het leven 
alles waard maken. Bewust hebben jullie dit allemaal niet echt meegemaakt, maar 
ik jullie des te meer wel. Wat is nu een betere besteding van je spaarzame vrije 
uren dan spelen (of TV kijken/dansen) met je drie dochters? Jullie lekkere knuffels 
en kussen hebben me veel geholpen bij mijn promotie. Daarnaast ben ik erg blij dat 
jullie redelijk snel na de geboorte doorsliepen (respectievelijk drie weken, zes en 
drie maanden) en razendsnel zindelijk waren. Schatten alle goeds, en denk er aan 
dat papa eerst jullie vriendjes moet goedkeuren voordat er gezoend wordt! 
 
Nou Daphne, lieve schat dit is het dan, het proefschrift dat zoveel tijd en 
soms frustratie gekost heeft. Ondanks dat je, sinds we elkaar kennen, wist dat ik 
graag chirurg wilde worden, is het altijd anders dan je van tevoren denkt. Met een 
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Nou Daphne, lieve schat dit is het dan, het proefschrift dat zoveel tijd en 
soms frustratie gekost heeft. Ondanks dat je, sinds we elkaar kennen, wist dat ik 
graag chirurg wilde worden, is het altijd anders dan je van tevoren denkt. Met een 
proefschrift, opleiding, diensten en drie prachtige kinderen is het voor mij 
enigszins druk, maar voor jou met je eigen werk erbij nog veel drukker. Schat, je 
weet dat ik heel veel van je hou en zal er weer meer zijn de komende tijd. Samen 
verder richting nog een hele hoop mooie jaren! 
 
18.50 uur 
Rij nu echt naar huis, zet het eten maar aan 
 –XXX– je edje 
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5.7 Curriculum vitae 
 
Edo Oscar Aarts werd op zondag 14 februari 1982 geboren te Arnhem. 
Zijn gehele jeugd heeft hij in Oosterbeek gewoond. Na het behalen van het Vwo-
diploma aan het Katholiek Gelders College in 2000 startte hij met de studie 
medische biologie aan de Radboud Universiteit Nijmegen. Het volgende 
academisch jaar werd hij alsnog ingeloot voor de studie Geneeskunde aan dezelfde 
universiteit. Gedurende de gehele opleiding was hij zeer geïnteresseerd in de 
heelkunst. In 2006 startte zijn co-schappen en kwam na twee stages bij de afdeling 
chirurgie in het Rijnstate ziekenhuis in Arnhem in 2008 terug voor een 
wetenschappelijke stage. Dit onderzoek leidde tot een eerste publicatie in de 
bariatrische chirurgie. Na het afronden van deze stage behaalde hij in december 
2008 zijn doctoraal en artsexamen. Nog voor het behalen van dit examen begon hij 
onder leiding van Frits Berends en Ignace Janssen als onderzoeker in de 
bariatrische chirurgie. Deze werkzaamheden werden gecombineerd met het 
assisteren tijdens bariatrische ingrepen.  
Dit onderzoek heeft geleid tot een verscheidenheid aan artikelen die 
tezamen hebben geresulteerd in dit proefschrift. Tijdens dit promotietraject heeft 
Edo de resultaten van zijn onderzoek gepresenteerd op vele nationale en 
internationale congressen. 
Sinds begin 2011 is hij in opleiding tot chirurg, de eerste twee jaar  aan de 
Radboud Universiteit Nijmegen onder leiding van Prof. dr. Kees van Laarhoven. In 
januari 2013 keerde hij terug in het Rijnstate in Arnhem om zijn opleiding te 
vervolgen onder dr. Michel Rijnen als opleider. Het onderzoeken kan hij nog niet 
loslaten aangezien er gedurende deze opleiding tijd vrij gemaakt is om onderzoek 
te verrichten en promovendi te begeleiden.  
Edo woont al jaren samen met Daphne Gankema met als kroon op deze 
liefde hun drie kinderen, Laura Fransisca, Anne Sofie en Amy Lotte. 
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heelkunst. In 2006 startte zijn co-schappen en kwam na twee stages bij de afdeling 
chirurgie in het Rijnstate ziekenhuis in Arnhem in 2008 terug voor een 
wetenschappelijke stage. Dit onderzoek leidde tot een eerste publicatie in de 
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Sinds begin 2011 is hij in opleiding tot chirurg, de eerste twee jaar  aan de 
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vervolgen onder dr. Michel Rijnen als opleider. Het onderzoeken kan hij nog niet 
loslaten aangezien er gedurende deze opleiding tijd vrij gemaakt is om onderzoek 
te verrichten en promovendi te begeleiden.  
Edo woont al jaren samen met Daphne Gankema met als kroon op deze 
liefde hun drie kinderen, Laura Fransisca, Anne Sofie en Amy Lotte. 
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